Plant membrane bound O-acyl transferase (MBOAT) family protein sequences and their uses for altering fatty acid compositions

ABSTRACT

This invention is in the field of biotechnology, in particular, this pertains to polynucleotide sequences encoding membrane bound O-acyltransferase genes and the use of these acyltransferases for altering fatty acid profiles in oilseed plants. Methods for increasing elongation and desaturation conversion efficiencies are also disclosed.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.61/290,172, filed Dec. 24, 2009, which is incorporated herein byreference in its entirety.

FIELD OF THE INVENTION

This invention is in the field of biotechnology, in particular, thispertains to polynucleotide sequences encoding membrane boundO-acyltransferase genes and the use of these acyltransferases foraltering fatty acid profiles in oilseed plants.

BACKGROUND OF THE INVENTION

Plant lipids have a variety of industrial and nutritional uses and arecentral to plant membrane function and climatic adaptation. These lipidsrepresent a vast array of chemical structures, and these structuresdetermine the physiological and industrial properties of the lipid. Manyof these structures result either directly or indirectly from metabolicprocesses that alter the degree of unsaturation of the lipid. Differentmetabolic regimes in different plants produce these altered lipids, andeither domestication of exotic plant species or modification ofagronomically adapted species is usually required to produceeconomically large amounts of the desired lipid.

There are serious limitations to using mutagenesis to alter fatty acidcomposition and content. Screens will rarely uncover mutations that a)result in a dominant (“gain-of-function”) phenotype, b) are in genesthat are essential for plant growth, and c) are in an enzyme that is notrate-limiting and that is encoded by more than one gene. In cases wheredesired phenotypes are available in mutant crop lines, theirintrogression into elite lines by traditional breeding techniques isslow and expensive, since the desired oil compositions are likely theresult of several recessive genes.

Recent molecular and cellular biology techniques offer the potential forovercoming some of the limitations of the mutagenesis approach,including the need for extensive breeding. Some of the particularlyuseful technologies are seed-specific expression of foreign genes intransgenic plants [see Goldberg et al. (1989) Cell 56:149-160], and theuse of antisense RNA to inhibit plant target genes in a dominant andtissue-specific manner [see van der Krol et al. (1988) Gene 72:45-50].Other advances include the transfer of foreign genes into elitecommercial varieties of commercial oilcrops, such as soybean [Chee et al(1989) Plant Physiol. 91:1212-1218; Christou et al. (1989) Proc. Natl.Acad. Sci. U.S.A. 86:7500-7504; Hinchee et al. (1988) Bio/Technology6:915-922; EPO publication 0 301 749 A2], rapeseed [De Block et al.(1989) Plant Physiol. 91:694-701], and sunflower [Everett et al. (1987)Bio/Technology 5:1201-1204], and the use of genes as restrictionfragment length polymorphism (RFLP) markers in a breeding program, whichmakes introgression of recessive traits into elite lines rapid and lessexpensive [Tanksley et al. (1989) Bio/Technology 7:257-264]. However,application of each of these technologies requires identification andisolation of commercially-important genes.

Glycerophospholipids in biological membranes are metabolically activeand participate in a series of deacylation-reacylation reactions, whichmay lead to accumulation of polyunsaturated fatty acids (PUFAs) at thesn-2 position of the glycerol backbone. The reacylation reaction isbelieved to be catalyzed by Acyl-CoA:lysophosphatidylcholineacyltransferase (LPCAT)), which catalyzes the acyl-CoA-dependentacylation of lysophosphatidylcholine (LPC) to producePhosphatidylcholine (PC) and CoA. LPCAT activity may affect theincorporation of fatty acyl moieties at the sn-2 position of PC wherePUFA are formed and may indirectly influence seed triacylglycerol (TAG)composition. LPCAT activity is associated with two structurally distinctprotein families, wherein one belongs to the Lysophosphatidic acidacyltransferase (LPAAT) family of proteins and the other belongs to themembrane bound O-acyltransferase [“MBOAT”] family of proteins. In yeast,YOR175c, an acyltransferase belonging to the MBOAT family of proteins,has recently been shown to represent a major acyl-CoA dependentlysophospholipid acyltransferase (Wayne et al.; JBC, 2007,282:28344-28352). It further was shown by Sandro Sonnino (FEBS Letters,2007, 581:5511-5516) that the yeast acyiglycerol acyltransferase LCA1(YOR175c) is a key component of the Lands cycle for phosphatidylcholineturnover.

Stanford et al. (JBC, 2007, 282:30562-30569) found that in yeast theLTP1 gene encodes for an acyltransferase that uses a variety oflysophospholipid species. Together with Slc1, Lpt1p seems to mediate theincorporation of unsaturated acyl chains into the sn-2 position ofphospholipids.

Benghezal et al. (JBC, 2007, 282:30845-30855) show that Slc1p and Slc4pappear to be active not only as 1-acylglycerol-3-phosphateO-acyltransferases but also appear to be involved in fatty acid exchangeat the sn-2-position of mature glycerophospholipids.

A newly discovered human LPCAT (LPCAT3), which has distinct substratepreferences, has been identified (Kazachkov et al., Lipids, 2008,43:895-902). Kazachkov et al. suggest that LPCAT3 is involved inphospholipids remodeling to achieve appropriate membrane lipid fattyacid composition.

Four human MBOATs have been expressed in yeast and two of them, MBOAT5and MBOAT7 have been implicated in arachidonate recycling, thusregulating free arachidonic acid levels and leukotriene synthesis inneutrophils (Gijon et al., JBC, 2008, 283:30235-30245).

Altogether more than 300 different fatty acids are known to occur inseed TG. Chain length may range from less than 8 to over 22 carbons. Theposition and number of double bonds may also be unusual, and hydroxyl,epoxy, or other functional groups can modify the acyl chain. The specialphysical and chemical properties of the unusual plant fatty acids havebeen exploited for centuries. Approximately one-third of all vegetableoil is used for non-food purposes. The ability to transfer genes forunusual fatty acid production from exotic wild species to high yieldingoilcrops is now providing, for example, the ability to produce newrenewable agricultural products (Biochemistry of lipids, lipoproteinsand membranes, ed. D. E. Vance and J. Vance, 1996 Elsevier Science).

Given the acyl-editing activity of the MBOAT protein family of genes, itis of interest to find other plant homologs with similar activities andcharacterize the effect of their expression on seed oil composition.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE DESCRIPTIONS

FIG. 1 illustrates the ω-3/ω-6 fatty acid biosynthetic pathway.

The invention can be more fully understood from the following detaileddescription and the accompanying sequence descriptions, which form apart of this application.

The following sequences comply with 37 C.F.R. §§1.821-1.825(“Requirements for patent applications Containing Nucleotide Sequencesand/or Amino Acid Sequence Disclosures—the Sequence Rules”) and areconsistent with World Intellectual Property Organization (WIPO) StandardST.25 (1998) and the sequence listing requirements of the EPO and PCT(Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of theAdministrative Instructions). The symbols and format used for nucleotideand amino acid sequence data comply with the rules set forth in 37C.F.R. §1.822.

SEQ ID NO:1 corresponds to the cDNA insert sequence from esc1c.pk007.c17(CoMBOAT).

SEQ ID NO:2 corresponds to the ORF encoded by SEQ ID NO:1.

SEQ ID NO:3 corresponds to the amino acid sequence encode by SEQ IDNO:2.

SEQ ID NO:4 corresponds to the amino acid sequence of the MBOAT familyprotein from Vitis vinifera (GI:225426775).

SEQ ID NO:5 corresponds to the amino acid sequence of the MBOAT familyprotein from Arebidopsis thaliana (GI:22329514).

SEQ ID NO:6 corresponds to cDNA insert sequence from fds1n.pk001.k4(McMBOAT).

SEQ ID NO:7 corresponds to the McLPCAT 5Race primer.

SEQ ID NO:8 corresponds to the McLPCATnew1 primer.

SEQ ID NO:9 corresponds to the McMBOAT 5′RACE sequence.

SEQ ID NO:10 corresponds to the McMBOAT full cDNA sequence.

SEQ ID NO:11 corresponds to the ORF encoded by SEQ ID NO:10.

SEQ ID NO:12 corresponds to the amino acid sequence encoded by SEQ IDNO:11.

SEQ ID NO:13 corresponds to the cDNA insert sequence from esc1c.pk002.d16 (CoDGAT2).

SEQ ID NO:14 corresponds to the ORF encoded by SEQ ID NO:13.

SEQ ID NO:15 corresponds to the amino acid sequence encoded by SEQ IDNO:14.

SEQ ID NO:16 corresponds to the hypothetical protein from Vitis vinifera(GI:225431649).

SEQ ID NO:17 corresponds to the amino acid sequence of diacylglycerolacyltransferase from Elaeis oleifera.

SEQ ID NO:18 corresponds to the DNA insert sequence from fds.pk0003.97(McDGAT2).

SEQ ID NO:19 corresponds to the McDGAT2 Race1 primer.

SEQ ID NO:20 corresponds to the McDGAT2 5′Race sequence.

SEQ ID NO:21 corresponds to the McDGAT2 Not5 primer.

SEQ ID NO:22 corresponds to the McDGAT2 Not3 primer.

SEQ ID NO:23 corresponds to the McDGAT2 sequence flanked by NotI sites.

SEQ ID NO:24 corresponds to the full McDGAT2 cDNA sequence.

SEQ ID NO:25 corresponds to the ORF encoded by SEQ ID NO:24.

SEQ ID NO:26 corresponds to the amino acid sequence encoded by SEQ IDNO:25.

SEQ ID NO:27 corresponds to diacylglycerol acyltransferase fromArabidopsis thaliana.

SEQ ID NO:28 corresponds to the nucleotide sequence of vector pHD40.

SEQ ID NO:29 corresponds to the nucleotide sequence of vector pKR1543.

SEQ ID NO:30 corresponds to the gene coding sequence of the Momordicacharantia conjugase (McConj).

SEQ ID NO:31 corresponds to the nucleotide sequence of vector pKR458.

SEQ ID NO:32 corresponds to the McLPCATNOt5 primer.

SEQ ID NO:33 corresponds to the McLPCATNot3 primer.

SEQ ID NO:34 corresponds to the nucleotide sequence of vector pHD41.

SEQ ID NO:35 corresponds to the nucleotide sequence of vector pKR1548.

SEQ ID NO:36 corresponds to the nucleotide sequence of vector pKR1556.

SEQ ID NO:37 corresponds to the nucleotide sequence of vector pKR1562.

SEQ ID NO:38 corresponds to the CoDGAT-5Not primer.

SEQ ID NO:39 corresponds to the CoDGAT-3Not primer.

SEQ ID NO:40 corresponds to the nucleotide sequence of vector pKR1493.

SEQ ID NO:41 corresponds to the nucleotide sequence of the ORF ofCalendula officinalis fatty acid conjugase (CoConj).

SEQ ID NO:42 corresponds to the nucleotide sequence of vector pKR1487.

SEQ ID NO:43 corresponds to the CoLPCAT-5Not primer.

SEQ ID NO:44 corresponds to the CoLPCATNco-3 primer.

SEQ ID NO:45 corresponds to the CoLPCATNco-5 primer.

SEQ ID NO:46 corresponds to the CoLPCAT-3Not primer.

SEQ ID NO:47 corresponds to the nucleotide sequence of CoMBOAT with theNcoI site removed.

SEQ ID NO:48 corresponds to the nucleotide sequence of vector pLF166.

SEQ ID NO:49 corresponds to the nucleotide sequence of vector pKR1492.

SEQ ID NO:50 corresponds to the nucleotide sequence of vector pKR1498.

SEQ ID NO:51 corresponds to the nucleotide sequence of vector pKR1504.

SEQ ID NO:52 corresponds to the nucleotide sequence of vector pKR539.

SEQ ID NO:53 corresponds to the nucleotide sequence of vector pKR1563.

SEQ ID NO:54 corresponds to the nucleotide sequence of vector pKR1564.

SEQ ID NO:55 corresponds to the nucleotide sequence of vector pKR1565.

SEQ ID NO:56 corresponds to the nucleotide sequence of vector pKR1507.

SEQ ID NO:57 corresponds to the nucleotide sequence of vector pKR1508.

SEQ ID NO:58 corresponds to the nucleotide sequence of vector pKR1509.

SEQ ID NO:59 corresponds to the nucleotide sequence of vector pKR1510.

SEQ ID NO:60 corresponds to the nucleotide sequence of vector pKR1561.

SEQ ID NO:61 corresponds to the nucleotide sequence of vector pKR1544.

SEQ ID NO:62 corresponds to the nucleotide sequence of vector pKR1549.

SEQ ID NO:63 corresponds to the nucleotide sequence of vector pKR1546.

SEQ ID NO:64 corresponds to the nucleotide sequence of vector pKR1557.

SEQ ID NO:65 corresponds to the nucleotide sequence of vector pKR1560.

SEQ ID NO:66 corresponds to the nucleotide sequence of vector pKR1545.

SEQ ID NO:67 corresponds to the nucleotide sequence of vector pKR1550.

SEQ ID NO:68 corresponds to the nucleotide sequence of vector pKR1547.

SEQ ID NO:69 corresponds to the nucleotide sequence of vector pKR1558.

SEQ ID NO:70 corresponds to the nucleotide sequence of vector pKR1559.

SEQ ID NO:71 corresponds to the nucleotide sequence of vector pKR1552.

SEQ ID NO:72 corresponds to the nucleotide sequence of vector pKR1554.

SEQ ID NO:73 corresponds to the nucleotide sequence of vector pKR1022.

SEQ ID NO:74 corresponds to the nucleotide sequence of vector pKR1553.

SEQ ID NO:75 corresponds to the nucleotide sequence of vector pKR1555.

SEQ ID NO:76 corresponds to the nucleotide sequence of vector pLF167.

SEQ ID NO:77 corresponds to the nucleotide sequence encoding the fattyacid desaturase (nt1-nt 1149 (STOP)) from Vernonia galamensis.

SEQ ID NO:78 corresponds to the amino acid sequence encoded by SEQ IDNO:77.

SEQ ID NO:79 corresponds to the nucleotide sequence encoding anepoxidase from Vernonia galamensis.

SEQ ID NO:80 corresponds to the amino acid sequence encoded by SEQ IDNO:79.

SEQ ID NO:81 corresponds to the nucleotide sequence encoding the delta-5acyl-CoA desaturase from Limnanthes alba.

SEQ ID NO:82 corresponds to the amino acid sequence encoded by SEQ IDNO:81.

SEQ ID NO:83 corresponds to the nucleotide sequence encoding the fattyacyl-CoA elongase from Limnanthes alba.

SEQ ID NO:84 corresponds to the amino acid sequence encoded by SEQ IDNO:83.

SEQ ID NO:85 corresponds to the nucleotide sequence encoding the aconjugase from Impatiens balsamina.

SEQ ID NO:86 corresponds to the amino acid sequence encoded by SEQ IDNO:85.

SEQ ID NO:87 corresponds to the nucleotide sequence encoding a conjugasefrom Momordica charantia.

SEQ ID NO:88 corresponds to the amino acid sequence encoded by SEQ IDNO:87.

SEQ ID NO:89 corresponds to the nucleotide sequence encoding a conjugasefrom Chrysobalanus icaco.

SEQ ID NO:90 corresponds to the amino acid sequence encoded by SEQ IDNO:89.

SEQ ID NO:91 corresponds to the nucleotide sequence encoding a conjugasefrom Licania michauxii.

SEQ ID NO:92 corresponds to the amino acid sequence encoded by SEQ IDNO:91.

SEQ ID NO:93 corresponds to the nucleotide sequence encoding a conjugasefrom Aleurites fordii.

SEQ ID NO:94 corresponds to the amino acid sequence encoded by SEQ IDNO:93.

SEQ ID NO:95 corresponds to the nucleotide sequence encoding a Class IIconjugase from Aleurites fordii.

SEQ ID NO:96 corresponds to the amino acid sequence encoded by SEQ IDNO:95.

SEQ ID NO:97 corresponds to the amino acid sequence from the hydroxylasefrom Ricinus communis.

SEQ ID NO:98 corresponds to the nucleotide sequence of a conjugase fromCalendula officialis.

SEQ ID NO:99 corresponds to the amino acid sequence encoded by SEQ IDNO:98.

SEQ ID NO:100 corresponds to the nucleotide sequence of a conjugase fromCalendula officialis.

SEQ ID NO:101 corresponds to the amino acid sequence encoded by SEQ IDNO:100.

SEQ ID NO:102 corresponds to the nucleotide sequence of a conjugase fromDimorphotheca sinuata.

SEQ ID NO:103 corresponds to the amino acid sequence encoded by SEQ IDNO:102.

SEQ ID NO:104 corresponds to the nucleotide sequence of a conjugase fromDimorphotheca sinuata.

SEQ ID NO:105 corresponds to the amino acid sequence encoded by SEQ IDNO:104.

SEQ ID NO:106 corresponds to the nucleotide sequence of vector pKR272.

SEQ ID NO:107 corresponds to the nucleotide sequence of vector pKR278.

SEQ ID NO:108 corresponds to the forward primer RcHydroxy-5.

SEQ ID NO:109 corresponds to the reverse primer RcHydroxy-3.

SEQ ID NO:110 corresponds to the nucleotide sequence of vector pLF241.

SEQ ID NO:111 corresponds to the nucleotide sequence of vector pKR1687.

SEQ ID NO:112 corresponds to the nucleotide sequence of vector pKR1742.

SEQ ID NO:113 corresponds to the nucleotide sequence of vector pKR1733.

SEQ ID NO:114 corresponds to the nucleotide sequence of vector pKR1745.

SEQ ID NO:115 corresponds to the nucleotide sequence of vector pKR966.

SEQ ID NO:116 corresponds to the nucleotide sequence of vector pKR1542.

SEQ ID NO:117 corresponds to the nucleotide sequence of vector pKR1743.

SEQ ID NO:118 corresponds to the nucleotide sequence of vector pKR1734.

SEQ ID NO:119 corresponds to the nucleotide sequence of vector pKR1746.

SEQ ID NO:120 corresponds to the GmMBOAT1 genomic sequence.

SEQ ID NO:121 corresponds to the GmMBOAT1 coding sequence.

SEQ ID NO:122 corresponds to the GmMBOAT1 amino acid sequence.

SEQ ID NO:123 corresponds to the GmMBOAT2 genomic sequence.

SEQ ID NO:124 corresponds to the GmMBOAT2 coding sequence.

SEQ ID NO:125 corresponds to the GmMBOAT2 amino acid sequence.

SEQ ID NO:126 corresponds to the GmLPCAT1-5 primer.

SEQ ID NO:127 corresponds to the GmLPCAT1-3 primer.

SEQ ID NO:128 corresponds to the nucleotide sequence of vector pLF164.

SEQ ID NO:129 corresponds to the GmLPCAT2-5 primer.

SEQ ID NO:130 corresponds to the nucleotide sequence of vector pLF165.

SEQ ID NO:131 corresponds to the nucleotide sequence of vector pKR1813.

SEQ ID NO:132 corresponds to the nucleotide sequence of vector pKR1814.

SEQ ID NO:133 corresponds to the nucleotide sequence of vector pKR1821.

SEQ ID NO:134 corresponds to the nucleotide sequence of vector pKR1822.

SEQ ID NO:135 corresponds to the cDNA insert sequence fromeel1c.pk002.h9 (EuphMBOAT).

SEQ ID NO:136 corresponds to the ORF encoded by SEQ ID NO:135.

SEQ ID NO:137 corresponds to the amino acid sequence encoded by SEQ IDNO:136.

SEQ ID NO:138 corresponds to the EIMBOAT-5Not primer.

SEQ ID NO:139 corresponds to the oEU mb-2 primer.

SEQ ID NO:140 corresponds to the nucleotide sequence of vector pKR1823.

SEQ ID NO:141 corresponds to the nucleotide sequence of vector pKR1827.

SEQ ID NO:142 corresponds to the nucleotide sequence of vector pKR1836.

SEQ ID NO:143 corresponds to the nucleotide sequence of vector pKR1815.

SEQ ID NO:144 corresponds to the nucleotide sequence of vector pKR1835.

SEQ ID NO:145 corresponds to the nucleotide sequence of vector pKR1203.

SEQ ID NO:146 corresponds to the nucleotide sequence of vector pHD1.

SEQ ID NO:147 corresponds to the nucleotide sequence of vector pKR1645.

SEQ ID NO:148 corresponds to the nucleotide sequence of vector pKR1646.

SEQ ID NO:149 corresponds to the nucleotide sequence of vector pKR1649.

SEQ ID NO:150 corresponds to the nucleotide sequence of vector pKR1650.

SEQ ID NO:151 corresponds to the nucleotide sequence of vector pKR1818.

SEQ ID NO:152 corresponds to the nucleotide sequence of vector pKR1826,

SEQ ID NO:153 corresponds to the nucleotide sequence of vector pKR1844.

SEQ ID NO:154 corresponds to the nucleotide sequence of vector pKR1671.

SEQ ID NO:155 corresponds to the nucleotide sequence of vector pKR1672.

SEQ ID NO:156 corresponds to the nucleotide sequence of vector pKR1673.

SEQ ID NO:157 corresponds to the nucleotide sequence of vector pKR1674.

SEQ ID NO:158 corresponds to the nucleotide sequence of vector pKR1845.

SUMMARY OF THE INVENTION

The present invention concerns an isolated polynucleotide comprising:

-   -   (a) a nucleotide sequence encoding a polypeptide with MBOAT        activity, wherein, based on the Clustal V method of alignment        with pairwise alignment default parameters of KTUPLE=1, GAP        PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5, the polypeptide has        an amino acid sequence of at least 80% sequence identity when        compared to SEQ ID NO:3, 12, 123, 126, or 137; or    -   (b) the full complement of the nucleotide sequence of (a).

In a second embodiment the present invention concerns an isolatedpolynucleotide comprising:

-   -   (a) a nucleotide sequence encoding a polypeptide with DGAT        activity, wherein, based on the Clustal V method of alignment        with pairwise alignment default parameters of KTUPLE=1, GAP        PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5, the polypeptide has        an amino acid sequence of at least 80% sequence identity when        compared to SEQ ID NO:15 or 26; or    -   (b) the full complement of the nucleotide sequence of (a).

In a third embodiment, the invention concerns a recombinant DNAconstruct comprising any of the isolated polynucleotides of theinvention operably linked to at least one regulatory sequence.

In a fourth embodiment, the present invention concerns a cell comprisingin its genome the recombinant DNA construct of the invention. Such cellscan be plant cells, microbial cells or yeast cells.

In a fifth embodiment, the invention concerns a method for transforminga cell, comprising transforming a cell with a recombinant construct ofthe invention or an isolated polynucleotide of the invention andselecting those cells transformed with the recombinant construct or theisolated polynucleotide.

In a sixth embodiment, the invention concerns transgenic seed comprisingin its genome the recombinant construct of the invention or a transgenicseed obtained from a plant made by a method of the invention. Also ofinterest is oil or by-products obtained from such transgenic seeds.

In a seventh embodiment, the invention concerns a method for increasingthe content of at least one unusual fatty acid in an oilseed plant cellcomprising:

-   -   (a) transforming the oilseed plant cell with:        -   (i) any of the recombinant constructs of the invention; and        -   (ii) at least one additional recombinant construct            comprising an isolated polynucleotide, operably linked to at            least one regulatory sequence, encoding a polypeptide            selected from the group consisting of a delta-4 desaturase,            a delta-5 desaturase, a delta-6 desaturase, a delta-8            desaturase, a delta-12 desaturase, a delta-15 desaturase, a            delta-17 desaturase, a delta-9 desaturase, a delta-9            elongase, a C14/16 elongase, a C16/18 elongase, a C18/20            elongase, a C20/22 elongase, a DGAT, an MBOAT, a fatty acid            conjugase, a hydroxylase, an acetylenase, an epoxidase and a            multizyme;    -   (b) regeneating an oilseed plant from the transformed cell of        step (a); and    -   (c) selecting those seeds obtained from the plants of step (b)        having an increased level of at least one unusual fatty acid        when compared to the level in seeds obtained from a transgenic        plant comprising at least one recombinant construct comprising        an isolated polynucleotide, operably linked to at least one        regulatory sequence, encoding a polypeptide selected from the        group consisting of a delta-4 desaturase, a delta-5 desaturase,        a delta-6 desaturase, a delta-8 desaturase, a delta-12        desaturase, a delta-15 desaturase, a delta-17 desaturase, a        delta-9 desaturase, a delta-9 elongase, a C14/16 elongase, a        C16118 elongase, a C18/20 elongase, a C20/22 elongase, a DGAT,        an MBOAT, a fatty acid conjugase, a hydroxylase, an acetylenase,        an epoxidase and a multizyme.

In an eighth embodiment the invention concerns a method for increasingat least one conversion efficiency, wherein said conversion efficiencyis at least one selected from the group consisting of: C₁₈ to C₂₀elongation, delta-6 desaturation, the delta-9 elongation, delta-8desaturation, conjugation to Eleostearic acid and conjugation toCalendic acid, in an oilseed plant cell comprising:

-   -   (a) transforming the oilseed plant cell with:        -   (i) any of the recombinant constructs of the invention; and        -   (ii) at least one additional recombinant construct            comprising an isolated polynucleotide, operably linked to at            least one regulatory sequence, encoding a polypeptide            selected from the group consisting of a delta-4 desaturase,            a delta-5 desaturase, a delta-6 desaturase, a delta-8            desaturase, a delta-12 desaturase, a delta-15 desaturase, a            delta-17 desaturase, a delta-9 desaturase, a delta-9            elongase, a C14/16 elongase, a C16/18 elongase, a C18/20            elongase, a C20/22 elongase, a DGAT, an MBOAT, a fatty acid            conjugase, a hydroxylase, an acetylenase, an epoxidase and a            multizyme;    -   (b) regeneating an oilseed plant from the transformed cell of        step (a); and    -   (c) selecting those seeds obtained from the plants of step (b)        having an increased C₁₈ to C₂₀ elongation conversion efficiency        and an increased delta-6 desaturation conversion efficiency when        compared to the level in seeds obtained from a transgenic plant        comprising at least one recombinant construct comprising an        isolated polynucleotide, operably linked to at least one        regulatory sequence, encoding a polypeptide selected from the        group consisting of a delta-4 desaturase, a delta-5 desaturase,        a delta-6 desaturase, a delta-8 desaturase, a delta-12        desaturase, a delta-15 desaturase, a delta-17 desaturase, a        delta-9 desaturase, a delta-9 elongase, a C14/16 elongase, a        C16/18 elongase, a C18120 elongase and a C20/22 elongase, a        DGAT, an MBOAT, a fatty acid conjugase, a hydroxylase, an        acetylenase, an epoxidase and a multizyme.

In a ninth embodiment the invention concerns a method wherein the C₁ toC₂₀ elongation conversion efficiency is increased at least 1.1-fold andthe delta-6 desaturation conversion efficiency is increased at least2-fold; or the delta-9 elongation conversion efficiency is increased byat least 1.1-fold and the delta-8 desaturation conversion efficiency isincreased by at least 1.2-fold; or the conjugation conversion efficiencyto Eleostearic acid is at least 1.2-fold; or the conjugation conversionefficiency to Calendic acid is at least 2.5-fold.

The invention further concerns methods for the production of increasedlevels of unusual fatty acids, wherein the unusual fatty acid include,but are not limited to, GLA, STA, EDA, ERA, DGLA, ETA, ELEO and CAL.

In another embodiment, the invention concerns an oilseed plantcomprising in its genome the recombinant construct(s) of the invention.Suitable oilseed plants include, but are not limited to, soybean,Brassica species, sunflower, maize, cotton, flax, and safflower.

Also of interest are transgenic seeds and progeny plants obtained fromsuch oilseed plants as well as oil or by-products obtained from thesetransgenic seeds.

In yet another embodiment, the invention concerns food or feedincorporating an oil or seed of the invention or food or feed comprisingan ingredient derived from the processing of the seeds.

DETAILED DESCRIPTION OF THE INVENTION

The disclosure of each reference set forth herein is hereby incorporatedby reference in its entirety.

As used herein and in the appended claims, the singular forms “a”, “an”,and “the” include plural reference unless the context clearly dictatesotherwise. Thus, for example, reference to “a plant” includes aplurality of such plants, reference to “a cell” includes one or morecells and equivalents thereof known to those skilled in the art, and soforth.

In the context of this disclosure, a number of terms and abbreviationsare used. The following definitions are provided.

“Open reading frame” is abbreviated ORF.

“Polymerase chain reaction” is abbreviated PCR.

“American Type Culture Collection” is abbreviated ATCC.

Acyl-CoA:sterol-acyltransferase” is abbreviated ARE2.

“Phospholipid:diacylglycerol acyltransferase” is abbreviated PDAT.

“Diacylglycerol acyltransferase” is abbreviated DAG AT or DGAT.

“Diacylglycerol” is abbreviated DAG.

“Triacylglycerol(s)” are abbreviated TAG(s) or TG(s).

“Co-enzyme A” is abbreviated CoA.

“Membrane membrane bound O-acyl transferase” is abbreviated MBOAT.

“Polyunsaturated fatty acid(s)” is abbreviated PUFA(s).

The term “fatty acids” refers to long chain aliphatic acids (alkanoicacids) of varying chain length, from about C₁₂ to C₂₂ (although bothlonger and shorter chain-length acids are known). The predominant chainlengths are between C₁₆ and C₂₂. The structure of a fatty acid isrepresented by a simple notation system of “X:Y”, where X is the totalnumber of carbon (C) atoms in the particular fatty acid and Y is thenumber of double bonds.

Generally, fatty acids are classified as saturated or unsaturated. Theterm “saturated fatty acids” refers to those fatty acids that have no“double bonds” between their carbon backbone. In contrast, “unsaturatedfatty acids” have “double bonds” along their carbon backbones (which aremost commonly in the cis-configuration). “Monounsaturated fatty acids”have only one “double bond” along the carbon backbone (e.g., usuallybetween the 9^(th) and 10^(th) carbon atom as for palmitoleic acid(16:1) and oleic acid (18:1)), while “polyunsaturated fatty acids” (or“PUFAs”) have at least two double bonds along the carbon backbone (e.g.,between the 9^(th) and 10^(th), and 12^(th) and 13^(th) carbon atoms forlinoleic acid (18:2); and between the 9^(th) and 10^(th), 12^(th) and13^(th) and 15^(th) and 16^(th) for α-linolenic acid (18:3)).

The term “unusual fatty acid(s)” refers to fatty acids that deviate fromthe norm due to differences in chain length (i.e. greater than 18carbons, shorter than 14 carbons), position, or number of double bonds(i.e., polyunsaturated), or due to the presence of modifications otherthan simple double bonds (i.e. hydroxylation, acetylation, epoxy groupsetc.) and includes, but is not limited to, the fatty acids listed inTable 1.

TABLE 1 Crepenynic N/A* cis-9-octadecen-12-ynoic 18:2 DehydroerepenynicN/A* cis-9,14-octadecadien-12-ynoic 18:3 Linoleic LAcis-9,12-octadecadienoic 18:2 Eicosadienoic EDA cis-11,14-eicosadienoic20:2 Gamma-linolenic GLA cis-6,9,12-octadecatrienoic 18:3 Dihomo-γ- DGLAcis-8,11,14-eicosatrienoic 20:3 Linolenic Sciadonic SCIcis-5,11,14-eicosatrienoic  20:3b Arachidonic ARAcis-5,8,11,14-eicosatetraenoic 20:4 Alpha-linolenic ALAcis-9,12,15-octadecatrienoic 18:3 Stearidonic STA cis-6,9,12,15- 18:4octadecatetraenoic Eicosenoic N/A* cis-5 eicosenoic 20:1 EicosatrienoicETrA or cis-11,14,17-eicosatrienoic 20:3 ERA Eicosa-tetraenoic ETAcis-8,11,14,17-eicosatetraenoic 20:4 Juniperonic JUPcis-5,11,14,17-eicosatrienoic  20:4b Eicosa-pentaenoic EPAcis-5,8,11,14,17- 20:5 eicosapentaenoic Docosatrienoic DRAcis-10,13,16-docosatrienoic 22:3 Docosa-tetraenoic DTAcis-7,10,13,16-docosatetraenoic 22:4 Docosa-pentaenoic DPAn-6cis-4,7,10,13,16- 22:5 docosapentaenoic Docosa-pentaenoic DPAcis-7,10,13,16,19- 22:5 docosapentaenoic Docosa-hexaenoic DMAcis-4,7,10,13,16,19- 22:6 docosahexaenoic Alpha-eleostearic ELEO cis-9,trans-11, trans-13 18:3 octadecatrienoic Dimorphecolic DM hydroxy-9,trans-10, trans-12 18:2 octadecadienoic Calendic CAL trans-8, trans-10,cis-12 18:3 octadecatrienoic Alpha-parinaric PAR cis-9, trans-11,trans-13, cis-15 18:4 octadecatetraenoic Ricinoleic N/A* Hydroxy-12,cis-9 octadecenoic 18:1 Petroselinic N/A* cis-6 octadecenoic 18:1Vernolic N/A* Epoxy-9, trans-12 octadecenoic 18:1 *not available

“Desaturase” is a polypeptide that can desaturate, i.e., introduce adouble bond, in one or more fatty acids to produce a fatty acid orprecursor of interest. Despite use of the omega-reference systemthroughout the specification to refer to specific fatty acids, it ismore convenient to indicate the activity of a desaturase by countingfrom the carboxyl end of the substrate using the delta-system. Forexample delta-8 desaturases will desaturate a fatty acid between theeighth and ninth carbon atom numbered from the carboxyl-terminal end ofthe molecule and can, for example, catalyze the conversion of EDA toDGLA and/or ETrA to ETA. Other useful fatty acid desaturases include,for example: (1) delta-5 desaturases that catalyze the conversion ofDGLA to ARA and/or ETA to EPA; (2) delta-6 desaturases that catalyze theconversion of LA to GLA and/or ALA to STA; (3) delta-4 desaturases thatcatalyze the conversion of DPA to DHA; (4) delta-12 desaturases thatcatalyze the conversion of oleic acid to LA; (5) delta-15 desaturasesthat catalyze the conversion of LA to ALA and/or GLA to STA; (6)delta-17 desaturases that catalyze the conversion of ARA to EPA and/orDGLA to ETA; and (7) delta-9 desaturases that catalyze the conversion ofpalmitic acid to palmitoleic acid (16:1) and/or stearic acid to oleicacid (18:1). In the art, delta-15 and delta-17 desaturases are alsooccasionally referred to as “omega-3 desaturases”, “ω-3 desaturases”,and/or “ω-3 desaturases”, based on their ability to convert omega-6fatty acids into their omega-3 counterparts (e.g., conversion of LA intoALA and ARA into EPA, respectively). In some embodiments, it is mostdesirable to empirically determine the specificity of a particular fattyacid desaturase by transforming a suitable host with the gene for thefatty acid desaturase and determining its effect on the fatty acidprofile of the host.

In addition to the desaturases, of particular interest herein are plantfatty acid modifying enzymes that can produce any of the “unusual fattyacids” described above.

The term “PUFA biosynthetic pathway” refers to a metabolic process thatconverts oleic acid to LA, EDA, GLA, DGLA, ARA, ALA, STA, ETrA (ERA),ETA, EPA, DPA and DHA. This process is well described in the literature(e.g., see PCT Publication No. WO 2006/052870). Simplistically, thisprocess involves elongation of the carbon chain through the addition ofcarbon atoms and desaturation of the molecule through the addition ofdouble bonds, via a series of special desaturation and elongationenzymes (i.e., “PUFA biosynthetic pathway enzymes”) present in theendoplasmic reticulim membrane. More specifically, “PUFA biosyntheticpathway enzyme” refers to any of the following enzymes (and genes whichencode said enzymes) associated with the biosynthesis of a PUFA,including: a delta-4 desaturase, a delta-5 desaturase, a delta-6desaturase, a delta-12 desaturase, a delta-15 desaturase, a delta-17desaturase, a delta-9 desaturase, a delta-8 desaturase, a delta-9elongase, a C_(14/16) elongase, a C_(16/18) elongase, a C_(18/20)elongase and/or a C_(20/22) elongase.

The term “elongase system” refers to a suite of four enzymes that areresponsible for elongation of a fatty acid carbon chain to produce afatty acid that is two carbons longer than the fatty acid substrate thatthe elongase system acts upon. More specifically, the process ofelongation occurs in association with fatty acid synthase, whereby CoAis the acyl carrier (Lassner et al., Plant Cell 8:281-292 (1996)). Inthe first step, which has been found to be both substrate-specific andalso rate-limiting, malonyl-CoA is condensed with a long-chain acyl-CoAto yield carbon dioxide (CO₂) and a b-ketoacyl-CoA (where the acylmoiety has been elongated by two carbon atoms). Subsequent reactionsinclude reduction to b-hydroxyacyl-CoA, dehydration to an enoyl-CoA anda second reduction to yield the elongated acyl-CoA. Examples ofreactions catalyzed by elongase systems are the conversion of GLA toDGLA, STA to ETA, LA to EDA, ALA to ETRA and EPA to DPA.

The term “fatty acid conjugase” in the context of this invention refersto an enzyme that catalyzes the introduction into a fatty acid of atleast two double bonds separated by a single bond. Examples of fattyacid conjugases include, but are not limited to: SEQ ID NO: 86, 88, 90,92, 94, 96, 99, 101, 103, and 105.

The term “acetylenase” in the context of this invention refers to anenzyme that facilitates the introduction of a triple bond into a fattyacid. Examples of acetylenases include, but are not limited to thesequence from Crepins alpine with NCBI General IdentificationNo.:17366029.

The term “hydroxylase” in the context of this invention refers to anenzyme that facilitates the introduction of one or more hydroxyl groupsinto a compound (e.g. fatty acid) thereby oxidizing it. An examples of ahydroxylase includes, but is not limited to: SEQ ID NO:97.

The term “epoxidase” in the context of this invention refers to anenzyme that catalyzes the insertion of an oxygen molecule into acarbon-carbon double bond to form an epoxide. An example of anexpoxidase includes, but is not limited to: SEQ ID NO:80.

The term “multizyme” in the context of this invention refers to a singlepolypeptide having at least two independent and separable enzymaticactivities, wherein the at least two activities are selected from thegroup consisting of: delta-4 desaturase, a delta-5 desaturase, a delta-6desaturase, a delta-8 desaturase, a delta-12 desaturase, a delta-15desaturase, a delta-17 desaturase, a delta-9 desaturase, a delta-9elongase, a C14/16 elongase, a C16/18 elongase, a C18/20 elongase, aC20/22 elongase, a DGAT, a MBOAT, a fatty acid conjugase, a hydroxylase,an acetylenase, and an epoxidase activity. Preferably, the multizymecomprises a first enzymatic activity linked to a second enzymaticactivity.

The term “fusion protein” is used interchangeably with the term“multizyme”. Thus, a “fusion protein” refers to a single polypeptidehaving at least two independent and separable enzymatic activities.

The term “fusion gene” refers to a polynucleotide or gene that encodes amultizyme. A fusion gene can be constructed by linking at least two DNAfragments, wherein each DNA fragment encodes for an independent andseparate enzyme activity. An example of a fusion gene has been describedin Published U.S. Patent Application No. 2008/0254191, in which a fusiongene was constructed by linking a delta-9 elongase (D9Elo) and a delta-8desaturase using a linker. Similarly fusion genes can be constructed byone skilled in the art with at least two of the polypeptides selectedfrom the group consisting of: delta-4 desaturase, a delta-5 desaturase,a delta-6 desaturase, a delta-8 desaturase, a delta-12 desaturase, adelta-15 desaturase, a delta-17 desaturase, a delta-9 desaturase, adelta-9 elongase, a C14/16 elongase, a C16/18 elongase, a C18/20elongase, a C20/22 elongase, a DGAT, a MBOAT, a fatty acid conjugase, ahydroxylase and an epoxidase.

One skilled in the art will be able to identify various candidate genesencoding each of the enzymes desired. Useful desaturase and elongasesequences may be derived from any source, e.g., isolated from a naturalsource (from bacteria, algae, fungi, plants, animals, etc.), producedvia a semi-synthetic route or synthesized de novo. Although theparticular source of the desaturase and elongase genes introduced intothe host is not critical, considerations for choosing a specificpolypeptide having desaturase or elongase activity include: (1) thesubstrate specificity of the polypeptide; (2) whether the polypeptide ora component thereof is a rate-limiting enzyme; (3) whether thedesaturase or elongase is essential for synthesis of a desired PUFA;and/or (4) co-factors required by the polypeptide. The expressedpolypeptide preferably has parameters compatible with the biochemicalenvironment of its location in the host cell (see PCT Publication No. WO2004/101757 for additional details).

In additional embodiments, it will also be useful to consider theconversion efficiency of each particular desaturase and/or elongase.More specifically, since each enzyme rarely functions with 100%efficiency to convert substrate to product, the final lipid profile ofunpurified oils produced in a host cell will typically be a mixture ofvarious PUFAs consisting of the desired omega-3/omega-6 fatty acid, aswell as various upstream intermediary PUFAs. Thus, consideration of eachenzyme's conversion efficiency is also a variable when optimizingbiosynthesis of a desired fatty acid that must be considered in light ofthe final desired lipid profile of the product.

With each of the considerations above in mind, candidate genes havingthe appropriate desaturase and elongase activities (e.g., delta-6desaturases, C_(18/20) elongases, delta-5 desaturases, delta-17desaturases, delta-15 desaturases, delta-9 desaturases, delta-12desaturases, C_(14/16) elongases, C_(16/18) elongases, delta-9elongases, delta-8 desaturases, delta-4 desaturases and C_(20/22)elongases) can be identified according to publicly available literature(e.g., GenBank), the patent literature, and experimental analysis oforganisms having the ability to produce PUFAs. These genes will besuitable for introduction into a specific host organism, to enable orenhance the organism's synthesis of PUFAs.

The terms “conversion efficiency” and “percent substrate conversion”refer to the efficiency by which a particular enzyme (e.g., adesaturase) can convert substrate to product. The conversion efficiencyis measured according to the following formula:([product]/[substrate+product])*100, where ‘product’ includes theimmediate product and all products in the pathway derived from it.

“Microbial oils” or “single cell oils” are those oils naturally producedby microorganisms (e.g., algae, oleaginous yeasts and filamentous fungi)during their lifespan. The term “oil” refers to a lipid substance thatis liquid at 25° C. and usually polyunsaturated. In contrast, the term“fat” refers to a lipid substance that is solid at 25° C. and usuallysaturated.

“Lipid bodies” refer to lipid droplets that usually are bounded byspecific proteins and a monolayer of phospholipid. These organelles aresites where most organisms transport/store neutral lipids. Lipid bodiesare thought to arise from microdomains of the endoplasmic reticulum thatcontain TAG-biosynthesis enzymes, and their synthesis and size appear tobe controlled by specific protein components.

“Neutral lipids” refer to those lipids commonly found in cells in lipidbodies as storage fats and oils and are so called, because at cellularpH, the lipids bear no charged groups. Generally, they are completelynon-polar with no affinity for water. Neutral lipids generally refer tomono-, di-, and/or triesters of glycerol with fatty acids, also calledmonoacylglycerol, diacylglycerol or TAG, respectively (or collectively,acylglycerols). A hydrolysis reaction must occur to release free fattyacids from acylglycerols.

The terms “triacylglycerol”, “oil” and “TAGs” refer to neutral lipidscomposed of three fatty acyl residues esterified to a glycerol molecule(and such terms will be used interchangeably throughout the presentdisclosure herein). Such oils can contain long chain PUFAs, as well asshorter saturated and unsaturated fatty acids and longer chain saturatedfatty acids. Thus, “oil biosynthesis” generically refers to thesynthesis of TAGs in the cell.

The term “DAG AT” or “DGAT” refers to a diacylglycerol acyltransferase(also known as an acyl-CoA-diacylglycerol acyltransferase or adiacylglycerol O-acyltransferase) (EC 2.3.1.20). This enzyme isresponsible for the conversion of acyl-CoA and 1,2-diacylglycerol to TAGand CoA (thereby involved in the terminal step of TAG biosynthesis). Twofamilies of DAG AT enzymes exist: DGAT1 and DGAT2. The former familyshares homology with the acyl-CoA:cholesterol acyltransferase (ACAT)gene family, while the latter family is unrelated (Lardizabal et al., J.Biol. Chem. 276(42):38862-28869 (2001)).

The term “MBOAT” refers to membrane bound O-acyltransferase family ofproteins.

As used herein, “nucleic acid” means a polynucleotide and includessingle or double-stranded polymer of deoxyribonucleotide orribonucleotide bases. Nucleic acids may also include fragments andmodified nucleotides. Thus, the terms “polynucleotide”, “nucleic acidsequence”, “nucleotide sequence” or “nucleic acid fragment” are usedinterchangeably and is a polymer of RNA or DNA that is single- ordouble-stranded, optionally containing synthetic, non-natural or alterednucleotide bases. Nucleotides (usually found in their 5′-monophosphateform) are referred to by their single letter designation as follows: “A”for adenylate or deoxyadenylate (for RNA or DNA, respectively), “C” forcytidylate or deosycytidylate, “G” for guanylate or deoxyguanylate, “U”for uridlate, “T” for deosythymidylate, “R” for purines (A or G), “Y”for pyrimidiens (C or T), “K” for G or T, “H” for A or C or T, “I” forinosine, and “N” for any nucleotide.

The terms “subfragment that is functionally equivalent” and“functionally equivalent subfragment” are used interchangeably herein.These terms refer to a portion or subsequence of an isolated nucleicacid fragment in which the ability to alter gene expression or produce acertain phenotype is retained whether or not the fragment or subfragmentencodes an active enzyme. For example, the fragment or subfragment canbe used in the design of chimeric genes to produce the desired phenotypein a transformed plant. Chimeric genes can be designed for use insuppression by linking a nucleic acid fragment or subfragment thereof,whether or not it encodes an active enzyme, in the sense or antisenseorientation relative to a plant promoter sequence.

The term “conserved domain” or “motif” means a set of amino acidsconserved at specific positions along an aligned sequence ofevolutionarily related proteins. While amino acids at other positionscan vary between homologous proteins, amino acids that are highlyconserved at specific positions indicate amino acids that are essentialin the structure, the stability, or the activity of a protein. Becausethey are identified by their high degree of conservation in alignedsequences of a family of protein homologues, they can be used asidentifiers, or “signatures”, to determine if a protein with a newlydetermined sequence belongs to a previously identified protein family.

The terms “homology”, “homologous”, “substantially similar” and“corresponding substantially” are used interchangeably herein. Theyrefer to nucleic acid fragments wherein changes in one or morenucleotide bases do not affect the ability of the nucleic acid fragmentto mediate gene expression or produce a certain phenotype. These termsalso refer to modifications of the nucleic acid fragments of the instantinvention such as deletion or insertion of one or more nucleotides thatdo not substantially alter the functional properties of the resultingnucleic acid fragment relative to the initial, unmodified fragment. Itis therefore understood, as those skilled in the art will appreciate,that the invention encompasses more than the specific exemplarysequences.

Moreover, the skilled artisan recognizes that substantially similarnucleic acid sequences encompassed by this invention are also defined bytheir ability to hybridize (under moderately stringent conditions, e.g.,0.5×SSC, 0.1% SDS, 60° C.) with the sequences exemplified herein, or toany portion of the nucleotide sequences disclosed herein and which arefunctionally equivalent to any of the nucleic acid sequences disclosedherein. Stringency conditions can be adjusted to screen for moderatelysimilar fragments, such as homologous sequences from distantly relatedorganisms, to highly similar fragments, such as genes that duplicatefunctional enzymes from closely related organisms. Post-hybridizationwashes determine stringency conditions.

The term “selectively hybridizes” includes reference to hybridization,under stringent hybridization conditions, of a nucleic acid sequence toa specified nucleic acid target sequence to a detectably greater degree(e.g., at least 2-fold over background) than its hybridization tonon-target nucleic acid sequences and to the substantial exclusion ofnon-target nucleic acids. Selectively hybridizing sequences typicallyhave about at least 80% sequence identity, or 90% sequence identity, upto and including 100% sequence identity (i.e., fully complementary) witheach other.

The term “stringent conditions” or “stringent hybridization conditions”includes reference to conditions under which a probe will selectivelyhybridize to its target sequence. Stringent conditions aresequence-dependent and will be different in different circumstances. Bycontrolling the stringency of the hybridization and/or washingconditions, target sequences can be identified which are 100%complementary to the probe (homologous probing). Alternatively,stringency conditions can be adjusted to allow some mismatching insequences so that lower degrees of similarity are detected (heterologousprobing). Generally, a probe is less than about 1000 nucleotides inlength, optionally less than 500 nucleotides in length.

Typically, stringent conditions will be those in which the saltconcentration is less than about 1.5 M Na ion, typically about 0.01 to1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and thetemperature is at least about 30° C. for short probes (e.g., 10 to 50nucleotides) and at least about 60° C. for long probes (e.g., greaterthan 50 nucleotides). Stringent conditions may also be achieved with theaddition of destabilizing agents such as formamide. Exemplary lowstringency conditions include hybridization with a buffer solution of 30to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37° C.,and a wash in 1× to 2×SSC (20×SSC=3.0 M NaCl/0.3 M trisodium citrate) at50 to 55° C. Exemplary moderate stringency conditions includehybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at 37° C., and awash in 0.5× to 1×SSC at 55 to 60° C. Exemplary high stringencyconditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at37° C., and a wash in 0.1×SSC at 60 to 65° C.

Specificity is typically the function of post-hybridization washes, thecritical factors being the ionic strength and temperature of the finalwash solution. For DNA-DNA hybrids, the T_(m) can be approximated fromthe equation of Meinkoth et al., Anal. Biochem. 138:267-284 (1984):T_(m)=81.5° C.+16.6 (log M)+0.41 (% GC)−0.61 (% form)−500/L; where M isthe molarity of monovalent cations, % GC is the percentage of guanosineand cytosine nucleotides in the DNA, % form is the percentage offormamide in the hybridization solution, and L is the length of thehybrid in base pairs. The T_(m) is the temperature (under defined ionicstrength and pH) at which 50% of a complementary target sequencehybridizes to a perfectly matched probe. T_(m) is reduced by about 1° C.for each 1% of mismatching; thus, T_(m), hybridization and/or washconditions can be adjusted to hybridize to sequences of the desiredidentity. For example, if sequences with ≧90% identity are sought, theT_(m) can be decreased 10° C. Generally, stringent conditions areselected to be about 5° C. lower than the thermal melting point (T_(m))for the specific sequence and its complement at a defined ionic strengthand pH. However, severely stringent conditions can utilize ahybridization and/or wash at 1, 2, 3, or 4° C. lower than the thermalmelting point (T_(m)); moderately stringent conditions can utilize ahybridization and/or wash at 6, 7, 8, 9, or 10° C. lower than thethermal melting point (T_(m)); low stringency conditions can utilize ahybridization and/or wash at 11, 12, 13, 14, 15, or 20° C. lower thanthe thermal melting point (T_(m)). Using the equation, hybridization andwash compositions, and desired T_(m), those of ordinary skill willunderstand that variations in the stringency of hybridization and/orwash solutions are inherently described. If the desired degree ofmismatching results in a T_(m) of less than 45° C. (aqueous solution) or32° C. (formamide solution) it is preferred to increase the SSCconcentration so that a higher temperature can be used. An extensiveguide to the hybridization of nucleic acids is found in Tijssen,Laboratory Techniques in Biochemistry and MolecularBiology—Hybridization with Nucleic Acid Probes, Part I, Chapter 2“Overview of principles of hybridization and the strategy of nucleicacid probe assays”, Elsevier, N.Y. (1993); and Current Protocols inMolecular Biology, Chapter 2, Ausubel et al., Eds., Greene Publishingand Wiley-Interscience, New York (1995). Hybridization and/or washconditions can be applied for at least 10, 30, 60, 90, 120, or 240minutes.

“Sequence identity” or “identity” in the context of nucleic acid orpolypeptide sequences refers to the nucleic acid bases or amino acidresidues in two sequences that are the same when aligned for maximumcorrespondence over a specified comparison window. Thus, “percentage ofsequence identity” refers to the value determined by comparing twooptimally aligned sequences over a comparison window, wherein theportion of the polynucleotide or polypeptide sequence in the comparisonwindow may comprise additions or deletions (i.e., gaps) as compared tothe reference sequence (which does not comprise additions or deletions)for optimal alignment of the two sequences. The percentage is calculatedby determining the number of positions at which the identical nucleicacid base or amino acid residue occurs in both sequences to yield thenumber of matched positions, dividing the number of matched positions bythe total number of positions in the window of comparison andmultiplying the results by 100 to yield the percentage of sequenceidentity. Useful examples of percent sequence identities include, butare not limited to, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%,or any integer percentage from 50% to 100%. These identities can bedetermined using any of the programs described herein.

Sequence alignments and percent identity or similarity calculations maybe determined using a variety of comparison methods designed to detecthomologous sequences including, but not limited to, the MegAlign™program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.,Madison, Wis.). Within the context of this application it will beunderstood that where sequence analysis software is used for analysis,that the results of the analysis will be based on the “default values”of the program referenced, unless otherwise specified. As used herein“default values” will mean any set of values or parameters thatoriginally load with the software when first initialized.

The “Clustal V method of alignment” corresponds to the alignment methodlabeled Clustal V (described by Higgins and Sharp, CABIOS. 5:151-153(1989); Higgins, D. G. et al. (1992) Comput. Appl. Biosci. 8:189-191)and found in the MegAlign™ program of the LASERGENE bioinformaticscomputing suite (DNASTAR Inc., Madison, Wis.). For multiple alignments,the default values correspond to GAP PENALTY=10 and GAP LENGTHPENALTY=10. Default parameters for pairwise alignments and calculationof percent identity of protein sequences using the Clustal method areKTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. For nucleicacids these parameters are KTUPLE=2, GAP PENALTY=5, WINDOW=4 andDIAGONALS SAVED=4. After alignment of the sequences using the Clustal Vprogram, it is possible to obtain a “percent identity” by viewing the“sequence distances” table in the same program.

“BLASTN method of alignment” is an algorithm provided by the NationalCenter for Biotechnology Information (NCBI) to compare nucleotidesequences using default parameters.

It is well understood by one skilled in the art that many levels ofsequence identity are useful in identifying polypeptides, from otherspecies, wherein such polypeptides have the same or similar function oractivity. Useful examples of percent identities include, but are notlimited to, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or anyinteger percentage from 50% to 100%. Indeed, any integer amino acididentity from 50% to 100% may be useful in describing the presentinvention, such as 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%,61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%,75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Also, ofinterest is any full-length or partial complement of this isolatednucleotide fragment.

“Gene” refers to a nucleic acid fragment that expresses a specificprotein, including regulatory sequences preceding (5′ non-codingsequences) and following (3′ non-coding sequences) the coding sequence.“Native gene” refers to a gene as found in nature with its ownregulatory sequences. “Chimeric gene” refers to any gene that is not anative gene, comprising regulatory and coding sequences that are notfound together in nature. Accordingly, a chimeric gene may compriseregulatory sequences and coding sequences that are derived fromdifferent sources, or regulatory sequences and coding sequences derivedfrom the same source, but arranged in a manner different than that foundin nature. A “foreign” gene refers to a gene not normally found in thehost organism, but that is introduced into the host organism by genetransfer. Foreign genes can comprise native genes inserted into anon-native organism, or chimeric genes. A “transgene” is a gene that hasbeen introduced into the genome by a transformation procedure.

The term “genome” as it applies to a plant cells encompasses not onlychromosomal DNA found within the nucleus, but organelle DNA found withinsubcellular components (e.g., mitochondrial, plastid) of the cell.

A “codon-optimized gene” is a gene having its frequency of codon usagedesigned to mimic the frequency of preferred codon usage of the hostcell.

An “allele” is one of several alternative forms of a gene occupying agiven locus on a chromosome. When all the alleles present at a givenlocus on a chromosome are the same that plant is homozygous at thatlocus. If the alleles present at a given locus on a chromosome differthat plant is heterozygous at that locus.

“Coding sequence” refers to a DNA sequence that codes for a specificamino acid sequence. “Regulatory sequences” refer to nucleotidesequences located upstream (5′ non-coding sequences), within, ordownstream (3′ non-coding sequences) of a coding sequence, and whichinfluence the transcription, RNA processing or stability, or translationof the associated coding sequence. Regulatory sequences may include, butare not limited to: promoters, translation leader sequences, introns,polyadenylation recognition sequences, RNA processing sites, effectorbinding sites and stem-loop structures.

“Promoter” refers to a DNA sequence capable of controlling theexpression of a coding sequence or functional RNA. The promoter sequenceconsists of proximal and more distal upstream elements, the latterelements often referred to as enhancers. Accordingly, an “enhancer” is aDNA sequence that can stimulate promoter activity, and may be an innateelement of the promoter or a heterologous element inserted to enhancethe level or tissue-specificity of a promoter. Promoters may be derivedin their entirety from a native gene, or be composed of differentelements derived from different promoters found in nature, or evencomprise synthetic DNA segments. It is understood by those skilled inthe art that different promoters may direct the expression of a gene indifferent tissues or cell types, or at different stages of development,or in response to different environmental conditions. It is furtherrecognized that since in most cases the exact boundaries of regulatorysequences have not been completely defined, DNA fragments of somevariation may have identical promoter activity. Promoters that cause agene to be expressed in most cell types at most times are commonlyreferred to as “constitutive promoters”. New promoters of various typesuseful in plant cells are constantly being discovered; numerous examplesmay be found in the compilation by Okamuro, J. K., and Goldberg, R. B.Biochemistry of Plants 15:1-82 (1989).

“Translation leader sequence” refers to a polynucleotide sequencelocated between the promoter sequence of a gene and the coding sequence.The translation leader sequence is present in the fully processed mRNAupstream of the translation start sequence. The translation leadersequence may affect processing of the primary transcript to mRNA, mRNAstability or translation efficiency. Examples of translation leadersequences have been described (Turner, R. and Foster, G. D., Mol.Biotechnol. 3:225-236 (1995)).

“3′ non-coding sequences”, “transcription terminator” or “terminationsequences” refer to DNA sequences located downstream of a codingsequence and include polyadenylation recognition sequences and othersequences encoding regulatory signals capable of affecting mRNAprocessing or gene expression. The polyadenylation signal is usuallycharacterized by affecting the addition of polyadenylic acid tracts tothe 3′ end of the mRNA precursor. The use of different 3′ non-codingsequences is exemplified by Ingelbrecht, I. L., et al. Plant Cell1:671-680 (1989).

“RNA transcript” refers to the product resulting from RNApolymerase-catalyzed transcription of a DNA sequence. When the RNAtranscript is a perfect complementary copy of the DNA sequence, it isreferred to as the primary transcript. An RNA transcript is referred toas the mature RNA when it is an RNA sequence derived frompost-transcriptional processing of the primary transcript. “MessengerRNA” or “mRNA” refers to the RNA that is without introns and that can betranslated into protein by the cell. “cDNA” refers to a DNA that iscomplementary to, and synthesized from, an mRNA template using theenzyme reverse transcriptase. The cDNA can be single-stranded orconverted into double-stranded form using the Klenow fragment of DNApolymerase I. “Sense” RNA refers to RNA transcript that includes themRNA and can be translated into protein within a cell or in vitro.“Antisense RNA” refers to an RNA transcript that is complementary to allor part of a target primary transcript or mRNA, and that blocks theexpression of a target gene (U.S. Pat. No. 5,107,065). Thecomplementarity of an antisense RNA may be with any part of the specificgene transcript, i.e., at the 5′ non-coding sequence, 3′ non-codingsequence, introns, or the coding sequence. “Functional RNA” refers toantisense RNA, ribozyme RNA, or other RNA that may not be translated butyet has an effect on cellular processes. The terms “complement” and“reverse complement” are used interchangeably herein with respect tomRNA transcripts, and are meant to define the antisense RNA of themessage.

The term “operably linked” refers to the association of nucleic acidsequences on a single nucleic acid fragment so that the function of oneis regulated by the other. For example, a promoter is operably linkedwith a coding sequence when it is capable of regulating the expressionof that coding sequence (i.e., the coding sequence is under thetranscriptional control of the promoter). Coding sequences can beoperably linked to regulatory sequences in a sense or antisenseorientation. In another example, the complementary RNA regions of theinvention can be operably linked, either directly or indirectly, 5′ tothe target mRNA, or 3′ to the target mRNA, or within the target mRNA, ora first complementary region is 5′ and its complement is 3′ to thetarget mRNA.

Standard recombinant DNA and molecular cloning techniques used hereinare well known in the art and are described more fully in Sambrook, J.,Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual;Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y. (1989)(hereinafter “Sambrook et al., 1989”). Transformation methods are wellknown to those skilled in the art and are described infra.

“PCR” or “polymerase chain reaction” is a technique for the synthesis oflarge quantities of specific DNA segments and consists of a series ofrepetitive cycles (Perkin Elmer Cetus Instruments, Norwalk, Conn.).Typically, the double-stranded DNA is heat denatured, the two primerscomplementary to the 3′ boundaries of the target segment are annealed atlow temperature and then extended at an intermediate temperature. Oneset of these three consecutive steps is referred to as a “cycle”.

The term “recombinant” refers to an artificial combination of twootherwise separated segments of sequence, e.g., by chemical synthesis orby the manipulation of isolated segments of nucleic acids by geneticengineering techniques.

The terms “plasmid”, “vector” and “cassette” refer to an extrachromosomal element often carrying genes that are not part of thecentral metabolism of the cell, and usually in the form of circulardouble-stranded DNA fragments. Such elements may be autonomouslyreplicating sequences, genome integrating sequences, phage or nucleotidesequences, linear or circular, of a single- or double-stranded DNA orRNA, derived from any source, in which a number of nucleotide sequenceshave been joined or recombined into a unique construction which iscapable of introducing a promoter fragment and DNA sequence for aselected gene product along with appropriate 3′ untranslated sequenceinto a cell. “Transformation cassette” refers to a specific vectorcontaining a foreign gene and having elements in addition to the foreigngene that facilitates transformation of a particular host cell.“Expression cassette” refers to a specific vector containing a foreigngene and having elements in addition to the foreign gene that allow forenhanced expression of that gene in a foreign host (i.e., to a discretenucleic acid fragment into which a nucleic acid sequence or fragment canbe moved).

The terms “recombinant construct”, “expression construct”, “chimericconstruct”, “construct”, and “recombinant DNA construct” are usedinterchangeably herein. A recombinant construct comprises an artificialcombination of nucleic acid fragments, e.g., regulatory and codingsequences that are not found together in nature. For example, a chimericconstruct may comprise regulatory sequences and coding sequences thatare derived from different sources, or regulatory sequences and codingsequences derived from the same source, but arranged in a mannerdifferent than that found in nature. Such a construct may be used byitself or may be used in conjunction with a vector. If a vector is used,then the choice of vector is dependent upon the method that will be usedto transform host cells as is well known to those skilled in the art.For example, a plasmid vector can be used. The skilled artisan is wellaware of the genetic elements that must be present on the vector inorder to successfully transform, select and propagate host cellscomprising any of the isolated nucleic acid fragments of the invention.The skilled artisan will also recognize that different independenttransformation events will result in different levels and patterns ofexpression (Jones et al., EMBO J. 4:2411-2418 (1985); De Almeida et al.,Mol. Gen. Genetics 218:78-86 (1989)), and thus that multiple events mustbe screened in order to obtain lines displaying the desired expressionlevel and pattern. Such screening may be accomplished by Southernanalysis of DNA, Northern analysis of mRNA expression, immunoblottinganalysis of protein expression, or phenotypic analysis, among others.

The term “expression”, as used herein, refers to the production of afunctional end-product (e.g., a mRNA or a protein [either precursor ormature]).

The term “introduced” means providing a nucleic acid (e.g., expressionconstruct) or protein into a cell. Introduced includes reference to theincorporation of a nucleic acid into a eukaryotic or prokaryotic cellwhere the nucleic acid may be incorporated into the genome of the cell,and includes reference to the transient provision of a nucleic acid orprotein to the cell. Introduced includes reference to stable ortransient transformation methods, as well as sexually crossing. Thus,“introduced” in the context of inserting a nucleic acid fragment (e.g.,a recombinant DNA construct/expression construct) into a cell, means“transfection” or “transformation” or “transduction” and includesreference to the incorporation of a nucleic acid fragment into aeukaryotic or prokaryotic cell where the nucleic acid fragment may beincorporated into the genome of the cell (e.g., chromosome, plasmid,plastid or mitochondrial DNA), converted into an autonomous replicon, ortransiently expressed (e.g., transfected mRNA).

“Mature” protein refers to a post-translationally processed polypeptide(i.e., one from which any pre- or propeptides present in the primarytranslation product have been removed). “Precursor” protein refers tothe primary product of translation of mRNA (i.e., with pre- andpropeptides still present). Pre- and propeptides may be but are notlimited to intracellular localization signals.

“Stable transformation” refers to the transfer of a nucleic acidfragment into a genome of a host organism, including both nuclear andorganellar genomes, resulting in genetically stable inheritance. Incontrast, “transient transformation” refers to the transfer of a nucleicacid fragment into the nucleus, or DNA-containing organelle, of a hostorganism resulting in gene expression without integration or stableinheritance. Host organisms containing the transformed nucleic acidfragments are referred to as “transgenic” organisms.

As used herein, “transgenic” refers to a plant or a cell which compriseswithin its genome a heterologous polynucleotide. Preferably, theheterologous polynucleotide is stably integrated within the genome suchthat the polynucleotide is passed on to successive generations. Theheterologous polynucleotide may be integrated into the genome alone oras part of an expression construct. Transgenic is used herein to includeany cell, cell line, callus, tissue, plant part or plant, the genotypeof which has been altered by the presence of heterologous nucleic acidincluding those transgenics initially so altered as well as thosecreated by sexual crosses or asexual propagation from the initialtransgenic. The term “transgenic” as used herein does not encompass thealteration of the genome (chromosomal or extra-chromosomal) byconventional plant breeding methods or by naturally occurring eventssuch as random cross-fertilization, non-recombinant viral infection,non-recombinant bacterial transformation, non-recombinant transposition,or spontaneous mutation. “Antisense inhibition” refers to the productionof antisense RNA transcripts capable of suppressing the expression ofthe target protein. “Co-suppression” refers to the production of senseRNA transcripts capable of suppressing the expression of identical orsubstantially similar foreign or endogenous genes (U.S. Pat. No.5,231,020). Co-suppression constructs in plants previously have beendesigned by focusing on overexpression of a nucleic acid sequence havinghomology to an endogenous mRNA, in the sense orientation, which resultsin the reduction of all RNA having homology to the overexpressedsequence (Vaucheret et al., Plant J. 16:651-659 (1998); Gura, Nature404:804-808 (2000)). The overall efficiency of this phenomenon is low,and the extent of the RNA reduction is widely variable. More recent workhas described the use of “hairpin” structures that incorporate all, orpart, of an mRNA encoding sequence in a complementary orientation thatresults in a potential “stem-loop” structure for the expressed RNA (PCTPublication No. WO 99/53050; PCT Publication No. WO 02/00904). Thisincreases the frequency of co-suppression in the recovered transgenicplants. Another variation describes the use of plant viral sequences todirect the suppression, or “silencing”, of proximal mRNA encodingsequences (PCT Publication No. WO 98/36083). Both of theseco-suppressing phenomena have not been elucidated mechanistically,although genetic evidence has begun to unravel this complex situation(Elmayan et al., Plant Cell 10:1747-1757 (1998)).

The term “oleaginous” refers to those organisms that tend to store theirenergy source in the form of lipid (Weete, In: Fungal LipidBiochemistry, 2^(nd) Ed., Plenum, 1980). A class of plants identified asoleaginous are commonly referred to as “oilseed” plants. Examples ofoilseed plants include, but are not limited to: soybean (Glycine andSoja sp.), flax (Linum sp.), rapeseed (Brassica sp.), maize, cotton,safflower (Carthamus sp.) and sunflower (Helianthus sp.).

The term “plant” refers to whole plants, plant organs, plant tissues,seeds, plant cells, seeds and progeny of the same. Plant cells include,without limitation, cells from seeds, suspension cultures, embryos,meristematic regions, callus tissue, leaves, roots, shoots,gametophytes, sporophytes, pollen and microspores.

“Progeny” comprises any subsequent generation of a plant.

“Non-transgenic, null segregant soybean seed” refers to a near isogenicplant or seed that lacks the transgene, and/or a parental plant used inthe transformation process to obtain the transgenic event. Nullsegregants can be plants or seed that do not contain the transgenictrait due to normal genetic segregation during propagation of theheterozygous transgenic plants.

A “kernel” is the corn caryopsis, consisting of a mature embryo andendosperm which are products of double fertilization. The term “corn” or“maize” represents any variety, cultivar, or population of Zea mays L.

“Grain” comprises mature corn kernels produced by commercial growers foron farm use or for sale to customers in both cases for purposes otherthan growing or reproducing the species. The “seed” is the mature cornkernel produced for the purpose of propagating the species and for saleto commercial growers. As used herein the terms seeds, kernels, andgrains can be used interchangeably. The “embryo” or also termed “germ”is a young sporophytic plant, before the start of a period of rapidgrowth (seed germination). The embryo (germ) of corn contains the vastmajority of the oil found in the kernel. The structure of embryo incereal grain includes the embryonic axis and the scutellum. The“scutellum” is the single cotyledon of a cereal grain embryo,specialized for absorption of the endosperm.

The “aleurone” is a proteinaceous material, usually in the form of smallgranules, occurring in the outermost cell layer of the endosperm of cornand other grains.

The present invention concerns a method for increasing the content of atleast one unusual fatty acid in an oilseed plant cell comprising:

-   -   (a) transforming the oilseed plant with:        -   (i) a first recombinant DNA construct comprising an isolated            polynucleotide encoding at least one DGAT polypeptide or at            least one MBOAT polypeptide operably linked to at least one            regulatory sequence; and        -   (ii) at least one additional recombinant construct            comprising an isolated polynucleotide, operably linked to at            least one regulatory sequence, encoding a polypeptide            selected from the group consisting of a delta-4 desaturase,            a delta-5 desaturase, a delta-6 desaturase, a delta-8            desaturase, a delta-12 desaturase, a delta-15 desaturase, a            delta-17 desaturase, a delta-9 desaturase, a delta-9            elongase, a C14/16 elongase, a Ca6/18 elongase, a C18/20            elongase, a C20/22 elongase, a DGAT, an MBOAT, a fatty acid            conjugase, a hydroxylase, an acetylenase, an epoxidase and a            multizyme;    -   (b) regeneating an oilseed plant from the transformed cell of        step (a); and    -   (c) selecting those seeds obtained from the plants of step (b)        having an increased level of at least one unusual fatty acid        when compared to the level in seeds obtained from a transgenic        plant comprising at least one recombinant construct comprising        an isolated polynucleotide, operably linked to at least one        regulatory sequence, encoding a polypeptide selected from the        group consisting of a delta-4 desaturase, a delta-5 desaturase,        a delta-6 desaturase, a delta-8 desaturase, a delta-12        desaturase, a delta-15 desaturase, a delta-17 desaturase, a        delta-9 desaturase, a delta-9 elongase, a C14/16 elongase, a        C16/18 elongase, a C18/20 elongase, a C20/22 elongase, a DGAT,        an MBOAT, a fatty acid conjugase, a hydroxylase, an acetylenase,        an epoxidase and a multizyme.

The present invention furthermore concerns an isolated polynucleotidecomprising a nucleotide sequence encoding a polypeptide with MBOATactivity, wherein, based on the Clustal V method of alignment withpairwise alignment default parameters of KTUPLE=1, GAP PENALTY=3,WINDOW=5 and DIAGONALS SAVED=5, the polypeptide has an amino acidsequence of at least 80%, 85%, 90%, 95%, or 100% sequence identity whencompared to SEQ ID NO:3, 12, 123, 126, or 137; or the full complement ofthe nucleotide sequence.

Another embodiment of the present invention comprises an isolatedpolynucleotide comprising a nucleotide sequence encoding a polypeptidewith DGAT activity, wherein, based on the Clustal V method of alignmentwith pairwise alignment default parameters of KTUPLE=1, GAP PENALTY=3,WINDOW=5 and DIAGONALS SAVED=5, the polypeptide has an amino acidsequence of at least 80%, 85%, 90%, 95%, or 100% sequence identity whencompared to SEQ ID NO:15 or 26; or the full complement of the nucleotidesequence.

Recombinant DNA constructs comprising the polynucleotides of the presentinvention are also part of the embodiments.

Furthermore host cells comprising in its genome any of the recombinantconstructs of the present invention are part of the embodiments. Thehost cell can be a plant cell, a microbial cell or a yeast cell. Usefuloilseed host plants comprise, but are not limited to soybean, Brassicaspecies, sunflower, maize, cotton, flax, and safflower.

Another embodiment of the present invention comprises a method forincreasing at least one conversion efficiency, wherein said conversionefficiency is at least one selected from the group consisting of: C₁₈ toC₂₀ elongation, delta-6 desaturation, the delta-9 elongation, delta-8desaturation, conjugation to Eleostearic acid and conjugation toCalendic acid, in an oilseed plant cell comprising a first recombinantDNA construct comprising an isolated polynucleotide encoding at leastone MBOAT polypeptide operably linked to at least one regulatorysequence; and at least one additional recombinant construct comprisingan isolated polynucleotide, operably linked to at least one regulatorysequence, encoding a polypeptide selected from the group consisting of adelta-4 desaturase, a delta-5 desaturase, a delta-6 desaturase, adelta-8 desaturase, a delta-12 desaturase, a delta-15 desaturase, adelta-17 desaturase, a delta-9 desaturase, a delta-9 elongase, a C14/16elongase, a C16/18 elongase, a C18/20 elongase, a C20122 elongase, aDGAT, an MBOAT, a fatty acid conjugase, a hydroxylase, an acetylenase,an epoxidase and a multizyme; regenerating an oilseed plant from thetransformed cell; and selecting those seeds obtained from the plants ofthe regenerating step having at least one increase in conversionefficiency, wherein said increase in conversion efficiency is at leastone selected from the group consisting of: C₁₈ to C₂₀ elongation,delta-6 desaturation, the delta-9 elongation, delta-8 desaturation,conjugation to Eleostearic acid and conjugation to Calendic acid, whencompared to the level in seeds obtained from a transgenic plantcomprising at least one recombinant construct comprising an isolatedpolynucleotide, operably linked to at least one regulatory sequence,encoding a polypeptide selected from the group consisting of a delta-4desaturase, a delta-5 desaturase, a delta-6 desaturase, a delta-8desaturase, a delta-12 desaturase, a delta-15 desaturase, a delta-17desaturase, a delta-9 desaturase, a delta-9 elongase, a C14/16 elongase,a C16/18 elongase, a C18/20 elongase and a C20/22 elongase, a DGAT, anMBOAT, a fatty acid conjugase, a hydroxylase, an acetylenase, anepoxidase and a multizyme.

Furthermore, the present invention concerns methods to increase the C₁₈to C₂₀ elongation conversion efficiency at least 1.1, 1.2, 1.3, 1.4,1.5, 1.6, 1.7, 1.8, 1.8, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8,2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.2, 4.2,4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6,5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0,7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4,8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8,9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11-foldand the delta-6 desaturation conversion efficiency is increased at least2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3,3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.2, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7,4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1,6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5,7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9,9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2,10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11-fold; or the delta-9elongation conversion efficiency is increased by at least 1.1, 1.2, 1.3,1.4, 1.5, 1.6, 1.7, 1.8, 1.8, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7,2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.2,4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5,5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9,7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3,8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7,9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9,11-fold and the delta-8 desaturation conversion efficiency is increasedby at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.8, 2.0, 2.1, 2.2, 2.3,2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7,3.8, 3.9, 4.0, 4.2, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1,5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5,6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9,8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3,9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6,10.7, 10.8, 10.9, 11-fold; or the conjugation conversion efficiency toEleostearic acid is at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.8,2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3,3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.2, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7,4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1,6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5,7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9,9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2,10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11-fold; or the conjugationconversion efficiency to Calendic acid is at least 2.5, 2.6, 2.7, 2.8,2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.2, 4.2,4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6,5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0,7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4,8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8,9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9,11-fold.

Another embodiment of the invention concerns a method for increasing thecontent of at least one unusual fatty acid in an oilseed plant cellcomprising a first recombinant DNA construct comprising an isolatedpolynucleotide encoding at least one DGAT polypeptide operably linked toat least one regulatory sequence; and at least one additionalrecombinant construct comprising an isolated polynucleotide, operablylinked to at least one regulatory sequence, encoding a polypeptideselected from the group consisting of a delta-4 desaturase, a delta-5desaturase, a delta-6 desaturase, a delta-8 desaturase, a delta-12desaturase, a delta-15 desaturase, a delta-17 desaturase, a delta-9desaturase, a delta-9 elongase, a C14/16 elongase, a C16/18 elongase, aC18120 elongase, a C20/22 elongase, a DGAT, an MBOAT, a fatty acidconjugase, a hydroxylase, an acetylenase, an epoxidase and a multizyme;regeneating an oilseed plant from the transformed cell and selectingthose seeds obtained from the plants of the regenerating step having anincreased level of at least one unusual fatty acid when compared to thelevel in seeds obtained from a transgenic plant comprising at least onerecombinant construct comprising an isolated polynucleotide, operablylinked to at least one regulatory sequence, encoding a polypeptideselected from the group consisting of a delta-4 desaturase, a delta-5desaturase, a delta-6 desaturase, a delta-8 desaturase, a delta-12desaturase, a delta-15 desaturase, a delta-17 desaturase, a delta-9desaturase, a delta-9 elongase, a C14/16 elongase, a C16/18 elongase, aC18120 elongase, a C20/22 elongase, a DGAT, an MBOAT, a fatty acidconjugase, a hydroxylase, an acetylenase, an epoxidase and a multizyme.

Unusual fatty acids of particular interest include, but are not limitedto, GLA, STA, EDA, ERA, DGLA, ETA, ELEO and CAL.

Suitable oilseed plants to practice the invention include, but are notlimited to, soybean, Brassica species, sunflower, maize, cotton, flaxand safflower.

Seeds and oils obtained from the transgenic plants or seeds of theinvention are also of interest, as are feed and food incorporating theseeds or oils of the invention.

A transgenic oilseed of the invention can comprise a recombinantconstruct having at least one MBOAT and/or DGAT sequence. This DGATsequence can be selected from the group consisting of DGAT1, DGAT2 andDGAT1 in combination with DGAT2. Furthermore, at least one DGAT sequencecan be from Yarrowia. Examples of suitable MBOAT and DGAT sequences thatcan be used to practice the invention are discussed in the Examplesbelow. Those skilled in the art will appreciate that the instantinvention includes, but is not limited to, the MBOAT and DGAT sequencesdisclosed herein. Furthermore, the transgenic oilseed of the inventioncan comprise a recombinant constructs having at least one MBOAT and/orDGAT sequence and at least one additional recombinant constructcomprising an isolated polynucleotide, operably linked to at lest oneregulatory sequence, encoding a polypeptide selected from the groupconsisting of a delta-4 desaturase, a delta-5 desaturase, a delta-6desaturase, a delta-8 desaturase, a delta-12 desaturase, a delta-15desaturase, a delta-17 desaturase, a delta-9 desaturase, a delta-9elongase, a C14/16 elongase, a C16118 elongase, a C18/20 elongase, aC20/22 elongase, a fatty acid conjugase, a hydroxylase, an acetylenase,an epoxidase and a multizyme.

Such a recombinant construct would comprise different components such asa promoter which is a DNA sequence that directs cellular machinery of aplant to produce RNA from the contiguous coding sequence downstream (3′)of the promoter. The promoter region influences the rate, developmentalstage, and cell type in which the RNA transcript of the gene is made.The RNA transcript is processed to produce mRNA which serves as atemplate for translation of the RNA sequence into the amino acidsequence of the encoded polypeptide. The 5′ non-translated leadersequence is a region of the mRNA upstream of the protein coding regionthat may play a role in initiation and translation of the mRNA. The 3′transcription termination/polyadenylation signal is a non-translatedregion downstream of the protein coding region that functions in theplant cell to cause termination of the RNA transcript and the additionof polyadenylate nucleotides to the 3′ end of the RNA.

The origin of the promoter chosen to drive expression of the codingsequences of the invention is not important as long as it has sufficienttranscriptional activity to accomplish the invention by expressingtranslatable mRNA for the desired nucleic acid fragments in the desiredhost tissue at the right time. Either heterologous or non-heterologous(i.e., endogenous) promoters can be used to practice the invention. Forexample, suitable promoters include, but are not limited to: the alphaprime subunit of beta conglycinin promoter, the Kunitz trypsin inhibitor3 promoter, the annexin promoter, the glycinin Gy1 promoter, the betasubunit of beta conglycinin promoter, the P34/Gly Bd m 30K promoter, thealbumin promoter, the Leg A1 promoter and the Leg A2 promoter.

The annexin, or P34, promoter is described in PCT Publication No. WO2004/071178. The level of activity of the annexin promoter is comparableto that of many known strong promoters, such as: (1) the CaMV 35Spromoter (Atanassova et al., Plant Mol. Biol. 37:275-285 (1998); Battrawand Hall, Plant Mol. Biol. 15:527-538 (1990); Holtorf et al., Plant Mol.Biol. 29:637-646 (1995); Jefferson et al., EMBO J. 6:3901-3907 (1987);Wilmink et al., Plant Mol. Biol. 28:949-955 (1995)); (2) the Arabidopsisoleosin promoters (Plant et al., Plant Mol. Biol. 25:193-205 (1994); Li,Texas A&M University Ph.D. dissertation, pp. 107-128 (1997)); (3) theArabidopsis ubiquitin extension protein promoters (Callis et al., J.Biol. Chem. 265(21):12486-93 (1990)); (4) a tomato ubiquitin genepromoter (Rollfinke et al., Gene. 211(2):267-76 (1998)); (5) a soybeanheat shock protein promoter (Schoffl et al., Mol Gen Genet.217(2-3):246-53 (1989)); and, (6) a maize H3 histone gene promoter(Atanassova et al., Plant Mot Biol. 37(2):275-85 (1989)).

Another useful feature of the annexin promoter is its expression profilein developing seeds. The annexin promoter is most active in developingseeds at early stages (before 10 days after pollination) and is largelyquiescent in later stages. The expression profile of the annexinpromoter is different from that of many seed-specific promoters, e.g.,seed storage protein promoters, which often provide highest activity inlater stages of development (Chen et al., Dev. Genet. 10:112-122 (1989);Ellerstrom et al., Plant Mol. Biol. 32:1019-1027 (1996); Keddie et al.,Plant Mol. Biol. 24:327-340 (1994); Plant et al., (supra); Li, (supra)).The annexin promoter has a more conventional expression profile butremains distinct from other known seed specific promoters. Thus, theannexin promoter will be a very attractive candidate whenoverexpression, or suppression, of a gene in embryos is desired at anearly developing stage. For example, it may be desirable to overexpressa gene regulating early embryo development or a gene involved in themetabolism prior to seed maturation.

Following identification of an appropriate promoter suitable forexpression of a specific coding sequence of the invention, the promoteris then operably linked in a sense orientation using conventional meanswell known to those skilled in the art.

Standard recombinant DNA and molecular cloning techniques used hereinare well known in the art and are described more fully in Sambrook etal., 1989 or Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D.,Seidman, J. G., Smith, J. A. and Struhl, K., Eds.; In Current Protocolsin Molecular Biology; John Wiley and Sons: New York, 1990.

Once the recombinant construct has been made, it may then be introducedinto a plant cell of choice by methods well known to those of ordinaryskill in the art (e.g., transfection, transformation andelectroporation). Oilseed plant cells are the preferred plant cells. Thetransformed plant cell is then cultured and regenerated under suitableconditions permitting selection of those transformed soybean cell(s).

Such recombinant constructs may be introduced into one plant cell or,alternatively, each construct may be introduced into separate plantcells.

Expression in a plant cell may be accomplished in a transient or stablefashion as is described above.

Also within the scope of this invention are seeds or plant partsobtained from such transformed plants.

Plant parts include differentiated and undifferentiated tissuesincluding, but not limited to, the following: roots, stems, shoots,leaves, pollen, seeds, tumor tissue and various forms of cells andculture (e.g., single cells, protoplasts, embryos and callus tissue).The plant tissue may be in plant or in a plant organ, tissue or cellculture.

The term “plant organ” refers to plant tissue or a group of tissues thatconstitute a morphologically and functionally distinct part of a plant.The term “genome” refers to the following: (1) the entire complement ofgenetic material (genes and non-coding sequences) that is present ineach cell of an organism, or virus or organelle; and/or (2) a completeset of chromosomes inherited as a (haploid) unit from one parent.

Methods for transforming dicots (primarily by use of Agrobacteriumtumefaciens) and obtaining transgenic plants have been published, amongothers, for: cotton (U.S. Pat. No. 5,004,863; U.S. Pat. No. 5,159,135);soybean (U.S. Pat. No. 5,569,834; U.S. Pat. No. 5,416,011); Brassica(U.S. Pat. No. 5,463,174); peanut (Cheng et al. Plant Cell Rep.15:653-657 (1996); McKently et al. Plant Cell Rep. 14:699-703 (1995));papaya (Ling, K. et al. Bio/technology 9:752-758 (1991)); and pea (Grantet al. Plant Cell Rep. 15:254-258 (1995)). For a review of othercommonly used methods of plant transformation see Newell, C. A. (Mol.Biotechnol. 16:53-65 (2000)). One of these methods of transformationuses Agrobacterium rhizogenes (Tepfler, M. and Casse-Delbart, F.Microbiol. Sci. 4:24-28 (1987)). Transformation of soybeans using directdelivery of DNA has been published using PEG fusion (PCT Publication No.WO 92/17598), electroporation (Chowrira, G. M. et al., Mol. Biotechnol.3:17-23 (1995); Christou, P. et al., Proc. Natl. Acad. Sci. U.S.A.84:3962-3966 (1987)), microinjection and particle bombardement (McCabe,D. E. et. al., Bio/Technology 6:923 (1988); Christou et al., PlantPhysiol. 87:671-674 (1988)).

There are a variety of methods for the regeneration of plants from planttissue. The particular method of regeneration will depend on thestarting plant tissue and the particular plant species to beregenerated. The regeneration, development and cultivation of plantsfrom single plant protoplast transformants or from various transformedexplants is well known in the art (Weissbach and Weissbach, In: Methodsfor Plant Molecular Biology, (Eds.), Academic: San Diego, Calif.(1988)). This regeneration and growth process typically includes thesteps of selection of transformed cells and culturing thoseindividualized cells through the usual stages of embryonic developmentthrough the rooted plantlet stage. Transgenic embryos and seeds aresimilarly regenerated. The resulting transgenic rooted shoots arethereafter planted in an appropriate plant growth medium such as soil.Preferably, the regenerated plants are self-pollinated to providehomozygous transgenic plants. Otherwise, pollen obtained from theregenerated plants is crossed to seed-grown plants of agronomicallyimportant lines. Conversely, pollen from plants of these important linesis used to pollinate regenerated plants. A transgenic plant of thepresent invention containing a desired polypeptide is cultivated usingmethods well known to one skilled in the art.

In addition to the above discussed procedures, practitioners arefamiliar with the standard resource materials which describe specificconditions and procedures for: the construction, manipulation andisolation of macromolecules (e.g., DNA molecules, plasmids, etc.); thegeneration of recombinant DNA fragments and recombinant expressionconstructs; and, the screening and isolating of clones. See, forexample: Sambrook et al., 1989; Maliga et al., Methods in PlantMolecular Biology, Cold Spring Harbor: NY (1995); Birren et al., GenomeAnalysis: Detecting Genes, Vol. 1, Cold Spring Harbor: NY (1998); Birrenet al., Genome Analysis: Analyzing DNA, Vol. 2, Cold Spring Harbor: NY(1998); Plant Molecular Biology: A Laboratory Manual, eds. Clark,Springer: NY (1997).

Transformation of monocotyledons using electroporation, particlebombardment, and Agrobacterium have been reported. Transformation andplant regeneration have been achieved in asparagus (Bytebier et al.,Proc. Natl. Acad. Sci. (USA) 84:5354, (1987)); barley (Wan and Lemaux,Plant Physiol 104:37 (1994)); Zea mays (Rhodes et al., Science 240:204(1988), Gordon-Kamm et al., Plant Cell 2:603-618 (1990), Fromm et al.,Bio/Technology 8:833 (1990), Koziel et al., Bio/Technology 11: 194,(1993), Armstrong et al., Crop Science 35:550-557 (1995)); oat (Somerset al., Bio/Technology 10: 15 89 (1992)); orchard grass (Horn et al.,Plant Cell Rep. 7:469 (1988)); rice (Toriyama et al., TheorAppl. Genet.205:34, (1986); Part et al., Plant Mol. Biol. 32:1135-1148, (1996);Abedinia et al., Aust. J. Plant Physiol. 24:133-141 (1997); Zhang andWu, Theor. Appl. Genet. 76:835 (1988); Zhang et al. Plant Cell Rep.7:379, (1988); Battraw and Hall, Plant Sci. 86:191-202 (1992); Christouet al., Bio/Technology 9:957 (1991)); rye (De la Pena et al., Nature325:274 (1987)); sugarcane (Bower and Birch, Plant J. 2:409 (1992));tall fescue (Wang et al., Bio/Technology 10:691 (1992)), and wheat(Vasil et al., Bio/Technology 10:667 (1992); U.S. Pat. No. 5,631,152).

Assays for gene expression based on the transient expression of clonednucleic acid constructs have been developed by introducing the nucleicacid molecules into plant cells by polyethylene glycol treatment,electroporation, or particle bombardment (Marcotte et al., Nature335:454-457 (1988); Marcotte et al., Plant Cell 1:523-532 (1989);McCarty et al., Cell 66:895-905 (1991); Hattori et al., Genes Dev.6:609-618 (1992); Goff et al., EMBO J. 9:2517-2522 (1990)).

Transient expression systems may be used to functionally dissect geneconstructs (see generally, Maliga et al., Methods in Plant MolecularBiology, Cold Spring Harbor Press (1995)). It is understood that any ofthe nucleic acid molecules of the present invention can be introducedinto a plant cell in a permanent or transient manner in combination withother genetic elements such as vectors, promoters, enhancers etc.

In addition to the above discussed procedures, practitioners arefamiliar with the standard resource materials which describe specificconditions and procedures for the construction, manipulation andisolation of macromolecules (e.g., DNA molecules, plasmids, etc.),generation of recombinant organisms and the screening and isolating ofclones (see for example, Sambrook et al., 1989; Maliga et al., Methodsin Plant Molecular Biology, Cold Spring Harbor Press (1995); Birren etal., Genome Analysis Detecting Genes, 1, Cold Spring Harbor, N.Y.(1998); Birren et al., Genome Analysis: Analyzing DNA, 2, Cold SpringHarbor, N.Y. (1998); Plant Molecular Biology: A Laboratory Manual, eds.Clark, Springer, N.Y. (1997)).

The transgenic oilseeds of the invention can be processed to yield oil,protein products and/or by-products that are derivatives obtained byprocessing that have commercial value. One example, of many, useful forillustrating this point are transgenic soybean seeds of the inventionwhich can be processed to yield soy oil, soy products and/or soyby-products.

“Soy products” can include, but are not limited to, those items listedin Table 1A.

TABLE 1A Soy Protein Products Derived from Soybean Seeds^(a) WholeSoybean Products Roasted Soybeans Baked Soybeans Soy Sprouts Soy MilkProcessed Soy Protein Products Full Fat and Defatted Flours Soy GritsSoy Hypocotyls Soybean Meal Soy Milk Soy Protein Isolates Soy ProteinConcentrates Textured Soy Proteins Textured Flours and ConcentratesTextured Concentrates Textured Isolates Specialty Soy Foods/IngredientsSoy Milk Tofu Tempeh Miso Soy Sauce Hydrolyzed Vegetable ProteinWhipping Protein ^(a)See Soy Protein Products: Characteristics,Nutritional Aspects and Utilization (1987). Soy Protein Council.

“Processing” refers to any physical and chemical methods used to obtainthe products listed in Table 1A and includes, but is not limited to,heat conditioning, flaking and grinding, extrusion, solvent extraction,or aqueous soaking and extraction of whole or partial seeds.Furthermore, “processing” includes the methods used to concentrate andisolate soy protein from whole or partial seeds, as well as the varioustraditional Oriental methods in preparing fermented soy food products.Trading Standards and Specifications have been established for many ofthese products (see National Oilseed Processors Association Yearbook andTrading Rules 1991-1992). Products referred to as being “high protein”or “low protein” are those as described by these StandardSpecifications. “NSI” refers to the Nitrogen Solubility Index as definedby the American Oil Chemists' Society Method Ac4 41. “KOH NitrogenSolubility” is an indicator of soybean meal quality and refers to theamount of nitrogen soluble in 0.036 M KOH under the conditions asdescribed by Araba and Dale [(1990) Poult. Sci. 69:76-83]. “White”flakes refer to flaked, dehulled cotyledons that have been defatted andtreated with controlled moist heat to have an NSI of about 85 to 90.This term can also refer to a flour with a similar NSI that has beenground to pass through a No. 100 U.S. Standard Screen size. “Cooked”refers to a soy protein product, typically a flour, with an NSI of about20 to 60. “Toasted” refers to a soy protein product, typically a flour,with an NSI below 20. “Grits” refer to defatted, dehulled cotyledonshaving a U.S. Standard screen size of between No. 10 and 80. “SoyProtein Concentrates” refer to those products produced from dehulled,defatted soybeans by three basic processes: acid leaching (at about pH4.5), extraction with alcohol (about 55-80%), and denaturing the proteinwith moist heat prior to extraction with water. Conditions typicallyused to prepare soy protein concentrates have been described by Pass[(1975) U.S. Pat. No. 3,897,574; Campbell et al., (1985) in New ProteinFoods, ed. by Altschul and Wilcke, Academic Press, Vol. 5, Chapter 10,Seed Storage Proteins, pp 302-338]. “Extrusion” refers to processeswhereby material (grits, flour or concentrate) is passed through ajacketed auger using high pressures and temperatures as a means ofaltering the texture of the material. “Texturing” and “structuring”refer to extrusion processes used to modify the physical characteristicsof the material. The characteristics of these processes, includingthermoplastic extrusion, have been described previously [Atkinson (1970)U.S. Pat. No. 3,488,770, Horan (1985) In New Protein Foods, ed. byAltschul and Wilcke, Academic Press, Vol. 1A, Chapter 8, pp 367-414].Moreover, conditions used during extrusion processing of complexfoodstuff mixtures that include soy protein products have been describedpreviously [Rokey (1983) Feed Manufacturing Technology III, 222-237;McCulloch, U.S. Pat. No. 4,454,804].

TABLE 1B Generalized Steps for Soybean Oil and Byproduct ProductionProcess Impurities Removed and/or Step Process By-Products Obtained #1soybean seed #2 oil extraction meal #3 Degumming lecithin #4 alkali orphysical gums, free fatty acids, refining pigments #5 water washing soap#6 Bleaching color, soap, metal #7 (hydrogenation) #8 (winterization)stearine #9 Deodorization free fatty acids, tocopherols, sterols,volatiles #10  oil products

More specifically, soybean seeds are cleaned, tempered, dehulled, andflaked, thereby increasing the efficiency of oil extraction. Oilextraction is usually accomplished by solvent (e.g., hexane) extractionbut can also be achieved by a combination of physical pressure and/orsolvent extraction. The resulting oil is called crude oil. The crude oilmay be degummed by hydrating phospholipids and other polar and neutrallipid complexes that facilitate their separation from the nonhydrating,triglyceride fraction (soybean oil). The resulting lecithin gums may befurther processed to make commercially important lecithin products usedin a variety of food and industrial products as emulsification andrelease (i.e., antisticking) agents. Degummed oil may be further refinedfor the removal of impurities (primarily free fatty acids, pigments andresidual gums). Refining is accomplished by the addition of a causticagent that reacts with free fatty acid to form soap and hydratesphosphatides and proteins in the crude oil. Water is used to wash outtraces of soap formed during refining. The soapstock byproduct may beused directly in animal feeds or acidulated to recover the free fattyacids. Color is removed through adsorption with a bleaching earth thatremoves most of the chlorophyll and carotenoid compounds. The refinedoil can be hydrogenated, thereby resulting in fats with various meltingproperties and textures. Winterization (fractionation) may be used toremove stearine from the hydrogenated oil through crystallization undercarefully controlled cooling conditions. Deodorization (principally viasteam distillation under vacuum) is the last step and is designed toremove compounds which impart odor or flavor to the oil. Other valuablebyproducts such as tocopherols and sterols may be removed during thedeodorization process. Deodorized distillate containing these byproductsmay be sold for production of natural vitamin E and other high-valuepharmaceutical products. Refined, bleached, (hydrogenated, fractionated)and deodorized oils and fats may be packaged and sold directly orfurther processed into more specialized products. A more detailedreference to soybean seed processing, soybean oil production, andbyproduct utilization can be found in Erickson, Practical Handbook ofSoybean Processing and Utilization, The American Oil Chemists' Societyand United Soybean Board (1995). Soybean oil is liquid at roomtemperature because it is relatively low in saturated fatty acids whencompared with oils such as coconut, palm, palm kernel, and cocoa butter.

Plant and microbial oils containing PUFAs that have been refined and/orpurified can be hydrogenated, thereby resulting in fats with variousmelting properties and textures. Many processed fats (including spreads,confectionary fats, hard butters, margarines, baking shortenings, etc.)require varying degrees of solidity at room temperature and can only beproduced through alteration of the source oil's physical properties.This is most commonly achieved through catalytic hydrogenation.

Hydrogenation is a chemical reaction in which hydrogen is added to theunsaturated fatty acid double bonds with the aid of a catalyst such asnickel. For example, high oleic soybean oil contains unsaturated oleic,linoleic, and linolenic fatty acids, and each of these can behydrogenated. Hydrogenation has two primary effects. First, theoxidative stability of the oil is increased as a result of the reductionof the unsaturated fatty acid content. Second, the physical propertiesof the oil are changed because the fatty acid modifications increase themelting point resulting in a semi-liquid or solid fat at roomtemperature.

There are many variables which affect the hydrogenation reaction, whichin turn alter the composition of the final product. Operating conditionsincluding pressure, temperature, catalyst type and concentration,agitation, and reactor design are among the more important parametersthat can be controlled. Selective hydrogenation conditions can be usedto hydrogenate the more unsaturated fatty acids in preference to theless unsaturated ones. Very light or brush hydrogenation is oftenemployed to increase stability of liquid oils. Further hydrogenationconverts a liquid oil to a physically solid fat. The degree ofhydrogenation depends on the desired performance and meltingcharacteristics designed for the particular end product. Liquidshortenings (used in the manufacture of baking products, solid fats andshortenings used for commercial frying and roasting operations) and basestocks for margarine manufacture are among the myriad of possible oiland fat products achieved through hydrogenation. A more detaileddescription of hydrogenation and hydrogenated products can be found inPatterson, H. B. W., Hydrogenation of Fats and Oils: Theory andPractice. The American Oil Chemists' Society (1994).

Hydrogenated oils have become somewhat controversial due to the presenceof trans-fatty acid isomers that result from the hydrogenation process.Ingestion of large amounts of trans-isomers has been linked withdetrimental health effects including increased ratios of low density tohigh density lipoproteins in the blood plasma and increased risk ofcoronary heart disease.

Oleaginous organisms can be, but are not limited to, Torulasporadelbrueckii, Pichia anomala, Debaryomyces hansenii, Candida zeylanoides,Lipomyces starkeyi, Mucor circinelloides, Phaffia rhodozyma, Rhodotorulaglutinis, Cryptococcus curvatus, Mortierella alpina, and Yarrowialipolytica.

EXAMPLES

The present invention is further defined in the following Examples, inwhich parts and percentages are by weight and degrees are Celsius,unless otherwise stated. It should be understood that these Examples,while indicating preferred embodiments of the invention, are given byway of illustration only. From the above discussion and these Examples,one skilled in the art can ascertain the essential characteristics ofthis invention, and without departing from the spirit and scope thereof,can make various changes and modifications of the invention to adapt itto various usages and conditions. Thus, various modifications of theinvention in addition to those shown and described herein will beapparent to those skilled in the art from the foregoing description.Such modifications are also intended to fall within the scope of theappended claims.

The meaning of abbreviations is as follows: “sec” means second(s), “min”means minute(s), “h” means hour(s), “d” means day(s), “μL” meansmicroliter(s), “mL” means milliliter(s), “L” means liter(s), “μM” meansmicromolar, “mM” means millimolar, “M” means molar, “mmol” meansmillimole(s), “μmole” mean micromole(s), “g” means gram(s), “μg” meansmicrogram(s), “ng” means nanogram(s), “U” means unit(s), “bp” means basepair(s) and “kB” means kilobase(s).

Example 1 Identification of Membrane Bound O-Acyltransferase (MBOAT)Homologs from Calendula officinalis and Momordica charantia and cDNALibraries

cDNA libraries representing mRNAs from developing seeds of Calendulaofficinalis and Momordica charantia were prepared and insert cDNAfragments were sequenced as previously described in U.S. Pat. No.7,230,090 and U.S. Pat. No. 7,244,563 (the contents of which are herebyincorporated by reference), respectively.

cDNAs clones encoding Calendula officinalis and Momordica charantiamembrane bound o-acyltransferase (MBOAT) homologs were identified byconducting BLAST (Basic Local Alignment Search Tool; Altschul et al., J.Mol. Biol. 215:403-410 (1993)) searches for similarity to sequencescontained in the BLAST “nr” database (comprising all non-redundantGenBank CDS translations, sequences derived from the 3-dimensionalstructure Brookhaven Protein Data Bank, the last major release of theSWISS-PROT protein sequence database, EMBL and DDBJ databases). All cDNAsequences from either library were analyzed for similarity to allpublicly available DNA sequences contained in the “nr” database usingthe BLASTN algorithm provided by the National Center for BiotechnologyInformation (NCBI). The DNA sequences were translated in all readingframes and compared for similarity to all publicly available proteinsequences contained in the “nr” database using the BLASTX algorithm(Gish and States, Nat. Genet. 3:266-272 (1993)) provided by the NCBI.For convenience, the P-value (probability) of observing a match of acDNA sequence to a sequence contained in the searched databases merelyby chance as calculated by BLAST are reported herein as “pLog” values,which represent the negative of the logarithm of the reported P-value.Accordingly, the greater the pLog value, the greater the likelihood thatthe cDNA sequence and the BLAST “hit” represent homologous proteins.

Calendula officinalis Sequence

The BLASTX search using the nucleotide sequence from Calendulaofficinalis cDNA clone ecs1c.pk007.c17 revealed similarity of theprotein encoded by the cDNA to an o-acyltransferase (membrane bound)domain containing protein from Ricinus communis (Accession No. EEF51096(GI:223549608)). The sequence of the entire Calendual officinalis cDNAinsert in clone ecs1c.pk007.c17 was determined, and the full cDNAsequence is shown in SEQ ID NO:1. Sequence for the coding sequence (CDS)is shown in SEQ ID NO:2. Sequence for the corresponding deduced aminoacid sequence is shown in SEQ ID NO:3.

The full amino acid sequence of the protein coded for by ecs1c.pk007.c17(SEQ ID NO:3) was evaluated by BLASTP for similarity to all publiclyavailable protein sequences contained in the “nr” database and yieldedan E value of 0 (361/463 identical amino acids) versus the hypotheticalprotein (MBOAT family) from Vitis vinifera (NCBI Accession No.XP_(—)002282807 (GI:225426775); SEQ ID NO:4) and yielded an E value of 0(344/463 identical amino acids) versus the membrane bound O-acyltransferase (MBOAT) family protein from Arabidopsis thaliana (NCBIAccession No. NP_(—)172724 (GI:22329514); SEQ ID NO:5). BLAST scores andprobabilities indicate that the instant nucleic acid fragment (SEQ IDNO:2) encodes an entire membrane o-acyltransferase gene, hereby namedCoMBOAT.

The amino acid sequence of CoMBOAT (SEQ ID NO:3) is 75.5% identical tothat of Vitis vinifera (SEQ ID NO:4) using the Clustal V method.Sequence percent identity calculations performed by the Clustal V method(Higgins, D. G. and Sharp, P. M., Comput. Appl. Biosci. 5:151-153(1989); Higgins et al., Comput. Appl. Biosci. 8:189-191 (1992)) weredone using the MegAlign™ v6.1 program of the LASERGENE bioinformaticscomputing suite (supra) with the default parameters for pairwisealignment (KTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5 andGAP LENGTH PENALTY=10).

Momordica charantia Sequence

The BLASTX search using the nucleotide sequence from Momordica charantiacDNA clone fds1n.pk001.k4 revealed similarity of the protein encoded bythe cDNA to the hypothetical protein (MBOAT family) from Vitis vinifera(SEQ ID NO:4) The sequence of the entire Momordica charantia cDNA clonefds1n.pk001.k4 was determined, and the full cDNA sequence is shown inSEQ ID NO:6. Analysis of the entire cDNA sequence from Momordicacharantia cDNA clone fds1n.pk001.k4 (SEQ ID NO:6) by BlastX against the“nr” database suggested that the cDNA insert was lacking sequence at the5′ end and was not full length.

In order to obtain sequence for the 5′ end of the gene found infds1n.pk001.k4 (SEQ ID NO:6), 5′ RACE was carried out. Total RNA wasisolated from developing Momordica charantia seeds using the trizolreagent (Invitrogen, Carlsbad, Calif.), according to the manufacturer'sprotocol. Approximately 5 μg of resulting total RNA was combined witholigonucleotide oligodT and first strand cDNA was synthesized using the5′ RACE System for Rapid Amplification of cDNA Ends, Version 2.0 (Cat.No. 18374-058, Invitrogen Corporation, Carlsbad, Calif.) following themanufacturer's protocol. Subsequent PCR amplification from the cDNAusing Taq polymerase (Invitrogen Corporation) following themanufacturer's protocol and using McLPCAT 5Race (SEQ ID NO:7) and the 5′RACE Abridged Anchor Primer provided in the 5′ RACE kit, followed by asecond round of PCR using McLPCATnew1 (SEQ ID NO:8) and the AbridgedUniversal Amplification Primer provided in the 5′ RACE kit resulted in aPCR product which was cloned and sequenced. The resulting 5′ RACEsequence obtained is set forth in SEQ ID NO:9.

Combining the 5′ RACE sequence (SEQ ID NO:9) with that from cDNA clonefds1n.pk001.1(4 (SEQ ID NO:6) yields a full cDNA sequence which is setforth in SEQ ID NO:10. Sequence for the coding sequence (CDS) is shownin SEQ ID NO:11. Sequence for the corresponding deduced amino acidsequence is shown in SEQ ID NO:12.

The full amino acid sequence of Momordica charantia MBOAT homolog (SEQID NO:12) was evaluated by BLASTP for similarity to all publiclyavailable protein sequences contained in the “nr” database and yieldedan E value of 0 (366/465 identical amino acids) versus the hypotheticalprotein (MBOAT family) from Vitis vinifera (SEQ ID NO:4) and yielded anE value of 0 (3491463 identical amino adds) versus the membrane boundO-acyl transferase (MBOAT) family protein from Arabidopsis thaliana (SEQID NO:5). BLAST scores and probabilities indicate that the instantnucleic acid fragment (SEQ ID NO:11) encodes an entire membraneo-acyltransferase gene, hereby named McMBOAT.

The amino acid sequence of McMBOAT (SEQ ID NO:12) is 80.6% identical tothat of Vitis vinifera (SEQ ID NO:4) using the Clustal V method usingthe default settings described above. Additionally, the amino acidsequence on McMBOAT (SEQ ID NO:12) is 74.5% identical to that of CoMBOAT(SEQ ID NO:3) when compared using Clustal V as described in Example 1.

Example 2 Identification of Diacylglycerol Acyltransferase (DGAT2)Homologs from Calendula officinalis and Momordica charantia and cDNALibraries

cDNA libraries representing mRNAs from developing seeds of Calendulaofficinalis and Momordica charantia were prepared and insert cDNAfragments were sequenced as described in U.S. Pat. No. 7,230,090 andU.S. Pat. No. 7,244,563, respectively.

cDNAs clones encoding Calendula officinalis and Momordica charantiadiacylglycerol acyltransferase type 2 (DGAT2) homologs were identifiedby conducting BLAST searches for similarity to sequences contained inthe BLAST “nr” database as described in Example 1.

Calendula officinalis Sequence

The BLASTX search using the nucleotide sequence from Calendulaofficinalis cDNA clone ecs1c.pk002.d16 revealed similarity of theprotein encoded by the cDNA to a type 2 acyl-CoA diacylglycerolacyltransferase from Ricinus communis (NCBI Accession No. AB183668(GI:114848908)). The sequence of the entire Calendula officinalis cDNAinsert in clone ecs1c.pk002.d16 was determined and the full cDNAsequence is shown in SEQ ID NO:13. Sequence for the coding sequence(CDS) is shown in SEQ ID NO:14. Sequence for the corresponding deducedamino acid sequence is shown in SEQ ID NO:15.

The full amino acid sequence of the protein coded for by ecs1c.pk002.d16(SEQ ID NO:15) was evaluated by BLASTP for similarity to all publiclyavailable protein sequences contained in the “nr” database and yieldedan E value of 5.3e-96 (178/302 identical amino acids) versus thehypothetical protein from Vitis vinifera (NCBI Accession No.XP_(—)002263626 (GI:225431649); SEQ ID NO:16) and yielded an E value of1.3e-92 (172/302 identical amino acids) versus the diacylglycerolacyltransferase from Elaeis oleifera (NCBI Accession No. ACO35365(GI:225904451); SEQ ID NO:17). BLAST scores and probabilities indicatethat the instant nucleic acid fragment (SEQ ID NO:14) encodes an entireDGAT2 gene, hereby named CoDGAT2.

The amino acid sequence of CoDGAT2 (SEQ ID NO:15) is 53.9% identical tothat of Vitis vinifera (SEQ ID NO:16) using the Clustal V method.Sequence percent identity calculations performed by the Clustal V methodwere as described in Example 1.

Momordica charantia Sequence

The BLASTX search using the nucleotide sequence from Momordica charantiacDNA clone fds.pk0003.g7 revealed similarity of the protein encoded bythe cDNA to a putative type-2 acyl-CoA:diacylglycerol acyltransferase bfrom Brassica napus (NCBI Accession No. AC090188 (GI:226897458)). Thesequence of the entire Momordica charantia cDNA clone fds.pk0003.g7 wasdetermined and the full cDNA sequence is shown in SEQ ID NO:18. Analysisof the entire cDNA sequence from Momordica charantia cDNA clonefds.pk0003.g7 (SEQ ID NO:18) by BlastX against the “nr” databasesuggested that the cDNA contained an unspliced intron at the 5′ end.

In order to obtain a correct sequence for the 5′ end for the Momordicacharantia DGAT2 homolog gene, 5′ RACE was carried out. First strand cDNAsynthesized as described in Example 1 was amplified with Taq polymerase(Invitrogen Corporation) following the manufacturer's protocol and usingoligonucleotide McDGAT2 Race1 (SEQ ID NO:19) and the 5′ RACE AbridgedAnchor Primer from the 5′ RACE kit. This resulted in a PCR product whichwas cloned and sequenced. The resulting 5′ RACE sequence obtained is setforth in SEQ ID NO:20 and confirmed an unspliced intron had been presentin clone fds.pk0003.g7 (SEQ ID NO:18). But, when the 5′ RACE sequence(SEQ ID NO:20) was combined with the sequence from clone fds.pk0003.g7(SEQ ID NO:18) and evaluated by BlastX against the “nr” database, theresults suggested that the sequence still contained another unsplicedintron at the 5′ end but downstream (i.e. in the 3′ direction) ofoligonucleotide McDGAT2 Race1 (SEQ ID NO:19). In order to evaluate thisand obtain the correct cDNA sequence, oligonucleotides McDGAT2 Not5 (SEQID NO:21) and McDGAT2 Not3 (SEQ ID NO:22) were used to amplify theputative full length coding sequence from the first strand cDNA usingTaq polymerase (Invitrogen Corporation) and following the manufacturer'sprotocol. The sequence from the resulting PCR product and containingNotI sites flanking the Momordica charantia gene is set forth in SEQ IDNO:23 again showed that fds.pk0003.g7 contained a second unsplicedintron. A full, corrected cDNA sequence for the Momordica DGAT2 homologis set forth in SEQ ID NO:24. Sequence for the coding sequence (CDS) isshown in SEQ ID NO:25. Sequence for the corresponding deduced amino acidsequence is shown in SEQ ID NO:26.

The full amino acid sequence of the Momordica charantia DGAT2 homolog(SEQ ID NO:26) was evaluated by BLASTP for similarity to all publiclyavailable protein sequences contained in the “nr” database and yieldedan E value of e-128 (223/318 identical amino acids) versus thehypothetical protein from Vitis vinifera (SEQ ID NO:16) and yielded an Evalue of e-118 (201/299 identical amino acids) versus the diacylglycerolacyltransferase from Arabidopsis thaliana (NCBI Accession No.NP_(—)566952 (GI:18409359); SEQ ID NO:27). BLAST scores andprobabilities indicate that the instant nucleic acid fragment (SEQ IDNO:25) encodes an entire DGAT2 gene, hereby named McDGAT2.

The amino acid sequence of McDGAT2 (SEQ ID NO:26) is 68.5% identical tothat of Vitis vinifera (SEQ ID NO:16) using the Clustal V method usingthe default settings described in Example 1. Additionally, the aminoacid sequence on McDGAT2 (SEQ ID NO:26) is 51.1% identical to that ofCoDGAT2 (SEQ ID NO:15) when compared using Clustal V as described inExample 1.

Example 3 Construction of Soybean Expression Vectors for Co-ExpressingMomordica charantia Conjugase (McConj) with McDGAT2 and/or McMBOAT

McDGAT2 (SEQ ID NO:25) was PCR amplified from the first strand cDNA asdescribed in Example 2 and the resulting PCR product, flanked by NotIsites, was cloned into the pGEM®-T Easy Vector (Promega) following themanufacturer's protocol to produce pHD40 (SEQ ID NO:28). The NotIfragment of pHD40, containing McDGAT2, was cloned into the NotI site ofpKR974, which was previously described in PCT Publication No. WO2008/137516 (the contents of which is incorporated by reference), toproduce pKR1543 (SEQ ID NO:29). In pKR1543, McDGAT2 is under control ofthe soy glycinin Gy1 promoter.

Cloning of the Momordica charantia fatty acid conjugase (McConj; SEQ IDNO:30) flanked by NotI sites into soybean expression vector KS67 wasdescribed previously in U.S. Pat. No. 7,244,563, and the expressionvector described there is hereby named pKmo-1. The NotI fragment ofpKmo-1, containing McConj, was cloned into the NotI site of pKR72, whichwas previously described in PCT Publication No. WO 2004/071467 (thecontents of which is incorporated by reference), to produce pKR458 (SEQID NO:31). In pKR458, McConj is under control of the soybeta-conglycinin promoter.

McMBOAT was PCR amplified from the first strand cDNA described inExample 1 using Tag polymerase (Invitrogen Corporation) following themanufacturer's protocol with oligonucleotide McLPCATNot5 (SEQ ID NO:32)and McLPCATNot3 (SEQ ID NO:33). The resulting PCR product was clonedinto the pGEM®-T Easy Vector (Promega) following the manufacturer'sprotocol to produce pHD41 (SEQ ID NO:34). The NotI fragment of pHD41(SEQ ID NO:34), containing McMBOAT, was cloned into the NotI site ofpKR457, which was previously described in U.S. Pat. No. 7,256,033 (thecontents of which is incorporated by reference). The resultingintermediate vector containing McMBOAT under control of the soy KTipromoter was digested with BsiWI and the fragment containing McMBOAT wascloned into the BsiWI site of pKR458 (SEQ ID NO:31) to produce pKR1548(SEQ ID NO:35). In pKR1548, McConj is under control of the soybeta-conglycinin promoter and McMBOAT is under control of the KTipromoter.

The SbfI fragment of pKR1543 (SEQ ID NO:29), containing McDGAT2, wascloned into the SbfI site of pKR1548 (SEQ ID NO:35) to produce pKR1556(SEQ ID NO:36). In pKR1556, McConj is under control of the soybeta-conglycinin promoter, McMBOAT is under control of the KTi promoterand McDGAT2 is under control of the soy glycinin Gy1 promoter.

Plasmid pKR1556 (SEQ ID NO:36) was digested with BsiWI and the fragmentcontaining McConj and McDGAT2 was religated to produce pKR1562 (SEQ IDNO:37). In pKR1562, McConj is under control of the soy beta-conglycininpromoter, and McDGAT2 is under control of the soy glycinin Gy1 promoter.

Example 4 Construction of Soybean Expression Vectors for Co-ExpressingCalendula officinalis Conjugase (CoConj) with CoDGAT2 and/or CoMBOAT

CoDGAT2 (SEQ ID NO:14) was PCR amplified from clone ecs1c.pk002.d16,described in Example 2, using the Phusion™ High-Fidelity DNA Polymerase(Cat. No. F553S, Finnzymes Oy, Finland) following the manufacturer'sprotocol and using oligonucleotide CoDGAT-5Not (SEQ ID NO:38) andCoDGAT-3Not (SEQ ID NO:39). The resulting DNA fragment was cloned intothe pCR-Blunt® cloning vector using the Zero Blunt® PCR Cloning Kit(Invitrogen Corporation), following the manufacturer's protocol, toproduce pLF167 (SEQ ID NO:76). The NotI fragment of pLF167 (SEQ IDNO:76), containing CoDGAT2, was cloned into the NotI site of pKR407,previously described in PCT Publication No. WO 2008/124048 (the contentsof which is incorporated by reference), to produce pKR1493 (SEQ IDNO:40). In pKR1493, CoDGAT2 is under control of the soy glycinin Gy1promoter.

Cloning of the Calendula officinalis fatty acid conjugase (CoConj; SEQID NO:41) flanked by NotI sites into a yeast expression vector wasdescribed previously in U.S. Pat. No. 7,230,090, and the expressionvector described there is hereby named pY32. The NotI fragment of pY32,containing McConj, was cloned into the NotI site of pKR72, which waspreviously described in PCT Publication No. WO 2004/071467, to producepKR1487 (SEQ ID NO:42). In pKR1487, CoConj is under control of the soybeta-conglycinin promoter.

The 5′ end of CoMBOAT (SEQ ID NO:2) was PCR amplified from cloneecs1c.pk007.c17, described in Example 1, using the Phusion™High-Fidelity DNA Polymerase (Cat. No. F553S, Finnzymes Oy, Finland)following the manufacturer's protocol and using oligonucleotideCoLPCAT-5Not (SEQ ID NO:43) and CoLPCATNco-3 (SEQ ID NO:44), which wasdesigned to delete an internal NcoI site but not alter the amino acidsequence. The 3′ end of CoMBOAT (SEQ ID NO:2) was PCR amplified fromclone ecs1c.pk007.c17 similarly but using oligonucleotide CoLPCATNco-5(SEQ ID NO:45), which was designed to delete an internal NcoI site, butnot alter the amino acid sequence, and CoLPCAT-3Not (SEQ ID NO:46). Theresulting PCR products were purified, combined and re-amplified usingCoLPCAT-5Not (SEQ ID NO:43) and CoLPCAT-3Not (SEQ ID NO:46). The new DNAsequence of CoMBOAT which has the NotI site removed but does not changethe encoded amino acid sequence is set forth in SEQ ID NO:47. Theresulting DNA fragment was cloned into the pCR-Blunt® cloning vectorusing the Zero Blunt® PCR Cloning Kit (Invitrogen Corporation),following the manufacturer's protocol, to produce pLF166 (SEQ ID NO:48).The NotI fragment of pLF166 (SEQ ID NO:48), containing CoMBOAT, wascloned into the NotI site of pKR457, which was previously described inU.S. Pat. No. 7,256,033. The resulting intermediate vector containingCoMBOAT under control of the soy KTi promoter was digested with BsiWIand the fragment containing CoMBOAT was cloned into the BsiWI site ofpKR1487 (SEQ ID NO:42) to produce pKR1492 (SEQ ID NO:49). In pKR1492,CoConj is under control of the soy beta-conglycinin promoter, andCoMBOAT is under control of the KTi promoter.

The PstI fragment of pKR1493 (SEQ ID NO:40), containing CoDGAT2 wascloned into the SbfI site of pKR1492 (SEQ ID NO:49) to produce pKR1498(SEQ ID NO:50). In pKR1498, CoConj is under control of the soybeta-conglycinin promoter, CoMBOAT is under control of the KTi promoter,and CoDGAT2 is under control of the soy glycinin Gy1 promoter.

Plasmid pKR1498 (SEQ ID NO:50) was digested with BsiWI and the fragmentcontaining CoConj and CoDGAT2 was religated to produce pKR1504 (SEQ IDNO:51). In pKR1504, CoConj is under control of the soy beta-conglycininpromoter, and CoDGAT2 is under control of the soy glycinin Gy1 promoter.

Example 5 Construction of Arabidopsis Expression Vectors forCo-Expressing McConj with McDGAT2 and/or McMBOAT and for Co-expressingCoConj with CoDGAT2 and/or CoMBOAT

An Arabidopsis binary vector (pKR92) containing a unique AscI site forcloning expression cassettes was previously described in WO 2007/061845(the contents of which are incorporated by reference).

The AscI fragment of pKR458 (SEQ ID NO:31), containing McConj, wascloned into the AscI site of pKR92 to produce pKR539 (SEQ ID NO:52).

The AscI fragment of pKR1548 (SEQ ID NO:35), containing McConj andMcMBOAT, was cloned into the AscI site of pKR92 to produce pKR1563 (SEQID NO:53).

The AscI fragment of pKR1556 (SEQ ID NO:36), containing McConj, McMBOATand McDGAT2, was cloned into the AscI site of pKR92 to produce pKR1564(SEQ ID NO:54).

The AscI fragment of pKR1562 (SEQ ID NO:37), containing McConj andMcDGAT2, was cloned into the AscI site of pKR92 to produce pKR1565 (SEQID NO:55).

The AscI fragment of pKR1487 (SEQ ID NO:42), containing CoConj, wascloned into the AscI site of pKR92 to produce pKR1507 (SEQ ID NO:56).

The AscI fragment of pKR1492 (SEQ ID NO:49), containing CoConj andCoMBOAT, was cloned into the AscI site of pKR92 to produce pKR1508 (SEQID NO:57).

The AscI fragment of pKR1498 (SEQ ID NO:50), containing CoConj, CoMBOATand CoDGAT2, was cloned into the AscI site of pKR92 to produce pKR1509(SEQ ID NO:58).

The AscI fragment of pKR1504 (SEQ ID NO:51), containing CoConj andCoDGAT2, was cloned into the AscI site of pKR92 to produce pKR1510 (SEQID NO:59).

Example 6 Construction of Soybean Expression Vectors for Co-ExpressingMortierella alpine Delta-6 Desaturase (MaD6Des) and Mortierella alpinaElongase (MaElo) with Either CoMBOAT or McMBOAT

The construction of plasmids pKR272 (SEQ ID NO:106) was previouslydescribed in U.S. Pat. No. 7,256,033 and consisted of releasing theGy1/Maelo/IegA2 cassette from plasmid pKR270 by digestion with BsiWI andSbfI and was cloned into the BsiWI/SbfI sites of plasmid pKR269(containing the delta-6 desaturase, the T7prom/hpt/T7term cassette andthe bacterial ori region). This was designated as plasmid pKR272 (SEQ IDNO:106). Plasmid pKR278 was constructed as described below. A startingplasmid pKR85, containing the hygromycin B phosphotransferase gene (HPT)(Gritz, L. and Davies, J., Gene 25:179-188 (1983)), flanked by the T7promoter and transcription terminator (T7prom/hpt/T7term cassette), anda bacterial origin of replication (ori) for selection and replication inbacteria (e.g., E. coli) was used. In addition, pKR72 also contains thehygromycin B phosphotransferase gene, flanked by the 35S promoter (Odellet al., Nature 313:810-812 (1985)) and NOS 3′ transcription terminator(Depicker et al., J. Mol. Appl. Genet. 1:561-570 (1982)) (35S/hpt/NOS3′cassette) for selection in plants such as soybean. Plasmid pKR85 alsocontains a NotI restriction site, flanked by the promoter for the α′subunit of β-conglycinin (Beachy et al., EMBO J. 4:3047-3053 (1985)) andthe 3′ transcription termination region of the phaseolin gene (Doyle etal., J. Biol. Chem. 261:9228-9238 (1986)), called Bcon/NotI/Phas3′cassette.

The Bcon/NotI/Phas3′ cassette was removed from pKR85 by digestion withHindIII and the resulting fragment was re-ligated to produce pKR278 (SEQID NO:107).

The AscI fragment of pKR272, containing the Mortierella alpina delta-6desaturase (MaD6Des) and the Mortierella alpine elongase (MaElo), wascloned into the AscI site of pKR278 to produce pKR1561 (SEQ ID NO:60).In pKR1561, MaD6Des is under control of the soy beta-conglycininpromoter and MaElo is under control of the soy glycinin Gy1 promoter.

The intermediate vector, containing McMBOAT under control of the soy KTipromoter described in Example 3, was digested with BsiWI and thefragment containing McMBOAT was cloned into the BsiWI site of pKR272 toproduce pKR1544 (SEQ ID NO:61). The AscI fragment of pKR1544 (SEQ IDNO:61), containing MaD6Des, MaElo and McMBOAT, was cloned into the AscIsite of pKR278 to produce pKR1549 (SEQ ID NO:62). In pKR1549, MaD6Des isunder control of the soy beta-conglycinin promoter, MaElo is undercontrol of the soy glycinin Gy1 promoter and McMBOAT is under control ofthe soy KTi promoter.

The intermediate vector, containing CoMBOAT under control of the soy KTipromoter described in Example 4, was digested with BsiWI and thefragment containing CoMBOAT was cloned into the BsiWI site of pKR272 toproduce pKR1546 (SEQ ID NO:63). The AscI fragment of pKR1546 (SEQ IDNO:63), containing MaD6Des, MaElo and CoMBOAT, was cloned into the AscIsite of pKR278 to produce pKR1557 (SEQ ID NO:64). In pKR1557, MaD6Des isunder control of the soy beta-conglycinin promoter, MaElo is undercontrol of the soy glycinin Gy1 promoter and CoMBOAT is under control ofthe soy KTi promoter.

Example 7 Construction of Soybean Expression Vectors for Co-ExpressingEuglena gracilis Delta-9 Elongase (EgD9Elo) and Tetruetreptiapomquetensis Delta-8 Desaturase (TpomD8Des) with Either CoMBOAT orMcMBOAT

The construction of plasmid pKR1020r was previously described in PCTPublication No. WO 2008/063340, the contents of which are incorporatedby reference. The AscI fragment of pKR1020r, containing the Euglenagracilis delta-9 elongase (EgD9Elo) and the Tetruetreptia pomquetensisdelta-8 desaturase (TpomD8Des), was cloned into the AscI site of pKR278to produce pKR1560 (SEQ ID NO:65). In pKR1560, EgD9Elo is under controlof the soy beta-conglycinin promoter, and TpomD8Des is under control ofthe soy glycinin Gy1 promoter.

The intermediate vector, containing McMBOAT under control of the soy KTipromoter described in Example 3, was digested with BsiWI and thefragment containing McMBOAT was cloned into the BsiWI site of pKR1020rto produce pKR1545 (SEQ ID NO:66). The AscI fragment of pKR1545 (SEQ IDNO:66), containing EgD9Elo, TpomD8Des and McMBOAT, was cloned into theAscI site of pKR278 to produce pKR1550 (SEQ ID NO:67). In pKR1550,EgD9Elo is under control of the soy beta-conglycinin promoter, TpomD8Desis under control of the soy glycinin Gy1 promoter and McMBOAT is undercontrol of the soy KTi promoter.

The intermediate vector, containing CoMBOAT under control of the soy KTipromoter described in Example 4, was digested with BsiWI and thefragment containing CoMBOAT was cloned into the BsiWI site of pKR1020Rto produce pKR1547 (SEQ ID NO:68). The AscI fragment of pKR1547 (SEQ IDNO:68), containing EgD9Elo, TpomD8Des and CoMBOAT, was cloned into theAscI site of pKR278 to produce pKR1558 (SEQ ID NO:69). In pKR1558,EgD9Elo is under control of the soy beta-conglycinin promoter, TpomD8Desis under control of the soy glycinin Gy1 promoter and CoMBOAT is undercontrol of the soy KTi promoter.

Example 8 Construction of Arabidopsis Expression Vectors forCo-Expressing MaD6Des and MaElo with McMBOAT or CoMBOAT and forCo-Expressing EgD9Elo and TpomD8Des with McMBOAT or CoMBOAT

The AscI fragment of pKR272, containing MaD6Des and MaElo, was clonedinto the AscI site of pKR92 to produce pKR1559 (SEQ ID NO:70).

The AscI fragment of pKR1544 (SEQ ID NO:61), containing MaD6Des, MaEloand McMBOAT, was cloned into the AscI site of pKR92 to produce pKR1552(SEQ ID NO:71).

The AscI fragment of pKR1546 (SEQ ID NO:63), containing MaD6Des, MaEloand CoMBOAT, was cloned into the AscI site pKR92 to produce pKR1554 (SEQID NO:72).

The AscI fragment of pKR1020r, containing EgD9Elo and TpomD8Des, wascloned into the AscI site of pKR92 to produce pKR1022 (SEQ ID NO:73).

The AscI fragment of pKR1545 (SEQ ID NO:66), containing EgD9Elo,TpomD8Des and McMBOAT, was cloned into the AscI site of pKR92 to producepKR1553 (SEQ ID NO:74).

The AscI fragment of pKR1547 (SEQ ID NO:68), containing EgD9Elo,TpomD8Des and CoMBOAT, was cloned into the AscI site of pKR92 to producepKR1555 (SEQ ID NO:75).

Example 9 Co-Expressing MaD6Des and MaElo (Delta-6 Desaturase Pathway)with McMBOAT or CoMBOAT in Arabidopsis Seed

Generation and Analysis of Transgenic Arabidopsis Lines:

Plasmid DNA of pKR1559 (SEQ ID NO:70), comprising MaD6Des and MaElo,pKR1552 (SEQ ID NO:71), comprising MaD6Des, MaElo and McMBOAT, orpKR1554 (SEQ ID NO:72), comprising MaD6Des, MaElo and CoMBOAT, wasintroduced into Agrobacterium tumefaciens NTL4 (Luo et al, MolecularPlant-Microbe Interactions 14(1):98-103 (2001)) by electroporation.Briefly, 1 μg plasmid DNA was mixed with 100 μL of electro-competentcells on ice. The cell suspension was transferred to a 100 μL electrooration curette (1 mm gap width) and electroporated using a BIORADelectro orator set to 1 kV, 400Ω and 25 μF. Cells were transferred to 1mL LB medium and incubated for 2 h at 30° C. Cells were plated onto LBmedium containing 50 μg/mL kanamycin. Plates were incubated at 30° C.for 60 h. Recombinant agrobacterium cultures (500 mL LB, 50 μg/mLkanamycin) were inoculated from single colonies of transformedagrobacterium cells and grown at 30° C. for 60 h. Cells were harvestedby centrifugation (5000×g, 10 min) and resuspended in 1 L of 5% (WN)sucrose containing 0.05% (V/V) Silwet.

Arabidopsis plants were grown in soil at a density of 30 plants per 100cm² pot in metromix 360 soil mixture for 4 weeks (22° C., permanentlight, 100 μE m⁻²s⁻¹). Plants were repeatedly dipped into theagrobacterium suspension harboring the binary vectors and kept in adark, high humidity environment for 24 h. Plants were grown for four tofive weeks under standard plant growth conditions described above, andplant material was harvested and dried for one week at ambienttemperatures in paper bags. Seeds were harvested using a 0.425 mm meshbrass sieve.

Cleaned Arabidopsis seeds (2 g, corresponding to about 100,000 seeds)were sterilized by washes in 45 mL of 80% ethanol, 0.01% triton X-100,followed by 45 mL of 30% (V/V) household bleach in water, 0.01% tritonX-100 and finally by repeated rinsing in sterile water. Aliquots of20,000 seeds were transferred to square plates (20×20 cm) containing 150mL of sterile plant growth medium comprised of 0.5×MS salts, 1.0% (WN)sucrose, 0.05 MES/KOH (pH 5.8), 200 μg/mL timentin, and 50 μg/mLkanamycin solidified with 10 g/L agar. Homogeneous dispersion of theseed on the medium was facilitated by mixing the aqueous seed suspensionwith an equal volume of melted plant growth medium, Plates wereincubated under standard growth conditions for ten days.

Kanamycin-resistant seedlings were transferred to soil (Metromix 360)and grown to maturity for 8-10 weeks as described above. For eachconstruct, approximately 24 individual kanamycin resistant seedlings(events) were planted and plants were grown in flats with 36 inserts. T2seeds were harvested from individual plants and the fatty acidcomposition of the seed oil was determined as follows.

Analysis of the Fatty Acid Profile of Arabdidopsis Seed

Bulk T2 seed lipid fatty acid profiles for each event were obtained bytransesterification with TMSH to form fatty acid methyl esters (FAME).For each event, a small scoopful of seeds (approximately 25-50 seed eachscoopful) was crushed in 50 μL of TMSH in a 1.5 mL eppendorf tube. Aftershaking in TMSH for 15 min, 400 μL of heptane was added and the tubeswere vortexed well, shaken for an additional 15 min and centrifuged at13,000×g for 1 min. After shaking, the heptane layer was removed intoglass GC vials and the fatty acid methyl esters were analyzed asfollows.

Fatty acid methyl esters (1 μL injected from hexane layer) wereseparated and quantified using a Hewlett-Packard 6890 Gas Chromatographfitted with an Omegawax 320 fused silica capillary column (Catalog#24152, Supelco Inc.). The oven temperature was programmed to hold at220° C. for 2.6 min, increase to 240° C. at 20° C./min and then hold foran additional 2.4 min. Carrier gas was supplied by a Whatman hydrogengenerator. Retention times were compared to those for methyl esters ofstandards commercially available (Nu-Chek Prep, Inc.). Results for fattyacid analysis of T2 bulk seed pools for events from Arabidopsistransformed with pKR1559 (SEQ ID NO:70), comprising MaD6Des and MaElo,pKR1552 (SEQ ID NO:71), comprising MaD6Des, MaElo and McMBOAT, orpKR1554 (SEQ ID NO:72), comprising MaD6Des, MaElo and CoMBOAT aresummarized in TABLEs 2, 3, and 4, respectively. A typical fatty acidprofile for wild-type Arabidopsis seed is also shown in TABLE 2.

In the Tables, the fatty acid profiles as a weight percent of totalfatty acids are shown where 16:0 is palmitic acid, 18:0 is stearic acid,18:1 is oleic acid, 18:2 is linoleic acid, GLA is gamma-linolenic acid,18:3 is alpha-linolenic acid, STA is stearidonic acid, 20:1 iseicosenoic acid [20:1(Δ11)], EDA is eicosadienoic acid [20:2(Δ11,14)],DGLA is dihomo-gamma-linolenic acid, ERA is eicosatrienoic acid[20:3(Δ11,14,17)] and ETA is eicosatetraenoic acid [20:1(Δ8,11,14,17)].The sum of GLA+STA, EDA+ERA or DGLA+ETA is also shown. Results for eachevent are sorted according to DGLA+ETA concentrations in decreasingorder. The average fatty acid profiles for the five events havinghighest DGLA+ETA content from each experiment are also shown in eachtable (Avg. **).

TABLE 2 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1559 comprising MaD6Des and MaElo GLA +EDA + DGLA + Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:1 EDA DGLA ERAETA STA ERA ETA 17 9.1 3.0 11.1 21.8 8.1 16.7 2.8 17.5 3.1 5.2 0.0 1.610.9 3.1 6.8 16 9.3 2.8 10.8 22.5 8.2 18.4 2.8 15.6 3.0 5.1 0.0 1.5 11.13.0 6.6 23 8.4 2.6 12.0 23.9 7.2 17.5 2.2 17.3 3.0 4.6 0.0 1.2 9.4 3.05.8 15 8.3 2.8 12.5 24.4 6.8 17.6 1.9 17.9 2.9 3.9 0.0 0.9 8.7 2.9 4.822 8.2 2.7 12.9 24.4 7.5 17.1 2.1 17.8 2.8 3.7 0.0 0.9 9.6 2.8 4.6 148.6 3.0 11.7 22.3 7.6 18.1 2.6 18.8 2.8 3.4 0.0 1.1 10.2 2.8 4.5 11 8.33.1 12.5 21.4 9.0 16.7 2.9 19.4 2.6 3.3 0.0 0.9 11.9 2.6 4.1 13 8.7 13.20.0 25.3 6.8 18.5 2.1 18.5 2.7 3.2 0.0 0.9 9.0 2.7 4.1 18 7.9 2.9 14.324.1 6.6 16.5 1.9 19.3 2.6 3.1 0.0 0.8 8.5 2.6 3.9 6 7.8 3.0 14.5 23.57.3 16.4 2.0 18.0 2.6 3.0 1.1 0.7 9.3 3.7 3.7 2 7.4 2.9 15.2 25.7 5.716.4 1.4 18.9 2.5 2.4 0.9 0.5 7.1 3.4 2.9 3 7.5 2.8 15.3 26.7 4.2 17.41.1 19.0 2.7 1.8 1.0 0.5 5.3 3.6 2.3 1 8.2 2.8 15.3 29.2 2.5 19.0 0.618.6 2.0 1.1 0.5 0.3 3.1 2.5 1.4 20 8.4 2.6 14.9 31.3 1.2 19.2 0.3 19.42.3 0.4 0.0 0.0 1.5 2.3 0.4 9 8.6 2.8 16.0 31.2 1.0 19.8 0.2 17.5 2.00.3 0.5 0.0 1.2 2.5 0.3 19 8.9 2.8 13.7 32.7 0.4 21.1 0.1 16.8 3.4 0.20.0 0.0 0.5 3.4 0.2 7 8.0 2.9 16.1 30.9 0.1 20.4 0.0 18.8 2.1 0.1 0.60.0 0.2 2.7 0.1 10 7.1 2.3 18.8 30.2 0.3 20.0 0.1 19.4 1.5 0.1 0.4 0.00.4 1.8 0.1 21 7.3 2.2 16.3 32.2 0.2 20.2 0.0 19.5 2.1 0.1 0.0 0.0 0.22.1 0.1 4 8.1 2.7 18.3 36.4 0.1 15.1 0.0 15.0 3.3 0.0 1.1 0.0 0.1 4.30.0 5 8.6 2.8 15.5 24.9 8.4 18.1 2.3 17.1 1.8 0.0 0.5 0.0 10.7 2.3 0.0 87.3 2.6 17.9 29.9 0.1 21.0 0.0 19.0 1.7 0.0 0.4 0.0 0.1 2.2 0.0 12 7.52.0 17.1 28.7 0.0 22.2 0.0 20.8 1.8 0.0 0.0 0.0 0.0 1.8 0.0 Avg.** 8.62.8 11.9 23.4 7.6 17.5 2.4 17.2 3.0 4.5 0.0 1.2 9.9 3.0 5.7

TABLE 3 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1552 comprising MaD6Des, MaElo andMcMBOAT GLA + EDA + DGLA + Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:1EDA DGLA ERA ETA STA ERA ETA 9 10.0 3.8 9.8 7.6 19.3 6.4 5.9 11.3 3.316.3 2.2 4.1 25.2 5.5 20.4 17 8.3 3.0 11.6 18.9 9.0 12.3 2.4 12.9 3.213.0 1.7 3.4 11.5 5.0 16.5 11 9.2 3.3 11.6 18.5 9.9 11.4 2.6 12.4 3.212.9 1.6 3.4 12.4 4.8 16.3 18 9.2 3.2 13.4 12.2 16.5 9.1 4.7 10.8 3.012.8 1.9 3.0 21.2 4.9 15.8 1 8.4 3.7 10.3 12.2 16.4 9.5 5.0 13.5 3.112.1 2.2 3.4 21.4 5.4 15.5 16 9.0 3.2 11.3 18.8 9.9 13.1 3.0 13.2 3.210.5 1.7 3.1 12.9 4.9 13.6 19 8.6 3.9 11.5 13.1 17.2 9.4 4.5 13.7 3.110.5 2.0 2.5 21.7 5.1 13.0 2 7.5 3.3 11.7 15.7 13.8 12.4 3.9 16.6 3.18.0 1.9 2.2 17.7 5.0 10.2 6 7.6 3.2 12.2 16.0 14.4 13.0 4.2 15.2 3.0 7.31.9 1.9 18.6 5.0 9.2 13 7.9 3.1 11.9 21.0 9.4 15.8 2.5 16.4 2.7 6.2 1.31.7 11.9 4.0 7.9 3 7.8 3.1 13.1 23.2 6.4 16.8 1.6 16.2 3.0 5.8 1.6 1.58.0 4.6 7.3 15 7.7 3.0 12.9 24.6 6.3 15.9 1.5 16.7 3.1 5.6 1.4 1.4 7.84.4 7.0 21 8.1 3.2 12.2 22.4 8.2 16.1 2.1 17.0 2.8 5.4 1.3 1.3 10.3 4.16.7 14 7.9 2.9 14.3 24.9 5.6 16.7 1.4 17.0 2.7 4.3 1.2 1.0 7.0 3.9 5.3 47.5 3.1 13.6 24.7 5.5 17.5 1.4 17.9 2.8 3.8 1.3 0.9 6.9 4.0 4.7 10 8.92.9 15.7 28.3 3.7 16.9 0.9 14.0 3.3 3.2 1.4 0.7 4.6 4.8 3.9 5 8.6 2.914.7 28.3 4.2 17.1 1.1 14.6 3.3 3.0 1.4 0.9 5.3 4.7 3.8 20 7.7 3.0 14.931.9 0.7 18.5 0.1 17.8 3.5 0.4 1.4 0.1 0.8 4.9 0.5 12 8.1 2.7 15.7 32.20.2 20.3 0.1 18.0 1.8 0.3 0.4 0.1 0.3 2.2 0.4 7 7.6 2.7 17.1 33.0 0.318.9 0.1 17.8 1.9 0.2 0.5 0.0 0.3 2.4 0.2 8 7.9 3.1 16.0 26.7 4.6 19.61.4 18.4 1.8 0.0 0.5 0.0 6.0 2.3 0.0 Avg.** 9.0 3.4 11.4 13.9 14.2 9.84.1 12.2 3.2 13.4 1.9 3.5 18.3 5.1 16.9 Col-1 8.0 2.8 15.7 31.3 0.3 20.70.0 18.6 2.0 0.2 0.5 0.0 0.3 2.4 0.2

TABLE 4 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1554 comprising MaD6Des, MaElo andCoMBOAT GLA + EDA + DGLA + Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:1EDA DGLA ERA ETA STA ERA ETA 10 10.4 3.6 9.0 7.6 22.2 7.3 6.3 13.2 2.313.0 1.3 4.0 28.5 3.5 17.0 3 10.9 4.0 17.5 2.3 13.7 14.9 3.6 17.7 2.89.1 1.5 2.2 17.3 4.4 11.2 2 11.1 3.9 18.8 1.2 11.2 17.5 2.9 18.5 3.2 8.41.4 2.0 14.1 4.6 10.3 13 8.1 3.2 12.1 17.1 13.2 13.1 4.1 14.7 2.9 7.61.8 2.1 17.3 4.7 9.7 9 9.1 3.4 14.9 20.3 8.5 13.4 2.3 15.0 2.7 7.4 1.31.8 10.8 4.0 9.2 4 11.3 3.7 14.1 2.3 18.2 15.9 5.5 16.3 2.4 7.2 1.3 1.923.6 3.7 9.1 14 9.9 3.6 12.8 17.6 14.7 12.6 3.6 14.1 2.1 6.6 0.9 1.518.3 3.0 8.2 7 9.4 3.3 13.1 19.4 12.9 13.7 3.6 13.1 2.3 6.4 1.2 1.6 16.63.5 8.0 5 8.9 3.1 12.2 17.9 14.4 13.2 3.9 15.1 2.3 6.1 1.2 1.5 18.4 3.67.6 11 7.6 3.2 12.5 18.8 10.9 15.1 3.3 16.8 3.0 5.6 1.8 1.5 14.2 4.7 7.18 8.8 3.3 10.9 19.6 11.1 15.7 3.6 16.3 2.6 5.2 1.3 1.5 14.7 3.9 6.7 18.2 2.9 15.1 27.0 0.2 13.8 0.0 13.3 9.6 4.3 4.8 1.0 0.2 14.4 5.2 12 8.42.9 11.6 23.3 7.6 18.5 2.3 17.1 2.8 3.1 1.4 0.9 10.0 4.2 4.0 6 8.6 3.115.0 22.4 10.3 17.5 3.0 17.1 1.9 0.4 0.6 0.0 13.3 2.4 0.4 Avg.** 9.9 3.614.4 9.7 13.8 13.2 3.8 15.8 2.8 9.1 1.5 2.4 17.6 4.2 11.5

A summary of the average fatty acid profiles for the five events havinghighest DGLA+ETA content from each experiment (Avg. **) is shown inTABLE 5. In TABLE 5, the calculated % delta-6 desaturation conversionefficiency (% D6) is also shown for the average of the five eventshaving highest DGLA+ETA content from each experiment where the % D6 wascalculated by dividing the sum of the average weight percent (wt. %) forGLA, STA, DGLA and ETA by the sum of the average wt. % for 18:2, 18:3,GLA, STA, DGLA and ETA and multiplying by 100 to express as a %.Similarly, the calculated % C₁₈ to C₂₀ elongation conversion efficiency(% Elo) is shown in TABLE 5 for the average of the five events havinghighest DGLA+ETA content from each experiment where the % Elo wascalculated by dividing the sum of the average weight percent (wt. %) forDGLA and ETA by the sum of the average wt. % for GLA, STA, DGLA and ETAand multiplying by 100 to express as a %. Also shown in TABLE 5 is therelative % desaturation (Rel % D6) and relative % elongation (Rel % Elo)for each experiment where the % D6 or % Elo for the experiment isdivided by the % D6 or % Elo for that of pKR1559 (MaD6, MaElo).

TABLE 5 Comparison of the average fatty acid profiles for the 5 bestevents for MBOATs co-expressed with a Mortiella alpina delta- 6desaturase and Mortiella alpina elongase (delta-6 PUFA patheway) inArabidopsis Experiment Rel Rel Avg.** 16:0 18:0 18:1 18:2 GLA 18:3 STA20:1 EDA DGLA ERA ETA % D6 % Elo % D6 % Elo pKR1559 8.6 2.8 11.9 23.47.6 17.5 2.4 17.2 3.0 4.5 0.0 1.2 27.7 36.3 1.00 1.00 (MaD6, MaElo)pKR1552 9.0 3.4 11.4 13.9 14.2 9.8 4.1 12.2 3.2 13.4 1.9 3.5 59.8 49.02.16 1.35 (MaD6, MaElo, McMBOAT) pKR1554 9.9 3.6 14.4 9.7 13.8 13.2 3.815.8 2.8 9.1 1.5 2.4 55.8 40.2 2.02 1.11 (MaD6, MaElo, CoMBOAT)

TABLEs 2-5 demonstrate that co-expression of either McMBOAT or CoMBOATalong with MaD6Des and MaElo leads to higher % D6 and % Elo activity inArabidopsis seed. % D6 and % Elo is higher with McMBOAT than withCoMBOAT and both are higher than without co-expression of an MBOAT.

Example 10 Co-Expressing EgD9Elo and TpomD8Des (Delta-9 ElongasePathway) with McMBOAT or CoMBOAT in Arabidopsis Seed

Plasmid DNA of pKR1022 (SEQ ID NO:73), comprising EgD9Elo and TpomD8Des,pKR1553 (SEQ ID NO:74), comprising EgD9Elo, TpomD8Des and McMBOAT, orpKR1555 (SEQ ID NO:75), comprising EgD9Elo, TpomD8Des and CoMBOAT, wastransformed into Arabidopsis, transgenic plants were selected and grown,seeds were harvested and lipid fatty acid profiles were analyzed exactlyas described in Example 9.

Results for fatty acid analysis of T2 bulk seed pools for individualevents are summarized in TABLEs 6, 7, and 8, respectively. In theTables, the fatty acid profiles as a weight percent of total fatty acidsare shown exactly as described in Example 9.

TABLE 6 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1022 comprising EgD9Elo and TpomD8DesGLA + EDA + DGLA + Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:1 EDADGLA ERA ETA STA ERA ETA 16 9.0 2.8 15.2 22.2 0.2 10.5 0.0 12.4 10.1 8.96.0 2.6 0.2 16.2 11.5 6 8.1 2.9 17.2 26.1 0.2 14.7 0.0 14.9 6.5 4.8 3.41.2 0.2 9.9 6.1 4 7.6 2.7 18.0 25.7 0.1 14.6 0.0 15.3 6.4 4.5 3.7 1.40.1 10.1 5.9 17 7.2 2.9 17.1 27.2 0.0 13.4 0.0 16.7 7.5 3.6 3.7 0.8 0.011.1 4.3 7 8.3 3.0 14.8 27.7 0.1 14.3 0.0 15.5 8.0 3.4 4.2 0.8 0.1 12.24.2 11 8.0 2.9 15.8 27.9 0.0 14.6 0.0 15.7 7.3 3.3 3.7 0.8 0.0 11.0 4.113 7.6 3.1 16.2 27.1 0.0 13.9 0.0 16.7 7.8 3.0 4.0 0.7 0.0 11.8 3.7 147.8 2.9 15.4 26.8 0.0 15.2 0.0 16.3 7.9 2.8 4.3 0.7 0.0 12.2 3.5 2 7.72.7 16.4 28.0 0.0 14.5 0.0 16.0 7.6 2.7 3.7 0.6 0.0 11.3 3.4 10 7.7 2.614.3 25.0 0.0 12.4 0.0 14.1 13.7 2.5 7.1 0.5 0.0 20.9 3.0 5 8.7 2.9 12.625.8 0.1 15.9 0.0 14.6 10.0 2.3 6.5 0.6 0.1 16.5 3.0 9 7.4 2.7 14.3 25.40.0 14.7 0.0 15.5 11.0 2.2 6.2 0.6 0.0 17.2 2.8 15 8.4 2.7 13.0 26.0 0.013.0 0.0 13.3 13.9 2.0 7.4 0.3 0.0 21.3 2.3 8 7.4 2.8 16.4 27.9 0.0 15.00.0 16.5 8.0 1.7 3.9 0.3 0.0 11.9 2.0 12 8.4 2.8 13.9 27.0 0.0 16.1 0.015.1 9.4 1.5 5.4 0.3 0.0 14.8 1.8 3 7.7 2.7 15.5 30.3 0.0 18.7 0.0 19.33.8 0.6 1.2 0.2 0.0 5.0 0.8 1 8.2 2.8 16.9 32.3 0.0 19.4 0.0 18.3 1.80.0 0.3 0.0 0.0 2.2 0.0 Avg.** 8.0 2.9 16.5 25.8 0.1 13.5 0.0 15.0 7.75.0 4.2 1.3 0.1 11.9 6.4

TABLE 7 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1553 comprising EgD9Elo, TpomD8Des andMcMBOAT GLA + EDA + DGLA + Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:1EDA DGLA ERA ETA STA ERA ETA 10 9.1 2.8 17.6 22.0 0.3 8.8 0.0 10.0 10.211.5 5.0 2.8 0.3 15.1 14.3 9 9.6 3.1 15.4 21.9 0.2 10.0 0.0 11.3 11.68.7 5.9 2.4 0.2 17.5 11.0 12 9.6 2.8 17.0 24.9 0.0 12.1 0.0 11.7 7.7 9.03.3 1.9 0.0 11.0 10.9 1 8.7 3.1 14.0 22.9 0.0 11.2 0.0 11.2 11.8 8.1 6.82.2 0.0 18.6 10.3 7 9.6 3.0 14.7 24.4 0.0 12.8 0.0 11.6 9.6 7.3 5.0 2.00.0 14.6 9.3 2 8.6 2.7 16.1 27.9 0.0 11.4 0.0 12.9 9.0 6.6 3.5 1.4 0.012.5 8.0 4 8.2 3.0 14.5 26.5 0.0 15.0 0.0 14.0 8.2 4.6 4.7 1.2 0.0 12.95.8 8 8.5 2.7 17.3 28.8 0.2 15.0 0.0 15.3 4.9 3.8 2.4 1.1 0.2 7.3 4.9 118.9 2.9 14.0 27.5 0.4 15.6 0.0 12.8 8.5 3.9 4.6 0.9 0.4 13.1 4.8 3 8.32.9 15.1 28.0 0.0 14.9 0.0 13.4 8.6 3.6 4.4 0.8 0.0 13.0 4.4 13 8.4 2.417.3 31.9 0.0 16.2 0.0 16.2 4.5 1.4 1.6 0.0 0.0 6.0 1.4 5 8.2 2.7 15.831.6 0.0 21.1 0.0 17.8 2.1 0.0 0.6 0.0 0.0 2.7 0.0 6 8.2 2.7 14.3 27.20.0 14.1 0.0 12.3 14.7 0.0 6.4 0.0 0.0 21.2 0.0 14 8.4 2.6 16.7 33.5 0.019.4 0.0 17.3 1.8 0.0 0.4 0.0 0.0 2.1 0.0 Avg.** 9.3 2.9 15.7 23.2 0.111.0 0.0 11.2 10.2 8.9 5.2 2.3 0.1 15.4 11.2

TABLE 8 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1555 comprising EgD9Elo, TpomD8Des andCoMBOAT GLA + EDA + DGLA + Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:1EDA DGLA ERA ETA STA ERA ETA 7 8.3 2.8 17.9 23.3 0.2 10.5 0.0 12.0 9.37.9 5.2 2.5 0.2 14.5 10.4 3 8.5 3.0 16.4 25.6 0.2 13.0 0.0 14.1 7.7 5.94.1 1.6 0.2 11.8 7.5 20 8.6 2.9 13.3 24.9 0.3 12.6 0.1 12.9 11.0 5.6 6.11.6 0.4 17.0 7.2 6 8.7 3.1 14.1 25.6 0.1 13.1 0.1 13.8 9.8 5.2 5.1 1.30.2 14.9 6.6 11 7.4 2.6 16.9 27.0 0.1 13.4 0.0 14.5 7.9 5.0 4.0 1.3 0.211.9 6.2 17 7.8 3.2 14.6 26.5 0.1 14.3 0.0 16.0 7.8 4.1 4.6 1.1 0.1 12.45.2 19 7.4 3.2 15.3 26.4 0.1 14.3 0.0 16.1 7.6 4.2 4.4 1.1 0.2 12.0 5.210 7.8 2.8 16.5 27.7 0.1 14.9 0.0 15.5 6.5 3.8 3.2 1.1 0.1 9.7 4.8 187.9 3.3 14.2 29.0 0.1 14.8 0.0 15.2 6.8 3.7 3.9 1.1 0.1 10.8 4.8 15 7.73.1 14.7 27.0 0.1 16.0 0.1 16.2 6.6 3.7 3.9 1.1 0.1 10.5 4.7 8 8.1 3.014.2 26.5 0.1 14.0 0.1 14.2 9.9 3.6 5.5 0.9 0.1 15.4 4.5 16 8.1 2.9 14.127.8 0.1 16.1 0.1 15.5 7.1 3.5 3.8 0.9 0.1 11.0 4.4 1 7.6 2.8 15.2 27.50.1 14.7 0.0 15.8 7.7 3.5 4.2 0.9 0.1 11.9 4.3 5 7.9 3.3 15.6 27.2 0.115.8 0.0 15.4 6.6 3.3 3.9 0.9 0.1 10.5 4.2 21 7.8 3.0 13.9 26.3 0.1 15.00.0 16.0 8.6 3.4 4.9 0.8 0.1 13.5 4.2 9 7.9 2.9 14.8 28.0 0.0 14.5 0.016.5 7.7 2.9 4.0 0.7 0.0 11.8 3.6 12 8.2 3.0 14.0 28.2 0.0 15.8 0.1 15.67.6 2.8 4.0 0.7 0.1 11.6 3.5 2 7.9 2.7 13.5 25.8 0.1 14.8 0.1 13.7 11.92.1 6.8 0.5 0.2 18.7 2.7 4 7.3 2.7 15.9 31.3 0.3 20.2 0.0 19.5 2.2 0.20.5 0.0 0.3 2.6 0.2 13 6.8 2.3 14.5 28.1 0.0 12.9 0.0 14.3 14.6 0.1 6.20.0 0.0 20.8 0.1 14 7.2 2.7 15.5 29.0 0.0 22.2 0.1 20.2 2.3 0.1 0.7 0.00.1 3.0 0.1 Avg. 8.3 2.9 15.7 25.3 0.2 12.5 0.0 13.5 9.1 5.9 4.9 1.7 0.314.0 7.6 **

A summary of the average fatty acid profiles for the five events havinghighest DGLA+ETA content from each experiment (Avg. **) is shown inTABLE 9. In TABLE 9, the calculated % delta-9 elongation conversionefficiency (% D9Elo) is also shown for the average of the five eventshaving highest DGLA+ETA content from each experiment where the % D9Elowas calculated by dividing the sum of the average weight percent (wt. %)for EDA, ERA, DGLA and ETA by the sum of the average wt. % for 18:2,18:3, EDA, ERA, DGLA and ETA and multiplying by 100 to express as a %.Similarly, the calculated % delta-8 desaturation conversion efficiency(% D8) is shown in TABLE 9 for the average of the five events havinghighest DGLA+ETA content from each experiment where the % D8 wascalculated by dividing the sum of the average weight percent (wt. %) forDGLA and ETA by the sum of the average wt. % for EDA, ERA, DGLA and ETAand multiplying by 100 to express as a %. Also shown in TABLE 9 is therelative % delta-9 elongation (Rel % D9Elo) and relative % delta-8desaturation (Rel % D8) for each experiment where the % D69Elo or % D8for the experiment is divided by the % D9Elo or % D8 for that of pKR1022(EgD9Elo, TpomD8Des).

TABLE 9 Comparison of the average fatty acid profiles of the five bestevents for MBOATs co-expressed with a delta-9 elongase and delta-8desaturase (delta-9 elongase PUFA pathway) in Arabidopsis ExperimentAvg. ** 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:1 EDA DGLA ERA ETA % D9Elo %D8 Rel % D9Elo Rel % D8 pKR1022 8.0 2.9 16.5 25.8 0.1 13.5 0.0 15.0 7.75.0 4.2 1.3 31.6 34.0 1.00 1.00 (EgD9Elo, TpomD8Des) pKR1553 9.3 2.915.7 23.2 0.1 11.0 0.0 11.2 10.2 8.9 5.2 2.3 43.6 42.3 1.38 1.25(EgD9Elo TpomD8Des McMBOAT) pKR1555 8.3 2.9 15.7 25.3 0.2 12.5 0.0 13.59.1 5.9 4.9 1.7 36.3 35.1 1.15 1.03 EgD9Elo TpomD8Des CoMBOATTABLEs 6-9 demonstrate that co-expression of either McMBOAT or CoMBOATalong with MaD6Des and MaElo leads to higher % D9Elo activity inArabidopsis seed. % D9Elo is higher with McMBOAT than with CoMBOAT andboth are higher than without co-expression of an MBOAT. % D8 is alsoincreased with McMBOAT.

Example 11 Co-Expressing McConj with McDGAT2 and/or McMBOAT inArabidopsis Seed

Plasmid DNA of pKR539 (SEQ ID NO:52), comprising McConj, pKR1563 (SEQ IDNO:53), comprising McConj and McMBOAT, pKR1564 (SEQ ID NO:54),comprising McConj, McMBOAT and McDGAT2, or pKR1565 (SEQ ID NO:55),comprising McConj and McDGAT2, was transformed into Arabidopsis,transgenic plants were selected and grown, seeds were harvested andlipid fatty acid profiles were analyzed exactly as described in Example9,

Results for fatty acid analysis of T2 bulk seed pools for individualevents are summarized in TABLES 10, 11, 12, and 13, respectively. In theTables, the fatty acid profiles as a weight percent of total fatty acidsare shown where 16:0 is palmitic acid, 18:0 is stearic acid, 18:1 isoleic acid, 18:2 is linoleic acid, 18:3 is alpha-linolenic acid, 20:1 iseicosenoic acid [20:1(Δ11)], EDA is eicosadienoic acid [20:2(Δ11,14)]and ELEO is eleostearic acid. Results for each event are sortedaccording to elestearic acid concentrations in decreasing order. Theaverage fatty acid profiles for the five events having highest ELEOcontent from each experiment are also shown in each table (Avg. **)where only events having eleostearic acid greater than 1% are includedin the average calculation. When fewer than five events had ELEO greaterthan 1% then only those events were used in the calculation. In TABLE11, no events were obtained with ELEO greater than 1%.

TABLE 10 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR539 comprising McConj Event # 16:0 18:018:1 18:2 18:3 20:1 EDA ELEO 8 9.3 3.5 35.3 23.1 7.3 15.0 0.8 5.7 3 8.83.1 26.2 27.0 14.7 16.7 1.3 2.3 12 8.1 2.7 22.6 30.4 14.9 17.8 1.6 1.920 8.1 2.8 29.1 27.2 13.5 17.2 0.9 1.2 17 7.6 2.5 22.7 31.1 14.3 19.51.5 0.8 16 7.4 2.6 20.8 32.0 14.9 19.9 1.7 0.6 10 7.8 2.9 20.1 30.6 17.419.1 1.7 0.4 15 7.7 2.7 18.7 31.2 17.6 20.2 1.7 0.2 9 7.4 2.6 17.6 32.018.9 19.6 1.9 0.1 22 7.0 2.5 17.7 32.2 16.3 22.2 2.1 0.1 2 7.6 2.9 16.731.5 20.1 19.4 1.9 0.0 4 8.0 2.9 16.4 31.4 20.5 19.0 1.9 0.0 5 8.3 2.915.5 31.6 20.6 19.2 1.8 0.0 6 8.6 0.0 17.0 33.3 21.9 19.2 0.0 0.0 7 7.93.0 16.0 31.2 20.7 19.2 2.0 0.0 11 8.2 2.7 13.8 31.9 22.4 19.0 2.0 0.013 7.5 2.6 17.1 32.6 18.1 20.2 1.9 0.0 14 7.4 2.4 18.8 32.3 16.7 20.51.8 0.0 18 7.5 2.4 29.8 23.6 15.6 20.2 0.9 0.0 19 7.2 2.9 19.5 30.1 16.721.9 1.8 0.0 21 7.8 2.5 19.1 32.2 17.6 19.3 1.6 0.0 Avg. ** 8.6 3.0 28.326.9 12.6 16.7 1.1 2.8

TABLE 11 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1563 comprising McConj and McMBOAT Event# 16:0 18:0 18:1 18:2 18:3 20:1 EDA ELEO 9 7.7 3.0 24.3 28.9 17.2 16.81.4 0.8 18 8.6 2.6 17.4 32.3 19.6 17.5 1.7 0.4 1 7.5 2.4 20.4 34.4 15.917.8 1.6 0.0 2 8.5 2.8 15.9 32.7 20.5 17.6 1.9 0.0 3 7.7 2.8 14.7 32.321.2 19.1 2.2 0.0 4 13.5 2.6 15.0 36.0 19.7 11.7 1.4 0.0 5 7.6 2.5 17.434.1 18.9 17.4 1.9 0.0 6 8.1 2.9 16.2 32.0 20.3 18.4 2.0 0.0 7 8.0 2.915.4 31.7 21.3 18.6 2.0 0.0 8 9.1 2.9 13.1 33.4 22.1 17.3 2.1 0.0 10 7.42.2 18.1 34.9 17.7 18.0 1.8 0.0 11 7.8 2.2 17.4 34.8 17.9 17.9 1.9 0.012 8.0 2.4 16.4 32.4 19.5 19.4 1.9 0.0 13 7.8 2.4 16.5 31.9 20.7 18.91.7 0.0 14 8.9 2.7 13.9 31.9 22.3 18.4 1.9 0.0 15 7.7 2.3 18.0 34.4 17.718.1 1.8 0.0 16 7.5 2.4 18.2 33.0 17.3 19.9 1.7 0.0 17 7.6 2.2 17.9 32.918.8 18.8 1.7 0.0 19 7.7 2.3 17.8 35.5 17.7 17.1 1.8 0.0 Avg. * Nc**Nc** Nc** Nc** Nc** Nc** Nc** Nc** Nc**—Not calculated. No eventswith >1% ELEO were obtained.

TABLE 12 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1564 comprising McConj, McMBOAT andMcDGAT2 Event # 16:0 18:0 18:1 18:2 18:3 20:1 EDA ELEO 2 9.0 3.1 29.026.9 10.6 16.1 1.2 4.1 7 10.2 2.9 19.5 29.6 13.3 15.5 7.2 1.8 3 8.5 3.021.6 29.7 19.5 15.2 1.5 1.0 4 8.1 2.8 18.3 32.6 18.3 17.7 1.8 0.5 1 8.13.0 16.5 32.1 19.8 18.6 1.9 0.0 5 8.2 2.9 16.0 32.2 20.4 18.5 2.0 0.0 68.0 2.6 18.8 32.6 18.5 18.1 1.5 0.0 8 8.1 2.4 18.9 33.5 17.9 17.7 1.60.0 9 8.2 2.4 16.2 33.7 20.2 17.5 1.8 0.0 Avg. ** 9.2 3.0 23.4 28.7 14.415.6 3.3 2.3

TABLE 13 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1565 comprising McConj and McDGAT2 Event# 16:0 18:0 18:1 18:2 18:3 20:1 EDA ELEO 2 9.2 3.0 28.7 27.8 11.7 15.41.1 3.1 9 10.8 3.6 17.9 24.7 17.7 20.2 3.2 1.9 4 8.8 2.8 18.0 31.3 18.717.9 1.7 0.9 1 8.8 0.0 21.7 30.4 16.5 22.6 0.0 0.0 3 8.5 2.4 15.8 35.019.1 17.3 1.8 0.0 5 8.7 0.0 18.3 30.8 16.5 25.6 0.0 0.0 6 7.7 2.5 16.633.0 19.1 19.2 1.9 0.0 7 9.9 2.6 15.7 33.0 21.5 15.6 1.7 0.0 8 7.6 2.416.8 34.4 18.9 18.0 1.9 0.0 10 8.3 2.7 15.9 31.6 21.0 18.6 1.9 0.0 Avg.** 10.0 3.3 23.3 26.3 14.7 17.8 2.2 2.5

A summary of the average fatty acid profiles for the five events havinghighest ELEO content from each experiment (Avg. **) is shown in TABLE14. In TABLE 14, the calculated % conjugation conversion efficiency (%Conj) to Eleostearic acid (ELEO) is also shown for the average of thefive events having highest ELEO content from each experiment where the %Conj was calculated by dividing the sum of the average weight percent(wt. %) for ELEO by the sum of the average wt. % for 18:2 and ELEO andmultiplying by 100 to express as a %. Also shown in TABLE 14 is therelative % desaturation (Rel % Conj) for each experiment where the %Conj for the experiment is divided by the % Conj for that of pKR539(McConj).

TABLE 14 Comparison of the average fatty acid profiles of the top 5events for MBOAT and/or DGAT2 co-expressed with a Momordica conjugase inArabidopsis Rel Experiment 16:0 18:0 18:1 18:2 18:3 20:1 EDA Eleo % Conj% Conj pKR539 (McConj) 8.6 3.0 28.3 26.9 12.6 16.7 1.1 2.8 9.5 1.00pKR1563 NC* NC* NC* NC* NC* NC* NC* NC* NC* NC* (McConj, McMBOAT)pKR1564 9.2 3.0 23.4 28.7 14.4 15.6 3.3 2.3 7.5 0.79 (McConj, McMBOAT,McDGAT2) pKR1565 10.0  3.3 23.3 26.3 14.7 17.8 2.2 2.5 8.6 0.91 (McConj,McDGAT2)

Co-expression of McMBOAT and/or McDGAT2 with McConj does not appear togive higher concentrations of ELEO in Arabidopsis seed.

Example 12 Co-Expressing CoConj with CoDGAT2 and/or CoMBOAT inArabidopsis Seed

Plasmid DNA of pKR1507 (SEQ ID NO:56), comprising CoConj, pKR1508 (SEQID NO:57), comprising CoConj and CoMBOAT, pKR1509 (SEQ ID NO:58),comprising CoConj, CoMBOAT and CoDGAT2, or pKR1510 (SEQ ID NO:59),comprising CoConj and CoDGAT2, was transformed into Arabidopsis,transgenic plants were selected and grown, seeds were harvested andlipid fatty acid profiles were analyzed exactly as described in Example9.

Results for fatty acid analysis of T2 bulk seed pools for individualevents are summarized in TABLEs 15, 16, 17, and 18, respectively. In theTables, the fatty acid profiles as a weight percent of total fatty acidsare shown where 16:0 is palmitic acid, 18:0 is stearic acid, 18:1 isoleic acid, 18:2 is linoleic acid, 18:3 is alpha-linolenic acid, 20:1 iseicosenoic acid [20:1(Δ11)], EDA is eicosadienoic acid [20:2(Δ11,14)]and CAL is calendic acid. Results for each event are sorted according tocalendic acid concentrations in decreasing order. The average fatty acidprofiles for the five events having highest CAL content from eachexperiment are also shown in each table (Avg. **) where only eventshaving calendic acid greater than 1% are included in the averagecalculation.

TABLE 15 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1507 comprising CoConj Event # 16:0 18:018:1 18:2 18:3 20:1 EDA CAL 17 7.9 3.1 18.1 24.0 17.8 20.6 1.5 7.1 148.4 3.3 18.6 24.5 18.3 19.4 1.3 6.2 21 7.5 2.9 17.0 25.4 19.4 20.2 1.75.9 3 7.1 3.0 18.9 24.6 18.9 20.4 1.5 5.7 20 8.1 2.9 17.2 25.6 19.3 19.91.6 5.5 19 7.6 3.0 18.5 24.9 18.4 20.9 1.6 5.1 6 7.7 3.1 17.3 25.5 20.619.3 1.5 5.1 24 7.6 3.0 17.8 24.6 20.3 20.3 1.6 5.0 9 7.3 2.8 15.7 26.419.5 21.4 2.0 4.8 11 7.6 2.9 16.1 27.0 20.3 19.7 1.7 4.6 10 8.4 2.9 17.927.2 19.9 18.0 1.5 4.1 15 7.7 2.8 14.0 26.3 22.9 20.4 2.0 3.7 23 7.8 3.115.7 27.5 20.8 19.7 1.8 3.6 4 8.7 3.1 14.7 26.9 23.0 18.3 1.8 3.5 22 8.22.9 15.2 29.0 21.4 18.1 1.7 3.5 16 8.0 2.9 16.4 27.6 21.2 18.9 1.8 3.218 8.3 2.9 15.2 29.1 21.4 18.4 1.7 2.9 5 7.9 2.9 16.0 28.2 21.2 19.2 1.82.8 12 8.4 2.9 16.5 28.4 20.8 18.4 1.7 2.8 7 8.2 3.1 15.3 28.3 21.4 19.21.9 2.6 2 8.3 2.9 16.0 28.2 20.9 19.6 1.7 2.4 1 7.8 3.2 15.4 27.4 21.121.0 1.8 2.4 13 7.0 2.9 15.4 27.5 21.1 22.0 2.0 2.2 8 8.4 3.0 16.1 29.021.4 18.2 1.7 2.1 Avg. ** 7.8 3.1 17.9 24.8 18.8 20.1 1.5 6.0

TABLE 16 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1508 comprising CoConj and CoMBOAT Event# 16:0 18:0 18:1 18:2 18:3 20:1 EDA CAL 4 7.3 3.1 19.9 22.9 17.6 20.41.3 7.6 21 6.6 3.2 17.6 24.0 18.0 23.3 1.8 5.6 18 7.9 3.1 19.1 25.5 17.719.7 1.5 5.4 22 7.4 3.3 18.6 25.6 17.1 21.2 1.6 5.3 16 7.0 3.1 19.1 25.117.6 21.2 1.6 5.2 3 7.5 2.9 17.7 27.0 19.2 18.9 1.7 5.0 14 7.0 3.1 18.125.6 19.2 20.7 1.7 4.5 10 7.4 3.1 18.4 25.6 19.2 20.4 1.7 4.4 13 7.1 2.917.8 27.6 18.8 19.6 1.7 4.4 11 7.1 3.1 17.9 27.6 18.3 20.1 1.8 4.1 7 7.63.0 17.4 27.7 19.2 19.3 1.7 4.1 6 7.9 2.8 17.0 28.5 20.5 17.6 1.7 4.0 87.7 2.9 16.6 29.0 18.9 19.3 1.7 3.9 12 7.5 3.0 18.0 28.1 18.9 18.9 1.73.8 19 7.4 3.0 17.4 27.4 18.8 20.5 1.8 3.6 9 7.4 3.0 17.0 28.7 19.2 19.41.8 3.5 5 7.9 2.8 17.2 29.6 19.3 18.2 1.7 3.3 20 7.9 3.3 16.7 28.0 20.518.9 1.8 2.9 23 7.3 3.0 15.6 28.3 19.5 21.4 2.0 2.8 15 6.7 2.7 18.2 28.518.4 20.9 1.9 2.7 1 7.3 2.9 17.0 27.8 21.0 19.5 1.8 2.7 2 8.7 3.0 14.630.1 21.5 18.3 1.8 2.0 17 7.5 3.0 16.5 29.2 19.3 20.5 1.9 2.0 Avg. **7.2 3.1 18.9 24.6 17.6 21.1 1.6 5.8

TABLE 17 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1509 comprising CoConj, CoMBOAT andCoDGAT2 Event # 16:0 18:0 18:1 18:2 18:3 20:1 EDA CAL pKR1509-18 7.3 3.017.9 21.4 16.3 23.0 1.5 9.5 pKR1509-14 8.1 3.2 18.0 23.1 16.3 21.1 1.58.8 pKR1509-1 8.7 3.4 16.9 23.1 15.0 23.0 1.5 8.4 pKR1509-5 8.2 3.2 17.724.0 16.8 20.3 1.5 8.3 pKR1509-15 7.8 3.3 17.8 22.7 17.7 21.1 1.6 8.1pKR1509-16 7.9 3.2 17.7 23.4 18.4 19.8 1.6 7.9 pKR1509-8 8.2 3.3 17.224.2 17.8 20.5 1.6 7.2 pKR1509-12 7.5 3.1 18.0 24.6 16.6 21.3 1.6 7.2pKR1509-4 7.8 3.2 17.4 27.1 17.4 20.5 1.8 4.8 pKR1509-17 8.0 3.0 15.927.3 19.2 20.0 1.9 4.8 pKR1509-22 7.4 3.0 16.9 26.9 18.7 20.6 1.8 4.6pKR1509-11 8.4 3.2 15.8 28.5 19.1 19.0 1.7 4.2 pKR1509-2 6.8 2.9 16.126.6 19.4 22.4 2.0 3.7 pKR1509-20 8.1 3.1 16.7 28.7 18.8 19.1 1.8 3.6pKR1509-7 8.1 3.0 17.1 28.5 19.0 19.0 1.7 3.6 pKR1509-6 7.2 2.8 15.928.8 18.4 21.3 2.0 3.6 pKR1509-13 8.0 3.1 16.5 28.2 19.9 19.2 1.8 3.3pKR1509-9 8.0 3.0 15.0 28.8 20.1 20.2 2.0 2.8 pKR1509-19 8.4 3.0 16.130.7 18.7 18.9 1.9 2.3 pKR1509-3 8.0 2.9 16.2 29.5 20.1 19.3 1.9 2.0pKR1509-21 8.6 3.1 15.2 29.6 21.0 18.8 1.9 1.9 pKR1509-23 8.4 3.1 16.830.2 20.2 17.7 1.8 1.8 pKR1509-10 6.8 2.9 15.9 30.1 19.7 22.1 2.2 0.2Avg. ** 8.0 3.2 17.6 22.9 16.4 21.7 1.5 8.6

TABLE 18 Fatty Acid Analysis of T2 bulk seed pools for events fromArabidopsis transformed with pKR1510 comprising CoConj and CoDGAT2.pKR1510 (CoConj, CoDGAT2) Event # 16:0 18:0 18:1 18:2 18:3 20:1 EDA CAL13 7.6 3.3 19.1 21.6 17.5 21.6 1.4 8.0 1 7.4 3.1 17.8 22.4 18.0 21.8 1.67.9 22 8.1 3.0 16.9 23.2 19.4 20.1 1.6 7.8 14 8.5 3.3 17.0 24.0 18.520.5 1.6 6.6 5 7.5 2.9 18.2 25.4 18.7 20.0 1.6 5.8 21 7.4 2.8 15.3 25.520.2 21.2 1.8 5.7 11 8.9 3.3 18.6 25.3 16.1 21.0 1.6 5.2 24 8.0 3.3 17.026.5 19.7 19.0 1.7 4.9 9 7.6 3.1 16.2 27.0 19.5 20.2 1.8 4.5 20 8.3 3.114.8 28.0 20.4 19.1 1.9 4.4 17 8.0 3.3 15.0 28.3 20.1 19.5 2.0 3.8 168.0 2.8 15.6 27.2 21.3 19.6 1.8 3.6 23 8.5 3.0 15.8 28.0 20.5 18.9 2.03.3 18 8.0 3.0 16.9 28.8 20.1 18.4 1.7 2.9 3 7.6 3.0 16.6 28.4 19.5 20.21.9 2.8 10 7.9 3.0 16.3 28.7 20.6 19.0 1.9 2.6 19 7.6 2.9 16.7 29.1 19.819.8 1.9 2.3 2 8.5 3.3 15.5 29.6 20.2 18.9 1.8 2.2 7 7.9 2.8 16.2 29.719.9 19.5 1.9 2.2 6 8.2 3.0 14.6 30.1 21.0 19.1 2.0 1.9 15 7.8 3.0 14.529.1 21.1 20.6 2.0 1.9 8 8.2 2.9 16.3 30.0 20.4 18.6 1.8 1.7 4 8.5 3.115.5 31.1 21.0 18.7 2.0 0.0 12 8.5 3.1 16.0 32.0 20.7 17.8 1.8 0.0 Avg.** 7.8 3.1 17.8 23.3 18.4 20.8 1.5 7.2

A summary of the average fatty acid profiles for the five events havinghighest CAL content from each experiment (Avg. **) is shown in TABLE 19.In TABLE 19, the calculated % conjugation conversion efficiency (% Conj)to Calendic acid (CAL) is also shown for the average of the five eventshaving highest CAL content from each experiment where the % Conj wascalculated by dividing the sum of the average weight percent (wt. %) forCAL by the sum of the average wt. % for 18:2 and CAL and multiplying by100 to express as a %. Also shown in TABLE 19 is the relative %desaturation (Rel % Conj) for each experiment where the % Conj for theexperiment is divided by the % Conj for that of pKR1507 (CoConj).

TABLE 19 Comparing average fatty acid profiles for MBOATs co-expressedwith a Calendula conjugase in Arabidopsis Rel Experiment 16:0 18:0 18:118:2 18:3 20:1 EDA Cal % Conj % Conj pKR1507 (CoConj) 7.8 3.1 17.9 24.818.8 20.1 1.5 6.0 19.6 2.06 pKR1508 (CoConj, 7.2 3.1 18.9 24.6 17.6 21.11.6 5.8 19.1 2.01 CoMBOAT) pKR1509 8.0 3.2 17.6 22.9 16.4 21.7 1.5 8.627.4 2.88 (CoConj, CoMBOAT, CoDGAT2) pKR1510 7.8 3.1 17.8 23.3 18.4 20.81.5 7.2 23.7 2.49 (CoConj, CoDGAT2) Co-expression of CoMBOAT with CoConjdoes not appear to give higher concentrations of CAL in Arabidopsisseed. Co-expression of CoDGAT or CoMBOAT and CoDGAT2 with CoConjincreases the % Conj activity which leads to higher concentrations ofCAL in seed.

Example 13 Co-Expressing McConj with McDGAT2 and/or McMBOAT in SoySomatic Embryos

Soybean expression vectors pKR458 (SEQ ID NO:31), comprising McConj,pKR1548 (SEQ ID NO:35), comprising McConj and McMBOAT, pKR1556 (SEQ IDNO:36), comprising McConj, McMBOAT and McDGAT2, and pKR1562 (SEQ IDNO:37), comprising McConj and McDGAT2 were transformed into soy andlipid fatty acid profiles were analyzed as described below.

Culture Conditions:

Soybean embryogenic suspension cultures (cv. Jack) were maintained in 35mL liquid medium SB196 (infra) on a rotary shaker, 150 rpm, 26° C. withcool white fluorescent lights on 16:8 h day/night photoperiod at lightintensity of 60-85 μE/m²/s. Cultures were subcultured every 7 days totwo weeks by inoculating approximately 35 mg of tissue into 35 mL offresh liquid SB196 (the preferred subculture interval is every 7 days).

Soybean embryogenic suspension cultures were transformed with thesoybean expression plasmids by the method of particle gun bombardment(Klein et al., Nature 327:70 (1987)) using a DuPont Biolistic PDS1000/HEinstrument (helium retrofit) for all transformations.

Soybean Embryogenic Suspension Culture Initiation:

Soybean cultures were initiated twice each month with 5-7 days betweeneach initiation. Pods with immature seeds from available soybean plants45-55 days after planting were picked, removed from their shells andplaced into a sterilized magenta box. The soybean seeds were sterilizedby shaking them for 15 min in a 5% Clorox solution with 1 drop of ivorysoap (i.e., 95 mL of autoclaved distilled water plus 5 mL Clorox and 1drop of soap, mixed well). Seeds were rinsed using 2 1-liter bottles ofsterile distilled water, and those less than 4 mm were placed onindividual microscope slides. The small end of the seed was cut and thecotyledons pressed out of the seed coat. Cotyledons were transferred toplates containing SB199 medium (25-30 cotyledons per plate) for 2 weeks,then transferred to SB1 for 2-4 weeks. Plates were wrapped with fibertape. After this time, secondary embryos were cut and placed into SB196liquid media for 7 days.

Preparation of DNA for Bombardment:

A 50 μL aliquot of sterile distilled water containing 1 mg of goldparticles was added to 5 μL of a 1 μg/μL DNA solution (intact expressionvector as described herein), 50 μL 2.5M CaCl₂ and 20 μL of 0.1 Mspermidine. The mixture was pulsed 5 times on level 4 of a vortex shakerand spun for 5 sec in a bench microfuge. After a wash with 150 μL of100% ethanol, the pellet was suspended by sonication in 85 μL of 100%ethanol. Five μL of DNA suspension was dispensed to each flying disk ofthe Biolistic PDS1000/HE instrument disk. Each 5 μL aliquot containedapproximately 0.058 mg gold particles per bombardment (i.e., per disk).

Tissue Preparation and Bombardment with DNA:

Approximately 100-150 mg of 7 day old embryonic suspension cultures wereplaced in an empty, sterile 60×15 mm petri dish and the dish was placedinside of an empty 150×25 mm Petri dish. Tissue was bombarded 1 shot perplate with membrane rupture pressure set at 650 PSI, and the chamber wasevacuated to a vacuum of 27-28 inches of mercury. Tissue was placedapproximately 2.5 inches from the retaining/stopping screen.

Selection of Transformed Embryos:

Transformed embryos were selected using hygromycin as the selectablemarker. Specifically, following bombardment, the tissue was placed intofresh SB196 media and cultured as described above. Six to eight dayspost-bombardment, the SB196 is exchanged with fresh SB196 containing 30mg/L hygromycin. The selection media was refreshed weekly. Four to sixweeks post-selection, green, transformed tissue was observed growingfrom untransformed, necrotic embryogenic clusters. Isolated, greentissue was removed and inoculated into multi-well plates to generatenew, clonally propagated, transformed embryogenic suspension cultures.

Embryo Maturation:

Transformed embryogenic clusters were removed to SB228 (SHaM) liquidmedia, 35 mL in 250 mL Erlenmeyer flask, and grown for 2-3 weeks. Tissuecultured in SB228 was maintained on a rotary shaker, 130 rpm, 26° C.with cool white fluorescent lights on 16:8 h day/night photoperiod atlight intensity of 60-85 μE/m²/s. After this period, embryos wereanalyzed for alterations in their fatty acid compositions as describedsupra.

Media Recipes:

SB 196—FN Lite Liquid Proliferation Medium (per Liter)

MS FeEDTA - 100x Stock 1 10 mL MS Sulfate - 100x Stock 2 10 mL FN LiteHalides - 100x Stock 3 10 mL FN Lite P, B, Mo - 100x Stock 4 10 mL B5vitamins (1 mL/L) 1.0 mL 2,4-D (10 mg/L final concentration) 1.0 mL KNO₃2.83 gm (NH₄)₂SO₄ 0.463 gm Asparagine 1.0 gm Sucrose (1%) 10 gm pH 5.8

FN Lite Stock Solutions

Stock Number 1000 mL 500 mL 1 MS Fe EDTA 100x Stock Na₂ EDTA* 3.724 g1.862 g FeSO₄—7H₂O 2.784 g 1.392 g 2 MS Sulfate 100x stock MgSO₄—7H₂O37.0 g 18.5 g MnSO₄—H₂O 1.69 g 0.845 g ZnSO₄—7H₂O 0.86 g 0.43 gCuSO₄—5H₂O 0.0025 g 0.00125 g 3 FN Lite Halides 100x Stock CaCl₂—2H₂O30.0 g 15.0 g KI 0.083 g 0.0715 g CoCl₂—6H₂O 0.0025 g 0.00125 g 4 FNLite P, B, Mo 100x Stock KH₂PO₄ 18.5 g 9.25 g H₃BO₃ 0.62 g 0.31 gNa₂MoO₄—2H₂O 0.025 g 0.0125 g *Add first, dissolve in dark bottle whilestirring

SB1 Solid Medium (per Liter)

-   -   1 package MS salts (Gibcol BRL—Cat. No. 11117-066)    -   1 mL B5 vitamins 1000× stock    -   31.5 g Glucose    -   2 mL 2,4-D (20 mg/L final concentration)    -   pH 5.7    -   8 g TC agar

SB199 Solid Medium (per Liter)

-   -   1 package MS salts (Gibco/BRL—Cat. No. 11117-066)    -   1 mL B5 vitamins 1000× stock    -   30 g Sucrose    -   4 ml 2,4-D (40 mg/L final concentration)    -   pH 7.0    -   2 gm Gelrite

SB 166 Solid Medium (per Liter)

-   -   1 package MS salts (Gibco/BRL—Cat. No. 11117-066)    -   1 mL B5 vitamins 1000× stock    -   60 g maltose    -   750 mg MgCl₂ hexahydrate    -   5 g Activated charcoal    -   pH 5.7    -   2 g Gelrite

SB 103 Solid Medium (per Liter)

-   -   1 package MS salts (Gibco/BRL—Cat. No. 11117-066)    -   1 mL B5 vitamins 1000× stock    -   60 g maltose    -   750 mg MgCl₂ hexahydrate    -   pH 5.7    -   2 g Gelrite

SB 71-4 Solid Medium (per Liter)

-   -   1 bottle Gamborg's B5 salts w/sucrose (Gibco/BRL—Cat. No.        21153-036)    -   pH 5.7    -   5 g TC agar

B5 Vitamins Stock (Per 100 mL)

Store aliquots at −20° C.

-   -   10 g Myo-inositol    -   100 mg Nicotinic acid    -   100 mg Pyridoxine HCl    -   1 g Thiamine

If the solution does not dissolve quickly enough, apply a low level ofheat via the hot stir plate.

SB 228—Soybean Histodifferentiation & Maturation (SHaM) (per Liter)

DDI H₂O 600 ml FN-Lite Macro Salts for SHaM 10X 100 ml MS Micro Salts1000x 1 ml MS FeEDTA 100x 10 ml CaCl 100x 6.82 ml B5 Vitamins 1000x 1 mlL-Methionine 0.149 g Sucrose 30 g Sorbitol 30 g Adjust volume to 900 mLpH 5.8 Autoclave Add to cooled media (≦30° C.): *Glutamine (Final conc.30 mM) 4% 110 mL *Note: Final volume will be 1010 mL after glutamineaddition.

Because glutamine degrades relatively rapidly, it may be preferable toadd immediately prior to using media. Expiration 2 weeks after glutamineis added; base media can be kept longer w/o glutamine.

FN-Lite Macro for SHAM 10×—Stock #1 (per Liter)

(NH₄)₂SO₄ (Ammonium Sulfate) 4.63 g KNO₃ (Potassium Nitrate) 28.3 gMgSO₄*7H₂0 (Magnesium Sulfate Heptahydrate)  3.7 g KH₂PO₄ (PotassiumPhosphate, Monobasic) 1.85 g Bring to volume Autoclave

MS Micro 1000×—Stock #2 (per 1 liter)

H₃BO₃ (Boric Acid) 6.2 g MnSO₄*H₂O (Manganese Sulfate Monohydrate) 16.9g ZnSO₄*7H₂0 (Zinc Sulfate Heptahydrate) 8.6 g Na₂MoO₄*2H₂0 (SodiumMolybdate Dihydrate) 0.25 g CuSO₄*5H₂0 (Copper Sulfate Pentahydrate)0.025 g CoCl₂*6H₂0 (Cobalt Chloride Hexahydrate) 0.025 g KI (PotassiumIodide) 0.8300 g Bring to volume Autoclave

FeEDTA 100×—Stock #3 (per liter)

Na₂EDTA* (Sodium EDTA) 3.73 g FeSO₄*7H₂0 (Iron Sulfate Heptahydrate)2.78 g Bring to Volume Solution is photosensitive. Bottle(s) should bewrapped in foil to omit light. Autoclave *EDTA must be completelydissolved before adding iron.

Ca 100×—Stock #4 (per liter)

CaCl₂*2H₂0 (Calcium Chloride Dihydrate) 44 g Bring to Volume Autoclave

B5 Vitamin 1000×—Stock #5 (per Liter)

Thiamine*HCl 10 g Nicotinic Acid 1 g Pyridoxine*HCl 1 g Myo-Inositol 100g Bring to Volume Store frozen

4% Glutamine—Stock #6 (per Liter)

DDI water heated to 30° C. 900 ml L-Glutamine 40 g Gradually add whilestirring and applying low heat. Do not exceed 35° C. Bring to VolumeFilter Sterilize Store frozen* *Note: Warm thawed stock in 31° C. bathto fully dissolve crystals.Lipid Fatty Acid Analysis:

Somatic embryos were harvested after two weeks of culture in the liquidmaturation medium SB228 (SHaM) liquid media. Approximately 30 eventsfrom each transformation with soybean expression vectors pKR458 (SEQ IDNO:31), comprising McConj, pKR1548 (SEQ ID NO:35), comprising McConj andMcMBOAT, pKR1556 (SEQ ID NO:36), comprising McConj, McMBOAT and McDGAT2,and pKR1562 (SEQ ID NO:37), comprising McConj and McDGAT2 were analyzed.Embryos generated for a given event were harvested in bulk, frozen in a−80° C. freezer and dried by lyophilization for 48 h.

Dried embryos from each event were ground to a fine powder using agenogrinder vial (½″×2″ polycarbonate) and a steel ball (SPEX Centriprep(Metuchen, N.J., U.S.A.). Grinding time was 30 sec at 1450 oscillationsper min. Lipids were transesterified from approximately 50 mg of dried,ground embryo powder with TMSH for 15 min and FAMEs were extracted into400 μL of heptane and analyzed by GC as described for Arabidopsis seedherein.

Fatty acid profiles for approximately 30 events from each transformationwith soybean expression vectors pKR458 (SEQ ID NO:31), comprising McConjand called experiment MSE2594, pKR1548 (SEQ ID NO:35), comprising McConjand McMBOAT and called experiment MSE2591, pKR1556 (SEQ ID NO:36),comprising McConj, McMBOAT and McDGAT2 and called experiment MSE2592,and pKR1562 (SEQ ID NO:37), comprising McConj and McDGAT2 and calledexperiment MSE2593 are summarized in TABLES 20, 21, 22, and 23,respectively.

In the Tables, the fatty acid profiles as a weight percent of totalfatty acids are shown where 16:0 is palmitic acid, 18:0 is stearic acid,18:1 is oleic acid, 18:2 is linoleic acid, 18:3 is alpha-linolenic acidand ELEO is eleostearic acid. Results for each event are sortedaccording to ELEO concentrations in decreasing order. The average fattyacid profiles for the five events having highest ELEO content from eachexperiment are also shown in each table (Avg. **) where only eventshaving eleostearic acid greater than 1% are included in the averagecalculation.

TABLE 20 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR458 comprising McConj (MSE2594) Event # 16:0 18:0 18:1 18:2 18:3 ELEO17 12.9 4.3 43.1 26.0 7.1 6.7 9 12.6 3.8 29.8 38.5 9.7 5.7 29 14.3 3.529.8 36.7 11.3 4.3 11 13.7 3.7 33.8 33.1 11.7 4.0 26 15.0 4.0 29.1 37.111.5 3.3 10 15.7 4.6 26.0 38.4 12.1 3.3 12 17.5 6.1 20.1 38.2 16.4 1.727 15.6 4.8 32.4 36.0 9.6 1.7 2 15.2 4.6 27.6 39.1 12.3 1.2 23 16.6 4.826.7 36.1 14.6 1.2 30 16.5 4.2 17.8 42.9 17.4 1.1 19 17.7 4.1 15.3 46.515.7 0.7 28 16.8 4.6 21.6 39.9 16.7 0.4 1 16.6 4.9 20.0 41.0 17.5 0.0 316.2 6.4 18.7 40.5 18.2 0.0 4 17.3 4.2 18.1 43.8 16.7 0.0 5 18.0 4.215.9 43.1 18.8 0.0 6 18.1 5.1 16.1 39.6 21.2 0.0 7 18.4 4.8 16.3 36.224.4 0.0 8 17.5 5.1 17.3 40.0 20.1 0.0 13 18.0 4.6 17.1 41.1 19.2 0.0 1416.4 4.8 23.0 41.8 14.0 0.0 15 16.9 4.7 21.0 40.5 17.0 0.0 16 18.8 4.315.0 44.5 17.4 0.0 18 17.9 5.8 21.1 38.7 16.5 0.0 20 19.0 4.8 13.2 40.322.6 0.0 21 17.6 4.7 17.4 41.0 19.3 0.0 22 19.1 4.4 12.9 40.1 23.4 0.024 16.7 5.0 21.4 40.0 17.0 0.0 25 16.4 5.1 23.2 39.7 15.6 0.0 Avg. **13.7 3.9 33.1 34.3 10.3 4.8

TABLE 21 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1548 comprising McConj and McMBOAT (MSE2591) MSE2591 (McConj,McMBOAT) Event # 16:0 18:0 18:1 18:2 18:3 Eleo 26 10.7 3.2 50.3 22.9 4.97.9 17 11.6 3.5 45.2 27.0 5.2 7.5 5 12.1 3.4 43.4 28.1 5.7 7.4 4 12.63.7 46.2 23.9 7.4 6.2 21 11.9 3.7 43.8 26.9 7.9 5.8 7 14.3 3.9 34.5 31.310.3 5.7 19 12.2 4.0 47.4 24.6 6.2 5.6 20 13.1 4.0 39.5 28.7 9.2 5.4 812.8 4.1 39.4 29.9 8.7 5.0 23 13.0 4.3 39.9 30.2 8.2 4.5 2 12.5 3.8 34.530.5 14.3 4.4 14 13.5 3.8 32.8 33.2 12.7 3.9 15 15.5 5.0 27.8 33.9 15.02.9 22 14.6 5.0 36.0 31.8 10.0 2.6 16 14.6 5.3 33.6 35.8 8.5 2.2 10 14.75.0 34.1 32.2 11.8 2.1 25 16.5 5.5 28.4 33.7 14.2 1.8 3 16.4 4.8 27.634.3 15.4 1.5 27 15.8 4.9 25.0 37.9 15.0 1.3 24 15.4 5.5 33.6 35.8 8.71.0 30 15.4 5.5 39.0 30.6 8.8 0.8 1 18.8 5.2 16.7 35.4 24.0 0.0 6 16.65.3 28.0 37.9 12.2 0.0 9 17.2 4.8 18.8 39.1 20.2 0.0 11 18.3 5.2 19.638.3 18.5 0.0 12 18.2 5.6 20.6 37.0 18.6 0.0 13 15.4 5.3 25.9 38.7 14.70.0 18 16.4 5.5 23.2 40.7 14.1 0.0 28 16.7 4.7 22.5 39.6 16.4 0.0 2916.6 4.6 17.7 43.0 18.1 0.0 Avg. ** 11.8 3.5 45.8 25.7 6.2 7.0

TABLE 22 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1556 comprising McConj, McMBOAT and McDGAT2 (MSE2592) MSE2592(McConj, McMBOAT, McDGAT2) Event # 16:0 18:0 18:1 18:2 18:3 Eleo 29 8.93.9 38.3 24.6 6.2 18.1 28 10.1 4.8 43.8 22.8 4.8 13.7 30 9.1 3.4 46.823.0 4.6 13.1 25 11.5 4.5 35.2 29.8 6.8 12.3 9 12.2 4.7 26.1 35.4 10.910.7 7 10.9 4.1 46.1 24.0 4.9 10.0 32 11.7 3.7 32.8 34.6 7.2 9.9 22 10.94.5 42.1 27.7 5.7 9.2 5 10.2 3.6 48.3 24.8 4.3 8.8 2 10.6 4.5 41.2 28.56.7 8.4 21 12.2 4.1 39.7 27.6 8.2 8.2 11 13.1 6.5 25.7 36.5 12.6 5.7 1513.9 3.9 31.0 34.6 10.9 5.6 10 13.9 5.1 25.5 37.6 12.8 5.1 20 13.8 6.927.0 35.9 11.7 4.6 14 13.1 6.5 27.8 36.6 11.5 4.5 27 13.9 5.7 22.6 38.515.8 3.5 6 14.1 5.4 24.3 45.8 7.7 2.6 19 14.0 6.7 26.3 39.5 11.1 2.5 114.8 6.4 22.7 39.1 15.2 1.9 3 14.4 6.2 20.3 41.5 15.7 1.9 26 14.5 6.526.0 39.5 11.6 1.8 23 15.3 6.3 20.1 40.6 15.9 1.8 13 15.2 5.7 18.9 45.413.2 1.5 18 14.5 8.6 25.6 41.4 9.3 0.6 24 14.5 7.3 26.8 39.2 11.9 0.3 415.0 8.2 30.4 36.3 10.1 0.0 8 18.2 4.8 9.1 44.8 23.2 0.0 12 15.0 7.718.0 45.3 14.1 0.0 16 16.1 6.6 15.7 44.2 17.3 0.0 17 16.2 6.8 15.3 45.416.4 0.0 31 15.9 6.8 15.5 42.9 19.0 0.0 Avg. ** 10.4 4.3 38.0 27.1 6.613.6

TABLE 23 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1562 comprising McConj and McDGAT2 (MSE2593) Event # 16:0 18:0 18:118:2 18:3 Eleo 13 11.8 2.9 39.3 25.9 8.2 10.2 21 12.2 3.3 40.6 29.7 7.17.1 5 11.0 4.4 40.3 31.1 5.9 6.8 14 13.0 4.3 33.2 33.0 9.2 6.3 24 11.74.3 40.2 28.3 8.9 6.0 10 11.8 4.5 41.0 30.5 5.9 5.7 16 12.1 4.0 44.827.1 6.8 5.2 27 14.1 4.6 34.9 31.8 9.6 5.0 9 14.2 4.9 28.9 33.6 13.9 4.419 12.5 4.8 34.5 35.3 8.5 4.4 20 14.1 4.3 34.8 32.4 10.1 4.3 8 14.0 4.233.4 33.6 10.6 4.2 6 14.2 4.4 37.9 30.1 9.3 4.1 26 13.4 4.9 40.6 28.88.2 4.1 12 12.1 4.2 44.8 29.1 5.7 4.1 22 15.4 5.3 29.9 35.3 10.2 3.9 2313.8 4.9 34.1 33.0 10.3 3.8 11 14.4 4.7 32.9 32.1 12.3 3.6 3 14.6 5.133.2 33.2 10.4 3.4 30 14.0 4.6 22.8 40.0 15.7 2.8 29 15.6 6.3 22.2 37.816.0 2.1 28 14.8 5.7 33.0 32.3 12.3 1.9 2 16.9 4.2 20.1 41.2 16.6 1.1 116.5 6.3 16.1 44.4 16.0 0.6 17 16.8 4.7 19.9 40.8 17.2 0.5 4 18.4 4.914.7 39.9 22.2 0.0 7 17.9 4.6 16.6 42.0 18.9 0.0 15 18.1 4.4 17.0 39.621.0 0.0 18 16.8 6.1 16.8 40.1 20.1 0.0 25 18.4 6.2 12.7 42.3 20.3 0.0Avg.** 11.9 3.8 38.7 29.6 7.8 7.3

A summary of the average fatty acid profiles for the five events havinghighest ELEO content from each experiment (Avg. **) is shown in TABLE24. In TABLE 24, the calculated % conjugation conversion efficiency (%Conj) to Eleostearic acid (ELEO) is also shown for the average of thefive events having highest ELEO content from each experiment where the %Conj was calculated by dividing the sum of the average weight percent(wt. %) for ELEO by the sum of the average wt. % for 18:2 and ELEO andmultiplying by 100 to express as a %. Also shown in TABLE 24 is therelative % desaturation (Rel % Conj) for each experiment where the %Conj for the experiment is divided by the % Conj for that of MSE2594(McConj).

TABLE 24 Comparing average fatty acid profiles for MBOAT and/or DGAT2co-expressed with a Momordica conjugase in Soy Somatic Embryos Rel %Experiment 16:0 18:0 18:1 18:2 18:3 Eleo % Conj Conj MSE2594 13.7 3.933.1 34.3 10.3 4.8 12.6 1.00 (McConj) MSE2591 11.8 3.5 45.8 25.7 6.2 7.021.3 1.70 (McConj, McMBOAT) MSE2592 10.4 4.3 38.0 27.1 6.6 13.6 33.72.69 (McConj, McMBOAT, McDGAT2) MSE2593 11.9 3.8 38.7 29.6 7.8 7.3 19.81.57 (McConj, McDGAT2)

TABLEs 20-24 demonstrate that co-expression of McMBOAT and/or McDGAT2with McConj increases % Conj activity which leads to higherconcentrations of ELEO in soy somatic embryos. McMBOAT and McDGAT2co-expressed with McConj gives higher concentrations of ELEO than eitherMcMBOAT or McDGAT2 co-expressed with McConj individually.

Example 14 Co-Expressing CoConj with CoMBOAT or CoMBOAT and CoDGAT2 inSoy Somatic Embryos

Soybean expression vectors pKR1487 (SEQ ID NO:42), comprising CoConj andcalled experiment MSE2542, pKR1492 (SEQ ID NO:49), comprising CoConj andCoMBOAT and called experiment MSE2543 and pKR1498 (SEQ ID NO:50),comprising CoConj, CoMBOAT and CoDGAT2 and called experiment MSE2545were transformed into soy, somatic embryos were harvested and lipidfatty acid profiles were analyzed exactly as described in Example 13,and results are summarized in TABLEs 25, 26, and 27, respectively.

In the Tables, the fatty acid profiles as a weight percent of totalfatty acids are shown where 16:0 is palmitic acid, 18:0 is stearic acid,18:1 is oleic acid, 18:2 is linoleic acid, 18:3 is alpha-linolenic acidand CAL is calendic acid. Results for each event are sorted according toCAL concentrations in decreasing order. The average fatty acid profilesfor the five events having highest CAL content from each experiment arealso shown in each table (Avg. **) where only events having calendicacid greater than 1% are included in the average calculation.

TABLE 25 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1487 comprising CoConj (MSE2542) Event # 16:0 18:0 18:1 18:2 18:3 CAL23 14.6 5.1 21.9 38.1 17.1 3.2 10 18.3 5.5 17.5 37.9 19.4 1.5 3 17.1 6.221.5 37.1 17.2 1.0 13 17.5 5.6 19.3 36.7 20.4 0.6 11 16.2 4.1 17.8 40.620.9 0.5 1 17.5 4.9 17.6 38.3 21.8 0.0 2 17.6 5.4 21.5 37.6 17.9 0.0 417.4 4.6 16.5 39.6 21.9 0.0 5 17.1 5.3 18.2 38.9 20.5 0.0 6 17.4 5.418.6 37.3 21.2 0.0 7 16.9 4.9 17.5 40.1 20.6 0.0 8 17.1 5.2 15.5 39.023.1 0.0 9 17.1 5.5 20.8 37.9 18.7 0.0 12 17.8 4.9 15.0 39.5 22.8 0.0 1416.8 5.2 17.8 40.1 20.0 0.0 15 17.2 5.0 18.9 39.5 19.3 0.0 16 17.1 5.917.7 37.9 21.4 0.0 17 17.1 4.7 15.6 40.3 22.3 0.0 18 18.5 4.7 13.5 38.325.0 0.0 19 15.7 5.3 17.4 45.7 15.9 0.0 20 17.4 5.3 18.9 39.9 18.4 0.022 17.2 5.2 18.4 39.0 20.2 0.0 24 16.9 5.0 16.1 40.4 21.6 0.0 26 17.44.6 12.3 41.8 23.9 0.0 27 17.6 5.5 20.3 37.6 19.0 0.0 28 16.9 4.8 17.940.5 19.9 0.0 30 16.8 5.7 17.5 39.7 20.2 0.0 31 16.8 5.3 17.9 38.9 21.10.0 Avg.** 16.7 5.3 19.6 38.1 19.0 1.3

TABLE 26 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1492 comprising CoConj and CoMBOAT (MSE2543) Event # 16:0 18:0 18:118:2 18:3 CAL 4 15.2 5.2 17.4 36.4 20.3 5.5 10 14.9 5.4 22.7 35.5 16.74.8 1 15.2 4.9 19.7 35.5 20.0 4.7 2 14.0 6.5 23.0 36.2 16.1 4.2 11 13.65.8 28.2 33.0 16.0 3.4 17 15.4 5.3 24.6 35.7 15.7 3.4 29 13.4 6.3 23.242.7 12.1 2.3 3 15.3 6.5 22.6 36.8 16.4 2.2 8 15.7 5.4 22.0 36.4 18.22.2 26 14.5 5.8 23.6 39.0 15.2 2.0 19 16.2 6.2 21.8 38.5 15.5 1.8 2014.8 6.3 26.2 35.7 15.3 1.8 30 15.8 6.5 22.8 39.1 14.4 1.5 6 16.5 5.019.0 39.2 19.6 0.7 22 17.2 6.1 21.5 38.6 16.1 0.5 13 16.3 4.8 18.4 38.721.3 0.4 7 15.8 7.8 18.5 41.7 15.7 0.4 5 19.3 5.4 14.5 40.6 20.2 0.0 917.6 5.5 18.3 40.7 18.0 0.0 12 17.1 6.0 21.3 39.2 16.4 0.0 14 16.9 5.523.7 38.2 15.7 0.0 15 17.4 5.8 20.3 37.6 18.9 0.0 16 17.2 5.9 20.2 40.715.9 0.0 18 17.1 5.5 21.0 38.5 17.9 0.0 21 16.9 6.2 22.1 38.4 16.3 0.023 17.3 6.3 22.4 36.2 17.8 0.0 24 18.2 6.3 18.6 39.4 17.6 0.0 25 17.35.7 20.1 38.4 18.5 0.0 27 17.1 5.7 21.4 38.1 17.7 0.0 28 16.8 7.7 25.235.1 15.1 0.0 Avg.** 14.6 5.6 22.2 35.3 17.8 4.5

TABLE 27 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1498 comprising CoConj, CoMBOAT and CoDGAT2 (MSE2545) Event # 16:018:0 18:1 18:2 18:3 CAL 25 13.4 6.3 24.0 32.1 16.8 7.4 4 13.6 5.9 25.031.6 17.3 6.6 2 13.9 5.6 18.1 42.9 13.4 6.0 16 13.5 5.7 23.3 36.0 16.05.4 21 14.9 5.7 24.3 34.5 16.8 3.8 14 15.6 4.7 16.6 38.1 22.5 2.4 2916.3 6.1 22.2 35.1 18.0 2.3 30 15.8 7.3 18.4 41.1 16.0 1.4 8 15.5 7.219.0 41.3 15.9 1.1 13 15.6 5.5 21.6 38.2 18.2 0.9 15 15.6 6.6 23.5 35.318.0 0.9 23 16.3 5.0 18.6 40.0 19.4 0.7 5 16.4 5.0 17.8 39.9 20.1 0.7 1716.8 5.6 18.7 36.8 21.5 0.6 22 16.6 5.0 17.6 38.4 21.9 0.6 11 16.7 6.122.5 37.4 17.1 0.4 10 15.4 6.2 24.6 37.0 16.5 0.4 28 16.8 6.0 20.3 39.717.0 0.3 24 15.9 6.0 22.8 38.2 16.8 0.2 1 16.2 5.5 18.2 37.5 22.7 0.0 316.9 6.3 20.3 39.5 17.0 0.0 6 16.1 5.9 21.3 38.5 18.2 0.0 7 16.0 7.225.1 36.3 15.3 0.0 9 15.8 6.5 24.2 38.3 15.2 0.0 12 17.0 5.4 19.6 39.618.5 0.0 18 16.9 4.9 18.2 38.7 21.4 0.0 19 16.3 6.4 24.9 36.5 16.0 0.020 16.1 6.7 24.9 37.7 14.5 0.0 26 16.4 5.0 20.0 39.0 19.6 0.0 27 17.56.4 22.1 37.1 16.9 0.0 31 17.7 6.0 18.7 36.5 21.1 0.0 Avg.** 13.8 5.923.0 35.4 16.1 5.8

A summary of the average fatty acid profiles for the five events havinghighest CAL content from each experiment (Avg. **) is shown in TABLE 28.In TABLE 28, the calculated % conjugation conversion efficiency (% Conj)to Calendic acid (CAL) is also shown for the average of the five eventshaving highest CAL content from each experiment where the % Conj wascalculated by dividing the sum of the average weight percent (wt. %) forCAL by the sum of the average wt. % for 18:2 and CAL and multiplying by100 to express as a %. Also shown in TABLE 28 is the relative %desaturation (Rel % Conj) for each experiment where the % Conj for theexperiment is divided by the % Conj for that of MSE2542 (CoConj).

TABLE 28 Comparing average fatty acid profiles for MBOATs co-expressedwith a Calendula conjugase in Soy Somatic Embryos Rel Experiment 16:018:0 18:1 18:2 18:3 Cal % Conj % Conj MSE2542 16.7 5.3 19.6 38.1 19.01.3 3.3 1.00 (CoConj) MSE2543 14.6 5.6 22.2 35.3 17.8 4.5 11.3 3.37(CoConj, CoMBOAT) MSE2544 13.8 5.9 23.0 35.4 16.1 5.8 14.3 4.25 (CoConj,CoMBOAT, CoDGAT2)

TABLEs 25-28 demonstrate that co-expression of CoMBOAT or CoMBOAT andCoDGAT2 with CoConj gives higher % Conj activity which leads to higherconcentrations of CAL in soy somatic embryos. CoMBOAT and CoDGAT2co-expressed with CoConj gives higher concentrations of CAL than CoMBOATco-expressed with CoConj individually. Results were not obtained forCoDGAT2 co-expressed individually with CoConj due to contamination ofthe experiment.

Example 15 Co-Expressing MaD6Des and MaElo (Delta-6 Desaturase Pathway)with Either CoMBOAT or McMBOAT in Soy Somatic Embryos

Soybean expression vectors pKR1561 (SEQ ID NO:60), comprising MaD6Desand MaElo and called experiments MSE2597, pKR1549 (SEQ ID NO:62),comprising MaD6Des, MaElo and McMBOAT and called experiment MSE2595 andpKR1557 (SEQ ID NO:64), comprising MaD6Des, MaElo and CoMBOAT and calledexperiment MSE2596 were transformed into soy, somatic embryos wereharvested and lipid fatty acid profiles were analyzed exactly asdescribed in Example 13 and results are summarized in TABLEs 29, 30 and31, respectively.

In the Tables, the fatty acid profiles as a weight percent of totalfatty acids are shown where 16:0 is palmitic acid, 18:0 is stearic acid,18:1 is oleic acid, 18:2 is linoleic acid, GLA is gamma-linolenic acid,18:3 is alpha-linolenic acid, STA is stearidonic acid, DGLA isdihomo-gamma-linolenic acid and ETA is eicosatetraenoic acid[20:1(Δ8,11,14,17)]. The sum of GLA+STA and DGLA+ETA is also shown.Results for each event are sorted according to DGLA+ETA concentrationsin decreasing order. The average fatty acid profiles for the five eventshaving highest DGLA+ETA content from each experiment are also shown ineach table (Avg. **).

TABLE 29 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1561 comprising MaD6Des and MaElo (MSE2597) GLA + EDA + DGLA + Event# 16:0 18:0 18:1 18:2 GLA 18:3 STA EDA DGLA ERA ETA STA ERA ETA 10 15.27.3 16.5 14.9 18.0 8.7 2.5 1.8 12.1 1.1 1.7 20.5 3.0 13.8 22 16.1 6.023.0 6.8 25.8 4.6 3.0 0.6 12.5 0.1 1.6 28.8 0.7 14.1 20 13.8 7.4 21.113.3 21.5 6.8 2.0 1.1 11.3 0.6 1.1 23.5 1.7 12.4 1 13.6 7.4 25.8 9.122.6 5.0 2.6 1.3 10.9 0.5 1.4 25.1 1.8 12.3 29 13.8 7.1 23.0 15.3 18.57.3 1.8 1.2 10.3 0.6 1.1 20.3 1.8 11.4 24 14.3 6.5 21.0 12.5 22.8 7.62.7 1.0 9.7 0.5 1.4 25.5 1.6 11.1 14 13.9 6.6 22.5 16.6 21.0 6.0 1.6 1.09.6 0.4 0.9 22.5 1.4 10.4 16 14.1 7.0 27.7 11.8 19.7 6.3 2.2 0.8 8.9 0.31.2 21.9 1.1 10.1 13 15.3 6.9 22.4 15.3 17.6 8.2 2.1 1.8 8.4 0.8 1.119.7 2.6 9.5 28 14.4 6.3 24.7 19.8 13.9 9.2 1.5 1.0 7.8 0.5 0.8 15.4 1.58.6 23 16.2 5.5 22.5 12.1 27.0 6.4 3.2 0.4 5.8 0.0 0.8 30.2 0.5 6.6 815.6 5.9 19.2 15.6 24.0 9.5 3.3 0.4 5.6 0.1 0.8 27.3 0.5 6.4 21 14.6 5.323.3 26.6 11.7 10.4 1.2 0.8 5.2 0.4 0.5 12.9 1.2 5.7 6 16.0 6.0 17.332.5 7.8 11.8 1.0 2.1 4.2 0.7 0.4 8.8 2.9 4.6 2 17.8 5.8 17.3 38.0 0.419.7 0.5 0.0 0.6 0.0 0.0 0.9 0.0 0.6 25 18.5 5.3 15.9 39.4 1.9 17.9 0.60.3 0.3 0.0 0.0 2.5 0.3 0.3 15 18.3 4.6 11.0 42.6 1.1 21.5 0.7 0.0 0.30.0 0.0 1.8 0.0 0.3 3 18.9 4.2 12.3 40.5 1.8 21.2 0.7 0.1 0.3 0.0 0.02.5 0.1 0.3 27 14.8 6.6 20.2 33.3 9.8 10.6 1.0 2.7 0.3 0.8 0.0 10.8 3.40.3 17 16.1 6.0 19.3 38.8 0.8 15.1 0.5 2.3 0.3 0.8 0.0 1.3 3.0 0.3 518.8 5.1 12.7 40.3 0.9 21.3 0.6 0.1 0.2 0.0 0.0 1.5 0.1 0.2 4 16.5 5.816.4 39.8 0.2 15.4 0.4 3.9 0.2 1.4 0.0 0.6 5.4 0.2 12 19.1 5.3 15.0 40.60.4 18.8 0.5 0.0 0.2 0.0 0.0 0.9 0.0 0.2 11 17.9 5.1 15.3 41.2 0.2 19.40.6 0.2 0.1 0.0 0.0 0.8 0.2 0.1 7 17.1 5.0 18.7 39.8 0.3 17.3 0.5 0.70.1 0.5 0.0 0.8 1.2 0.1 30 16.5 5.6 13.8 42.2 0.2 16.8 0.4 3.3 0.1 1.20.0 0.6 4.5 0.1 9 14.4 7.2 15.0 37.4 0.2 13.6 0.4 8.6 0.0 3.2 0.0 0.611.8 0.0 18 17.2 5.8 19.9 38.8 0.1 17.7 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.019 14.1 7.5 18.4 38.4 0.0 12.4 0.4 6.8 0.0 2.1 0.0 0.4 8.8 0.0 26 14.74.5 17.2 18.7 33.2 8.1 3.3 0.3 0.0 0.0 0.0 36.5 0.3 0.0 Avg.** 14.5 7.021.9 11.9 21.2 6.5 2.4 1.2 11.4 0.6 1.4 23.6 1.8 12.8

TABLE 30 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1549 comprising MaD6Des, MaElo and McMBOAT (MSE2595) GLA + EDA +DGLA + Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA EDA DGLA ERA ETA STA ERAETA 19 14.7 6.5 16.4 15.5 18.2 7.6 1.8 1.4 15.8 0.6 1.5 20.0 2.1 17.2 2613.9 7.4 18.8 12.7 18.9 6.1 2.0 1.9 15.6 1.1 1.7 20.9 3.0 17.3 4 15.18.5 14.6 13.4 20.8 8.1 2.3 0.9 14.1 0.4 1.8 23.2 1.3 15.9 30 16.2 8.418.3 13.2 16.9 6.5 2.3 1.5 14.0 0.9 1.8 19.2 2.4 15.9 12 14.4 5.7 19.212.2 26.4 5.7 2.4 1.0 11.3 0.4 1.3 28.8 1.4 12.6 8 15.4 6.0 24.1 8.225.2 6.2 3.1 0.9 10.0 0.5 1.4 28.3 1.4 11.3 15 15.5 7.0 16.1 24.6 11.111.6 1.3 2.0 8.9 1.0 0.9 12.4 3.1 9.8 23 14.9 6.2 21.7 20.3 17.2 9.0 2.10.2 7.6 0.1 0.8 19.2 0.3 8.4 5 15.1 7.1 21.2 21.2 15.4 9.0 1.5 0.8 7.60.4 0.7 16.9 1.2 8.2 16 15.9 8.4 14.1 27.2 9.9 11.4 1.2 3.7 5.7 1.7 0.711.1 5.4 6.4 20 16.2 8.2 22.9 25.1 5.3 12.9 1.1 1.8 4.9 1.0 0.6 6.4 2.85.5 2 16.9 5.1 16.8 31.2 13.7 12.7 1.7 0.4 1.3 0.0 0.2 15.4 0.4 1.5 2814.5 6.4 11.7 36.1 1.2 15.5 0.7 9.4 1.4 3.1 0.0 1.9 12.4 1.4 3 13.9 7.815.7 34.8 0.8 13.2 0.4 9.2 0.7 3.4 0.0 1.3 12.6 0.7 14 16.2 8.6 16.538.4 0.3 14.2 0.4 3.5 0.6 1.2 0.0 0.7 4.8 0.6 22 18.0 5.2 15.9 41.0 0.517.9 0.7 0.3 0.5 0.0 0.0 1.2 0.3 0.5 21 16.1 7.9 15.6 40.1 1.0 16.0 0.41.7 0.4 0.7 0.1 1.4 2.3 0.5 17 14.4 7.5 17.2 37.7 0.8 12.0 0.4 7.2 0.52.3 0.0 1.2 9.4 0.5 1 18.0 4.9 14.9 40.3 0.3 20.7 0.5 0.0 0.4 0.0 0.00.8 0.0 0.4 9 16.5 6.5 21.2 38.0 0.2 16.7 0.4 0.1 0.3 0.0 0.0 0.6 0.10.3 11 16.4 6.0 15.2 44.1 0.1 17.4 0.4 0.0 0.3 0.0 0.0 0.4 0.0 0.3 2917.2 6.3 14.2 40.7 3.1 17.3 0.8 0.1 0.3 0.0 0.0 3.8 0.2 0.3 18 17.7 4.513.0 44.9 0.3 18.4 0.7 0.2 0.3 0.0 0.0 0.9 0.2 0.3 6 16.4 7.0 14.6 40.70.3 18.3 0.4 2.1 0.2 0.0 0.1 0.7 2.1 0.3 25 16.5 8.1 14.9 39.3 0.2 17.80.4 1.7 0.2 1.0 0.0 0.6 2.6 0.2 27 17.1 6.7 22.7 36.8 0.6 15.3 0.4 0.00.2 0.0 0.0 1.1 0.0 0.2 13 16.8 9.4 18.7 39.6 0.0 15.0 0.3 0.0 0.2 0.00.0 0.3 0.0 0.2 10 17.0 6.1 21.7 38.6 0.2 15.7 0.4 0.1 0.2 0.0 0.0 0.60.1 0.2 24 17.3 7.2 22.8 36.6 0.1 15.4 0.4 0.1 0.1 0.0 0.0 0.5 0.1 0.1 716.5 5.8 14.4 46.3 0.0 16.1 0.3 0.5 0.0 0.0 0.0 0.4 0.5 0.0 Avg.** 14.97.3 17.5 13.4 20.3 6.8 2.1 1.3 14.2 0.7 1.6 22.4 2.0 15.8

TABLE 31 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1557 comprising MaD6Des, MaElo and CoMBOAT (MSE2596). GLA + EDA +DGLA + Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA EDA DGLA ERA ETA STA ERAETA 19 13.4 12.9 17.2 11.5 17.0 5.7 1.6 1.2 17.2 0.7 1.6 18.7 1.9 18.724 15.3 7.0 19.8 13.5 20.2 6.7 1.9 0.7 13.2 0.3 1.3 22.2 1.0 14.5 8 14.38.3 24.6 12.4 16.1 6.4 1.7 1.1 13.0 0.7 1.3 17.8 1.8 14.4 30 14.9 9.916.2 17.7 13.9 9.1 1.5 1.8 12.6 1.0 1.3 15.4 2.9 13.9 23 13.6 9.5 15.415.7 22.0 6.4 1.8 1.2 12.7 0.5 1.1 23.8 1.7 13.8 28 14.6 8.2 22.6 15.415.1 7.9 1.9 1.6 10.4 1.0 1.3 17.0 2.6 11.7 22 14.4 7.2 22.6 18.7 14.39.4 1.6 0.8 9.5 0.5 1.1 15.9 1.3 10.5 7 13.8 9.8 15.9 26.7 9.5 9.2 1.02.8 9.5 1.1 0.7 10.5 3.9 10.2 11 15.3 8.6 17.8 31.2 9.3 10.6 1.0 0.2 5.30.1 0.5 10.3 0.3 5.9 4 16.6 4.5 14.5 40.4 5.7 13.3 0.7 0.5 3.2 0.2 0.36.4 0.7 3.6 12 18.0 5.3 15.7 37.0 1.3 20.9 0.6 0.0 1.2 0.0 0.0 1.9 0.01.2 14 16.3 6.5 19.1 36.9 1.2 16.1 0.5 1.6 0.9 0.7 0.1 1.7 2.4 1.1 917.0 5.7 15.0 34.4 7.4 18.2 1.3 0.1 0.8 0.0 0.2 8.6 0.1 1.0 6 16.3 8.016.4 39.8 1.3 15.6 0.4 0.7 0.9 0.4 0.1 1.7 1.1 1.0 16 16.9 6.5 13.7 38.44.5 18.5 0.8 0.0 0.7 0.0 0.0 5.3 0.0 0.7 29 16.3 5.5 13.1 37.9 0.6 20.80.6 2.8 0.6 1.8 0.1 1.1 4.6 0.7 2 14.9 7.2 17.7 44.4 0.5 14.3 0.3 0.00.6 0.0 0.1 0.8 0.0 0.7 10 14.7 7.5 17.6 44.8 0.2 14.4 0.3 0.1 0.5 0.00.0 0.4 0.1 0.5 25 17.1 6.1 19.3 36.0 1.6 16.5 0.5 1.7 0.4 1.0 0.0 2.02.6 0.4 5 14.7 7.9 14.4 25.6 26.5 8.3 2.2 0.1 0.3 0.0 0.0 28.7 0.1 0.417 18.1 5.0 13.5 27.6 18.8 14.0 2.6 0.1 0.3 0.0 0.0 21.4 0.1 0.3 20 18.05.9 19.3 40.0 0.3 15.8 0.5 0.0 0.2 0.0 0.0 0.8 0.0 0.2 18 17.3 7.3 16.843.1 0.2 14.8 0.3 0.1 0.2 0.0 0.0 0.5 0.1 0.2 3 15.1 6.9 15.1 38.6 0.115.0 0.5 6.3 0.2 2.3 0.0 0.6 8.6 0.2 13 17.1 6.9 14.6 41.5 0.3 19.0 0.40.1 0.2 0.0 0.0 0.6 0.1 0.2 27 17.4 5.6 12.3 31.4 14.7 15.6 2.3 0.5 0.20.0 0.0 17.0 0.5 0.2 1 17.5 5.4 19.9 38.4 0.5 17.8 0.5 0.0 0.0 0.0 0.01.0 0.0 0.0 15 18.9 4.8 12.0 41.3 0.1 22.3 0.6 0.0 0.0 0.0 0.0 0.7 0.00.0 21 17.2 5.2 16.1 40.9 3.2 16.7 0.7 0.0 0.0 0.0 0.0 3.8 0.0 0.0 2615.4 6.7 26.0 37.8 0.6 13.1 0.3 0.0 0.0 0.0 0.0 1.0 0.0 0.0 Avg.** 14.39.5 18.6 14.2 17.8 6.9 1.7 1.2 13.7 0.6 1.3 19.6 1.9 15.1

A summary of the average fatty acid profiles for the five events havinghighest DGLA+ETA content from each experiment (Avg. **) is shown inTABLE 32. In TABLE 32, the calculated % delta-6 desaturation conversionefficiency (% D6) is also shown for the average of the five eventshaving highest DGLA+ETA content from each experiment where the % D6 wascalculated by dividing the sum of the average weight percent (wt. %) forGLA, STA, DGLA and ETA by the sum of the average wt. % for 18:2, 18:3,GLA, STA, DGLA and ETA and multiplying by 100 to express as a %.Similarly, the calculated % C₁₈ to C₂₀ elongation conversion efficiency(% Elo) is shown in TABLE 32 for the average of the five events havinghighest DGLA+ETA content from each experiment where the % Elo wascalculated by dividing the sum of the average weight percent (wt. %) forDGLA and ETA by the sum of the average wt. % for GLA, STA, DGLA and ETAand multiplying by 100 to express as a %. Also shown in TABLE 32 is therelative % desaturation (Rel % D6) and relative % elongation (Rel % Elo)for each experiment where the % D6 or % Elo for the experiment isdivided by the % D6 or % Elo for that of MSE2597 (MaD6,MaElo).

TABLE 32 Comparing average fatty acid profiles for MBOATs co-expressedwith a delta-6 desaturase and Elongase (delta-6 desaturase PUFA pathway)in Soy Somatic Embryos Experiment 16:0 18:0 18:1 18:2 GLA 18:3 STA EDADGLA ERA ETA MSE2597 14.5 7.0 21.9 11.9 21.2 6.5 2.4 1.2 11.4 0.6 1.4(MaD6Des, MaElo) MSE2595 14.9 7.3 17.5 13.4 20.3 6.8 2.1 1.3 14.2 0.71.6 (MaD6Des, MaElo, McMBOAT) MSE2596 14.3 9.5 18.6 14.2 17.8 6.9 1.71.2 13.7 0.6 1.3 (MaD6Des, MaElo, CoMBOAT) GLA + EDA + DGLA + Rel RelExperiment STA ERA ETA % D6 % Elo % D6 % Elo MSE2597 23.6 1.8 12.8 66.735.3 1.00 1.00 (MaD6Des, MaElo) MSE2595 22.4 2.0 15.8 65.5 41.6 0.981.18 (MaD6Des, MaElo, McMBOAT) MSE2596 19.6 1.9 15.1 62.2 43.7 0.93 1.24(MaD6Des, MaElo, CoMBOAT)

TABLEs 29-32 demonstrate that co-expression of McMBOAT or CoMBOAT alongwith MaD6Des and MaElo leads to higher % Elo activity while % D6activity is largely unaffected. Therefore, higher concentrations ofDGLA+ETA are produced when either MBOAT is co-expressed with the MaD6Desand MaElo.

Example 16 Co-Expressing EgD9Elo and TpomD8Des (Delta-9 ElongasePathway) with Either CoMBOAT or McMBOAT in Soy Somatic Embryos

Soybean expression vectors pKR1560 (SEQ ID NO:65), comprising EgD9Eloand TpomD8Des and called experiment MSE2602, pKR1550 (SEQ ID NO:67),comprising EgD9Elo, TpomD8Des and McMBOAT and called experiment MSE2600and pKR1558 (SEQ ID NO:69), comprising EgD9Elo, TpomD8Des and CoMBOATand called experiment MSE2601 were transformed into soy, somatic embryoswere harvested and lipid fatty acid profiles were analyzed exactly asdescribed in Example 13, and results are summarized in TABLEs 33, 34 and35, respectively.

In the Tables, the fatty acid profiles as a weight percent of totalfatty acids are shown where 16:0 is palmitic acid, 18:0 is stearic acid,18:1 is oleic acid, 18:2 is linoleic acid, 18:3 is alpha-linolenic acid,EDA is eicosadienoic acid [20:2(Δ1,14)], DGLA is dihomo-gamma-linolenicacid, ERA is eicosatrienoic acid [20:3(Δ11,14,17)] and ETA iseicosatetraenoic acid [20:1(Δ8,11,14,17)]. The sum of EDA+ERA andDGLA+ETA is also shown. Results for each event are sorted according toDGLA+ETA concentrations in decreasing order. The average fatty acidprofiles for the five events having highest DGLA+ETA content from eachexperiment are also shown in each table (Avg. **)

TABLE 33 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1560 comprising EgD9Elo and TpomD8Des (MSE2602). Event # 16:0 18:018:1 18:2 18:3 EDA DGLA ERA ETA EDA + ERA DGLA + ETA 14 15.5 5.2 19.425.6 7.4 8.9 13.8 0.8 3.4 9.7 17.2 20 14.5 6.2 19.4 25.4 5.1 14.6 10.61.3 2.7 16.0 13.3 8 15.6 5.1 17.3 26.0 8.5 13.4 9.7 1.6 2.8 15.0 12.5 1714.9 5.4 18.1 22.0 6.7 18.1 9.1 2.6 3.0 20.6 12.1 11 15.3 5.3 18.9 26.58.2 12.8 9.5 1.2 2.5 14.0 12.0 21 14.1 5.7 21.6 25.0 5.6 15.0 9.2 1.42.4 16.5 11.6 23 14.6 5.4 20.0 26.9 7.5 15.2 6.6 2.2 1.6 17.3 8.3 2914.8 5.8 21.7 27.8 8.5 13.5 4.6 1.7 1.5 15.2 6.2 6 14.8 5.1 15.5 25.98.9 20.6 3.9 3.9 1.5 24.5 5.4 9 18.2 4.7 14.7 37.4 16.1 3.3 4.2 0.4 1.03.8 5.2 1 13.2 9.0 19.2 26.0 6.2 18.9 3.9 2.7 0.9 21.6 4.8 22 12.7 6.916.1 24.8 5.5 25.6 3.3 3.8 1.3 29.4 4.6 3 15.4 6.4 22.4 29.0 9.9 11.03.0 1.9 1.0 12.9 4.0 30 15.5 7.0 26.1 29.9 9.9 6.7 2.9 1.2 1.0 7.8 3.916 17.7 4.5 11.7 39.8 18.5 3.7 2.2 0.6 1.3 4.3 3.4 26 13.4 8.4 17.9 30.37.4 17.5 1.5 3.0 0.4 20.5 2.0 25 17.3 6.5 17.7 36.2 14.9 5.1 0.9 1.1 0.46.2 1.3 5 13.5 5.4 16.2 26.6 10.2 20.9 0.7 6.1 0.5 27.0 1.2 15 18.0 5.415.2 40.8 19.0 0.5 0.8 0.1 0.2 0.6 1.0 28 17.6 4.7 16.3 42.5 15.7 2.20.4 0.3 0.3 2.5 0.7 2 19.2 5.9 13.8 43.2 16.9 0.8 0.1 0.1 0.0 0.9 0.1 416.7 5.1 16.3 33.6 15.5 10.2 0.0 2.6 0.0 12.7 0.0 7 18.2 5.6 16.1 41.617.5 0.9 0.0 0.2 0.0 1.1 0.0 10 18.1 4.6 15.0 40.7 21.6 0.0 0.0 0.0 0.00.0 0.0 12 17.8 5.7 17.9 38.5 15.9 3.2 0.0 1.0 0.0 4.2 0.0 13 18.7 4.813.1 41.1 22.1 0.2 0.0 0.0 0.0 0.2 0.0 18 12.7 7.0 18.4 27.3 6.6 23.30.0 4.7 0.0 28.0 0.0 19 19.7 4.4 11.5 40.7 23.6 0.2 0.0 0.0 0.0 0.2 0.024 15.9 6.1 21.2 39.8 12.4 4.0 0.0 0.7 0.0 4.7 0.0 27 17.7 5.7 16.8 40.119.4 0.2 0.0 0.0 0.0 0.3 0.0 Avg.** 15.1 5.5 18.6 25.1 7.2 13.6 10.5 1.52.9 15.1 13.4

TABLE 34 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1550 comprising EgD9Elo, TpomD8Des and McMBOAT (MSE2600) Event # 16:018:0 18:1 18:2 18:3 EDA DGLA ERA ETA EDA + ERA DGLA + ETA 5 14.1 6.224.0 19.1 4.9 11.1 16.2 0.9 3.4 12.0 19.6 28 16.3 5.7 17.1 25.2 8.7 8.014.1 0.9 4.1 8.9 18.2 12 14.7 6.0 23.2 23.2 6.3 7.8 13.9 0.9 4.0 8.717.9 21 14.2 6.1 27.1 18.9 6.3 8.5 14.3 0.9 3.6 9.4 17.9 8 15.6 5.1 22.322.9 8.0 7.7 13.5 1.0 4.0 8.7 17.5 27 14.8 6.1 24.1 21.0 6.4 10.2 13.40.9 3.3 11.1 16.7 14 15.2 5.8 24.5 21.4 7.1 8.8 12.7 1.0 3.5 9.8 16.2 1814.0 5.3 15.8 23.6 6.7 17.7 11.4 2.2 3.3 19.9 14.7 10 15.7 5.3 21.5 22.79.0 9.9 10.8 1.5 3.6 11.4 14.4 4 13.7 6.3 25.6 19.9 5.6 13.5 11.8 1.22.4 14.7 14.3 26 16.3 4.8 15.4 27.5 11.3 9.5 10.3 1.2 3.7 10.7 14.0 1716.5 4.6 13.6 27.9 12.9 10.5 9.2 1.6 3.3 12.1 12.5 16 15.0 5.6 21.0 24.88.2 11.6 9.1 1.5 3.1 13.2 12.3 29 15.9 6.5 25.7 28.0 10.2 3.9 7.5 0.42.0 4.3 9.4 20 13.4 6.1 21.6 23.9 7.0 16.6 7.3 2.4 1.6 19.0 8.9 13 15.66.8 21.3 29.0 12.0 6.7 5.4 1.3 1.9 8.0 7.3 2 18.2 4.4 13.9 35.2 13.5 8.04.0 1.3 1.4 9.3 5.4 23 18.1 4.9 15.1 37.2 18.4 1.8 3.5 0.2 0.9 2.0 4.4 317.3 5.1 16.0 38.2 18.4 1.8 1.9 0.3 0.9 2.1 2.8 22 14.0 4.8 14.9 25.28.2 25.8 1.7 4.8 0.6 30.6 2.3 25 17.8 5.2 16.4 36.9 22.1 0.7 0.7 0.0 0.30.7 0.9 19 15.1 5.4 18.4 32.4 12.2 13.1 0.4 2.9 0.1 16.0 0.5 1 18.5 4.513.9 37.8 24.4 0.6 0.3 0.0 0.0 0.6 0.3 11 14.5 6.4 23.1 29.6 10.4 12.50.2 3.3 0.0 15.8 0.2 6 18.8 5.2 12.5 43.8 19.5 0.2 0.0 0.0 0.0 0.2 0.0 718.1 4.8 13.7 43.1 19.8 0.3 0.0 0.2 0.0 0.5 0.0 9 17.1 4.8 16.5 40.121.4 0.1 0.0 0.0 0.0 0.1 0.0 15 18.4 5.5 13.9 41.5 20.5 0.2 0.0 0.0 0.00.2 0.0 24 18.3 4.8 15.0 40.6 21.2 0.1 0.0 0.0 0.0 0.1 0.0 Avg.** 15.05.8 22.7 21.9 6.9 8.6 14.4 0.9 3.8 9.5 18.2

TABLE 35 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1558 comprising EgD9Elo, TpomD8Des and CoMBOAT (MSE2601) Event # 16:018:0 18:1 18:2 18:3 EDA DGLA ERA ETA EDA + ERA DGLA + ETA 21 14.2 5.217.9 16.8 4.5 18.0 18.9 1.2 3.4 19.2 22.3 20 16.0 5.1 17.2 23.6 8.2 10.216.0 0.7 3.1 10.9 19.0 2 18.1 4.1 7.1 25.8 16.4 8.4 13.7 1.6 4.8 10.018.5 4 14.3 5.8 20.4 20.0 5.9 14.2 14.5 1.4 3.6 15.6 18.1 10 14.8 6.120.1 19.9 5.1 14.9 14.5 1.2 3.4 16.2 17.9 19 17.2 4.8 15.5 24.9 9.8 9.013.6 1.1 4.1 10.1 17.7 17 15.6 5.0 20.8 20.0 5.9 13.9 14.3 1.1 3.3 15.017.6 1 15.6 5.4 16.2 21.5 5.6 17.0 13.3 1.7 3.6 18.7 17.0 30 14.1 6.015.0 20.8 4.7 22.0 13.0 1.7 2.8 23.7 15.8 11 14.0 7.1 29.9 18.0 4.9 11.011.1 1.1 2.8 12.1 14.0 24 14.4 6.5 21.7 21.8 5.5 15.2 10.7 1.4 2.7 16.713.4 15 16.1 5.1 15.2 29.9 10.3 9.7 10.2 1.0 2.6 10.7 12.7 5 15.9 5.119.0 21.8 8.6 15.1 9.3 2.2 3.0 17.3 12.3 23 13.8 8.8 18.4 25.9 6.6 15.27.7 1.6 1.9 16.8 9.5 6 14.2 5.8 21.9 20.5 7.2 17.5 6.8 3.5 2.7 21.0 9.516 16.1 6.0 19.5 30.3 11.5 6.8 7.2 0.6 2.0 7.4 9.2 13 16.0 5.4 17.9 29.812.6 10.4 4.7 1.6 1.5 12.0 6.2 27 17.9 5.1 16.4 35.4 17.4 2.8 3.5 0.51.0 3.3 4.5 28 14.7 5.7 24.3 29.1 6.7 14.6 2.0 2.1 0.8 16.8 2.8 7 10.87.5 22.8 16.3 3.4 32.7 1.8 4.2 0.6 36.9 2.4 22 15.1 5.4 19.0 29.4 13.012.7 1.6 3.4 0.4 16.1 2.0 8 17.8 6.1 20.6 39.1 14.5 0.6 1.3 0.0 0.0 0.61.3 25 17.1 5.8 22.8 35.8 17.0 0.7 0.5 0.0 0.2 0.7 0.7 18 18.1 6.2 17.437.6 19.3 0.6 0.4 0.0 0.3 0.6 0.7 12 14.1 4.7 16.5 28.4 7.2 23.4 0.5 5.10.1 28.5 0.6 3 18.4 6.3 17.2 37.8 19.7 0.4 0.3 0.0 0.0 0.4 0.3 9 14.56.0 25.9 26.7 8.9 15.2 0.0 2.9 0.0 18.1 0.0 14 14.5 5.3 15.0 34.3 10.117.1 0.0 3.6 0.0 20.8 0.0 26 17.2 6.5 17.5 38.7 20.2 0.0 0.0 0.0 0.0 0.00.0 29 15.6 5.1 13.1 33.0 11.8 17.4 0.0 3.9 0.0 21.3 0.0 Avg.** 15.5 5.216.5 21.2 8.0 13.2 15.5 1.2 3.6 14.4 19.2

A summary of the average fatty acid profiles for the five events havinghighest DGLA+ETA content from each experiment (Avg. **) is shown inTABLE 36. In TABLE 36, the calculated % delta-9 elongation conversionefficiency (% D9Elo) is also shown for the average of the five eventshaving highest DGLA+ETA content from each experiment where the % D9Elowas calculated by dividing the sum of the average weight percent (wt. %)for EDA, ERA, DGLA and ETA by the sum of the average wt. % for 18:2,18:3, EDA, ERA, DGLA and ETA and multiplying by 100 to express as a %.Similarly, the calculated % delta-8 desaturation conversion efficiency(% D8) is shown in TABLE 36 for the average of the five events havinghighest DGLA+ETA content from each experiment where the % D8 wascalculated by dividing the sum of the average weight percent (wt. %) forDGLA and ETA by the sum of the average wt. % for EDA, ERA, DGLA and ETAand multiplying by 100 to express as a %. Also shown in TABLE 36 is therelative % delta-9 elongation (Rel % D9Elo) and relative % delta-8desaturation (Rel % D8) for each experiment where the % D69Elo or % D8for the experiment is divided by the % D9Elo or % D8 for that of MSE2602(EgD9Elo, TpomD8Des).

TABLE 36 Comparison of the average fatty acid profiles for MBOATsco-expressed with a delta-9 elongase PUFA pathway in Soy Somatic EmbryosRel EDA + EDA + DGLA + % D9 % D9 Rel Experiment 16:0 18:0 18:1 18:2 18:3EDA DGLA ERA ETA ERA ERA ETA Elo % D8 Elo % D8 MSE2602 15.1 5.5 18.625.1 7.2 13.6 10.5 1.5 2.9 15.1 15.1 13.4 42.4 47.6 1.00 1.00 (EgD9Elo,TpomD8Des) MSE2600 15.0 5.8 22.7 21.9 6.9 8.6 14.4 0.9 3.8 9.5 9.5 18.247.7 65.8 1.12 1.38 (EgD9Elo, TpomD8Des, McMBOAT) MSE2601 15.5 5.2 16.521.2 8.0 13.2 15.5 1.2 3.6 14.4 14.4 19.2 49.2 57.7 1.16 1.21 (EgD9Elo,TpomD8Des, CoMBOAT)

TABLEs 33-36 demonstrate that co-expression of either McMBOAT or CoMBOATalong with EgD9elo and TpomD8Des leads to higher activities for both %D9Elo and % D8 activity in soy somatic embryos. These higher activitiesresult in higher concentrations of DGLA+ETA being made.

Example 17 Expression Vectors For Co-Expression of MBOAT and DGAT2 GenesWith Unusual Fatty Acid Biosynthetic Genes and/or PUFA Genes

In addition to the genes, promoters, terminators and gene cassettesdescribed herein, one skilled in the art can appreciate that otherpromoter/gene/terminator cassette combinations can be synthesized in away similar to, but not limited to, that described herein for theco-expression of MBOAT and DGAT2 genes with unusual fatty acidbiosynthetic genes. Similarly, it may be desirable to co-express MBOATsof the present invention or other MBOAT genes and DGAT2 genes of thepresent invention or other DGAT2 genes with the unusual fatty acidbiosynthetic genes of the present invention (CoConj, McConj, EgD9Elo,TpomD8Des, MaD6Des or MaElo) or other unusual fatty acid biosyntheticgenes.

For instance, PCT Publication No. WO 2004/071467 and U.S. Pat. No.7,129,089 describe the isolation of a number of promoter andtranscription terminator sequences for use in embryo-specific expressionin soybean. Furthermore, PCT Publication Nos. WO 2004/071467 and U.S.Pat. No. 7,129,089 describe the synthesis of multiplepromoter/gene/terminator cassette combinations by ligating individualpromoters, genes, and transcription terminators together in uniquecombinations. Generally, a NotI site flanked by the suitable promoter(such as those listed in, but not limited to, Table 37) and atranscription terminator (such as those listed in, but not limited to,Table 38) is used to clone the desired gene. NotI sites can be added toa gene of interest using PCR amplification with oligonucleotidesdesigned to introduce NotI sites at the 5′ and 3′ ends of the gene. Theresulting PCR product is then digested with NotI and cloned into asuitable promoter/NotI/terminator cassette. Although gene cloning intoexpression cassettes is often done using the NotI restriction enzyme,one skilled in the art can appreciate that a number of restrictionenzymes can be utilized to achieve the desired cassette. Further, oneskilled in the will appreciate that other cloning techniques including,but not limited to, PCR-based or recombination-based techniques can beused to generate suitable expression cassettes.

TABLE 37 Seed-specific Promoters Promoter Organism Promoter Referenceβ-conglycinin α′-subunit soybean Beachy et al., EMBO J. 4: 3047-3053(1985) kunitz trypsin inhibitor soybean Jofuku et al., Plant Cell 1:1079-1093 (1989) Annexin soybean U.S. Pat. No. 7,129,089 glycinin Gy1soybean WO 2004/071467 albumin 2S soybean U.S. Pat. No. 6,177,613legumin A1 pea Rerie et al., Mol. Gen. Genet. 225: 148-157 (1991)β-conglycinin β-subunit soybean WO 2004/071467 BD30 (also called P34)soybean U.S. Pat. No. 7,129,089 legumin A2 pea Rerie et al., Mol. Gen.Genet. 225: 148-157 (1991)

TABLE 38 Transcription Terminators Transcription Terminator OrganismReference phaseolin 3′ bean WO 2004/071467 kunitz trypsin inhibitor 3′soybean WO 2004/071467 BD30 (also called P34) 3′ soybean WO 2004/071467legumin A2 3′ pea WO 2004/071467 albumin 2S 3′ soybean WO 2004/071467

In addition, WO 2004/071467 and U.S. Pat. No. 7,129,089 describe thefurther linking together of individual promoter/gene/transcriptionterminator cassettes in unique combinations and orientations, along withsuitable selectable marker cassettes, in order to obtain the desiredphenotypic expression. Although this is done mainly using differentrestriction enzymes sites, one skilled in the art can appreciate that anumber of techniques can be utilized to achieve the desiredpromoter/gene/transcription terminator combination or orientations. Inso doing, any combination and orientation of embryo-specificpromoter/gene/transcription terminator cassettes can be achieved. Oneskilled in the art can also appreciate that these cassettes can belocated on individual DNA fragments or on multiple fragments whereco-expression of genes is the outcome of co-transformation of multipleDNA fragments.

Unusual fatty acid biosynthetic enzyme encoding genes (such as thoselisted in, but not limited to, Table 39) can be co-expressed with MBOATand/or DGAT2 genes using techniques described herein. NotI restrictionenzyme sites flanking unusual fatty acid biosynthetic genes are added,cloned into soybean expression vectors behind suitable promoters and areco-expressed with MBOAT and/or DGAT2 genes using methods describedherein. Genes can also be synthesized with appropriate restriction sitesflanking the gene of interest.

Similarly, it may be desirable to express other PUFA genes (such asthose described below in Table 39), for co-expression with MBOAT and/orDGAT2 genes of the present invention.

TABLE 39 Unusual Fatty Acid Biosynthetic Gene and Protein Sequences ntSEQ ID aa SEQ ID Function Organism Reference NO: NO: desaturase Vernoniagalamensis 5,846,784 77 78 epoxidase Vernonia galamensis 5,846,784 79 80delta-5 acyl-CoA Limanthes alba 6,838,594 & 81 82 desaturase 7,495,149fatty acyl-CoA elongase Limnanthes alba 6,838,594 & 83 84 7,495,149conjugase Impatiens balsamina 7,244,563 85 86 conjugase Momordicacharantia 7,244,563 87 88 conjugase Chrysobalanus icaco 7,244,563 89 90conjugase Licania michauxii 7,244,563 91 92 conjugase Aleurites fordii7,244,563 93 94 Class II conjugase Aleurites fordii 7,244,563 95 96hydroxylase Ricinis communis 7,244,563 — 97 Gi:722351 Conjugase(delta-9, Calendula officialis 6,593,514 & 98 99 CalFad2-1) 7,230,090Conjugase (delta-9, Calendula officialis 6,593,514 & 100 101 CalFad2-2)7,230,090 Conjugase (delta-12, Dimorphotheca 6,593,514 & 102 103DMFad2-1) sinuata 7,230,090 Conjugase (delta-9, Dimorphotheca 6,593,514& 104 105 DMFad2-2) sinuata 7,230,090

TABLE 40 PUFA Biosynthetic Pathway Genes Gene Organism Reference delta-6desaturase Saprolegnia diclina WO 2002/081668 delta-6 desaturaseMortierella alpina U.S. Pat. No. 5,968,809 elongase Mortierella alpinaWO 2000/12720 U.S. Pat. No. 6,403,349 delta-5 desaturase Mortierellaalpina U.S. Pat. No. 6,075,183 delta-5 desaturase Saprolegnia diclina WO2002/081668 delta-5 desaturase Peridinium sp. U.S. patent applicationNo. 11/748,637 delta-5 desaturase Euglena gracilis U.S. patentapplication No. 11/748,629 delta-15 desaturase Fusarium moniliforme WO2005/047479 delta-17 desaturase Saprolegnia diclina WO 2002/081668elongase Thraustochytrium WO 2002/08401 aureum U.S. Pat. No. 6,677,145elongase Pavlova sp. Pereira et al., Biochem. J. 384: 357-366 (2004)delta-4 desaturase Schizochytrium WO 2002/090493 aggregatum U.S. Pat.No. 7,045,683 delta-4 desaturase Isochrysis galbana WO 2002/090493 U.S.Pat. No. 7,045,683 delta-4 desaturase Thraustochytrium WO 2002/090493aureum U.S. Pat. No. 7,045,683 delta-4 desaturase Euglena gracilis U.S.patent application No. 10/552,127 delta-9 elongase Isochrysis galbana WO2002/077213 delta-9 elongase Euglena gracilis U.S. patent applicationNo. 11/601,563 delta-9 elongase Eutreptiella sp. U.S. patent applicationNo. CCMP389 11/601,564 delta-8 desaturase Euglena gracilis WO 2000/34439U.S. Pat. No. 6,825,017 WO 2004/057001 WO 2006/012325 delta-8 desaturaseEuglena gracilis WO 2000/34439 U.S. Pat. No. 6,825,017 WO 2004/057001 WO2006/012325 delta-8 desaturase Acanthamoeba Sayanova et al., FEBS Lett.castellanii 580: 1946-1952 (2006) delta-8 desaturase Pavlova salina WO2005/103253 delta-8 desaturase Pavlova lutheri U.S. patent applicationNo. 11/737,772 delta-8 desaturase Tetruetreptia U.S. patent applicationNo. pomquetensis 11/876,115 CCMP1491 delta-8 desaturase Eutreptiella sp.U.S. patent application No. CCMP389 11/876,115 delta-8 desaturaseEutreptiella U.S. patent application No. cf_gymnastica 11/876,115CCMP1594

For example, cloning of the Ricinus communis fatty acid hydroxylase(RcHyd; SEQ ID NO:97) from cDNA was described previously in U.S. Pat.No. 7,244,563. RcHyd is PCR amplified from cDNA using the Phusion™High-Fidelity DNA Polymerase (Cat. No. F553S, Finnzymes Oy, Finland)following the manufacturer's protocol and using oligonucleotideRcHydroxy-5 (SEQ ID NO:108) and RcHydroxy-3 (SEQ ID NO:109, which aredesigned to add NotI sites flanking RcHyd.

The resulting DNA fragment is cloned into the pCR-Blunt® cloning vectorusing the Zero Blunt® PCR Cloning Kit (Invitrogen Corporation),following the manufacturer's protocol

The NotI fragment, containing RcHyd, is cloned into the NotI site ofpKR72, which was previously described in PCT Publication No. WO2004/071467 (the contents of which is incorporated by reference), toproduce a soybean expression vector where RcHyd is under control of thesoy beta-conglycinin promoter.

Either McMBOAT or CoMBOAT, under control of the KTi promoter, can bereleased from intermediate cloning vectors described herein by digestionwith BsiWI and the fragment containing the MBOAT gene is cloned into theBsiWI site of the soy expression vector containing RcHyd to produce asoy expression vector where RcHyd is under control of the soybeta-conglycinin promoter and either McMBOAT or CoMBOAT is under controlof the KTi promoter.

Further, the SbfI fragment of pKR1543 (SEQ ID NO:29), containing McDGAT2or the PstI fragment of pKR1493 (SEQ ID NO:40), containing CoDGAT2 canbe cloned into these vectors to produced soybean expression vectorswhere the RcHyd is under control of the soy beta-conglycinin promoter,MBOAT is under control of the KTi promoter and DGAT2 is under control ofthe soy glycinin Gy1 promoter.

Subsequent cleavage of these vectors with BsiWI followed by relegationof the fragment containing RcHyd and either DGAT2 produces soyexpression vectors where RcHyd is under control of the soybeta-conglycinin promoter and DGAT2 is under control of the soy glycininGy1 promoter.

Cloning the AscI fragments from these soy expression vectors into theAscI site of pKR92 produces the corresponding set of Arabidopsisexpression vectors or expressing RcHyd with MBOAT and/or DGAT2 inArabidopsis seed.

Example 18 Construction of Soybean Expression Vectors for Co-ExpressingRicinus communis Hydroxylase (RcHyd) with McDGAT2 and/or McMBOAT and forCo-Expressing Ricinus communis Hydroxylase (RcHyd) with CoDGAT2 and/orCoMBOAT

The Ricinus communis (Castor) fatty acid hydroxylase (RcHyd; SEQ IDNO:97) was described previously in U.S. Pat. No. 7,244,563. RcHyd wasPCR amplified from cDNA using oligonucleotide RcHydroxy-5 (SEQ IDNO:108) and RcHydroxy-3 (SEQ ID NO:109) exactly as described in Example17.

The resulting DNA fragment was cloned into the pCR-Blunt® cloning vectorusing the Zero Blunt® PCR Cloning Kit (Invitrogen Corporation),following the manufacturer's protocol to produce pLF241 (SEQ ID NO:110).

The NotI fragment of pLF241 (SEQ ID NO:110), containing RcHyd gene, wascloned into the NotI site of pKR72, which was previously described inPCT Publication No. WO 2004/071467, to produce pKR1687 (SEQ ID NO:111).In pKR1687, RcHyd is under control of the soy beta-conglycinin promoter.RcHyd generates the hydroxylated fatty acid (Ricinoleic acid) whenexpressed in soy.

The NotI fragment of pLF166 (SEQ ID NO:48), containing CoMBOAT, wascloned into the NotI site of pKR457, which was previously described inNo. U.S. Pat. No. 7,256,033. The resulting intermediate vectorcontaining CoMBOAT under control of the soy KTi promoter was digestedwith BsiWI, and the fragment containing CoMBOAT was cloned into theBsiWI site of pKR1687 (SEQ ID NO:111) to produce pKR1742 (SEQ IDNO:112). In pKR1742, RcHyd is under control of the soy beta-conglycininpromoter, and CoMBOAT is under control of the KTi promoter.

The PstI fragment of pKR1493 (SEQ ID NO:40), containing CoDGAT2, wascloned into the SbfI site of pKR1687 (SEQ ID NO:111) to produce pKR1733(SEQ ID NO:113). In pKR1733, RcHyd is under control of the soybeta-conglycinin promoter, and CoDGAT2 is under control of the soyglycinin Gy1 promoter.

The NotI fragment of pLF166 (SEQ ID NO:48), containing CoMBOAT, wascloned into the NotI site of pKR457, which was previously described inNo. U.S. Pat. No. 7,256,033. The resulting intermediate vectorcontaining CoMBOAT under control of the soy KTi promoter was digestedwith BsiWI, and the fragment containing CoMBOAT was cloned into theBsiWI site of pKR1733 (SEQ ID NO:113) to produce pKR1745 (SEQ IDNO:114). In pKR1745, RcHyd is under control of the soy beta-conglycininpromoter, CoDGAT2 is under control of the soy glycinin Gy1 promoter andCoMBOAT is under control of the KTi promoter.

A starting vector, pKR966 (SEQ ID NO:115) contains the Schizochytriumaggregatum delta-4 desaturase flanked by NotI sites behind the soy KTipromoter and followed by the soy KTi3 and soy albumin double terminator(described in BB1538).

The NotI fragment of pHD41 (SEQ ID NO:34), containing McMBOAT, wascloned into the NotI site of pKR966 (SEQ ID NO:115), containing the soyKTi promoter, to produce pKR1542 (SEQ ID NO:116).

The BsiWI fragment of pKR1542 (SEQ ID NO:116), containing McMBOAT, wascloned into the BsiWI site of pKR1687 (SEQ ID NO:111) to produce pKR1743(SEQ ID NO:117). In pKR1743, RcHyd is under control of the soybeta-conglycinin promoter, and McMBOAT is under control of the KTipromoter.

The SbfI fragment of pKR1543 (SEQ ID NO:29), containing McDGAT2, wascloned into the SbfI site of pKR1687 (SEQ ID NO:111) to produce pKR1734(SEQ ID NO:118). In pKR1734, RcHyd is under control of the soybeta-conglycinin promoter, and McDGAT2 is under control of the soyglycinin Gy1 promoter.

The BsiWI fragment of pKR1542 (SEQ ID NO:116), containing McMBOAT, wascloned into the BsiWI site of pKR1734 (SEQ ID NO:118) to produce pKR1746(SEQ ID NO:119). In pKR1746, RcHyd is under control of the soybeta-conglycinin promoter, McMBOAT is under control of the KTi promoterand McDGAT2 is under control of the soy glycinin Gy1 promoter.

Example 19 Co-Expressing RcHyd with McDGAT2 and/or McMBOAT or CoDGAT2and/or CoMBOAT in Soy Somatic Embryos

Soybean expression vectors pKR1687 (SEQ ID NO:111), comprising RcHyd,pKR1742 (SEQ ID NO:112), comprising RcHyd and CoMBOAT, pKR1733 (SEQ IDNO:113), comprising RcHyd and CoDGAT2, pKR1745 (SEQ ID NO:114),comprising RcHyd, CoMBOAT and CoDGAT2, pKR1743 (SEQ ID NO:117),comprising RcHyd and McMBOAT, pKR1734 (SEQ ID NO:118), comprising RcHydand McDGAT2 and pKR1746 (SEQ ID NO:119), comprising RcHyd, McMBOAT andMcDGAT2 were transformed into soy, and lipid fatty acid profiles and oilcontents were analyzed as described within.

Fatty acid profiles for approximately 30 events from each transformationare summarized in TABLEs 41, 42, 43, 44, 45, 46 and 47, respectively.

In the Tables, the fatty acid profiles as a weight percent of totalfatty acids are shown where 16:0 is palmitic acid, 18:0 is stearic acid,18:1 is oleic acid, 18:2 is linoleic acid, 18:3 is alpha-linolenic acidand Rcn is ricinoleic acid. Results for each event are sorted accordingto RCN concentrations in decreasing order. The average fatty acidprofiles for the five events having highest RCN content from eachexperiment are also shown in each table (Avg. **) where only eventshaving eleostearic acid greater than 1% are included in the averagecalculation.

TABLE 41 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1687 comprising RcHyd (MSE2738) MSE2738 (RcHyd) Event # 16:0 18:018:1 18:2 18:3 Rcn % Hydrox 2738-7 16.6 7.0 24.9 34.8 14.0 2.7 9.92738-20 17.0 5.2 19.3 41.6 15.2 1.6 7.7 2738-6 16.4 3.7 13.2 50.5 14.71.4 9.8 2738-10 16.8 6.1 24.3 35.5 15.9 1.4 5.5 2738-12 18.2 5.5 17.936.8 21.1 0.6 3.1 2738-8 17.9 4.5 14.8 42.2 20.2 0.4 3.0 2738-15 17.96.3 18.8 38.6 18.1 0.3 1.6 2738-30 19.3 5.6 15.6 42.7 16.7 0.2 1.12738-25 17.9 5.1 15.1 41.1 20.6 0.1 0.9 2738-1 18.1 5.3 16.0 41.3 19.40.0 0.0 2738-2 16.5 5.1 18.5 46.1 13.9 0.0 0.0 2738-3 17.6 5.4 18.2 40.018.8 0.0 0.0 2738-4 18.9 4.8 12.2 42.2 21.9 0.0 0.0 2738-5 18.1 4.0 14.948.9 14.2 0.0 0.0 2738-9 17.2 6.8 22.6 36.7 16.6 0.0 0.0 2738-11 18.35.4 16.5 39.0 20.8 0.0 0.0 2738-13 16.7 4.9 18.2 42.8 17.5 0.0 0.02738-14 16.5 5.9 19.1 41.7 16.7 0.0 0.0 2738-16 14.6 6.3 19.6 42.5 17.00.0 0.0 2738-17 17.0 4.9 14.8 40.8 22.5 0.0 0.0 2738-18 19.2 5.0 15.041.5 19.3 0.0 0.0 2738-19 16.8 5.8 19.5 41.6 16.3 0.0 0.0 2738-21 16.94.3 17.0 45.1 16.7 0.0 0.0 2738-22 16.3 5.3 19.1 41.7 17.6 0.0 0.02738-23 17.7 5.8 19.9 37.9 18.6 0.0 0.0 2738-24 17.0 5.6 18.7 42.7 16.20.0 0.0 2738-26 16.8 6.9 22.9 38.9 14.6 0.0 0.0 2738-27 16.3 5.5 17.841.2 19.2 0.0 0.0 2738-28 19.0 6.0 15.7 38.5 20.8 0.0 0.0 2738-29 17.54.6 16.5 43.6 17.8 0.0 0.0 Avg.* 16.7 5.5 20.4 40.6 14.9 1.8 8.2 Avg.**16.7 5.5 20.4 40.6 14.9 1.8 8.2

TABLE 42 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1742 comprising RcHyd & CoMBOAT (MSE2742) MSE2742 (RcHyd, CoMBOAT)Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2742- 18.2 7.3 21.4 28.613.6 10.9 33.7 14 2742-7 16.9 6.4 19.8 35.7 14.6 6.7 25.1 2742- 16.8 6.822.9 33.5 15.6 4.4 16.0 24 2742- 17.3 5.0 15.9 40.2 18.0 3.6 18.3 112742- 17.9 6.8 24.0 30.2 17.8 3.4 12.4 27 2742- 18.5 6.0 17.1 34.5 21.12.8 14.2 20 2742- 17.8 6.2 19.7 35.2 18.6 2.5 11.1 18 2742-9 16.3 6.523.1 34.5 17.2 2.4 9.5 2742- 17.5 5.8 17.2 36.5 21.2 1.7 9.2 13 2742-18.0 6.0 13.3 38.2 23.5 1.1 7.4 28 2742- 17.1 5.5 18.1 37.2 21.0 0.9 4.915 2742- 17.2 5.7 16.2 39.8 20.6 0.5 2.8 12 2742-1 18.3 5.2 15.0 42.419.1 0.0 0.0 2742-2 17.9 5.3 15.4 39.2 22.2 0.0 0.0 2742-3 17.1 4.5 11.039.3 28.1 0.0 0.0 2742-4 18.4 5.8 15.1 39.4 21.3 0.0 0.0 2742-5 19.3 5.314.0 39.5 22.0 0.0 0.0 2742-6 15.7 5.1 13.1 39.3 26.9 0.0 0.0 2742-817.8 5.4 16.2 36.2 24.5 0.0 0.0 2742- 18.2 5.3 15.1 42.2 19.2 0.0 0.0 102742- 18.6 5.2 16.4 38.0 21.8 0.0 0.0 16 2742- 18.8 5.6 15.9 38.5 21.20.0 0.0 17 2742- 17.9 5.6 16.7 39.5 20.2 0.0 0.0 19 2742- 16.9 5.4 15.241.4 21.1 0.0 0.0 21 2742- 17.7 5.6 15.8 39.9 21.0 0.0 0.0 22 2742- 17.75.6 15.4 39.5 21.7 0.0 0.0 23 2742- 17.6 5.4 16.8 40.2 19.9 0.0 0.0 252742- 17.4 5.2 16.2 40.3 20.8 0.0 0.0 26 2742- 18.3 5.2 14.8 41.4 20.30.0 0.0 29 2742- 18.4 5.9 15.8 38.5 21.5 0.0 0.0 30 Avg.* 17.5 6.3 19.434.7 18.1 3.9 15.7 Avg.** 17.4 6.5 20.8 33.6 15.9 5.8 21.1

TABLE 43 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1733 comprising RcHyd & CoDGAT2 (MSE2743) MSE2743 (RcHyd, CoDGAT2)Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2743-4 17.5 5.6 19.5 38.315.6 3.6 15.5 2743- 16.1 6.6 24.7 37.3 13.1 2.2 8.0 18 2743-7 18.6 6.818.5 35.8 18.4 1.9 9.5 2743- 16.7 7.1 28.1 34.2 12.1 1.9 6.3 28 2743-317.2 6.3 25.4 33.8 15.4 1.8 6.5 2743- 18.0 6.4 21.9 36.0 16.1 1.6 6.7 292743- 17.5 7.9 20.3 37.5 15.8 1.1 5.2 23 2743- 18.8 6.2 14.6 40.5 19.00.9 5.8 22 2743- 18.7 5.8 15.1 39.1 20.6 0.7 4.5 16 2743- 17.9 5.8 18.640.6 16.4 0.6 3.3 12 2743- 17.3 7.0 20.6 38.4 16.2 0.6 2.6 27 2743- 18.16.4 19.5 38.0 17.5 0.6 2.8 21 2743- 18.5 4.9 12.2 41.3 22.6 0.5 4.0 242743- 17.4 7.7 24.0 35.8 14.6 0.5 2.0 11 2743- 16.4 6.0 19.1 43.4 14.60.5 2.4 25 2743- 17.6 5.3 16.1 39.8 20.7 0.5 2.8 13 2743-1 17.6 5.7 18.038.4 20.3 0.0 0.0 2743-2 17.6 6.0 20.0 40.0 16.4 0.0 0.0 2743-5 17.5 6.218.9 38.2 19.3 0.0 0.0 2743-6 17.2 5.7 17.9 43.3 15.9 0.0 0.0 2743-817.8 6.4 18.7 39.4 17.6 0.0 0.0 2743-9 18.4 5.7 18.8 40.9 16.2 0.0 0.02743- 18.2 6.7 18.2 37.9 19.1 0.0 0.0 10 2743- 18.3 7.2 20.3 38.8 15.30.0 0.0 14 2743- 18.3 5.3 14.6 40.3 21.5 0.0 0.0 15 2743- 16.5 5.9 22.344.0 11.3 0.0 0.0 17 2743- 17.5 6.6 22.8 37.1 16.0 0.0 0.0 19 2743- 17.25.4 16.5 40.8 20.0 0.0 0.0 20 2743- 16.8 6.5 21.7 39.6 15.4 0.0 0.0 26Avg.* 17.4 6.7 22.6 36.1 15.2 2.0 8.2 Avg.** 17.2 6.5 23.2 35.9 14.9 2.39.2

TABLE 44 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1745 comprising RcHyd, CoMBOAT & CoDGAT2 (MSE2744) MSE2744 (RcHyd,CoMBOAT, CoDGAT2) Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2744-17.8 5.9 19.1 34.1 18.7 4.4 18.6 19 2744- 17.0 6.8 23.0 33.1 16.0 4.115.2 25 2744- 18.3 5.4 15.6 34.3 23.1 3.4 17.9 30 2744- 17.2 6.3 19.036.2 18.5 2.8 12.8 26 2744-4 17.4 5.7 17.5 36.3 21.0 2.1 10.5 2744- 17.06.0 20.7 35.0 19.2 2.0 8.9 28 2744- 15.6 5.2 19.1 33.8 24.4 1.9 8.9 132744- 17.1 5.0 19.2 36.7 20.2 1.7 8.2 17 2744- 17.3 5.0 13.6 38.4 24.31.4 9.5 21 2744-3 16.7 5.5 18.3 38.1 20.0 1.4 7.1 2744- 17.1 5.5 13.640.3 22.9 0.7 4.7 11 2744- 16.6 5.4 16.8 35.9 24.5 0.6 3.6 24 2744- 17.15.8 16.8 39.6 20.1 0.6 3.4 22 2744- 17.4 5.8 15.7 40.0 20.6 0.5 3.2 122744-1 15.7 5.6 16.9 38.9 22.9 0.0 0.0 2744-2 17.5 5.1 15.6 41.4 20.40.0 0.0 2744-5 17.4 6.8 20.3 36.0 19.5 0.0 0.0 2744-6 17.9 5.6 15.0 41.520.0 0.0 0.0 2744-7 17.3 7.6 19.3 36.3 19.5 0.0 0.0 2744-8 18.0 6.9 18.335.8 21.0 0.0 0.0 2744-9 17.7 7.2 16.4 36.9 21.8 0.0 0.0 2744- 18.5 5.714.9 37.9 23.1 0.0 0.0 10 2744- 17.3 5.3 16.6 39.4 21.3 0.0 0.0 14 2744-17.8 5.5 16.3 38.7 21.7 0.0 0.0 15 2744- 17.0 5.3 16.1 42.3 19.3 0.0 0.016 2744- 17.1 6.0 15.4 37.6 23.9 0.0 0.0 18 2744- 17.4 5.1 13.8 39.424.3 0.0 0.0 20 2744- 18.1 5.2 16.1 38.2 22.6 0.0 0.0 23 2744- 17.7 5.317.3 38.1 21.5 0.0 0.0 27 2744- 17.6 5.9 18.8 36.9 20.9 0.0 0.0 29 Avg.*17.2 5.7 18.5 35.6 20.5 2.5 11.8 Avg.** 17.5 6.0 18.9 34.8 19.4 3.4 15.0

TABLE 45 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1743 comprising RcHyd & McMBOAT (MSE2739) MSE2739 (RcHyd, McMBOAT)Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2739- 15.0 6.4 24.7 35.410.8 7.7 23.7 18 2739-5 18.1 6.8 21.7 31.7 14.0 7.7 26.1 2739- 18.4 7.922.1 31.6 12.4 7.6 25.6 32 2739- 16.4 5.0 20.7 39.2 13.0 5.6 21.4 152739- 17.8 5.4 18.6 40.0 13.3 5.1 21.6 28 2739- 18.2 6.1 20.0 37.5 14.14.1 17.1 11 2739-6 15.7 6.1 23.2 37.3 14.0 3.7 13.8 2739- 15.4 7.4 26.735.4 11.4 3.7 12.2 27 2739- 15.9 6.0 25.9 34.2 14.6 3.4 11.5 22 2739-15.2 6.8 26.7 35.6 12.6 3.0 10.0 13 2739- 17.2 5.9 27.3 31.1 15.5 3.09.8 24 2739-9 15.7 6.3 26.8 34.8 14.0 2.4 8.3 2739-8 16.8 5.1 25.7 33.217.1 2.2 8.0 2739- 16.6 6.2 23.9 35.7 15.5 2.1 8.2 29 2739-1 15.9 5.220.2 41.0 15.6 2.1 9.4 2739- 16.9 5.7 19.7 42.8 13.7 1.2 5.7 17 2739-315.3 5.0 25.0 40.3 13.1 1.2 4.5 2739- 16.1 5.3 15.9 43.0 19.4 0.4 2.4 252739-4 16.8 4.3 14.2 50.3 14.1 0.3 2.0 2739- 16.0 6.0 20.9 40.8 16.1 0.10.7 10 2739- 17.1 5.8 17.3 42.4 17.3 0.1 0.6 16 2739- 16.8 4.2 14.1 50.914.0 0.1 0.6 31 2739-2 16.9 5.3 16.6 40.9 20.3 0.0 0.0 2739-7 17.9 5.714.6 43.7 18.0 0.0 0.0 2739- 16.5 6.4 21.3 39.7 16.1 0.0 0.0 12 2739-16.4 5.1 14.2 43.0 21.2 0.0 0.0 14 2739- 16.8 5.9 16.8 40.5 20.0 0.0 0.019 2739- 16.5 5.8 17.5 40.0 20.2 0.0 0.0 20 2739- 18.4 4.2 13.7 41.322.4 0.0 0.0 21 2739- 19.2 4.6 13.1 42.5 20.6 0.0 0.0 23 2739- 18.1 5.615.3 39.3 21.8 0.0 0.0 26 2739- 16.2 5.7 17.5 44.1 16.5 0.0 0.0 30 Avg.*16.5 6.1 23.5 36.3 13.8 3.9 13.9 Avg.** 17.1 6.3 21.6 35.6 12.7 6.7 23.7

TABLE 46 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1734 comprising RcHyd & McDGAT2 (MSE2740) MSE2740 (RcHyd, McDGAT2)Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2740-1 15.6 8.7 32.2 28.49.5 5.7 15.1 2740-2 14.6 7.3 35.0 29.5 8.7 4.9 12.4 2740-3 15.2 6.7 30.131.7 12.1 4.3 12.5 2740- 15.2 8.2 34.3 29.1 9.3 3.8 10.0 30 2740- 16.86.6 28.0 32.2 13.9 2.5 8.1 17 2740- 16.7 4.9 19.9 42.6 14.5 1.5 6.9 102740- 17.5 6.0 20.0 37.0 18.1 1.4 6.5 13 2740- 17.1 5.8 22.6 37.3 16.31.0 4.1 21 2740-6 15.9 6.6 23.5 39.7 13.4 0.9 3.7 2740- 16.6 5.7 25.237.5 14.1 0.9 3.3 25 2740-7 16.8 5.3 16.1 40.2 21.2 0.4 2.6 2740-4 16.45.9 17.1 45.9 14.4 0.2 1.4 2740- 16.7 5.2 20.6 44.1 13.2 0.2 0.9 182740-5 17.7 5.4 17.6 43.6 15.7 0.0 0.0 2740-8 15.4 6.2 20.5 43.4 14.50.0 0.0 2740-9 15.8 4.9 16.1 47.1 16.1 0.0 0.0 2740- 16.0 4.8 15.0 43.520.7 0.0 0.0 11 2740- 16.5 6.3 21.2 41.9 14.2 0.0 0.0 12 2740- 16.4 4.924.3 36.3 18.1 0.0 0.0 14 2740- 15.9 6.1 26.2 37.4 14.4 0.0 0.0 15 2740-15.6 7.2 22.4 38.9 15.9 0.0 0.0 16 2740- 16.8 4.8 13.0 42.2 23.3 0.0 0.019 2740- 15.8 4.7 20.1 47.4 11.9 0.0 0.0 20 2740- 15.8 4.6 20.7 46.012.9 0.0 0.0 22 2740- 18.6 5.2 18.7 42.8 14.8 0.0 0.0 23 2740- 15.8 5.716.7 44.3 17.5 0.0 0.0 24 2740- 15.7 5.9 20.8 45.2 12.4 0.0 0.0 26 2740-17.2 6.7 22.9 39.4 13.9 0.0 0.0 27 2740- 14.8 6.5 24.0 42.5 12.1 0.0 0.028 2740- 17.0 5.1 15.6 45.7 16.5 0.0 0.0 29 2740- 17.0 5.0 15.5 42.220.4 0.0 0.0 31 Avg.* 16.1 6.8 27.8 33.5 12.8 3.1 9.4 Avg.** 15.5 7.531.9 30.2 10.7 4.2 11.6

TABLE 47 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1746 comprising RcHyd, McMBOAT & McDGAT2 (MSE2741) MSE2741 (RcHyd,McMBOAT, McDGAT2) Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2741-15.7 7.8 29.6 31.7 10.8 4.5 13.2 14 2741- 16.6 7.1 28.7 33.2 10.8 3.611.1 30 2741-1 16.2 6.3 25.7 37.0 11.3 3.5 12.1 2741- 17.0 6.9 26.2 34.114.1 1.7 6.1 10 2741- 17.9 4.9 16.1 44.0 15.6 1.5 8.3 15 2741-5 16.8 5.921.0 36.7 18.5 1.1 4.9 2741- 17.3 5.8 15.9 41.0 19.1 1.0 5.7 16 2741-616.2 5.3 15.1 44.0 18.8 0.5 3.3 2741-7 17.7 6.2 20.9 36.6 18.2 0.4 2.02741-8 16.4 5.7 18.9 43.3 15.4 0.3 1.5 2741-2 17.1 6.1 14.4 40.2 22.30.0 0.0 2741-3 18.3 6.0 17.6 38.5 19.6 0.0 0.0 2741-4 18.1 5.0 14.8 37.524.6 0.0 0.0 2741-9 17.7 5.7 15.2 40.8 20.5 0.0 0.0 2741- 17.6 6.5 18.741.5 15.8 0.0 0.0 11 2741- 17.6 6.0 17.2 41.7 17.4 0.0 0.0 12 2741- 16.75.9 18.0 41.6 17.8 0.0 0.0 13 2741- 18.2 5.8 18.3 41.8 15.9 0.0 0.0 172741- 17.0 6.2 17.2 42.0 17.6 0.0 0.0 18 2741- 14.9 7.0 21.0 43.2 14.00.0 0.0 19 2741- 17.7 5.2 15.5 40.0 21.6 0.0 0.0 20 2741- 15.5 6.5 25.242.4 10.4 0.0 0.0 21 2741- 16.9 6.3 21.2 39.6 16.0 0.0 0.0 22 2741- 17.76.1 18.0 40.8 17.5 0.0 0.0 23 2741- 18.3 6.3 18.5 37.5 19.3 0.0 0.0 242741- 19.2 5.0 13.8 40.1 21.8 0.0 0.0 25 2741- 17.4 6.6 20.4 39.9 15.70.0 0.0 26 2741- 16.8 6.0 19.5 43.4 14.4 0.0 0.0 27 2741- 16.2 6.6 23.840.5 12.8 0.0 0.0 28 2741- 15.9 7.7 23.4 41.5 11.6 0.0 0.0 29 2741- 17.74.6 15.3 49.3 13.2 0.0 0.0 31 Avg.* 16.8 6.4 23.3 36.8 14.3 2.4 8.8Avg.** 16.7 6.6 25.3 36.0 12.5 3.0 10.2

A summary of the average fatty acid profiles for the five events havinghighest RCN content from each experiment (Avg. **) is shown in TABLE 48.In TABLE 48, the calculated % hydroxylation conversion efficiency (%Hydrox) to RCN is also shown for the average of the five events havinghighest RCN content from each experiment where the % Hydrox wascalculated by dividing the sum of the average weight percent (wt. %) forRCN by the sum of the average wt. % for 18:1 and RCN and multiplying by100 to express as a %. Also shown in TABLE 48 is the relative %hydroxylation (Rel % Hydrox) for each experiment where the % Hydrox forthe experiment is divided by the % Hydrox for that of MSE2738 (RcHyd).

TABLE 48 Comparing average fatty acid profiles for MBOAT and/or DGAT2co- expressed with a Castor Hydroxylase in Soy Somatic Embryos Summaryfor top 5 events (RcHyd in Soy Somatic Embyros) Rel Experiment 16:0 18:018:1 18:2 18:3 Rcn % Hydrox % Hydrox MSE2738 (RcHyd)* 16.7 5.5 20.4 40.614.9 1.8 8.2 1.00 MSE2739 (RcHyd, McMBOAT) 17.1 6.3 21.6 35.6 12.7 6.723.7 2.88 MSE2740 (RcHyd, McDGAT2) 15.5 7.5 31.9 30.2 10.7 4.2 11.6 1.41MSE2741 (RcHyd, McDGAT2, McMBOAT) 16.7 6.6 25.3 36.0 12.5 3.0 10.2 1.24MSE2742 (RcHyd, CoMBOAT) 17.4 6.5 20.8 33.6 15.9 5.8 21.1 2.57 MSE2743(RcHyd, CoDGAT2) 17.2 6.5 23.2 35.9 14.9 2.3 9.2 1.12 MSE2744 (RcHyd,CoDGAT2, CoMBOAT) 17.5 6.0 18.9 34.8 19.4 3.4 15.0 1.83

Example 20 Construction of Soybean Expression Vectors for Co-ExpressingRicinus communis Hydroxylase (RcHyd) with GmMBOAT1, GmMBOAT2 orEuphMBOAT

Identifying and Cloning MBOAT Homologs from Soy

Soybean homologs of the Momordica MBOAT gene were identified byconducting BLAST (Basic Local Alignment Search Tool; Altschul et al., J.Mol. Biol. 215:403 410 (1993)) searches for similarity to sequencescontained in the Soybean Genome Project, DoE Joint Genome Institute“Glyma1.01” gene set Specifically, the TBLASTN algorithm provided byNational Center for Biotechnology Information (NCBI) was used withdefault parameters except the Filter Option was set to OFF.

In this way, two soy putative cDNA sequences were identified whichencoded proteins with homology to the Momordica MBOAT protein(Glyma17g14070, called GmMBOAT1 and Glyma05g03510, called GmMBOAT2) wereidentified. The genomic sequences, coding sequences and correspondingamino acid sequences for GmMBOAT1 and GmMBOAT2 are set forth as SEQ IDNO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124 andSEQ ID NO:125, respectively.

GmMBOAT1 was PCR amplified from a soy cDNA library usingoligonucleotides GmLPCAT1-5 (SEQ ID NO:126) and GmLPCAT1-3 (SEQ ID NO:127) and Phusion polymerase according to the manufacturer'sinstructions. The resulting DNA fragment was cloned into Zero Blunt PCRCloning Kit (Invitrogen Corporation), following the manufacturer'sprotocol, to produce pLF164 (SEQ ID NO:128).

GmMBOAT2 was PCR amplified in a similar way using oligonucleotidesGmLPCAT2-5 (SEQ ID NO:129) and GmLPCAT1-3 (SEQ ID NO:127). The resultingDNA fragment was cloned into Zero Blunt PCR Cloning Kit (InvitrogenCorporation), following the manufacturer's protocol, to produce pLF165(SEQ ID NO:130).

The NotI fragments of pLF164 (SEQ ID NO: 128) and pLF165 (SEQ IDNO:130), containing GmMBOAT1 and GmMBOAT2, respectively were cloned intothe NotI site of pKR966 (SEQ ID NO:115), containing the soy KTipromoter, to produce pKR1813 (SEQ ID NO:131) and pKR1814 (SEQ IDNO:132), respectively.

The BsiWI fragments of pKR1813 (SEQ ID NO:131) and pKR1814 (SEQ IDNO:132), containing GmMBOAT1 and GmMBOAT2, respectively, were clonedinto the BsiWI site of pKR1687 (SEQ ID NO:111) to produce pKR1821 (SEQID NO:133) and pKR1822 (SEQ ID NO:134), respectively.

Identifying and Cloning an MBOAT Homolog from Euphorbia

A cDNA library representing mRNAs from developing seeds of Euphorbialagascae was prepared, and insert cDNA fragments were sequenced aspreviously described in Published US Patent Application No.US20040139499 and Cahoon et al. [Transgenic Production of Epoxy FattyAcids by Expression of a Cytochrome P450 Enzyme from Euphorbia lagascaeSeed. (2002) Plant Physiology, Vol. 123, pages 615-624]. cDNAs clonesencoding Euphorbia lagascae membrane bound o-acyltransferase (MBOAT)homologs were identified by conducting BLAST (Basic Local AlignmentSearch Tool; Altschul et al., J. Mol. Biol. 215:403 410 (1993)) searchesfor similarity to sequences contained in the BLAST “nr” database(comprising all non-redundant GenBank CDS translations, sequencesderived from the 3-dimensional structure Brookhaven Protein Data Bank,the last major release of the SWISS PROT protein sequence database, EMBLand DDBJ databases). All cDNA sequences from either library wereanalyzed for similarity to all publicly available DNA sequencescontained in the “nr” database using the BLASTN algorithm provided bythe National Center for Biotechnology Information (NCBI). The DNAsequences were translated in all reading frames and compared forsimilarity to all publicly available protein sequences contained in the“nr” database using the BLASTX algorithm (Gish and States, Nat. Genet.3:266 272 (1993)) provided by the NCBI. For convenience, the P value(probability) of observing a match of a cDNA sequence to a sequencecontained in the searched databases merely by chance as calculated byBLAST are reported herein as “pLog” values, which represent the negativeof the logarithm of the reported P value. Accordingly, the greater thepLog value, the greater the likelihood that the cDNA sequence and theBLAST “hit” represent homologous proteins.

The BLASTX search using the nucleotide sequence from Euphorbia lagascaecDNA clone eel1c.pk002.h9 revealed similarity of the protein encoded bythe cDNA to a hypothetical protein from Ricinus communis (Accession No.XP_(—)002282807 (GI:225426775)) and to o-acyltransferase (membranebound) domain containing protein, putative from Ricinus communis(Accession No. XP_(—)002509709 (GI:255537285)). The sequence of theentire Euphorbia lagascae cDNA insert in clone eel1c.pk002.h9 wasdetermined and set forth in SEQ ID NO:135. The corresponding sequencefor the coding sequence (CDS) and deduced amino acid sequences are setforth in SEQ ID NO:136 and SEQ ID NO:137.

The Euphorbia MBOAT homolog (EuphMBOAT) was PCR amplified from ESTeel1c.pk002.h9 using oligonucleotides EIMBOAT-5Not (SEQ ID NO:138) andoEU mb-2 (SEQ ID NO:139) and Phusion polymerase according to themanufacturer's instructions. The resulting DNA fragment was cloned intoZero Blunt PCR Cloning Kit (Invitrogen Corporation), following themanufacturer's protocol, to produce pKR1823 (SEQ ID NO:140).

The NotI fragment of pKR1823 (SEQ ID NO:140), containing EuphMBOAT, wascloned into the NotI site of pKR966 (SEQ ID NO:115), containing the soyKTi promoter, to produce pKR1827 (SEQ ID NO:141).

The BsiWI fragment of pKR1827 (SEQ ID NO:141), containing EuphMBOAT wascloned into the BsiWI site of pKR1687 (SEQ ID NO:111) to produce pKR1836(SEQ ID NO:142).

Example 21 Co-Expressing RcHyd with GmMBOAT1, GmMBOAT2 or EuphMBOAT inSoy Somatic Embryos

Soybean expression vectors pKR1687 (SEQ ID NO:111), comprising RcHyd,pKR1821(SEQ ID NO:133), comprising RcHyd and GmMBOAT1, pKR1822 (SEQ IDNO:134), comprising RcHyd and GmMBOAT2 and pKR1836 (SEQ ID NO:142),comprising RcHyd and EuphMBOAT were transformed into soy, and lipidfatty acid profiles and oil contents were analyzed as described within.

Fatty acid profiles for approximately 30 events from each transformationare summarized in TABLEs 49, 50, 51, and 52, respectively.

In the Tables, the fatty acid profiles as a weight percent of totalfatty acids are shown where 16:0 is palmitic acid, 18:0 is stearic acid,18:1 is oleic acid, 18:2 is linoleic acid, 18:3 is alpha-linolenic acidand Rcn is ricinoleic acid. Results for each event are sorted accordingto RCN concentrations in decreasing order. The average fatty acidprofiles for the five events having highest RCN content from eachexperiment are also shown in each table (Avg. **) where only eventshaving eleostearic acid greater than 1% are included in the averagecalculation.

TABLE 49 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1687 comprising RcHyd (MSE2762) MSE2762 (RcHyd) Event # 16:0 18:018:1 18:2 18:3 Rcn % Hydrox 2762- 14.1 7.5 35.7 30.1 8.2 4.4 11.0 192762- 14.3 8.0 41.5 25.1 8.8 2.4 5.5 26 2762- 15.7 8.6 23.6 35.4 14.62.2 8.5 13 2762- 14.4 11.4 31.5 30.7 9.8 2.2 6.4 29 2762- 17.3 5.4 20.737.5 17.9 1.2 5.3 17 2762- 16.0 6.1 29.7 34.9 12.1 1.2 3.8 23 2762- 16.45.7 22.9 39.3 14.8 0.9 3.7 18 2762-8 15.8 8.6 30.5 33.4 11.0 0.8 2.42762- 15.4 7.6 34.0 31.7 10.8 0.5 1.4 10 2762- 14.8 8.3 21.8 42.9 11.80.4 1.6 28 2762-4 17.1 6.0 24.2 38.6 14.0 0.1 0.5 2762-2 15.7 6.9 28.235.7 13.4 0.1 0.4 2762- 14.9 9.0 38.4 27.3 10.3 0.1 0.3 24 2762-1 16.94.9 18.6 39.1 20.5 0.0 0.0 2762-3 15.6 6.7 23.1 38.0 16.5 0.0 0.0 2762-515.1 7.9 29.5 36.4 11.1 0.0 0.0 2762-6 15.7 7.2 29.5 35.4 12.1 0.0 0.02762-7 15.4 8.6 20.6 41.0 14.4 0.0 0.0 2762-9 16.5 6.6 26.3 36.2 14.40.0 0.0 2762- 16.3 6.5 26.2 35.8 15.2 0.0 0.0 11 2762- 15.0 8.0 35.130.5 11.4 0.0 0.0 12 2762- 16.5 6.3 25.3 36.0 15.8 0.0 0.0 14 2762- 16.76.8 24.0 37.9 14.6 0.0 0.0 15 2762- 18.4 6.5 25.4 35.4 14.3 0.0 0.0 162762- 15.5 9.4 32.7 31.3 11.1 0.0 0.0 20 2762- 16.9 5.1 18.5 42.0 17.50.0 0.0 21 2762- 16.1 6.4 25.1 39.0 13.3 0.0 0.0 22 2762- 16.9 5.6 20.438.5 18.5 0.0 0.0 25 2762- 15.8 6.9 28.3 35.9 13.2 0.0 0.0 27 2762- 16.75.5 22.9 39.5 15.4 0.0 0.0 30 2762- 17.4 5.5 18.5 40.9 17.8 0.0 0.0 31Avg.* 15.3 7.8 30.5 32.3 11.9 2.2 6.7 Avg.** 15.2 8.2 30.6 31.7 11.8 2.57.3

TABLE 50 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1821 comprising RcHyd & GmMBOAT1 (MSE2764) MSE2764 (RcHyd + GmMBOAT1)Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2764- 17.8 7.3 24.3 29.313.1 8.2 25.3 23 2764- 13.9 8.0 36.2 25.2 9.6 7.1 16.4 29 2764- 14.9 6.832.1 28.3 11.9 6.0 15.8 28 2764-2 15.2 6.9 34.1 28.9 12.5 2.5 6.8 2764-915.2 8.2 36.5 29.0 9.0 2.1 5.5 2764-6 15.8 7.2 30.1 33.7 11.5 1.7 5.42764-4 15.7 6.0 33.1 31.4 12.1 1.6 4.7 2764- 15.1 7.2 26.2 39.4 11.2 0.83.1 24 2764- 17.0 5.9 24.9 34.5 17.1 0.6 2.3 10 2764-5 16.5 6.9 27.136.9 12.1 0.3 1.1 2764- 16.2 6.3 20.4 42.4 14.7 0.1 0.4 18 2764-1 16.37.5 29.0 35.1 12.1 0.0 0.0 2764-3 15.8 8.4 31.5 33.6 10.7 0.0 0.0 2764-717.7 5.9 18.0 38.0 20.4 0.0 0.0 2764-8 16.1 7.0 26.2 39.1 11.6 0.0 0.02764- 16.6 6.4 20.7 39.6 16.8 0.0 0.0 11 2764- 17.8 5.7 21.0 38.3 17.30.0 0.0 12 2764- 16.5 7.1 27.1 35.9 13.3 0.0 0.0 13 2764- 16.4 6.6 23.339.5 14.2 0.0 0.0 14 2764- 16.3 7.1 26.4 37.1 13.1 0.0 0.0 15 2764- 16.66.2 22.5 38.8 16.0 0.0 0.0 16 2764- 15.8 7.7 30.6 33.4 12.5 0.0 0.0 172764- 16.6 6.4 26.1 39.8 11.1 0.0 0.0 19 2764- 15.9 6.9 33.3 32.0 12.00.0 0.0 20 2764- 16.5 7.2 25.2 38.3 12.8 0.0 0.0 21 2764- 16.1 6.9 25.338.5 13.1 0.0 0.0 22 2764- 16.8 6.2 20.1 37.4 19.5 0.0 0.0 25 2764- 15.77.7 30.2 35.0 11.4 0.0 0.0 26 2764- 17.3 5.3 19.0 39.9 18.5 0.0 0.0 272764- 18.1 5.1 16.2 35.0 25.5 0.0 0.0 30 Avg.* 15.5 7.2 32.3 29.4 11.44.2 11.4 Avg.** 15.4 7.4 32.6 28.1 11.2 5.2 14.0

TABLE 51 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1822 comprising RcHyd & GmMBOAT2 (MSE2765) MSE2765 (RcHyd + GmMBOAT2)Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2765-6 19.7 5.6 17.1 32.416.6 8.5 33.3 2765- 15.6 6.2 24.7 31.2 14.1 8.2 25.0 11 2765- 17.9 5.922.9 31.8 15.1 6.3 21.7 18 2765- 15.4 7.0 25.9 31.8 14.2 5.6 17.8 102765- 15.4 6.3 28.3 30.6 14.0 5.3 15.9 31 2765- 17.3 5.4 22.5 32.3 18.04.5 16.7 21 2765- 17.3 5.3 17.6 36.7 20.4 2.6 12.8 14 2765- 18.0 5.112.4 37.8 24.6 2.1 14.8 15 2765- 16.4 5.2 19.9 37.8 18.6 2.1 9.5 172765- 16.1 6.0 25.0 35.3 15.8 1.9 6.9 29 2765- 17.2 5.1 18.8 37.3 20.11.5 7.6 30 2765- 17.2 5.5 20.4 37.5 18.3 1.0 4.8 22 2765- 16.9 4.8 18.339.3 20.1 0.6 2.9 23 2765-1 17.9 5.2 18.9 38.0 19.5 0.5 2.6 2765- 18.55.3 15.6 36.6 23.4 0.5 3.1 16 2765- 16.7 5.7 19.4 38.3 19.5 0.4 2.0 242765-4 17.8 4.8 17.6 40.5 18.9 0.4 2.2 2765- 17.7 5.0 16.8 33.4 26.8 0.42.2 12 2765-5 16.1 4.7 12.4 40.8 25.8 0.2 1.7 2765-7 18.4 5.0 15.9 40.120.4 0.2 1.3 2765- 16.7 4.8 15.5 41.2 21.8 0.1 0.5 20 2765-2 18.0 5.717.1 39.9 19.3 0.0 0.0 2765-3 16.8 4.9 17.8 40.7 19.8 0.0 0.0 2765-818.1 4.6 15.5 38.2 23.6 0.0 0.0 2765-9 17.3 5.4 19.3 39.3 18.6 0.0 0.02765- 17.1 5.3 19.2 40.2 18.1 0.0 0.0 13 2765- 18.3 5.2 15.5 35.4 25.60.0 0.0 19 2765- 16.9 5.3 17.1 40.6 20.1 0.0 0.0 25 2765- 17.2 5.8 18.739.6 18.8 0.0 0.0 26 2765- 18.2 4.7 13.7 39.7 23.7 0.0 0.0 27 2765- 16.34.8 14.2 42.0 22.7 0.0 0.0 28 Avg.* 17.0 5.7 21.3 34.4 17.5 4.2 15.6Avg.** 16.8 6.2 23.8 31.6 14.8 6.8 22.7

TABLE 52 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1836 comprising RcHyd & EuphMBOAT (MSE2767) MSE2767 (RcHyd +EuphMBOAT) Event # 16:0 18:0 18:1 18:2 18:3 Rcn % Hydrox 2767- 15.7 7.235.1 25.3 10.3 6.4 15.3 28 2767- 16.4 6.7 27.5 33.3 11.6 4.6 14.2 172767- 17.2 5.9 22.6 32.8 17.2 4.5 16.5 29 2767-8 17.8 5.1 18.9 35.6 18.73.9 17.2 2767-4 17.3 6.1 26.4 33.4 13.6 3.2 10.8 2767-9 15.9 7.1 32.231.0 11.5 2.3 6.6 2767- 16.9 5.4 23.8 35.6 16.2 2.1 8.2 12 2767- 16.86.3 27.6 33.9 13.4 2.0 6.7 24 2767- 17.9 5.3 19.4 37.4 18.0 2.0 9.2 102767-3 17.5 6.7 25.3 34.8 13.8 1.9 6.8 2767-2 16.7 6.1 26.9 35.1 13.71.6 5.6 2767- 16.6 6.7 27.6 34.1 13.7 1.2 4.1 13 2767- 17.2 6.2 22.736.8 16.0 1.0 4.3 21 2767-7 17.5 5.8 22.9 34.6 18.3 0.9 3.7 2767- 16.76.3 31.3 31.7 13.2 0.7 2.2 27 2767- 18.2 6.4 26.0 35.5 13.6 0.3 1.2 312767-1 18.0 4.6 16.3 39.4 21.5 0.2 1.4 2767- 18.9 5.2 15.0 41.6 19.1 0.21.3 30 2767- 17.9 6.0 19.2 39.5 17.3 0.1 0.5 15 2767-5 19.4 5.1 18.242.2 15.1 0.0 0.0 2767-6 17.3 5.4 16.1 41.6 19.6 0.0 0.0 2767- 18.0 5.517.1 41.9 17.6 0.0 0.0 11 2767- 18.3 4.9 15.0 39.7 22.1 0.0 0.0 14 2767-17.1 7.0 28.4 34.2 13.4 0.0 0.0 16 2767- 18.0 5.3 22.7 33.8 20.3 0.0 0.018 2767- 16.9 6.9 26.7 36.0 13.5 0.0 0.0 19 2767- 17.6 5.1 17.4 40.419.6 0.0 0.0 20 2767- 16.7 6.8 26.8 36.8 12.9 0.0 0.0 22 2767- 18.2 5.517.7 40.3 18.2 0.0 0.0 23 2767- 18.1 5.6 20.5 39.2 16.6 0.0 0.0 25 2767-18.2 5.6 20.4 37.7 18.0 0.0 0.0 26 Avg.* 17.2 6.1 24.6 34.8 15.3 2.0 7.2Avg.** 16.9 6.2 26.1 32.1 14.3 4.5 14.8

A summary of the average fatty acid profiles for the five events havinghighest RCN content from each experiment (Avg. **) is shown in TABLE 53.In TABLE 53, the calculated % hydroxylation conversion efficiency (%Hydrox) to RCN is also shown for the average of the five events havinghighest RCN content from each experiment where the % Hydrox wascalculated by dividing the sum of the average weight percent (wt. %) forRCN by the sum of the average wt. % for 18:1 and RCN and multiplying by100 to express as a %. Also shown in TABLE 53 is the relative %hydroxylation (Rel % Hydrox) for each experiment where the % Hydrox forthe experiment is divided by the % Hydrox for that of MSE2738 (RcHyd).

TABLE 53 Comparing average fatty acid profiles for MBOAT co-expressedwith a Castor Hydroxylase in Soy Somatic Embryos Summary for top 5events (RcHyd in Soy Somatic Embyros) Rel Experiment 16:0 18:0 18:1 18:218:3 Rcn % Hyrox % Hydrox MSE2762 (RcHyd) 15.2 8.2 30.6 31.7 11.8 2.57.3 1.00 MSE2764 (RcHyd, GmMBOAT1) 15.4 7.4 32.6 28.1 11.2 5.2 14.0 1.91MSE2765 (RcHyd, GmMBOAT2) 16.8 6.2 23.8 31.6 14.8 6.8 22.7 3.10 MSE2767(RcHyd, EuphMBOAT) 16.9 6.2 26.1 32.1 14.3 4.5 14.8 2.02

Example 22 Construction of Soybean Expression Vectors for Co-ExpressingEuphorbia lagascae Cytochorme P450 (EuphEpox) with EuphMBOAT andCo-Expressing in Soy Somatice Embryos

Cloning EuphEpox and Construction of Co-Expression Vectors

The NotI fragment of plasmid pKR31, containing the open-reading frame ofthe cDNA for EST eel1c.pk002.14 flanked by NotI sites (EuphEpox) andwhich was previously described in Published US Patent Application No.US20040139499 and Cahoon et al. [Transgenic Production of Epoxy FattyAcids by Expression of a Cytochrome P450 Enzyme from Euphorbia lagascaeSeed. (2002) Plant Physiology, Vol. 123, pages 615-624] was cloned intothe NotI site of pKR72 to produce pKR1815 (SEQ ID NO:143). In pKR1815,EuphEpox is under control of the soy beta-conglycinin promoter. EuphEpoxgenerates the epoxidated fatty acid (Vernolic acid) when expressed insoy.

The BsiWI fragment of pKR1827 (SEQ ID NO:141), containing EuphMBOAT, wascloned into the BsiWI site of pKR1815 (SEQ ID NO:143) to produce pKR1835(SEQ ID NO:144).

Co-Expressing EuphEpox with EuphMBOAT in Soy Somatic Embryos

Soybean expression vectors pKR1815 (SEQ ID NO:143), comprising EuphEpoxand pKR1835 (SEQ ID NO:144), comprising EuphEpox and EuphMBOAT, weretransformed into soy and lipid fatty acid profiles and oil contents wereanalyzed as described within.

Fatty acid profiles for approximately 30 events from each transformationare summarized in TABLEs 54 and 55, respectively.

In the Tables, the fatty acid profiles as a weight percent of totalfatty acids are shown where 16:0 is palmitic acid, 18:0 is stearic acid,18:1 is oleic acid, 18:2 is linoleic acid, 18:3 is alpha-linolenic acidand VERN is Vernolic acid. Results for each event are sorted accordingto VERN concentrations in decreasing order. The average fatty acidprofiles for the five events having highest VERN content from eachexperiment are also shown in each table (Avg. **).

TABLE 54 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1815 comprising EuphEpox (MSE2763) MSE2763 (EuphP450) Event # 16:018:0 18:1 18:2 18:3 VERN % Epox 2763-5 16.7 4.7 18.3 38.6 21.2 0.5 1.32763-6 16.8 5.7 22.3 36.4 18.4 0.5 1.4 2763-1 16.9 5.6 20.1 37.2 19.80.4 1.1 2763- 17.6 5.5 18.7 37.8 20.1 0.3 0.7 31 2763- 16.4 4.3 13.637.7 27.7 0.3 0.7 10 2763- 17.9 6.3 19.6 38.2 17.9 0.2 0.6 12 2763- 17.65.7 22.0 37.8 16.7 0.2 0.6 29 2763-3 13.3 4.7 22.0 45.6 14.1 0.2 0.52763- 17.9 5.0 14.5 38.9 23.4 0.2 0.5 30 2763-4 16.3 4.8 17.6 41.0 20.00.2 0.4 2763- 17.2 5.2 15.5 38.6 23.4 0.1 0.4 25 2763- 17.7 5.1 17.938.5 20.7 0.1 0.3 17 2763-8 17.5 5.0 18.5 40.1 18.8 0.1 0.3 2763- 17.36.0 22.2 39.1 15.2 0.1 0.3 22 2763- 17.1 4.9 16.3 39.7 21.8 0.1 0.2 132763-2 17.2 4.9 15.4 39.0 23.5 0.0 0.0 2763-7 16.0 5.7 15.4 39.2 23.80.0 0.0 2763-9 17.4 5.4 17.0 37.9 22.2 0.0 0.0 2763- 16.5 5.1 17.6 39.920.8 0.0 0.0 11 2763- 16.7 5.0 21.5 36.3 20.6 0.0 0.0 14 2763- 17.5 5.419.5 39.4 18.1 0.0 0.0 15 2763- 16.4 4.5 17.1 40.3 21.7 0.0 0.0 16 2763-19.0 5.2 13.6 40.9 21.3 0.0 0.0 18 2763- 17.6 6.0 18.3 40.7 17.4 0.0 0.019 2763- 18.0 5.4 17.3 40.3 19.1 0.0 0.0 20 2763- 17.1 5.6 15.8 39.022.4 0.0 0.0 21 2763- 14.9 4.9 20.0 45.0 15.2 0.0 0.0 23 2763- 18.4 5.016.4 39.3 20.9 0.0 0.0 24 2763- 17.4 4.5 14.6 40.5 23.0 0.0 0.0 26 2763-17.6 6.4 20.5 37.1 18.4 0.0 0.0 27 2763- 18.1 5.5 16.7 38.0 21.7 0.0 0.028 Avg.* 16.7 5.2 18.9 38.9 19.9 0.3 0.9 Avg.** 16.9 5.2 18.6 37.6 21.40.4 1.0

TABLE 55 Fatty Acid Analysis from Soy Somatic Embyros transformed withpKR1835 comprising EuphEpox (MSE2766) MSE2766 (EuphP450 + EuphMBOAT)Event # 16:0 18:0 18:1 18:2 18:3 VERN % Epox 2766- 15.0 6.3 31.2 35.79.9 1.8 4.9 11 2766- 17.1 5.8 24.4 37.4 14.5 0.8 2.0 17 2766- 15.5 7.222.2 41.3 13.2 0.6 1.4 12 2766- 16.4 6.4 25.5 39.7 11.7 0.4 1.1 16 2766-17.8 6.3 23.5 36.0 16.0 0.4 1.1 15 2766-5 16.0 7.3 28.2 37.1 11.0 0.41.0 2766- 17.0 6.2 23.5 39.7 13.3 0.4 1.0 27 2766- 16.6 6.8 24.9 38.013.4 0.3 0.8 22 2766- 17.7 5.3 18.5 39.6 18.7 0.3 0.7 19 2766- 17.9 5.222.0 37.1 17.6 0.3 0.7 18 2766-4 17.9 6.4 23.2 38.0 14.2 0.3 0.7 2766-16.6 6.5 24.9 38.1 13.7 0.2 0.6 13 2766- 16.8 6.2 21.3 41.7 13.8 0.2 0.630 2766- 18.1 5.1 18.2 42.0 16.4 0.2 0.5 26 2766-1 16.8 7.0 22.1 39.014.9 0.2 0.5 2766- 17.8 5.6 17.6 39.6 19.2 0.2 0.4 10 2766- 17.5 5.920.2 38.9 17.3 0.1 0.2 21 2766-2 18.7 5.5 15.8 40.0 20.0 0.0 0.0 2766-316.9 7.2 26.1 36.7 13.1 0.0 0.0 2766-6 16.5 7.1 27.2 36.9 12.2 0.0 0.02766-7 15.9 7.3 29.8 34.7 12.3 0.0 0.0 2766-8 17.3 5.4 19.1 39.9 18.30.0 0.0 2766-9 16.6 8.0 28.5 34.8 12.1 0.0 0.0 2766- 16.7 7.3 26.5 36.712.8 0.0 0.0 14 2766- 17.6 5.1 16.9 41.0 19.4 0.0 0.0 20 2766- 17.7 5.318.0 40.4 18.5 0.0 0.0 23 2766- 17.8 6.2 22.1 35.6 18.3 0.0 0.0 24 2766-17.2 5.2 17.0 44.2 16.5 0.0 0.0 25 2766- 17.5 5.3 18.1 41.5 17.6 0.0 0.028 2766- 18.1 5.8 20.6 37.6 17.8 0.0 0.0 29 Avg.* 16.9 6.2 23.2 38.714.5 0.4 1.1 Avg.** 16.4 6.4 25.4 38.0 13.1 0.8 2.1

A summary of the average fatty acid profiles for the five events havinghighest VERN content from each experiment (Avg. **) is shown in TABLE56. In TABLE 56, the calculated % epoxidation conversion efficiency (%Epox) to VERN is also shown for the average of the five events havinghighest VERN content from each experiment where the % Epox wascalculated by dividing the sum of the average weight percent (wt. %) forVERN by the sum of the average wt. % for 18:2 and VERN and multiplyingby 100 to express as a %. Also shown in TABLE 56 is the relative %epoxidation (Rel % Epox) for each experiment where the % Epox for theexperiment is divided by the % Epox for that of MSE2763 (EuphEpox).

TABLE 56 Comparing average fatty acid profiles for EuphMBOATco-expressed with a Euphorbia cytochrome P450 in Soy Somatic EmbryosSummary for top 5 events (EuphEpox in Soy Somatic Embyros) Experiment16:0 18:0 18:1 18:2 18:3 VERN % Epox Rel % Epox MSE2763 (EuphEpox) 16.95.2 18.6 37.6 21.4 0.4 1.0 1.00 MSE2764 (EuphEpox, EuphMBOAT) 16.4 6.425.4 38.0 13.1 0.8 2.1 2.05

Example 23 Creating Transgenic Arabidopsis Background Events ExpressingLC-PUFA Fatty Acids

Arabidopsis background events were generated which expressed variousLC-PUFA fatty acid biosynthetic genes. These events were thentransformed with various MBOAT genes, and the effect on LC-PUFA fattyacid and oil concentrations was determined.

DGLA/ETA-Expressing Transgenic Event (MaD6des/MaD6Elo)

Construction of plasmid pKR1559, transformation into Arabidopsis (col-0)and analysis of T2 seed for fatty acid profiles was described above.Events producing DGLA/ETA and which segregated 3:1 for the transgenewere carried on, and T3 seed were harvested. Homozygous T3 seed fromthese events were found not to germinate on plates, but the fatty acidprofile for T3 seed from one representative event having good DGLNETAconcentrations and which was homozygous for the transgene (1559-17-11)is shown below. Because homozygous T3 seed did not germinate,heterozygous T3 seed was chosen for use as a DGLA/ETA-expressingbackground, and the fatty acid profile from seed from this event is alsoshown below in Table 57.

TABLE 57 Fatty acid profile of homozygous and heterozygous T3 seed fromevent 1559-17-11 expressing a delta-6 desaturase and delta-6 elongaseHeterozygous and Homozyogous T3 seed for pKR1559 (MaD6Des, MaElo)background event Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:0 20:1 EDADGLA ERA 1559-17-11 (het) 8.2 3.2 15.4 25.7 5.5 16.7 1.4 1.5 16.9 2.32.0 0.9 1559-17-11 (homo) 8.3 3.2 13.8 20.2 9.5 15.2 2.7 1.7 17.4 2.53.5 1.3 Event # ETA LA + ALA GLA + STA DGLA + ETA % D12Des % D6Des %D9Elo 1559-17-11 (het) 0.4 42.4 6.9 2.4 77% 18% 26% 1559-17-11 (homo)0.8 35.3 12.2 4.4 79% 32% 27%EDA/ERA-Expressing Transgenic Event (EgD9Elo)

Plasmid pKR926, containing the Euglena gracilis delta-9 elongase(EgD9Elo) behind the soy beta-conglycinin promoter in an Arabidopsisbinary transformation vector was described in BB1613. Plasmid pKR926 wastransformed into Arabidopsis (col-0) and transgenic plants were selectedand grown as described in herein. Events producing EDA/ERA and whichsegregated 3:1 for the transgene were carried on, and T3 seed wereharvested. Homozygous T3 seed or T4 seed from these events could not berecovered, likely due to germination issues with the homozygous seed,but the fatty acid profile for T4 seed from one representative eventhaving good EDA/ERA concentrations and which was heterozygous for thetransgene (926-5-4-1) is shown below in Table 58.

TABLE 58 Fatty acid profile of heterozygous T4 seed from event 926-5-4-1expressing a delta-9 elongase Heterozygous T4 seed for pKR926 (EgD9Elo)background event Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:0 20:1 EDAERA LA + ALA EDA + ERA % D12Des % D9Elo 926-5-4-1 8.8 2.9 12.2 27.5 0.012.1 0.0 1.4 13.5 15.1 6.5 39.6 21.5 83% 35% (het)EDA/ERA-Expressing Transgenic Event (EaD9Elo)

Plasmid pKR1191, containing the Euglena anabaena delta-9 elongase(EaD9Elo) behind the soy beta-conglycinin promoter, in an Arabidopsisbinary transformation vector was described in BB1613. Plasmid pKR1191was transformed into Arabidopsis (col-0), and transgenic plants wereselected and grown as described herein. Events producing EDA/ERA andwhich segregated 3:1 for the transgene were carried on, and T3 seed wereharvested. T3 seed from one event having good EDA/ERA concentrations andwhich was homozygous for the transgene (1191-4-11) was chosen for use asa EDA/ERA-expressing background, and the fatty acid profile from seedfrom this event is shown below in Table 59.

TABLE 59 Fatty acid profile of homozygous T3 seed from event 1191-4-11expressing a delta-9 elongase Homozygous T3 seed for pKR1191(EaD9Elo)background event Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:0 20:1 EDAERA LA + ALA EDA + ERA % D12Des % D9Elo 1191-4-11 7.3 3.2 12.4 24.6 0.011.5 0.0 1.4 14.2 16.9 8.4 36.1 25.4 83% 41%DGLA/ETA-Expressing Transgenic Event (EgD9Elo/TpomD8Des)

Construction of plasmid pKR1022, transformation into Arabidopsis (col-0)and analysis of T2 seed for fatty acid profiles was described herein.Events producing DGLA/ETA and which segregated 3:1 for the transgenewere carried on, and T3 seed were harvested. T3 seed from one eventhaving good DGLA/ETA concentrations and which was homozygous for thetransgene (1022-4-9) was chosen for use as a DGLA/ETA-expressingbackground, and the fatty acid profile from seed from this event isshown below in Table 60.

TABLE 60 Fatty acid profile of homozygous T3 seed from event 1022-4-9expressing a delta-9 elongase and delta-8 desaturase Homozygous T3 seedfor pKR1022 (EgD9Elo/TpomD8Des) background event Event # 16:0 18:0 18:118:2 GLA 18:3 STA 20:0 20:1 EDA DGLA ERA 1022-4-9 7.6 3.0 16.6 26.2 0.011.1 0.0 1.2 14.4 8.9 4.4 5.2 Event # ETA LA + ALA EDA + ERA DGLA + ETA% D12Des % D9Elo % D8Des 1022-4-9 1.2 37.3 14.1 5.6 77% 35% 28%DGLA/ETA-Expressing Transgenic Event (EaD9Elo/EaD8Des)

Plasmid pKR1192, containing the Euglena anabaena delta-9 elongase(EaD9Elo) behind the soy beta-conglycinin promoter and the Euglenaanabaena delta-8 desatursre behind the soy glycinin Gy1 promoter, in anArabidopsis binary transformation vector was described in BB1615.Plasmid pKR1192 was transformed into Arabidopsis (col-0), and transgenicplants were selected and grown as described herein. Events producingDGLA/ETA and which segregated 3:1 for the transgene were carried on, andT3 seed were harvested. T3 seed from one event having good DGLA/ETAconcentrations and which was homozygous for the transgene (1192-1-2) waschosen for use as a DGLA/ETA-expressing background, and the fatty acidprofile from seed from this event is shown below in Table 61.

TABLE 61 Fatty acid profile of homozygous T3 seed from event 1192-1-2expressing a delta-9 elongase and delta-8 desaturase Homozygous T3 seedfor pKR1192 (EaD9Elo/EaD8Des) background event Event # 16:0 18:0 18:118:2 GLA 18:3 STA 20:0 20:1 EDA DGLA ERA 1192-1-2 8.4 3.5 14.7 23.5 0.010.7 0.0 1.4 13.5 11.2 5.4 6.0 Event # ETA LA + ALA EDA + ERA DGLA + ETA% D12Des % D9Elo % D8Des 1192-1-2 1.7 34.2 17.2 7.2 80% 42% 29%DGLA/ETA-Expressing Transgenic Event (EgD9Elo-EaD8Des Fusion)

The AscI fragment of pKR1200 (Published U.S. Patent Application No.2008/0254191, incorporated herein by reference), containing the Euglenagracilis delta-9 elongase at the N-terminus fused to the Euglenaanabaena delta-8 desaturase at the C-terminus (EgD9Elo-EaD8Des fusion)behind the soy beta-conglycinin promoter, was cloned into the AscIfragment of pKR92 (Published U.S. Patent Application No 2007/0118929,incorporated herein by reference), an Arabidopsis binary transformationvector, to produce pKR1203 (SEQ ID NO:145). Plasmid pKR1203 wastransformed into Arabidopsis (col-0), and transgenic plants wereselected and grown as described herein. Events producing DGLA/ETA andwhich segregated 3:1 for the transgene were carried on, and T3 seed aswell as T4 seed were harvested. T4 seed from one event having goodDGLA/ETA concentrations and which was homozygous for the transgene(1203-13-1-5) was chosen for use as a DGLA/ETA-expressing background,and the fatty acid profile from seed from this event is shown below inTable 62.

TABLE 62 Fatty acid profile of homozygous T4 seed from event 1203-13-1-5expressing a delta-9 elongase and delta-8 desaturase fusion geneHomozygous T4 seed for pKR1203 (EgD9Elo-EaD8Des fusion) background eventEvent # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:0 20:1 EDA DGLA ERA1203-13-1-5 10.6 3.4 18.2 25.0 0.0 7.6 0.0 1.5 12.0 10.2 5.4 4.4 Event #ETA LA + ALA EDA + ERA DGLA + ETA % D12Des % D9Elo % D8Des 1203-13-1-51.4 32.6 14.6 6.9 75% 40% 32%ARA/EPA-Expressing Event (EaD9Elo/EaD8Des/EaD5Des)

Plasmid pKR1193, containing the Euglena anabaena delta-9 elongase(EaD9Elo) behind the soy beta-conglycinin promoter, the Euglena anabaenadelta-8 desaturase behind the soy glycinin Gy1 promoter and the Euglenaanabaena delta-5 desaturase behind soy beta-conglycinin promoter, in anArabidopsis binary transformation vector was described in Published U.S.Patent Application No. 2008/0194685, incorporated herein by reference.Plasmid pKR1193 was transformed into Arabidopsis (col-0), and transgenicplants were selected and grown as described herein. Events producingARA/EPA and which segregated 3:1 for the transgene were carried on, andT3 seed as well as T4 seed were harvested. T4 seed from one event havinggood ARA/EPA concentrations and which was homozygous for the transgene(1193-5-4-6) was chosen for use as an ARA/EPA-expressing background, andthe fatty acid profile from seed from this event is shown below in Table63.

TABLE 63 Fatty acid profile of homozygous T4 seed from event 1193-5-4-6)expressing a delta-9 elongase, a delta-8 desaturase and a delta-5desaturase. Homozygous T4 seed for pKR1193 (EaD9Elo/EaD8Des/EaD5Des)background event Event # 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:0 20:1 EDADGLA ARA ERA 1193-5-4-6 8.3 3.2 16.4 20.5 0.0 7.6 0.0 1.5 13.0 14.6 0.56.7 5.9 LA + EDA + DGLA + ARA + % % % % Event # ETA EPA ALA ERA ETA EPAD12Des D9Elo D8Des D5Des 1193-5-4-6 0.0 1.9 28.1 20.4 0.5 8.6 78% 51%31% 95%

Example 24 Cloning Soy, Momordica charantia, Calendula officianalis andEuphorbia laqascae MBOAT Homologs into Arabidopsis Binary Vectors andExpression in Various LC-PUFA Producing Backgrounds

Cloning Soy, Momordica charantia, Calendula officianalis and Euphorbialagascae MBOAT Homologs into Arabidopsis Binary Vectors

Arabidopsis binary expression plasmid pHD1, described in Published U.S.Patent Application No. 2005/0132441, incorporated herein by reference,contains a unique AscI site for cloning gene expression cassettes andhas the acetolactate synthase gene for selecting transgenic plants onsulfonylurea herbicides. An earlier clone of pHD1 was completelyresequenced and the sequence is set forth in SEQ ID NO:146.

The NotI fragments of pLF164 (SEQ ID NO:128) and pLF165 (SEQ ID NO:130),containing GmMBOAT1 and GmMBOAT2, respectively were cloned into the NotIsite of pKR72 (described in BB1538) to produce pKR1645 (SEQ ID NO:147)and pKR1646 (SEQ ID NO:148), respectively which allow for expression ofthe genes from the soy beta-conglycinin promoter.

The NotI fragments of pLF166 (SEQ ID NO:48) and pHD41 (SEQ ID NO:34),containing CoMBOAT and McMBOAT, respectively were cloned into the NotIsite of pKR72 (described in Published U.S. Patent Application No.2004/0172682, incorporated herein by reference) to produce pKR1649 (SEQID NO:149) and pKR1650 (SEQ ID NO:150), respectively which allow forexpression of the genes from the soy beta-conglycinin promoter.

The NotI fragment of pHD41 (SEQ ID NO:34), containing McMBOAT, wascloned into the NotI site of pKR193 (described in Published U.S. PatentApplication No. 2008/0254191, incorporated herein by reference) toproduce pKR1818SEQ ID NO:151).

The BsiWI fragment of pKR1818 (SEQ ID NO:151), containing the McMBOAT,was cloned into the BsiWI site of pKR277 (described in Published U.S.Patent Application No. 2008/0118623, incorporated herein by reference)to produce pKR1826 (SEQ ID NO:152).

The NotI fragment of pKR1823 (SEQ ID NO:140), containing EuphMBOAT, wascloned into the NotI site of pKR1826 (SEQ ID NO:152) to produce pKR1844(SEQ ID NO:153).

The AscI fragments of pKR1645 (SEQ ID NO:147), comprising GmMBOAT1,pKR1646SEQ ID NO:148), comprising GmMBOAT2, pKR1649 (SEQ ID NO:149),comprising CoMBOAT, pKR1650 (SEQ ID NO:150), comprising McMBOAT andpKR1844 (SEQ ID NO:153), comprising EuphMBOAT, respectively were allcloned into the AscI site of pHD1 (described in CL2432) to producepKR1671 (SEQ ID NO:154), pKR1672 (SEQ ID NO:155), pKR1673 (SEQ IDNO:156), pKR1674 (SEQ ID NO:157) and pKR1845 (SEQ ID NO:158),respectively.

Expressing Soy, Momordica charantia, Calendula officianalis andEuphorbia lagascae MBOAT Homologs in Various Unusual FattyAcid-Expressing Backgrounds

T3 or T4 seed from each Arabidopsis background described in Example 23above was planted in flats, and plants were grown and transformed witheither pHD1 (vector control), pKR1671 (GmMBOAT1), pKR1672 (GmMBOAT2),pKR1673 (CoMBOAT), pKR1674 (McMBOAT) or pKR1845 (EuphMBOAT) as describedin for Arabidopsis transformation herein. Transgenic seed were selectedby plating onto MS plates as described but substituting Kanamycin withGlean (sulfonylurea herbicide) at a concentration of 200 ppb. T1 plantswere grown, and T2 seed were harvested and analyzed for fatty acidprofile and oil content as described herein for each event. Results arepresented below in Tables 64, 65, 66, 67, 68, 69 and 70 for analysis ofT2 seed from a number of events for each LC-PUFA-containing backgroundtransformed. For DGLA/ETA-expressing event 1022-4-9, T3 seed was alsoobtained, and oil and fatty acid analysis was completed on threeseparate homozygous T3 seed batches and results in Table 71.

In the Tables, % delta-12 desaturation (% D12Des) was calculated bydividing the sum of the average weight percent (wt. %) for 18:2, 18:3,GLA, STA, DGLA, ETA, ARA and EPA by the sum of the average wt. % for18:1, 18:2, 18:3, GLA, STA, DGLA, ETA, ARA and EPA and multiplying by100 to express as a %.

For Arabidopsis backgrounds expressing a delta-6 desaturase pathway, thecalculated % delta-6 desaturase conversion efficiency (% D6Des) wascalculated by dividing the sum of the average weight percent (wt. %) forGLA, STA, DGLA, ETA, ARA and EPA by the sum of the average wt. % for18:2, 18:3, GLA, STA, DGLA, ETA, ARA and EPA and multiplying by 100 toexpress as a %. Similarly, the calculated % delta-6 elongase conversionefficiency (% D6Elo) was calculated by dividing the sum of the averageweight percent (wt. %) for DGLA, ETA, ARA and EPA by the sum of theaverage wt. % for GLA, STA, DGLA, ETA, ARA and EPA and multiplying by100 to express as a %.

For Arabidopsis backgrounds expressing a delta-9 elongase pathway, thecalculated % C₁₆ to C₂₀ elongation conversion efficiency (% D9Elo) wascalculated by dividing the sum of the average weight percent (wt. %) forEDA, ERA, DGLA, ETA, ARA and EPA by the sum of the average wt. % for18:2, 18:3, EDA, ERA, DGLA, ETA, ARA and EPA and multiplying by 100 toexpress as a %. Similarly, the calculated % delta-8 desaturaseconversion efficiency (% D8Des) was calculated by dividing the sum ofthe average weight percent (wt. %) for DGLA, ETA, ARA and EPA by the sumof the average wt. % for EDA, ERA, DGLA, ETA, ARA and EPA andmultiplying by 100 to express as a %.

The calculated % delta-5 desaturase conversion efficiency (% D5Des) wascalculated by dividing the sum of the average weight percent (wt. %) forARA and EPA by the sum of the average wt. % for DGLA, ETA, ARA and EPAand multiplying by 100 to express as a %.

If a certain fatty acid is not present in the pathway, it was notincluded in the calculations.

TABLE 64 Fatty acid profile of T2 seed from events expressing MBOATs inDGLA/ETA-expressing transgenic event 1559-17- 11 (MaD6des/MaD6Elo) T2seed for pKR1559 (MaD6Des, MaElo) background event transformed withvarious MBOATs Event # MBOAT Bkgrnd % Oil 16:0 18:0 18:1 18:2 GLA 18:3STA 20:0 20:1 EDA DGLA ERA ETA 1559-17-11 1559-17-11 8.2 3.2 15.4 25.75.5 16.7 1.4 1.5 16.9 2.3 2.0 0.9 0.4 (het) (het) 1559-17-11 1559-17-118.3 3.2 13.8 20.2 9.5 15.2 2.7 1.7 17.4 2.5 3.5 1.3 0.8 (homo) (homo)HD1-6 Vect Cont 1559-17-11 7.6 2.6 14.5 19.2 5.4 20.8 2.7 1.5 16.9 2.73.3 1.8 1.1 HD1-15 Vect Cont 1559-17-11 6.8 2.7 15.5 20.0 4.9 20.3 2.11.6 18.8 2.7 2.4 1.6 0.7 HD1-13 Vect Cont 1559-17-11 6.6 2.8 17.9 21.83.5 19.3 1.3 1.8 19.0 2.4 2.0 1.2 0.5 HD1-12 Vect Cont 1559-17-11 7.12.8 15.6 23.3 4.2 19.3 1.4 1.7 18.6 2.6 1.9 1.2 0.5 HD1-1 Vect Cont1559-17-11 7.7 3.3 15.8 25.9 4.8 16.7 1.2 1.6 17.6 2.3 1.8 0.9 0.4 HD1-8Vect Cont 1559-17-11 8.0 3.3 15.8 26.2 4.7 16.7 1.2 1.7 17.2 2.3 1.8 0.90.4 HD1-4 Vect Cont 1559-17-11 8.3 3.0 17.1 26.8 4.7 16.7 1.1 1.5 16.02.1 1.8 0.7 0.3 HD1-5 Vect Cont 1559-17-11 8.2 3.1 16.6 27.7 4.5 16.61.1 1.4 16.1 2.1 1.7 0.7 0.3 HD1-16 Vect Cont 1559-17-11 7.7 3.3 16.525.7 4.3 15.5 1.0 1.9 19.0 2.3 1.6 0.8 0.3 HD1-7 Vect Cont 1559-17-118.0 3.2 16.6 27.0 4.2 16.5 1.0 1.6 17.2 2.2 1.6 0.7 0.3 HD1-3 Vect Cont1559-17-11 7.9 3.2 15.9 26.4 4.2 17.1 1.0 1.7 17.7 2.3 1.5 0.8 0.3 HD1-2Vect Cont 1559-17-11 8.5 3.1 17.1 27.7 4.3 16.5 1.0 1.5 15.8 2.0 1.5 0.70.3 HD1-9 Vect Cont 1559-17-11 8.0 3.3 16.2 27.0 3.9 16.7 0.9 1.7 17.62.2 1.4 0.7 0.3 HD1-17 Vect Cont 1559-17-11 7.6 3.5 16.3 26.0 3.8 16.00.9 2.0 19.1 2.4 1.4 0.8 0.3 HD1-14 Vect Cont 1559-17-11 7.6 3.5 16.326.0 3.9 15.7 0.9 2.0 19.2 2.3 1.4 0.8 0.3 HD1-10 Vect Cont 1559-17-118.1 3.3 16.2 27.2 3.8 16.4 0.9 1.8 17.7 2.2 1.4 0.8 0.3 HD1-18 Vect Cont1559-17-11 8.1 3.4 16.6 26.6 3.8 16.0 0.9 1.9 18.3 2.2 1.3 0.7 0.3HD1-11 Vect Cont 1559-17-11 7.8 3.4 16.8 27.2 3.6 15.8 0.8 1.9 18.3 2.21.3 0.7 0.3 Top5 Avg. 7.2 2.8 15.9 22.0 4.5 19.3 1.7 1.6 18.2 2.5 2.31.3 0.6 1671-8 GmMBOAT1 1559-17-11 7.7 2.7 12.8 28.4 1.9 21.5 0.6 1.79.7 3.5 5.8 2.4 1.4 1671-10 GmMBOAT1 1559-17-11 7.8 2.6 13.1 29.0 1.921.4 0.6 1.6 9.6 3.3 5.8 2.2 1.3 1671-5 GmMBOAT1 1559-17-11 7.0 2.5 15.326.7 1.7 21.9 0.6 1.6 10.7 3.1 5.2 2.2 1.4 1671-12 GmMBOAT1 1559-17-116.7 2.7 15.0 29.2 1.7 18.8 0.5 1.7 11.5 3.8 5.4 2.1 1.0 1671-3 GmMBOAT11559-17-11 6.8 2.7 16.4 33.5 0.9 14.0 0.1 1.8 11.7 4.6 5.1 1.7 0.61671-2 GmMBOAT1 1559-17-11 7.6 2.6 11.9 29.4 2.4 22.8 0.7 1.7 9.6 3.44.5 2.3 1.1 1671-6 GmMBOAT1 1559-17-11 7.7 2.8 13.1 30.9 2.3 17.4 0.51.8 10.7 4.7 4.8 2.5 0.8 1671-14 GmMBOAT1 1559-17-11 7.6 2.7 13.4 31.72.0 19.9 0.5 1.6 11.3 3.1 3.8 1.6 0.8 1671-1 GmMBOAT1 1559-17-11 7.3 3.316.1 25.2 5.3 15.3 1.3 1.7 18.1 2.5 2.4 1.0 0.5 1671-16 GmMBOAT11559-17-11 8.0 3.3 15.7 25.6 5.4 16.3 1.3 1.7 17.1 2.3 2.0 0.9 0.41671-13 GmMBOAT1 1559-17-11 7.5 3.1 17.2 27.0 4.4 15.5 1.0 1.6 17.6 2.21.8 0.7 0.3 1671-18 GmMBOAT1 1559-17-11 8.1 3.1 15.9 26.4 4.8 16.6 1.21.6 17.1 2.2 1.8 0.8 0.4 1671-17 GmMBOAT1 1559-17-11 7.3 3.5 16.2 25.74.2 15.6 1.0 1.9 19.0 2.4 1.8 0.9 0.4 1671-9 GmMBOAT1 1559-17-11 7.6 3.315.9 25.9 4.6 16.1 1.1 1.8 18.3 2.4 1.7 0.9 0.4 1671-7 GmMBOAT11559-17-11 7.3 3.5 16.5 25.8 4.5 15.2 1.0 1.9 18.9 2.4 1.7 0.9 0.31671-4 GmMBOAT1 1559-17-11 7.7 3.4 16.8 26.6 4.0 15.5 0.9 1.9 18.0 2.41.6 0.8 0.3 1671-15 GmMBOAT1 1559-17-11 7.7 3.3 16.2 26.6 4.2 16.1 1.01.8 18.1 2.3 1.5 0.8 0.3 1671-11 GmMBOAT1 1559-17-11 7.6 3.4 16.2 26.33.7 16.3 0.9 1.9 18.6 2.3 1.5 0.8 0.3 Top5 Avg. 7.2 2.6 14.5 29.4 1.619.5 0.5 1.7 10.6 3.7 5.5 2.1 1.1 1672-14 GmMBOAT2 1559-17-11 8.2 2.412.7 25.8 2.0 23.3 0.8 1.3 8.7 2.6 7.7 2.1 2.5 1672-9 GmMBOAT21559-17-11 6.7 2.6 13.7 27.0 1.9 18.1 0.5 1.7 11.3 4.2 8.1 2.6 1.71672-8 GmMBOAT2 1559-17-11 6.9 2.5 11.7 24.4 2.9 22.1 1.0 1.7 11.7 3.37.3 2.5 2.1 1672-16 GmMBOAT2 1559-17-11 7.8 2.8 14.2 25.6 2.3 20.3 0.81.7 10.8 2.8 7.0 2.0 2.0 1672-1 GmMBOAT2 1559-17-11 7.6 2.7 18.2 25.42.0 19.5 0.6 1.7 11.1 2.5 5.6 1.6 1.5 1672-18 GmMBOAT2 1559-17-11 6.92.8 13.8 25.8 2.6 19.5 0.7 1.9 13.4 3.5 5.8 2.1 1.2 1672-12 GmMBOAT21559-17-11 7.1 2.7 13.1 27.7 1.6 20.9 0.5 1.8 12.8 3.1 5.5 1.9 1.41672-2 GmMBOAT2 1559-17-11 7.1 2.7 12.9 25.6 2.8 21.2 0.9 1.8 13.8 3.05.0 1.9 1.3 1672-11 GmMBOAT2 1559-17-11 6.5 2.7 14.0 26.1 2.6 20.5 0.81.7 14.0 3.2 4.8 1.9 1.2 1672-13 GmMBOAT2 1559-17-11 6.9 2.8 14.1 29.02.1 19.0 0.5 1.9 13.4 3.2 4.6 1.7 0.9 1672-15 GmMBOAT2 1559-17-11 6.62.8 14.8 26.9 2.4 19.3 0.7 1.8 15.0 3.1 4.1 1.6 0.9 1672-5 GmMBOAT21559-17-11 7.5 3.0 14.5 31.3 2.5 17.4 0.6 1.7 12.2 3.1 4.2 1.4 0.71672-7 GmMBOAT2 1559-17-11 7.6 3.2 15.2 29.0 2.5 17.3 0.6 1.9 15.5 2.73.0 1.0 0.5 1672-10 GmMBOAT2 1559-17-11 7.9 3.4 14.7 25.3 5.1 16.5 1.31.8 18.3 2.4 2.0 1.0 0.4 1672-3 GmMBOAT2 1559-17-11 7.7 3.1 15.7 26.24.9 16.9 1.2 1.5 17.4 2.3 1.9 0.9 0.4 1672-17 GmMBOAT2 1559-17-11 7.63.3 16.4 26.1 4.4 15.0 1.1 1.9 19.0 2.4 1.8 0.8 0.4 1672-6 GmMBOAT21559-17-11 8.1 3.1 16.0 26.9 4.4 16.8 1.1 1.6 17.2 2.2 1.5 0.8 0.31672-4 GmMBOAT2 1559-17-11 8.0 3.2 16.4 26.8 4.1 16.6 1.0 1.7 17.6 2.21.4 0.8 0.3 Top5 Avg. 7.5 2.6 14.1 25.6 2.2 20.6 0.7 1.6 10.7 3.1 7.12.2 2.0 1673-16 CoMBOAT 1559-17-11 7.5 2.9 13.3 23.8 4.7 16.9 1.3 1.816.5 3.0 5.4 1.6 1.2 1673-11 CoMBOAT 1559-17-11 7.2 2.6 17.6 22.8 2.919.5 1.1 1.5 14.1 2.8 4.8 1.7 1.4 1673-10 CoMBOAT 1559-17-11 7.4 3.416.5 25.7 0.2 11.6 0.0 1.6 15.9 8.9 3.7 4.4 0.8 1673-3 CoMBOAT1559-17-11 7.2 3.4 16.4 25.2 0.2 11.2 0.0 1.7 16.0 9.6 3.7 4.7 0.81673-2 CoMBOAT 1559-17-11 7.2 3.4 16.8 25.5 0.1 11.4 0.0 1.7 16.0 9.13.5 4.5 0.7 1673-12 CoMBOAT 1559-17-11 7.1 2.6 15.0 23.3 3.8 20.6 1.31.6 16.8 2.6 3.0 1.4 0.8 1673-15 CoMBOAT 1559-17-11 6.3 2.5 14.8 19.55.3 20.4 2.3 1.6 19.3 2.7 2.8 1.6 0.9 1673-17 CoMBOAT 1559-17-11 7.0 3.415.5 23.6 6.0 15.1 1.5 1.9 19.3 2.7 2.5 1.1 0.5 1673-8 CoMBOAT1559-17-11 7.6 3.2 15.6 24.9 6.0 15.1 1.4 1.7 17.8 2.5 2.5 1.0 0.51673-6 CoMBOAT 1559-17-11 8.2 3.2 14.9 25.1 6.0 16.8 1.6 1.5 16.5 2.42.3 1.0 0.5 1673-5 CoMBOAT 1559-17-11 7.7 3.2 15.5 25.2 5.5 16.3 1.4 1.617.6 2.5 2.2 1.0 0.5 1673-4 CoMBOAT 1559-17-11 7.4 3.4 16.9 25.7 4.914.7 1.1 1.9 18.5 2.4 1.9 0.9 0.4 1673-1 CoMBOAT 1559-17-11 7.4 3.4 16.025.3 4.7 15.6 1.1 1.9 19.0 2.5 1.8 0.9 0.4 1673-7 CoMBOAT 1559-17-11 7.43.3 16.5 25.2 4.8 15.5 1.2 1.9 18.9 2.4 1.8 0.9 0.4 1673-13 CoMBOAT1559-17-11 7.2 3.4 16.5 26.3 4.3 15.3 1.0 1.9 18.9 2.4 1.7 0.8 0.31673-9 CoMBOAT 1559-17-11 7.9 3.2 15.6 25.6 4.8 16.9 1.2 1.7 17.9 2.31.7 0.9 0.4 1673-18 CoMBOAT 1559-17-11 7.9 3.3 16.3 26.2 4.3 15.6 1.11.9 18.3 2.3 1.6 0.8 0.4 1673-14 CoMBOAT 1559-17-11 7.9 3.4 16.7 26.83.8 15.9 0.9 1.9 18.1 2.2 1.3 0.7 0.3 Top5 Avg. 7.3 3.1 16.1 24.6 1.614.1 0.5 1.7 15.7 6.7 4.2 3.4 1.0 1674-15 McMBOAT 1559-17-11 6.8 2.613.5 19.9 8.0 15.9 2.6 1.6 16.5 3.1 6.2 1.8 1.5 1674-11 McMBOAT1559-17-11 6.9 2.5 14.1 27.5 2.4 20.3 0.6 1.5 11.5 3.2 6.1 2.0 1.31674-6 McMBOAT 1559-17-11 7.9 2.7 14.2 25.2 2.7 20.8 0.9 1.7 12.4 2.55.7 1.7 1.6 1674-8 McMBOAT 1559-17-11 7.1 2.6 12.9 24.5 2.8 22.5 1.0 1.813.3 2.8 5.2 1.9 1.5 1674-1 McMBOAT 1559-17-11 6.6 2.7 13.9 24.6 3.420.1 1.0 1.8 14.6 3.1 5.0 1.9 1.3 1674-9 McMBOAT 1559-17-11 7.0 2.4 14.727.4 1.8 22.5 0.5 1.6 11.2 2.9 4.8 1.9 1.2 1674-2 McMBOAT 1559-17-11 6.82.8 13.9 25.4 3.4 19.6 0.9 1.8 14.7 3.1 4.8 1.8 1.1 1674-3 McMBOAT1559-17-11 6.7 2.8 14.9 26.2 2.8 20.0 0.8 1.8 15.4 2.9 3.4 1.5 0.81674-13 McMBOAT 1559-17-11 7.3 2.8 16.0 27.2 3.7 17.3 0.9 1.5 16.6 2.52.5 1.0 0.5 1674-14 McMBOAT 1559-17-11 8.2 3.1 14.4 25.8 5.5 17.1 1.41.5 17.0 2.3 2.2 0.9 0.5 1674-17 McMBOAT 1559-17-11 7.8 3.3 15.4 24.65.8 16.3 1.5 1.7 17.7 2.4 2.2 1.0 0.5 1674-18 McMBOAT 1559-17-11 8.3 3.315.5 25.2 5.6 16.6 1.5 1.6 16.7 2.3 2.0 1.0 0.4 1674-4 McMBOAT1559-17-11 7.5 3.4 15.7 25.3 4.5 16.1 1.1 1.9 18.9 2.5 1.8 1.0 0.41674-16 McMBOAT 1559-17-11 8.3 3.2 16.4 26.3 5.0 16.5 1.2 1.6 16.3 2.11.8 0.8 0.4 1674-10 McMBOAT 1559-17-11 8.6 3.1 14.9 26.9 4.8 17.4 1.21.5 16.4 2.2 1.7 0.8 0.4 1674-12 McMBOAT 1559-17-11 8.3 3.2 15.1 26.94.5 17.1 1.2 1.6 17.1 2.2 1.7 0.8 0.3 1674-5 McMBOAT 1559-17-11 7.6 3.216.4 26.5 4.3 15.9 1.0 1.7 18.2 2.3 1.7 0.8 0.3 1674-7 McMBOAT1559-17-11 7.5 3.4 17.0 26.6 3.9 15.4 0.9 1.9 18.7 2.2 1.4 0.7 0.3 Top5Avg. 7.1 2.6 13.7 24.3 3.9 19.9 1.2 1.7 13.7 3.0 5.6 1.8 1.4 1845-2EuphMBOAT 1559-17-11-8 23.2 7.5 3.4 12.1 18.6 8.6 13.7 2.1 2.0 15.4 3.58.6 2.4 0.0 1845-1 EuphMBOAT 1559-17-11-8 29.4 7.2 3.0 14.9 24.6 4.514.4 0.9 2.3 17.1 3.3 5.6 1.3 0.9 1845-13 EuphMBOAT 1559-17-11-8 31.07.5 2.9 14.1 22.8 6.4 14.5 1.5 2.1 17.6 3.1 4.9 1.5 1.0 1845-9 EuphMBOAT1559-17-11-8 28.9 6.7 3.0 16.0 24.1 4.0 15.2 1.0 2.3 17.0 2.9 5.0 1.30.9 1845-10 EuphMBOAT 1559-17-11-8 26.5 6.7 3.0 14.5 22.5 4.4 17.3 1.32.0 16.9 3.2 5.4 1.6 0.0 1845-7 EuphMBOAT 1559-17-11-8 31.7 7.0 3.1 15.321.2 5.3 16.5 1.5 2.2 18.1 2.8 4.3 1.3 0.9 1845-6 EuphMBOAT 1559-17-11-829.7 6.3 2.8 14.3 19.4 6.2 17.9 2.0 1.8 18.9 2.9 4.5 1.7 0.0 1845-8EuphMBOAT 1559-17-11-8 30.9 6.8 3.1 15.5 22.6 4.9 16.6 1.3 2.0 18.4 2.83.7 1.6 0.0 1845-14 EuphMBOAT 1559-17-11-8 30.2 6.7 2.8 14.4 23.0 4.617.9 1.4 1.8 18.4 2.9 3.6 1.5 0.0 1845-4 EuphMBOAT 1559-17-11-8 30.7 6.52.8 15.8 22.7 4.4 17.2 1.2 1.9 19.2 2.7 3.4 1.2 0.0 1845-12 EuphMBOAT1559-17-11-8 36.1 6.9 3.0 16.5 23.7 5.4 15.2 1.3 1.8 19.7 2.5 2.5 0.90.0 Top5 Avg. 27.8 7.1 3.1 14.3 22.5 5.6 15.0 1.4 2.2 16.8 3.2 5.9 1.60.6 Event # MBOAT Bkgrnd LA + ALA GLA + STA DGLA + ETA % D12Des % D6Des% D6Elo 1559-17-11 (het) 1559-17-11 (het) 42.4 6.9 2.4 77% 18% 26%1559-17-11 (homo) 1559-17-11 (homo) 35.3 12.2 4.4 79% 32% 27% HD1-6 VectCont 1559-17-11 40.0 8.1 4.4 78% 24% 35% HD1-15 Vect Cont 1559-17-1140.3 6.9 3.1 76% 20% 31% HD1-13 Vect Cont 1559-17-11 41.2 4.8 2.5 73%15% 34% HD1-12 Vect Cont 1559-17-11 42.5 5.6 2.3 76% 16% 29% HD1-1 VectCont 1559-17-11 42.6 6.0 2.2 76% 16% 27% HD1-8 Vect Cont 1559-17-11 42.95.9 2.2 76% 16% 27% HD1-4 Vect Cont 1559-17-11 43.5 5.8 2.1 75% 15% 27%HD1-5 Vect Cont 1559-17-11 44.3 5.6 2.0 76% 15% 26% HD1-16 Vect Cont1559-17-11 41.2 5.3 1.9 75% 15% 27% HD1-7 Vect Cont 1559-17-11 43.6 5.21.9 75% 14% 27% HD1-3 Vect Cont 1559-17-11 43.4 5.2 1.8 76% 14% 26%HD1-2 Vect Cont 1559-17-11 44.3 5.3 1.7 75% 14% 25% HD1-9 Vect Cont1559-17-11 43.6 4.9 1.7 76% 13% 26% HD1-17 Vect Cont 1559-17-11 41.9 4.71.7 75% 13% 26% HD1-14 Vect Cont 1559-17-11 41.8 4.8 1.7 75% 13% 26%HD1-10 Vect Cont 1559-17-11 43.5 4.7 1.6 75% 13% 26% HD1-18 Vect Cont1559-17-11 42.6 4.7 1.6 75% 13% 26% HD1-11 Vect Cont 1559-17-11 42.9 4.41.6 74% 12% 27% Top5 Avg. 41.3 6.3 2.9 76% 18% 31% 1671-8 GmMBOAT11559-17-11 49.8 2.5 7.2 82% 16% 75% 1671-10 GmMBOAT1 1559-17-11 50.3 2.47.1 82% 16% 75% 1671-5 GmMBOAT1 1559-17-11 48.6 2.3 6.7 79% 16% 74%1671-12 GmMBOAT1 1559-17-11 48.0 2.2 6.3 79% 15% 75% 1671-3 GmMBOAT11559-17-11 47.5 1.0 5.8 77% 12% 85% 1671-2 GmMBOAT1 1559-17-11 52.2 3.15.6 84% 14% 65% 1671-6 GmMBOAT1 1559-17-11 48.3 2.8 5.6 81% 15% 66%1671-14 GmMBOAT1 1559-17-11 51.6 2.6 4.5 81% 12% 64% 1671-1 GmMBOAT11559-17-11 40.4 6.6 2.9 76% 19% 31% 1671-16 GmMBOAT1 1559-17-11 41.9 6.82.4 76% 18% 26% 1671-13 GmMBOAT1 1559-17-11 42.6 5.3 2.2 74% 15% 29%1671-18 GmMBOAT1 1559-17-11 43.0 6.0 2.1 76% 16% 26% 1671-17 GmMBOAT11559-17-11 41.3 5.2 2.1 75% 15% 29% 1671-9 GmMBOAT1 1559-17-11 42.0 5.72.1 76% 16% 27% 1671-7 GmMBOAT1 1559-17-11 41.1 5.5 2.0 75% 16% 27%1671-4 GmMBOAT1 1559-17-11 42.1 5.0 1.9 75% 14% 28% 1671-15 GmMBOAT11559-17-11 42.6 5.3 1.9 75% 14% 26% 1671-11 GmMBOAT1 1559-17-11 42.6 4.71.8 75% 13% 28% Top5 Avg. 48.9 2.1 6.6 80% 15% 77% 1672-14 GmMBOAT21559-17-11 49.0 2.6 10.2 83% 21% 78% 1672-9 GmMBOAT2 1559-17-11 45.1 2.39.8 81% 21% 81% 1672-8 GmMBOAT2 1559-17-11 46.5 3.9 9.4 84% 22% 71%1672-16 GmMBOAT2 1559-17-11 45.9 3.1 9.0 80% 21% 75% 1672-1 GmMBOAT21559-17-11 44.9 2.6 7.1 75% 18% 73% 1672-18 GmMBOAT2 1559-17-11 45.3 3.37.0 80% 18% 68% 1672-12 GmMBOAT2 1559-17-11 48.6 2.1 6.9 82% 16% 76%1672-2 GmMBOAT2 1559-17-11 46.8 3.7 6.3 82% 18% 63% 1672-11 GmMBOAT21559-17-11 46.6 3.4 6.0 80% 17% 64% 1672-13 GmMBOAT2 1559-17-11 48.0 2.65.5 80% 14% 68% 1672-15 GmMBOAT2 1559-17-11 46.1 3.1 5.1 79% 15% 62%1672-5 GmMBOAT2 1559-17-11 48.7 3.1 4.9 80% 14% 62% 1672-7 GmMBOAT21559-17-11 46.4 3.0 3.5 78% 12% 54% 1672-10 GmMBOAT2 1559-17-11 41.8 6.42.4 78% 17% 27% 1672-3 GmMBOAT2 1559-17-11 43.0 6.1 2.3 77% 16% 27%1672-17 GmMBOAT2 1559-17-11 41.1 5.5 2.2 75% 16% 28% 1672-6 GmMBOAT21559-17-11 43.7 5.5 1.8 76% 14% 25% 1672-4 GmMBOAT2 1559-17-11 43.4 5.11.7 75% 14% 25% Top5 Avg. 46.3 2.9 9.1 81% 21% 76% 1673-16 CoMBOAT1559-17-11 40.7 6.1 6.6 80% 24% 52% 1673-11 CoMBOAT 1559-17-11 42.3 4.06.2 75% 19% 61% 1673-10 CoMBOAT 1559-17-11 37.3 0.2 4.6 72% 11% 97%1673-3 CoMBOAT 1559-17-11 36.4 0.2 4.4 71% 11% 97% 1673-2 CoMBOAT1559-17-11 36.9 0.1 4.2 71% 11% 97% 1673-12 CoMBOAT 1559-17-11 44.0 5.03.8 78% 17% 43% 1673-15 CoMBOAT 1559-17-11 39.9 7.6 3.7 78% 22% 33%1673-17 CoMBOAT 1559-17-11 38.7 7.5 3.1 76% 21% 29% 1673-8 CoMBOAT1559-17-11 40.0 7.4 3.1 76% 21% 29% 1673-6 CoMBOAT 1559-17-11 41.9 7.62.8 78% 20% 27% 1673-5 CoMBOAT 1559-17-11 41.5 6.9 2.7 77% 19% 28%1673-4 CoMBOAT 1559-17-11 40.4 6.0 2.2 74% 17% 27% 1673-1 CoMBOAT1559-17-11 40.9 5.8 2.2 75% 16% 27% 1673-7 CoMBOAT 1559-17-11 40.7 6.02.2 75% 17% 26% 1673-13 CoMBOAT 1559-17-11 41.6 5.3 2.1 75% 15% 28%1673-9 CoMBOAT 1559-17-11 42.5 6.1 2.1 76% 16% 25% 1673-18 CoMBOAT1559-17-11 41.8 5.4 2.0 75% 15% 27% 1673-14 CoMBOAT 1559-17-11 42.8 4.81.6 75% 13% 25% Top5 Avg. 38.7 2.1 5.2 74% 15% 81% 1674-15 McMBOAT1559-17-11 35.8 10.6 7.7 80% 34% 42% 1674-11 McMBOAT 1559-17-11 47.8 3.07.4 81% 18% 71% 1674-6 McMBOAT 1559-17-11 45.9 3.6 7.3 80% 19% 67%1674-8 McMBOAT 1559-17-11 47.0 3.8 6.8 82% 18% 64% 1674-1 McMBOAT1559-17-11 44.6 4.4 6.3 80% 19% 59% 1674-9 McMBOAT 1559-17-11 49.9 2.36.0 80% 14% 72% 1674-2 McMBOAT 1559-17-11 44.9 4.3 5.9 80% 18% 58%1674-3 McMBOAT 1559-17-11 46.2 3.6 4.2 78% 14% 54% 1674-13 McMBOAT1559-17-11 44.5 4.7 3.1 77% 15% 40% 1674-14 McMBOAT 1559-17-11 42.9 7.02.7 78% 18% 28% 1674-17 McMBOAT 1559-17-11 40.9 7.2 2.6 77% 19% 27%1674-18 McMBOAT 1559-17-11 41.8 7.1 2.4 77% 18% 25% 1674-4 McMBOAT1559-17-11 41.4 5.6 2.2 76% 16% 28% 1674-16 McMBOAT 1559-17-11 42.8 6.32.2 76% 16% 26% 1674-10 McMBOAT 1559-17-11 44.3 6.1 2.1 78% 16% 25%1674-12 McMBOAT 1559-17-11 44.0 5.7 2.0 77% 15% 26% 1674-5 McMBOAT1559-17-11 42.5 5.4 2.0 75% 15% 27% 1674-7 McMBOAT 1559-17-11 42.1 4.71.7 74% 13% 26% Top5 Avg. 44.2 5.1 7.1 80% 22% 61% 1845-2 EuphMBOAT1559-17-11-8 32.3 10.8 8.6 81% 38% 45% 1845-1 EuphMBOAT 1559-17-11-839.0 5.4 6.5 77% 23% 55% 1845-13 EuphMBOAT 1559-17-11-8 37.3 7.9 5.9 78%27% 43% 1845-9 EuphMBOAT 1559-17-11-8 39.3 5.0 5.9 76% 22% 54% 1845-10EuphMBOAT 1559-17-11-8 39.8 5.7 5.4 78% 22% 49% 1845-7 EuphMBOAT1559-17-11-8 37.6 6.8 5.3 76% 24% 44% 1845-6 EuphMBOAT 1559-17-11-8 37.38.2 4.5 78% 25% 35% 1845-8 EuphMBOAT 1559-17-11-8 39.2 6.2 3.7 76% 20%37% 1845-14 EuphMBOAT 1559-17-11-8 40.9 5.9 3.6 78% 19% 38% 1845-4EuphMBOAT 1559-17-11-8 39.9 5.6 3.4 76% 18% 38% 1845-12 EuphMBOAT1559-17-11-8 38.9 6.7 2.5 74% 19% 27% Top5 Avg. 37.5 6.9 6.5 78% 26% 49%

TABLE 65 Fatty acid profile of T2 seed from events expressing MBOATs inEDA/ERA-expressing transgenic event 926-5-4-1 (EgD9Elo) T2 seed forpKR926 (EgD9Elo) background event transformed with various MBOATs Event# MBOAT Bkgrnd % Oil 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:0 926-5-4-1 8.82.9 12.2 27.5 12.1 1.4 HD1-11 ALS 926-5-4-1 35.3 7.6 3.4 16.0 26.2 0.011.4 0.0 2.0 HD1-3 ALS 926-5-4-1 34.7 8.1 3.1 16.9 28.3 0.0 11.8 0.0 2.0HD1-9 ALS 926-5-4-1 28 7.0 2.9 18.2 26.2 0.0 13.5 0.0 2.2 HD1-1 ALS926-5-4-1 35 7.4 3.3 16.8 29.0 0.0 13.1 0.0 2.1 HD1-2 ALS 926-5-4-1 32.36.6 2.9 15.2 23.8 0.0 10.7 0.0 1.5 HD1-6 ALS 926-5-4-1 32.1 6.2 2.8 15.323.0 0.2 11.4 0.0 1.7 HD1-5 ALS 926-5-4-1 33.3 7.9 3.1 17.0 29.1 0.013.8 0.0 2.2 HD1-7 ALS 926-5-4-1 34.9 7.7 3.3 16.9 28.9 0.0 14.6 0.0 2.2HD1-4 ALS 926-5-4-1 31.1 6.3 2.6 15.2 23.8 0.0 12.1 0.0 1.6 HD1-10 ALS926-5-4-1 34.6 6.4 2.9 16.9 24.5 0.2 12.2 0.0 1.7 HD1-8 ALS 926-5-4-16.7 2.8 15.3 25.6 0.0 12.9 0.0 1.7 HD1-12 ALS 926-5-4-1 37.3 6.6 2.918.5 28.7 0.1 17.8 0.0 1.9 Top5 Avg. 33 7.3 3.1 16.6 26.7 0.0 12.1 0.02.0 pKR1672-8 GmMBOAT2 926-5-4-1 27.7 6.7 3.1 13.1 20.7 0.0 8.1 1.3 3.0pKR1672-4 GmMBOAT2 926-5-4-1 24.5 7.4 3.8 13.2 20.2 0.0 6.2 1.2 3.4pKR1672-1 GmMBOAT2 926-5-4-1 30.6 6.5 2.8 14.7 19.8 0.0 10.2 0.0 1.2pKR1672-9 GmMBOAT2 926-5-4-1 40.1 5.6 2.6 14.0 19.4 0.0 10.8 0.8 0.8pKR1672-2 GmMBOAT2 926-5-4-1 30.3 7.5 4.0 13.4 21.2 0.0 7.0 0.0 3.7pKR1672-6 GmMBOAT2 926-5-4-1 30 6.7 3.1 13.4 22.8 0.0 7.7 1.3 3.1pKR1672-7 GmMBOAT2 926-5-4-1 31.1 6.0 2.8 13.7 22.0 0.0 12.6 0.0 1.0pKR1672-5 GmMBOAT2 926-5-4-1 33 5.9 2.9 14.3 22.9 0.0 12.7 0.7 1.1pKR1672-3 GmMBOAT2 926-5-4-1 35.6 6.3 2.5 14.3 27.3 0.0 16.9 0.0 1.0Top5 Avg. 30.6 6.7 3.3 13.7 20.3 0.0 8.5 0.7 2.5 pKR1673-3 CoMBOAT926-5-4-1 35.7 7.3 2.6 10.2 24.0 0.0 14.7 0.0 1.3 pKR1673-1 CoMBOAT926-5-4-1 37.7 7.2 2.7 10.1 24.3 0.0 15.2 0.0 1.3 pKR1673-5 CoMBOAT926-5-4-1 41.3 7.4 3.2 11.3 25.0 0.0 13.4 0.0 1.4 pKR1673-2 CoMBOAT926-5-4-1 38.7 7.7 3.0 13.2 27.7 0.0 12.7 0.0 1.5 pKR1673-6 CoMBOAT926-5-4-1 40.8 8.2 3.1 14.2 28.4 0.0 13.1 0.0 1.5 pKR1673-4 CoMBOAT926-5-4-1 40.6 8.1 3.1 14.0 28.4 0.0 13.8 0.0 1.5 Top5 Avg. 38.8 7.6 2.911.8 25.9 0.0 13.8 0.0 1.4 pKR1674-10 McMBOAT 926-5-4-1 29.7 6.3 2.914.0 20.2 0.0 8.3 0.3 1.4 pKR1674-13 McMBOAT 926-5-4-1 32.6 6.6 2.9 13.021.3 0.0 7.6 1.1 2.8 pKR1674-12 McMBOAT 926-5-4-1 31.7 5.9 3.3 14.3 19.80.0 9.7 0.7 1.3 pKR1674-1 McMBOAT 926-5-4-1 30.6 6.5 3.1 12.6 21.2 0.08.9 2.5 2.9 pKR1674-15 McMBOAT 926-5-4-1 36 6.8 2.9 12.9 23.3 0.0 8.50.8 2.4 pKR1674-4 McMBOAT 926-5-4-1 27.4 6.7 2.9 11.4 21.6 0.0 10.7 0.91.2 pKR1674-16 McMBOAT 926-5-4-1 22.3 6.6 2.9 12.2 22.4 0.0 11.8 0.6 1.2pKR1674-3 McMBOAT 926-5-4-1 35.2 6.9 3.1 13.7 22.1 0.0 8.0 1.3 2.9pKR1674-7 McMBOAT 926-5-4-1 32.2 6.3 2.7 13.4 22.4 0.0 9.3 2.3 2.7pKR1674-11 McMBOAT 926-5-4-1 30.9 7.2 3.0 13.1 23.1 0.0 7.5 0.9 2.3pKR1674-6 McMBOAT 926-5-4-1 33.2 6.7 2.9 14.2 22.6 0.0 11.3 0.0 1.2pKR1674-9 McMBOAT 926-5-4-1 32.4 7.3 3.0 13.4 22.5 0.0 8.9 1.4 2.8pKR1674-8 McMBOAT 926-5-4-1 33.6 6.1 2.8 14.6 22.7 0.0 11.6 0.5 1.3pKR1674-5 McMBOAT 926-5-4-1 31.1 7.5 3.1 15.9 22.8 0.0 8.2 2.2 3.7pKR1674-14 McMBOAT 926-5-4-1 28.6 6.4 2.6 14.0 25.5 0.0 13.9 0.7 1.2pKR1674-2 McMBOAT 926-5-4-1 30.9 6.2 2.7 16.7 23.9 0.0 13.3 0.7 1.1 Top5Avg. 32.1 6.4 3.0 13.3 21.2 0.0 8.6 1.1 2.2 pKR1845-5 EuphMBOAT926-5-4-1 33.9 6.4 3.0 13.6 22.6 0.0 9.8 0.0 1.8 pKR1845-10 EuphMBOAT926-5-4-1 31.4 6.9 2.7 13.2 23.4 0.0 10.5 0.0 1.4 pKR1845-9 EuphMBOAT926-5-4-1 31.3 6.3 2.8 14.3 23.1 0.0 10.2 0.0 1.7 pKR1845-8 EuphMBOAT926-5-4-1 35.4 6.7 2.8 14.2 23.1 0.0 11.2 0.0 1.6 pKR1845-6 EuphMBOAT926-5-4-1 31.5 6.6 2.9 14.7 22.3 0.0 11.1 0.0 1.6 pKR1845-1 EuphMBOAT926-5-4-1 51.2 6.6 2.7 15.2 24.4 0.0 9.4 0.0 1.6 pKR1845-3 EuphMBOAT926-5-4-1 34.2 6.3 2.9 14.1 23.3 0.0 11.8 0.0 1.7 pKR1845-11 EuphMBOAT926-5-4-1 32 6.5 2.8 14.0 24.7 0.0 10.9 0.0 1.8 pKR1845-4 EuphMBOAT926-5-4-1 34.2 6.6 2.8 14.6 24.3 0.0 11.9 0.0 1.6 pKR1845-7 EuphMBOAT926-5-4-1 35.1 6.5 3.0 13.6 24.6 0.0 12.8 0.0 1.7 pKR1845-2 EuphMBOAT926-5-4-1 33 7.2 2.7 17.0 29.7 0.0 16.2 0.0 1.8 Top5 Avg. 32.7 6.6 2.814.0 22.9 0.0 10.5 0.0 1.6 LA + EDA + Event # MBOAT Bkgrnd 20:1 EDA ERAALA ERA % D12Des % D9Elo 926-5-4-1 13.5 15.1 6.5 39.6 21.5 83% 35%HD1-11 ALS 926-5-4-1 1.7 21.9 9.3 37.6 31.2 81% 45% HD1-3 ALS 926-5-4-11.9 19.7 7.8 40.1 27.6 80% 41% HD1-9 ALS 926-5-4-1 3.0 19.1 7.9 39.727.0 79% 41% HD1-1 ALS 926-5-4-1 1.8 18.8 7.9 42.1 26.6 80% 39% HD1-2ALS 926-5-4-1 14.0 18.1 7.3 34.5 25.4 80% 42% HD1-6 ALS 926-5-4-1 14.317.6 7.4 34.4 25.1 80% 42% HD1-5 ALS 926-5-4-1 1.9 17.6 7.2 43.0 24.880% 37% HD1-7 ALS 926-5-4-1 1.9 17.2 7.4 43.4 24.7 80% 36% HD1-4 ALS926-5-4-1 15.1 16.7 6.6 35.9 23.3 80% 39% HD1-10 ALS 926-5-4-1 15.2 14.55.6 36.7 20.0 77% 35% HD1-8 ALS 926-5-4-1 16.5 13.2 5.4 38.5 18.5 79%32% HD1-12 ALS 926-5-4-1 21.0 2.0 0.5 46.4 2.5 73% 5% Top5 Avg. 4.5 19.58.0 38.8 27.6 80% 42% pKR1672-8 GmMBOAT2 926-5-4-1 6.6 28.1 9.3 28.837.4 83% 57% pKR1672-4 GmMBOAT2 926-5-4-1 7.4 29.2 7.8 26.4 37.1 83% 58%pKR1672-1 GmMBOAT2 926-5-4-1 9.9 26.8 8.1 30.0 34.9 82% 54% pKR1672-9GmMBOAT2 926-5-4-1 8.5 25.8 9.0 30.2 34.8 82% 54% pKR1672-2 GmMBOAT2926-5-4-1 8.4 27.1 7.6 28.3 34.7 83% 55% pKR1672-6 GmMBOAT2 926-5-4-17.4 26.7 7.8 30.5 34.5 83% 53% pKR1672-7 GmMBOAT2 926-5-4-1 7.3 24.2 8.534.6 32.7 83% 49% pKR1672-5 GmMBOAT2 926-5-4-1 9.8 21.8 7.8 35.6 29.682% 45% pKR1672-3 GmMBOAT2 926-5-4-1 11.4 15.1 5.2 44.2 20.3 82% 31%Top5 Avg. 8.2 27.4 8.4 28.7 35.8 83% 55% pKR1673-3 CoMBOAT 926-5-4-111.0 18.9 10.1 38.6 29.0 87% 43% pKR1673-1 CoMBOAT 926-5-4-1 11.5 17.89.8 39.5 27.7 87% 41% pKR1673-5 CoMBOAT 926-5-4-1 11.6 17.9 8.8 38.426.7 85% 41% pKR1673-2 CoMBOAT 926-5-4-1 14.4 13.4 6.2 40.5 19.6 82% 33%pKR1673-6 CoMBOAT 926-5-4-1 14.6 11.6 5.3 41.5 16.8 80% 29% pKR1673-4CoMBOAT 926-5-4-1 14.9 11.0 5.1 42.2 16.1 81% 28% Top5 Avg. 12.6 15.98.0 39.7 24.0 84% 37% pKR1674-10 McMBOAT 926-5-4-1 6.6 31.0 9.1 28.540.1 83% 58% pKR1674-13 McMBOAT 926-5-4-1 6.5 29.5 8.7 28.9 38.2 84% 57%pKR1674-12 McMBOAT 926-5-4-1 8.6 27.1 9.3 29.5 36.4 82% 55% pKR1674-1McMBOAT 926-5-4-1 7.0 26.4 8.8 30.1 35.2 84% 54% pKR1674-15 McMBOAT926-5-4-1 7.6 26.5 8.4 31.8 34.9 84% 52% pKR1674-4 McMBOAT 926-5-4-1 8.025.8 8.8 32.3 34.5 85% 52% pKR1674-16 McMBOAT 926-5-4-1 8.4 25.1 8.834.2 33.9 85% 50% pKR1674-3 McMBOAT 926-5-4-1 8.6 25.4 8.1 30.0 33.5 82%53% pKR1674-7 McMBOAT 926-5-4-1 8.9 24.0 8.0 31.7 32.0 83% 50%pKR1674-11 McMBOAT 926-5-4-1 11.4 22.8 8.6 30.7 31.4 83% 51% pKR1674-6McMBOAT 926-5-4-1 10.1 23.8 7.0 34.0 30.9 82% 48% pKR1674-9 McMBOAT926-5-4-1 10.3 22.6 7.7 31.4 30.3 82% 49% pKR1674-8 McMBOAT 926-5-4-110.8 22.1 7.5 34.2 29.6 81% 46% pKR1674-5 McMBOAT 926-5-4-1 12.0 18.06.6 31.0 24.7 78% 44% pKR1674-14 McMBOAT 926-5-4-1 11.1 18.4 6.1 39.424.5 82% 38% pKR1674-2 McMBOAT 926-5-4-1 12.7 16.7 6.0 37.2 22.7 78% 38%Top5 Avg. 7.3 28.1 8.9 29.8 37.0 83% 55% pKR1845-5 EuphMBOAT 926-5-4-111.1 22.8 9.1 32.4 31.8 83% 50% pKR1845-10 EuphMBOAT 926-5-4-1 12.0 21.28.6 33.9 29.8 83% 47% pKR1845-9 EuphMBOAT 926-5-4-1 12.9 21.1 7.7 33.228.8 81% 46% pKR1845-8 EuphMBOAT 926-5-4-1 12.6 19.8 8.0 34.3 27.8 81%45% pKR1845-6 EuphMBOAT 926-5-4-1 13.1 19.9 7.9 33.4 27.8 81% 45%pKR1845-1 EuphMBOAT 926-5-4-1 13.0 19.8 7.4 33.8 27.2 80% 45% pKR1845-3EuphMBOAT 926-5-4-1 13.3 18.6 8.0 35.1 26.6 81% 43% pKR1845-11 EuphMBOAT926-5-4-1 12.9 19.4 6.9 35.7 26.4 82% 43% pKR1845-4 EuphMBOAT 926-5-4-114.1 17.4 6.7 36.2 24.1 80% 40% pKR1845-7 EuphMBOAT 926-5-4-1 15.5 15.66.9 37.3 22.4 81% 38% pKR1845-2 EuphMBOAT 926-5-4-1 19.1 4.9 1.3 45.96.3 75% 12% Top5 Avg. 12.3 20.9 8.3 33.4 29.2 82% 47%

TABLE 66 Fatty acid profile of T2 seed from events expressing MBOATs inEDA/ERA-expressing transgenic event 1191-4-11 (EaD9Elo) T2 seed forpKR1191(EaD9Elo) background event transformed with various MBOATs Event# MBOAT Bkgrnd % Oil 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:0 1191-4-11 7.33.2 12.4 24.6 0.0 11.5 0.0 1.4 HD1-4 Vect Cont 1191-4-11 34.5 7.7 2.712.2 21.0 0.0 9.7 0.0 1.1 HD1-11 Vect Cont 1191-4-11 29.5 8.1 2.4 11.621.7 0.0 9.5 0.0 1.2 HD1-7 Vect Cont 1191-4-11 34.8 8.0 2.6 11.0 21.40.0 10.4 0.0 1.2 HD1-1 Vect Cont 1191-4-11 32.6 8.5 2.5 9.5 21.9 0.011.7 0.0 1.2 HD1-8 Vect Cont 1191-4-11 33.1 7.5 2.6 11.2 22.2 0.0 10.80.0 1.1 HD1-2 Vect Cont 1191-4-11 32.9 6.9 2.5 11.5 21.6 0.0 11.8 0.01.1 HD1-10 Vect Cont 1191-4-11 30.4 6.8 2.4 11.9 20.9 0.0 13.3 0.0 1.2HD1-5 Vect Cont 1191-4-11 38.3 8.4 2.8 11.7 22.0 0.0 11.6 0.0 1.2 HD1-12Vect Cont 1191-4-11 37.3 7.7 2.8 11.1 23.0 0.0 12.1 0.0 1.1 HD1-3 VectCont 1191-4-11 27.5 8.4 2.6 10.6 23.1 0.0 12.5 0.0 1.2 HD1-13 Vect Cont1191-4-11 27.9 7.7 2.6 10.1 22.1 0.0 13.1 0.0 1.3 HD1-6 Vect Cont1191-4-11 32.1 7.4 2.4 12.0 21.6 0.0 14.3 0.0 1.0 HD1-9 Vect Cont1191-4-11 32.7 8.9 2.9 12.7 25.8 0.0 11.3 0.0 1.3 Top5 Avg. 32.9 8.0 2.611.1 21.6 0.0 10.4 0.0 1.2 1673-9 CoMBOAT 1191-4-11 30.5 8.4 2.8 10.817.8 0.0 8.4 0.0 1.1 1673-14 CoMBOAT 1191-4-11 26.9 7.2 2.6 11.4 17.70.0 8.3 0.0 1.0 1673-1 CoMBOAT 1191-4-11 29.5 7.6 2.4 9.1 18.7 0.0 10.00.0 1.3 1673-16 CoMBOAT 1191-4-11 37.6 7.2 2.6 11.2 18.4 0.0 9.4 0.0 1.11673-12 CoMBOAT 1191-4-11 37 6.9 2.4 11.4 18.5 0.0 8.9 0.0 1.1 1673-7CoMBOAT 1191-4-11 34.6 8.3 2.9 12.2 19.4 0.0 9.1 0.0 1.1 1673-11 CoMBOAT1191-4-11 34.3 7.8 2.2 10.7 19.1 0.0 9.5 0.0 1.2 1673-8 CoMBOAT1191-4-11 30.4 6.9 2.6 11.5 17.9 0.0 10.3 0.0 1.1 1673-6 CoMBOAT1191-4-11 31.4 7.1 2.7 11.2 18.8 0.0 10.1 0.0 1.1 1673-10 CoMBOAT1191-4-11 33.2 6.8 2.7 11.2 19.8 0.0 10.2 0.0 1.1 1673-5 CoMBOAT1191-4-11 29.3 8.0 2.7 9.2 20.1 0.0 10.7 0.0 1.5 1673-17 CoMBOAT1191-4-11 30.1 7.7 2.6 11.9 20.5 0.0 9.6 0.0 1.1 1673-2 CoMBOAT1191-4-11 33.8 7.1 2.6 12.7 20.8 0.0 8.2 0.0 1.1 1673-3 CoMBOAT1191-4-11 30.2 8.4 2.6 9.3 19.8 0.0 12.7 0.0 1.3 1673-13 CoMBOAT1191-4-11 37.8 7.9 2.8 10.9 21.0 0.0 10.6 0.0 1.2 1673-4 CoMBOAT1191-4-11 34.3 8.1 3.0 11.5 21.3 0.0 10.2 0.0 1.0 1673-15 CoMBOAT1191-4-11 35.9 8.4 3.0 11.3 21.5 0.0 10.1 0.0 1.2 Top5 Avg. 32.3 7.5 2.610.8 18.2 0.0 9.0 0.0 1.1 1674-10 McMBOAT 1191-4-11 27.4 7.4 2.5 8.713.4 0.0 5.3 0.0 1.2 1674-2 McMBOAT 1191-4-11 24 7.7 2.4 8.9 13.9 0.05.5 0.0 1.3 1674-11 McMBOAT 1191-4-11 33.2 6.3 2.7 11.0 13.8 0.2 5.2 0.01.2 1674-14 McMBOAT 1191-4-11 36.2 7.9 2.2 8.8 14.9 0.0 6.7 0.0 1.21674-13 McMBOAT 1191-4-11 29.9 7.3 2.6 11.2 14.7 0.0 6.4 0.0 1.0 1674-9McMBOAT 1191-4-11 36.4 7.8 2.7 12.7 15.2 0.0 5.6 0.0 0.9 1674-5 McMBOAT1191-4-11 26.1 7.1 2.6 11.2 15.3 0.0 6.1 0.0 1.0 1674-7 McMBOAT1191-4-11 39.7 7.6 2.5 10.8 15.1 0.0 6.6 0.0 1.0 1674-6 McMBOAT1191-4-11 30.2 7.8 2.5 7.4 17.4 0.0 8.1 0.0 1.2 1674-4 McMBOAT 1191-4-1131.8 8.1 2.8 11.2 18.0 0.0 7.8 0.0 1.1 1674-1 McMBOAT 1191-4-11 29.5 7.32.3 12.7 16.9 0.0 8.3 0.0 1.1 1674-12 McMBOAT 1191-4-11 33.2 8.1 2.6 9.319.7 0.0 7.5 0.0 1.2 1674-15 McMBOAT 1191-4-11 30.1 7.9 2.5 14.2 16.60.0 8.3 0.0 1.0 1674-3 McMBOAT 1191-4-11 36.5 7.3 2.6 11.8 20.5 0.0 12.40.0 1.1 1674-8 McMBOAT 1191-4-11 26 8.3 2.9 13.4 24.5 0.0 11.9 0.0 1.2Top5 Avg. 30.1 7.3 2.5 9.7 14.1 0.0 5.8 0.0 1.1 LA + EDA + Event # MBOATBkgrnd 20:1 EDA ERA ALA ERA % D12Des % D9Elo 1191-4-11 14.2 16.9 8.436.1 25.4 83% 41% HD1-4 Vect Cont 1191-4-11 10.0 23.2 12.3 30.7 35.5 84%54% HD1-11 Vect Cont 1191-4-11 8.8 23.4 12.1 31.2 35.5 85% 53% HD1-7Vect Cont 1191-4-11 8.9 22.9 12.5 31.8 35.4 86% 53% HD1-1 Vect Cont1191-4-11 9.2 21.5 12.8 33.6 34.3 88% 50% HD1-8 Vect Cont 1191-4-11 11.221.6 11.7 32.9 33.3 86% 50% HD1-2 Vect Cont 1191-4-11 11.8 21.0 11.733.4 32.7 85% 49% HD1-10 Vect Cont 1191-4-11 11.4 20.1 12.0 34.2 32.185% 48% HD1-5 Vect Cont 1191-4-11 9.2 20.1 11.6 33.5 31.8 85% 49% HD1-12Vect Cont 1191-4-11 10.9 20.1 11.2 35.0 31.3 86% 47% HD1-3 Vect Cont1191-4-11 9.8 19.2 11.5 35.7 30.7 86% 46% HD1-13 Vect Cont 1191-4-1111.2 19.1 11.4 35.2 30.5 87% 46% HD1-6 Vect Cont 1191-4-11 11.4 18.411.5 35.9 29.9 85% 45% HD1-9 Vect Cont 1191-4-11 11.7 16.7 7.8 37.1 24.683% 40% Top5 Avg. 9.6 22.5 12.3 32.1 34.8 86% 52% 1673-9 CoMBOAT1191-4-11 5.8 29.6 15.4 26.2 45.0 87% 63% 1673-14 CoMBOAT 1191-4-11 7.929.6 14.3 26.0 44.0 86% 63% 1673-1 CoMBOAT 1191-4-11 7.8 28.1 14.9 28.743.0 89% 60% 1673-16 CoMBOAT 1191-4-11 8.6 27.1 14.4 27.8 41.5 86% 60%1673-12 CoMBOAT 1191-4-11 9.2 27.6 13.9 27.4 41.5 86% 60% 1673-7 CoMBOAT1191-4-11 6.3 27.2 13.6 28.4 40.9 85% 59% 1673-11 CoMBOAT 1191-4-11 7.626.4 14.3 28.6 40.7 87% 59% 1673-8 CoMBOAT 1191-4-11 9.7 25.4 14.5 28.239.9 86% 59% 1673-6 CoMBOAT 1191-4-11 9.2 25.8 14.0 28.9 39.8 86% 58%1673-10 CoMBOAT 1191-4-11 10.1 25.1 13.1 30.0 38.1 86% 56% 1673-5CoMBOAT 1191-4-11 9.1 24.3 13.3 30.8 37.5 88% 55% 1673-17 CoMBOAT1191-4-11 8.0 25.4 12.0 30.1 37.5 85% 55% 1673-2 CoMBOAT 1191-4-11 10.225.4 11.8 29.0 37.3 84% 56% 1673-3 CoMBOAT 1191-4-11 8.8 22.9 14.1 32.537.0 88% 53% 1673-13 CoMBOAT 1191-4-11 8.6 23.7 13.2 31.6 37.0 86% 54%1673-4 CoMBOAT 1191-4-11 9.1 23.4 12.2 31.6 35.6 85% 53% 1673-15 CoMBOAT1191-4-11 8.6 23.6 11.4 31.5 35.0 85% 53% Top5 Avg. 7.9 28.4 14.6 27.243.0 87% 61% 1674-10 McMBOAT 1191-4-11 3.1 39.0 18.1 18.7 57.1 90% 75%1674-2 McMBOAT 1191-4-11 3.3 37.8 17.7 19.4 55.5 89% 74% 1674-11 McMBOAT1191-4-11 3.2 37.7 17.0 19.0 54.8 87% 74% 1674-14 McMBOAT 1191-4-11 4.234.9 17.5 21.6 52.4 89% 71% 1674-13 McMBOAT 1191-4-11 3.3 34.5 17.6 21.152.1 87% 71% 1674-9 McMBOAT 1191-4-11 3.0 36.8 14.3 20.8 51.2 85% 71%1674-5 McMBOAT 1191-4-11 4.7 34.9 15.9 21.3 50.8 87% 70% 1674-7 McMBOAT1191-4-11 4.3 33.8 16.8 21.7 50.6 87% 70% 1674-6 McMBOAT 1191-4-11 5.232.2 17.1 25.5 49.3 91% 66% 1674-4 McMBOAT 1191-4-11 5.4 30.7 14.9 25.845.6 86% 64% 1674-1 McMBOAT 1191-4-11 4.6 29.2 15.6 25.2 44.8 85% 64%1674-12 McMBOAT 1191-4-11 6.1 30.8 13.6 27.3 44.4 89% 62% 1674-15McMBOAT 1191-4-11 4.9 28.4 14.5 24.9 42.9 83% 63% 1674-3 McMBOAT1191-4-11 11.1 20.5 12.7 32.9 33.2 85% 50% 1674-8 McMBOAT 1191-4-11 11.516.8 8.4 36.4 25.3 82% 41% Top5 Avg. 3.4 36.8 17.6 20.0 54.4 88% 73%

TABLE 67 Fatty acid profile of T2 seed from events expressing MBOATs inDGLA/ETA-expressing transgenic event 1022-4-9 (EgD9Elo/TpomD8Des) T2seed for pKR1022 (EgD9Elo/TpomD8Des) background event transformed withvarious MBOATs Event # MBOAT Bkgrnd % Oil 16:0 18:0 18:1 18:2 GLA 18:3STA 20:0 20:1 EDA 1022-4-9 7.6 3.0 16.6 26.2 0.0 11.1 0.0 1.2 14.4 8.9HD1-18 Vect Cont 1022-4-9 7.7 2.4 12.8 20.6 0.0 15.5 0.0 1.3 11.8 10.9HD1-3 Vect Cont 1022-4-9 6.6 2.6 15.1 21.7 0.2 11.7 0.0 1.3 14.0 11.7HD1-8 Vect Cont 1022-4-9 7.6 2.7 15.4 20.0 0.2 13.2 0.0 1.4 11.8 11.8HD1-2 Vect Cont 1022-4-9 7.3 2.5 13.5 19.6 0.1 16.0 0.0 1.3 12.3 11.0HD1-5 Vect Cont 1022-4-9 6.9 2.5 18.6 19.0 0.1 12.6 0.0 1.3 11.4 12.0HD1-1 Vect Cont 1022-4-9 6.6 2.4 17.0 18.4 0.1 15.0 0.0 1.2 11.8 11.4HD1-7 Vect Cont 1022-4-9 6.1 2.6 16.5 18.9 0.1 14.3 0.0 1.5 13.5 11.1HD1-9 Vect Cont 1022-4-9 6.5 2.6 16.3 19.2 0.2 13.7 0.0 1.5 13.2 11.6HD1-14 Vect Cont 1022-4-9 7.3 2.7 14.2 20.2 0.1 13.3 0.0 1.6 12.8 12.3HD1-12 Vect Cont 1022-4-9 7.0 2.6 13.3 19.4 0.0 15.3 0.0 1.5 13.1 11.7HD1-10 Vect Cont 1022-4-9 7.3 2.6 13.5 20.8 0.0 15.2 0.0 1.5 13.0 11.1HD1-16 Vect Cont 1022-4-9 6.9 2.6 13.0 20.7 0.1 14.5 0.0 1.6 13.8 11.7HD1-17 Vect Cont 1022-4-9 6.4 2.6 15.8 19.6 0.2 13.9 0.0 1.5 13.4 11.8HD1-4 Vect Cont 1022-4-9 7.0 2.7 14.9 20.1 0.0 13.8 0.0 1.5 12.8 12.4HD1-15 Vect Cont 1022-4-9 7.3 3.4 14.6 23.4 0.1 12.0 0.0 1.6 15.9 9.9HD1-6 Vect Cont 1022-4-9 6.9 2.9 15.4 23.9 0.1 12.2 0.0 1.4 15.6 10.0HD1-11 Vect Cont 1022-4-9 6.7 3.3 14.9 24.1 0.1 11.7 0.0 1.6 15.7 10.4HD1-13 Vect Cont 1022-4-9 7.1 3.4 14.9 24.9 0.1 12.0 0.0 1.7 16.5 9.4Top5 7.2 2.5 15.1 20.2 0.1 13.8 0.0 1.4 12.2 11.5 Avg. 1671-12 GmMBOAT11022-4-9 7.5 2.7 18.2 12.6 0.2 4.3 0.0 1.2 4.5 17.5 1671-9 GmMBOAT11022-4-9 7.1 2.6 11.1 13.5 0.2 6.4 0.0 1.4 5.9 19.6 1671-6 GmMBOAT11022-4-9 7.1 2.5 14.6 13.0 0.2 5.6 0.0 1.3 5.5 18.3 1671-3 GmMBOAT11022-4-9 7.1 2.8 14.4 14.0 0.3 6.1 0.0 1.3 6.2 18.6 1671-7 GmMBOAT11022-4-9 7.6 3.1 14.9 15.0 0.0 5.5 0.0 1.3 6.6 17.8 1671-11 GmMBOAT11022-4-9 7.2 2.5 11.2 15.1 0.0 6.9 0.0 1.4 6.0 19.7 1671-13 GmMBOAT11022-4-9 7.0 2.6 10.7 14.8 0.0 7.0 0.0 1.5 6.4 19.9 1671-1 GmMBOAT11022-4-9 6.9 2.5 11.9 15.0 0.1 7.5 0.0 1.4 7.1 18.6 1671-5 GmMBOAT11022-4-9 7.6 2.6 11.6 16.4 0.0 7.4 0.0 1.4 7.0 18.2 1671-8 GmMBOAT11022-4-9 6.8 2.5 12.9 15.5 0.2 8.0 0.0 1.3 7.1 17.8 1671-4 GmMBOAT11022-4-9 6.5 2.5 13.9 16.5 0.2 7.8 0.0 1.4 8.1 17.8 1671-14 GmMBOAT11022-4-9 6.5 2.8 14.4 16.6 0.1 7.0 0.0 1.3 7.8 18.9 1671-10 GmMBOAT11022-4-9 6.6 2.3 17.0 19.1 0.1 14.2 0.0 1.3 12.0 11.9 1671-2 GmMBOAT11022-4-9 7.9 3.3 15.9 26.7 0.0 11.7 0.0 1.5 15.7 8.9 Top5 7.3 2.7 14.613.6 0.2 5.6 0.0 1.3 5.8 18.4 Avg. 1672-14 GmMBOAT2 1022-4-9 7.2 2.513.8 9.4 0.2 3.5 0.0 1.2 4.0 19.4 1672-12 GmMBOAT2 1022-4-9 6.8 2.7 12.712.1 0.2 4.9 0.0 1.4 4.9 20.1 1672-15 GmMBOAT2 1022-4-9 7.5 2.5 12.114.7 0.0 6.8 0.0 1.5 6.0 17.8 1672-10 GmMBOAT2 1022-4-9 6.3 2.4 14.712.6 0.1 6.2 0.0 1.4 6.2 18.9 1672-8 GmMBOAT2 1022-4-9 7.6 2.7 15.7 14.70.4 6.6 0.0 1.4 7.4 15.6 1672-3 GmMBOAT2 1022-4-9 6.9 2.5 11.6 14.3 0.16.8 0.0 1.5 6.8 19.5 1672-16 GmMBOAT2 1022-4-9 6.1 2.6 12.9 14.1 0.2 7.10.0 1.5 7.1 18.8 1672-2 GmMBOAT2 1022-4-9 6.8 2.5 14.3 15.2 0.2 6.5 0.01.5 6.9 17.9 1672-5 GmMBOAT2 1022-4-9 6.9 2.8 16.1 14.8 0.2 5.7 0.0 1.47.0 18.1 1672-9 GmMBOAT2 1022-4-9 6.7 2.5 11.1 15.2 0.0 8.7 0.0 1.5 7.318.0 1672-13 GmMBOAT2 1022-4-9 7.8 2.5 11.8 16.1 0.0 7.6 0.0 1.5 6.318.4 1672-4 GmMBOAT2 1022-4-9 6.6 2.4 13.6 15.6 0.2 7.8 0.0 1.5 7.2 17.71672-17 GmMBOAT2 1022-4-9 7.4 2.6 11.4 16.8 0.2 8.3 0.0 1.6 7.7 17.01672-7 GmMBOAT2 1022-4-9 7.3 2.5 11.4 16.8 0.1 8.3 0.0 1.5 7.1 17.81672-6 GmMBOAT2 1022-4-9 6.3 2.5 14.5 15.1 0.2 7.8 0.0 1.5 7.8 17.81672-11 GmMBOAT2 1022-4-9 7.0 2.6 10.6 17.3 0.0 8.9 0.0 1.5 7.7 17.81672-1 GmMBOAT2 1022-4-9 6.6 2.8 14.1 21.5 0.2 13.8 0.0 1.5 14.6 10.3Top5 7.1 2.6 13.8 12.7 0.2 5.6 0.0 1.4 5.7 18.4 Avg. 1673-10 CoMBOAT1022-4-9 7.4 2.5 11.2 14.1 0.0 8.2 0.0 1.5 7.0 17.3 1673-14 CoMBOAT1022-4-9 7.4 2.6 12.6 16.3 0.0 9.0 0.0 1.6 8.1 17.0 1673-11 CoMBOAT1022-4-9 6.8 2.4 15.3 15.5 0.2 9.1 0.0 1.3 7.1 16.2 1673-6 CoMBOAT1022-4-9 6.9 2.2 12.9 15.5 0.0 9.2 0.0 1.4 7.9 18.0 1673-2 CoMBOAT1022-4-9 7.3 2.5 12.8 16.8 0.0 9.8 0.0 1.6 8.6 16.3 1673-13 CoMBOAT1022-4-9 7.5 2.6 15.3 17.6 0.0 9.2 0.0 1.4 8.1 15.9 1673-9 CoMBOAT1022-4-9 6.5 2.5 15.4 16.1 0.1 9.1 0.0 1.6 8.5 17.0 1673-5 CoMBOAT1022-4-9 6.7 2.5 15.5 16.7 0.0 9.6 0.0 1.4 8.2 16.3 1673-1 CoMBOAT1022-4-9 6.4 2.3 12.2 20.5 0.1 9.1 0.0 1.4 9.6 17.1 1673-15 CoMBOAT1022-4-9 6.3 2.4 13.2 17.5 0.0 11.3 0.0 1.5 9.4 15.3 1673-3 CoMBOAT1022-4-9 6.2 2.4 13.0 18.0 0.1 11.0 0.0 1.6 10.2 15.6 1673-8 CoMBOAT1022-4-9 6.8 2.4 10.6 19.0 0.0 12.7 0.0 1.5 9.9 15.0 1673-7 CoMBOAT1022-4-9 6.8 2.5 15.2 18.4 0.1 10.3 0.0 1.5 9.4 15.7 1673-4 CoMBOAT1022-4-9 7.0 2.5 11.7 19.7 0.0 12.0 0.0 1.5 10.3 15.1 1673-16 CoMBOAT1022-4-9 6.8 2.4 11.2 20.4 0.0 12.8 0.0 1.4 10.4 15.0 1673-12 CoMBOAT1022-4-9 7.5 2.9 13.3 21.2 0.0 10.4 0.0 1.4 10.7 14.9 Top5 7.2 2.4 13.015.7 0.0 9.1 0.0 1.5 7.7 16.9 Avg. 1674-16 McMBOAT 1022-4-9 7.1 2.5 10.812.3 0.0 5.9 0.0 1.4 4.2 20.8 1674-11 McMBOAT 1022-4-9 7.6 2.4 17.4 14.10.2 6.1 0.0 1.2 5.4 18.0 1674-4 McMBOAT 1022-4-9 7.1 2.5 10.0 15.1 0.08.5 0.0 1.6 6.1 18.8 1674-17 McMBOAT 1022-4-9 6.9 2.4 13.9 14.4 0.1 7.30.0 1.4 5.1 19.1 1674-12 McMBOAT 1022-4-9 6.5 2.5 11.1 13.9 0.0 7.7 0.01.7 6.4 20.2 1674-13 McMBOAT 1022-4-9 6.5 2.5 16.2 13.5 0.2 6.4 0.0 1.66.1 19.1 1674-18 McMBOAT 1022-4-9 6.5 2.4 10.8 15.4 0.0 8.8 0.0 1.6 6.618.9 1674-6 McMBOAT 1022-4-9 7.0 2.3 10.1 16.9 0.0 9.7 0.0 1.5 7.0 17.81674-8 MCMBOAT 1022-4-9 7.2 2.6 10.5 17.0 0.2 9.0 0.0 1.8 7.9 16.71674-7 McMBOAT 1022-4-9 6.0 2.7 12.3 16.8 0.2 8.5 0.0 1.6 9.2 17.51674-1 McMBOAT 1022-4-9 6.3 2.3 11.5 16.7 0.0 9.5 0.0 1.5 7.1 18.31674-5 McMBOAT 1022-4-9 6.4 2.5 14.9 16.2 0.1 8.1 0.0 1.6 7.7 17.91674-2 MCMBOAT 1022-4-9 7.0 3.0 13.7 17.4 0.0 6.7 0.0 1.4 6.0 21.91674-9 McMBOAT 1022-4-9 7.0 3.3 12.3 18.6 0.0 6.9 0.0 1.7 7.0 21.31674-15 McMBOAT 1022-4-9 6.8 2.7 12.5 20.6 0.1 9.9 0.0 1.4 9.7 16.71674-14 McMBOAT 1022-4-9 8.4 2.8 16.0 19.1 0.0 10.6 0.0 1.4 9.7 14.11674-3 McMBOAT 1022-4-9 6.6 2.9 14.1 20.9 0.1 11.0 0.0 1.4 11.9 14.11674-10 McMBOAT 1022-4-9 6.6 2.7 14.4 21.0 0.0 14.0 0.0 1.6 13.9 12.3Top5 7.0 2.5 12.6 14.0 0.1 7.1 0.0 1.5 5.4 19.4 Avg. 1845-12 EuphMBOAT1022-4-9-2 24.3 6.6 3.0 18.5 16.5 0.0 7.5 0.0 1.8 10.6 13.3 1845-7EuphMBOAT 1022-4-9-2 27.7 6.6 2.8 16.0 17.9 0.0 7.6 0.0 1.5 10.8 16.61845-16 EuphMBOAT 1022-4-9-2 23.8 7.3 3.5 18.4 18.1 0.0 6.8 0.0 1.8 11.513.3 1845-8 EuphMBOAT 1022-4-9-2 28.8 6.9 3.1 17.6 18.7 0.0 7.8 0.0 1.611.7 13.8 1845-4 EuphMBOAT 1022-4-9-2 31.5 6.3 2.9 16.1 17.6 0.0 8.9 0.01.7 11.0 16.0 1845-2 EuphMBOAT 1022-4-9-2 27.2 6.4 3.1 17.0 18.0 0.0 8.60.0 1.8 12.4 13.8 1845-11 EuphMBOAT 1022-4-9-2 30.3 7.1 3.0 16.2 19.40.0 9.7 0.0 1.6 12.3 13.4 1845-15 EuphMBOAT 1022-4-9-2 31.8 6.3 2.7 13.718.0 0.0 12.4 0.0 1.7 12.3 14.1 1845-1 EuphMBOAT 1022-4-9-2 29.1 7.0 3.016.6 18.6 0.0 10.4 0.0 1.6 11.8 13.5 1845-5 EuphMBOAT 1022-4-9-2 30.37.2 3.0 17.3 19.3 0.0 10.1 0.0 1.5 11.4 13.3 1845-6 EuphMBOAT 1022-4-9-231.4 6.4 2.7 15.3 19.5 0.0 11.8 0.0 1.7 12.2 13.4 1845-3 EuphMBOAT1022-4.9-2 33.2 6.4 2.7 15.8 18.1 0.0 12.9 0.0 1.6 12.9 13.2 1845-17EuphMBOAT 1022-4-9-2 34.6 6.0 2.8 15.9 19.6 0.0 11.4 0.0 1.6 13.7 13.61845-10 EuphMBOAT 1022-4-9-2 33.6 6.6 3.0 15.5 21.3 0.0 11.5 0.0 1.714.0 11.8 1845-9 EuphMBOAT 1022-4-9-2 41.7 7.8 3.4 15.5 21.0 0.0 10.10.0 1.5 11.4 14.6 1845-13 EuphMBOAT 1022-4-9-2 35.3 7.1 2.9 16.1 21.30.0 11.5 0.0 1.5 13.2 12.3 1845-14 EuphMBOAT 1022-4-9-2 34.3 6.4 2.815.2 22.0 0.0 13.6 0.0 1.7 14.8 10.2 Top5 27.2 6.7 3.1 17.3 17.8 0.0 7.70.0 1.7 11.1 14.6 Avg. LA + EDA + DGLA + Event # MBOAT Bkgrnd DGLA ERAETA ALA ERA ETA % D12Des % D9Elo 1022-4-9 5.2 4.4 1.2 37.3 13.3 6.3 77%35% HD1-18 Vect Cont 1022-4-9 7.0 7.8 2.2 36.1 18.7 9.2 83% 44% HD1-3Vect Cont 1022-4-9 6.9 6.5 1.8 33.4 18.2 8.7 80% 45% HD1-8 Vect Cont1022-4-9 6.5 7.3 2.1 33.2 19.2 8.6 80% 46% HD1-2 Vect Cont 1022-4-9 6.08.1 2.2 35.6 19.1 8.2 82% 43% HD1-5 Vect Cont 1022-4-9 6.2 7.5 1.9 31.619.4 8.1 76% 47% HD1-1 Vect Cont 1022-4-9 5.8 8.2 2.0 33.4 19.6 7.9 78%45% HD1-7 Vect Cont 1022-4-9 5.9 7.6 2.0 33.2 18.7 7.8 78% 44% HD1-9Vect Cont 1022-4-9 5.9 7.5 1.9 33.0 19.0 7.8 79% 45% HD1-14 Vect Cont1022-4-9 5.9 7.5 1.8 33.6 19.8 7.7 81% 45% HD1-12 Vect Cont 1022-4-9 5.78.3 2.0 34.7 20.1 7.6 82% 44% HD1-10 Vect Cont 1022-4-9 5.6 7.6 1.8 35.918.7 7.4 82% 42% HD1-16 Vect Cont 1022-4-9 5.6 7.6 1.8 35.2 19.3 7.4 83%43% HD1-17 Vect Cont 1022-4-9 5.4 7.6 1.7 33.5 19.4 7.1 79% 44% HD1-4Vect Cont 1022-4-9 5.4 7.7 1.7 33.9 20.2 7.0 80% 45% HD1-15 Vect Cont1022-4-9 4.9 5.6 1.2 35.4 15.5 6.2 80% 38% HD1-6 Vect Cont 1022-4-9 4.85.6 1.2 36.1 15.5 6.1 79% 37% HD1-11 Vect Cont 1022-4-9 4.8 5.6 1.2 35.816.0 5.9 80% 38% HD1-13 Vect Cont 1022-4-9 4.1 5.1 1.0 36.9 14.4 5.1 79%35% Top5 6.5 7.4 2.0 34.0 18.9 8.6 80% 45% Avg. 1671-12 GmMBOAT11022-4-9 20.0 5.6 5.8 16.9 23.1 25.7 78% 74% 1671-9 GmMBOAT1 1022-4-918.8 7.8 5.8 19.8 27.4 24.6 87% 72% 1671-6 GmMBOAT1 1022-4-9 18.4 7.46.1 18.6 25.7 24.5 82% 73% 1671-3 GmMBOAT1 1022-4-9 17.5 6.8 4.9 20.125.4 22.4 83% 70% 1671-7 GmMBOAT1 1022-4-9 18.0 5.8 4.3 20.5 23.7 22.382% 69% 1671-11 GmMBOAT1 1022-4-9 16.7 8.1 5.2 21.9 27.8 21.9 86% 69%1671-13 GmMBOAT1 1022-4-9 16.2 8.8 5.3 21.8 28.6 21.5 87% 70% 1671-1GmMBOAT1 1022-4-9 15.5 8.3 5.3 22.5 26.9 20.8 85% 68% 1671-5 GmMBOAT11022-4-9 15.1 7.9 4.8 23.7 26.1 20.0 86% 66% 1671-8 GmMBOAT1 1022-4-914.8 8.2 4.9 23.5 26.0 19.8 84% 66% 1671-4 GmMBOAT1 1022-4-9 13.3 7.84.2 24.3 25.6 17.5 83% 64% 1671-14 GmMBOAT1 1022-4-9 13.7 7.1 3.7 23.626.0 17.4 82% 65% 1671-10 GmMBOAT1 1022-4-9 6.0 7.7 1.9 33.3 19.6 7.978% 45% 1671-2 GmMBOAT1 1022-4-9 3.4 4.3 0.7 38.4 13.2 4.2 78% 31% Top518.5 6.7 5.4 19.2 25.0 23.9 82% 72% Avg. 1672-14 GmMBOAT2 1022-4-9 24.76.2 7.7 12.9 25.7 32.4 84% 82% 1672-12 GmMBOAT2 1022-4-9 20.7 7.3 6.217.0 27.4 26.9 85% 76% 1672-15 GmMBOAT2 1022-4-9 16.3 8.4 6.4 21.5 26.222.7 85% 69% 1672-10 GmMBOAT2 1022-4-9 16.1 8.7 6.4 18.8 27.6 22.5 82%73% 1672-8 GmMBOAT2 1022-4-9 16.2 6.3 5.3 21.3 21.9 21.5 80% 67% 1672-3GmMBOAT2 1022-4-9 16.1 8.6 5.3 21.0 28.1 21.4 86% 70% 1672-16 GmMBOAT21022-4-9 16.0 8.6 5.2 21.1 27.4 21.2 84% 70% 1672-2 GmMBOAT2 1022-4-915.4 7.5 5.3 21.7 25.5 20.7 83% 68% 1672-5 GmMBOAT2 1022-4-9 16.0 6.64.4 20.6 24.7 20.4 80% 69% 1672-9 GmMBOAT2 1022-4-9 14.3 9.4 5.2 23.927.4 19.5 86% 66% 1672-13 GmMBOAT2 1022-4-9 14.0 8.8 5.2 23.7 27.2 19.286% 66% 1672-4 GmMBOAT2 1022-4-9 14.1 8.6 4.8 23.3 26.3 18.9 83% 66%1672-17 GmMBOAT2 1022-4-9 13.8 8.4 4.9 25.1 25.4 18.7 86% 64% 1672-7GmMBOAT2 1022-4-9 13.4 8.9 4.7 25.2 26.7 18.2 86% 64% 1672-6 GmMBOAT21022-4-9 13.3 8.5 4.6 23.0 26.3 18.0 82% 66% 1672-11 GmMBOAT2 1022-4-913.4 8.8 4.5 26.2 26.6 17.9 87% 63% 1672-1 GmMBOAT2 1022-4-9 6.1 6.6 1.935.3 16.9 8.0 81% 41% Top5 18.8 7.4 6.4 18.3 25.8 25.2 83% 73% Avg.1673-10 CoMBOAT 1022-4-9 15.9 8.7 6.2 22.3 25.9 22.1 86% 68% 1673-14CoMBOAT 1022-4-9 12.8 8.2 4.5 25.3 25.1 17.3 84% 63% 1673-11 CoMBOAT1022-4-9 12.5 8.9 4.8 24.6 25.1 17.2 81% 63% 1673-6 CoMBOAT 1022-4-912.1 9.5 4.5 24.8 27.5 16.5 84% 64% 1673-2 CoMBOAT 1022-4-9 11.5 8.6 4.226.6 24.9 15.7 84% 60% 1673-13 CoMBOAT 1022-4-9 10.9 7.7 3.7 26.8 23.714.6 81% 59% 1673-9 CoMBOAT 1022-4-9 10.7 8.8 3.7 25.1 25.8 14.5 81% 62%1673-5 CoMBOAT 1022-4-9 10.4 8.9 3.8 26.3 25.3 14.2 81% 60% 1673-1CoMBOAT 1022-4-9 11.4 7.2 2.6 29.6 24.3 14.0 85% 56% 1673-15 CoMBOAT1022-4-9 9.8 9.6 3.7 28.8 24.8 13.6 84% 57% 1673-3 CoMBOAT 1022-4-9 9.59.1 3.2 29.0 24.7 12.7 84% 56% 1673-8 CoMBOAT 1022-4-9 9.0 9.8 3.2 31.624.9 12.3 87% 54% 1673-7 CoMBOAT 1022-4-9 8.4 8.6 2.9 28.7 24.3 11.3 81%55% 1673-4 CoMBOAT 1022-4-9 8.6 8.8 2.8 31.7 23.9 11.3 85% 53% 1673-16CoMBOAT 1022-4-9 8.2 8.9 2.7 33.1 23.9 10.8 86% 51% 1673-12 CoMBOAT1022-4-9 8.0 7.4 2.4 31.6 22.3 10.4 83% 51% Top5 13.0 8.8 4.8 24.7 25.717.8 84% 64% Avg. 1674-16 McMBOAT 1022-4-9 18.3 10.4 6.4 18.2 31.1 24.787% 75% 1674-11 McMBOAT 1022-4-9 14.7 7.9 5.0 20.3 26.0 19.6 79% 69%1674-4 McMBOAT 1022-4-9 14.4 10.9 5.2 23.5 29.7 19.6 88% 68% 1674-17McMBOAT 1022-4-9 14.5 10.1 4.9 21.7 29.2 19.4 83% 69% 1674-12 McMBOAT1022-4-9 14.1 10.9 5.0 21.6 31.1 19.0 87% 70% 1674-13 McMBOAT 1022-4-913.8 9.3 4.8 19.9 28.3 18.6 81% 70% 1674-18 McMBOAT 1022-4-9 13.9 10.54.5 24.2 29.4 18.4 87% 66% 1674-6 McMBOAT 1022-4-9 13.0 10.3 4.4 26.628.1 17.4 88% 63% 1674-8 MCMBOAT 1022-4-9 12.4 9.8 5.0 26.0 26.5 17.487% 63% 1674-7 McMBOAT 1022-4-9 12.8 8.7 3.8 25.3 26.2 16.6 85% 63%1674-1 McMBOAT 1022-4-9 12.2 10.6 4.0 26.2 28.9 16.2 86% 63% 1674-5McMBOAT 1022-4-9 11.8 9.0 3.6 24.4 27.0 15.5 82% 64% 1674-2 MCMBOAT1022-4-9 12.1 8.0 2.6 24.1 29.9 14.8 83% 65% 1674-9 McMBOAT 1022-4-911.5 7.9 2.5 25.6 29.2 14.0 85% 63% 1674-15 McMBOAT 1022-4-9 9.3 8.1 2.330.5 24.8 11.6 84% 54% 1674-14 McMBOAT 1022-4-9 8.2 7.4 2.3 29.7 21.510.5 79% 52% 1674-3 McMBOAT 1022-4-9 8.4 6.5 2.0 31.9 20.6 10.4 82% 49%1674-10 McMBOAT 1022-4-9 4.6 7.6 1.4 35.0 19.9 6.0 81% 43% Top5 15.210.0 5.3 21.1 29.4 20.5 85% 70% Avg. 1845-12 EuphMBOAT 1022-4-9-2 10.97.1 4.2 24.0 20.4 15.1 76% 60% 1845-7 EuphMBOAT 1022-4-9-2 10.7 6.9 2.525.6 23.5 13.2 80% 59% 1845-16 EuphMBOAT 1022-4-9-2 10.2 6.0 3.0 24.919.3 13.2 76% 57% 1845-8 EuphMBOAT 1022-4-9-2 9.6 6.3 2.9 26.5 20.2 12.577% 55% 1845-4 EuphMBOAT 1022-4-9-2 9.3 7.3 2.8 26.5 23.3 12.2 79% 57%1845-2 EuphMBOAT 1022-4-9-2 9.1 6.8 3.0 26.6 20.6 12.1 78% 55% 1845-11EuphMBOAT 1022-4-9-2 8.3 6.7 2.3 29.1 20.1 10.6 79% 51% 1845-15EuphMBOAT 1022-4-9-2 7.8 8.4 2.7 30.3 22.5 10.5 82% 52% 1845-1 EuphMBOAT1022-4-9-2 8.0 7.1 2.4 29.0 20.6 10.4 78% 52% 1845-5 EuphMBOAT1022-4-9-2 7.9 6.7 2.2 29.4 20.0 10.1 77% 51% 1845-6 EuphMBOAT1022-4-9-2 7.1 7.4 2.6 31.2 20.8 9.7 80% 49% 1845-3 EuphMBOAT 1022-4.9-26.5 7.7 2.2 31.0 20.9 8.8 79% 49% 1845-17 EuphMBOAT 1022-4-9-2 6.6 7.01.8 31.0 20.6 8.4 79% 48% 1845-10 EuphMBOAT 1022-4-9-2 6.3 6.3 2.1 32.818.1 8.3 79% 45% 1845-9 EuphMBOAT 1022-4-9-2 6.7 6.4 1.5 31.1 21.0 8.280% 48% 1845-13 EuphMBOAT 1022-4-9-2 6.1 6.3 1.7 32.8 18.6 7.8 79% 45%1845-14 EuphMBOAT 1022-4-9-2 5.2 6.0 2.0 35.5 16.2 7.3 80% 40% Top5 10.16.7 3.1 25.5 21.3 13.2 78% 58% Avg.

TABLE 68 Fatty acid profile of T2 seed from events expressing MBOATs inDGLA/ETA-expressing transgenic event 1192-1-2 (EaD9Elo/EaD8Des) T2 seedfor 1192 (EaD9Elo/EaD8Des) background event transformed with variousMBOATs Event # MBOAT Bkgrnd % Oil 16:0 18:0 18:1 18:2 GLA 18:3 STA 20:020:1 EDA DGLA 1192-1-2 8.4 3.5 14.7 23.5 0.0 10.7 0.0 1.4 13.5 11.2 5.4HD1-4 Vect Cont 1192-1-2 37.6 12.6 3.2 24.8 11.7 0.5 6.0 0.0 1.6 7.7 9.49.9 HD1-7 Vect Cont 1192-1-2 35.0 11.2 3.5 19.9 16.9 0.0 11.0 0.0 1.38.0 7.5 8.9 HD1-13 Vect Cont 1192-1-2 32.3 8.8 3.0 17.4 16.7 0.5 11.10.0 1.3 9.7 9.9 8.6 HD1-9 Vect Cont 1192-1-2 9.6 8.6 3.0 20.2 15.4 0.610.5 0.0 1.3 8.8 10.6 8.0 HD1-6 Vect Cont 1192-1-2 33.8 10.9 2.8 19.217.0 0.2 8.1 0.0 1.3 9.2 10.6 8.3 HD1-10 Vect Cont 1192-1-2 23.6 10.12.7 18.2 17.5 0.0 11.1 0.0 1.4 8.6 10.2 8.2 HD1-5 Vect Cont 1192-1-228.5 8.7 3.3 16.3 19.0 0.5 10.1 0.0 1.3 10.8 10.8 8.3 HD1-11 Vect Cont1192-1-2 31.9 9.4 3.3 16.5 18.0 0.5 12.1 0.0 1.2 10.2 9.2 7.7 HD1-3 VectCont 1192-1-2 27.4 9.5 3.6 17.3 19.3 0.6 9.0 0.0 1.3 9.9 11.0 7.9 HD1-12Vect Cont 1192-1-2 22.9 10.4 2.5 23.9 15.8 0.0 12.4 0.0 1.2 7.8 8.4 6.4HD1-2 Vect Cont 1192-1-2 33.2 9.6 3.1 16.2 20.1 0.2 9.4 0.0 1.3 10.212.2 7.0 HD1-8 Vect Cont 1192-1-2 28.6 9.3 2.9 16.9 20.7 0.2 9.0 0.0 1.310.2 12.4 6.9 HD1-1 Vect Cont 1192-1-2 29.7 9.1 3.5 15.4 21.1 0.3 10.20.0 1.2 12.0 11.3 6.3 Top5 29.7 10.4 3.1 20.3 15.6 0.4 9.3 0.0 1.4 8.79.6 8.7 Avg. 1671-1 GmMBOAT1 1192-1-2 23.1 7.5 3.1 16.9 8.3 0.0 2.7 0.01.7 4.7 18.3 22.0 1671-4 GmMBOAT1 1192-1-2 24.9 7.4 3.3 18.0 10.3 0.03.5 0.0 1.5 6.2 18.6 19.4 1671-11 GmMBOAT1 1192-1-2 29.8 7.4 3.4 17.210.0 0.0 3.7 0.0 1.7 6.3 18.7 18.1 1671-9 GmMBOAT1 1192-1-2 28.7 7.2 3.519.8 9.1 0.0 3.0 0.0 1.7 6.2 18.6 18.2 1671-7 GmMBOAT1 1192-1-2 28.4 7.23.3 17.8 10.2 0.0 3.7 0.0 1.7 6.5 18.5 18.0 1671-6 GmMBOAT1 1192-1-228.0 8.0 3.3 17.4 10.4 0.0 3.6 0.0 1.5 6.1 19.4 18.6 1671-15 GmMBOAT11192-1-2 30.4 8.2 3.8 17.8 10.0 0.0 3.4 0.0 1.6 6.2 18.9 18.6 1671-3GmMBOAT1 1192-1-2 25.2 7.7 3.7 20.2 9.7 0.0 3.1 0.0 1.8 6.9 17.9 17.41671-12 GmMBOAT1 1192-1-2 29.6 7.9 3.5 18.6 10.2 0.0 3.9 0.0 1.5 6.418.5 17.0 1671-2 GmMBOAT1 1192-1-2 29.1 7.9 3.4 18.8 11.2 0.0 4.6 0.01.5 6.5 18.3 15.5 1671-8 GmMBOAT1 1192-1-2 26.5 8.3 3.7 21.6 10.8 0.03.8 0.0 1.5 6.9 17.1 16.2 1671-14 GmMBOAT1 1192-1-2 29.1 8.1 3.8 20.19.7 0.0 3.6 0.0 1.6 6.8 18.8 15.8 1671-16 GmMBOAT1 1192-1-2 30.8 8.4 3.620.6 10.9 0.0 3.8 0.0 1.3 6.3 18.4 16.0 1671-10 GmMBOAT1 1192-1-2 30.48.1 3.6 18.4 11.6 0.0 4.4 0.0 1.4 6.3 18.8 15.1 1671-5 GmMBOAT1 1192-1-227.6 7.4 3.8 20.5 10.4 0.0 3.5 0.0 1.8 7.1 18.6 15.0 1671-13 GmMBOAT11192-1-2 28.0 7.4 3.5 20.7 16.4 0.5 7.3 0.0 1.7 12.3 13.0 7.3 Top5 27.07.4 3.3 18.0 9.6 0.0 3.3 0.0 1.7 6.0 18.5 19.1 Avg. 1672-3 GmMBOAT21192-1-2 30.6 8.3 3.7 17.8 10.6 0.0 2.9 0.0 1.6 5.3 21.1 17.2 1672-4GmMBOAT2 1192-1-2 28.5 7.5 3.3 21.0 9.3 0.0 3.3 0.0 1.4 6.1 19.6 16.21672-9 GmMBOAT2 1192-1-2 23.7 8.1 3.4 20.7 10.1 0.0 3.5 0.0 1.7 6.8 17.515.7 1672-7 GmMBOAT2 1192-1-2 24.9 8.3 3.3 21.9 9.1 0.0 2.4 0.0 1.5 6.619.0 15.9 1672-8 GmMBOAT2 1192-1-2 31.2 7.6 3.5 20.7 10.6 0.2 3.5 0.01.3 7.2 19.7 15.6 1672-5 GmMBOAT2 1192-1-2 27.1 7.4 3.5 19.1 12.2 0.03.9 0.0 1.8 7.2 19.0 14.0 1672-2 GmMBOAT2 1192-1-2 26.5 7.9 3.5 21.711.1 0.0 4.0 0.0 1.4 7.5 18.2 13.9 1672-1 GmMBOAT2 1192-1-2 26.1 7.2 3.924.3 10.0 0.0 3.3 0.0 1.8 8.5 16.9 12.9 1672-6 GmMBOAT2 1192-1-2 28.37.6 3.7 21.4 10.9 0.0 4.2 0.0 1.5 8.1 18.2 12.9 Top5 27.8 8.0 3.4 20.49.9 0.0 3.1 0.0 1.5 6.4 19.4 16.1 Avg. 1673-5 CoMBOAT 1192-1-2 39.0 8.93.1 16.9 12.6 0.3 5.4 0.0 1.0 6.7 16.4 14.7 1673-4 CoMBOAT 1192-1-2 29.19.7 2.7 20.0 12.1 0.0 5.4 0.0 1.3 5.8 14.4 13.7 1673-6 CoMBOAT 1192-1-229.3 9.5 2.6 18.9 12.7 0.2 4.4 0.0 1.2 5.5 17.9 14.9 1673-7 CoMBOAT1192-1-2 24.9 9.3 3.3 19.5 13.1 0.6 6.7 0.0 1.3 7.4 11.9 13.2 1673-11CoMBOAT 1192-1-2 31.4 8.6 3.3 19.6 12.1 0.6 6.3 0.0 1.3 7.4 13.9 12.71673-8 CoMBOAT 1192-1-2 25.5 10.4 3.1 19.7 11.1 0.0 4.6 0.0 1.5 6.0 17.413.6 1673-12 CoMBOAT 1192-1-2 31.3 9.9 2.5 17.8 14.6 0.0 6.9 0.0 1.3 6.313.6 12.4 1673-2 CoMBOAT 1192-1-2 20.9 9.5 3.0 18.4 12.1 0.0 7.4 0.0 1.36.5 14.6 11.9 1673-10 CoMBOAT 1192-1-2 23.9 10.9 2.9 18.9 14.6 0.0 7.60.0 1.1 6.2 12.7 11.7 1673-1 CoMBOAT 1192-1-2 29.8 8.5 3.5 16.5 15.5 0.06.2 0.0 1.3 7.7 16.7 12.5 1673-3 CoMBOAT 1192-1-2 23.9 9.1 3.4 18.2 14.40.6 7.0 0.0 1.3 8.6 12.4 11.5 1673-9 CoMBOAT 1192-1-2 15.7 8.4 3.0 17.614.2 0.5 6.6 0.0 1.1 9.5 14.1 11.2 Top5 30.7 9.2 3.0 19.0 12.5 0.3 5.70.0 1.2 6.6 14.9 13.8 Avg. 1674-1 McMBOAT 1192-1-2 35.2 8.8 3.4 15.012.3 0.3 4.2 0.0 1.2 3.8 20.0 17.5 1674-4 McMBOAT 1192-1-2 27.9 9.4 2.818.9 9.7 0.0 3.8 0.0 1.4 4.4 18.9 16.5 1674-2 McMBOAT 1192-1-2 27.6 10.02.9 17.9 11.8 0.0 5.6 0.0 1.5 5.3 14.8 15.3 1674-3 McMBOAT 1192-1-2 24.08.8 3.1 18.6 12.4 0.4 5.0 0.0 1.2 5.1 16.0 15.3 1674-5 McMBOAT 1192-1-226.8 9.0 3.0 18.0 12.1 0.3 5.0 0.3 1.2 6.6 16.4 14.7 1674-7 McMBOAT1192-1-2 27.9 8.5 2.8 19.5 10.7 0.2 5.2 0.3 1.1 7.0 15.3 13.9 1674-8McMBOAT 1192-1-2 37.5 9.3 2.6 19.1 11.7 0.3 5.3 0.0 1.0 9.0 15.1 14.31674-6 McMBOAT 1192-1-2 25.0 8.5 2.4 17.2 13.1 0.0 6.4 0.0 1.1 8.3 15.713.8 Top5 28.3 9.2 3.0 17.7 11.6 0.2 4.7 0.1 1.3 5.0 17.2 15.8 Avg.1845-12 EuphMBOAT 1192-1-2 22.6 8.8 3.4 21.9 12.5 0.0 5.3 0.0 1.6 11.213.7 9.2 1845-6 EuphMBOAT 1192-1-2 25.9 7.7 3.5 20.9 14.6 0.0 6.6 0.01.7 10.7 14.6 8.4 1845-13 EuphMBOAT 1192-1-2 27.5 8.5 3.5 18.8 14.7 0.36.5 0.0 1.5 10.7 15.6 8.7 1845-11 EuphMBOAT 1192-1-2 25.3 7.9 3.6 20.214.1 0.3 6.0 0.0 1.6 11.5 15.4 8.5 1845-8 EuphMBOAT 1192-1-2 26.3 8.03.6 22.3 14.2 0.4 5.4 0.0 1.6 11.3 14.8 8.4 1845-2 EuphMBOAT 1192-1-227.8 7.9 3.6 21.2 14.7 0.0 6.7 0.0 1.7 11.6 13.8 8.0 1845-10 EuphMBOAT1192-1-2 25.2 7.9 3.8 21.6 14.4 0.0 6.1 0.0 1.8 11.6 14.2 8.1 1845-7EuphMBOAT 1192-1-2 26.7 7.8 3.4 18.1 15.5 0.4 7.0 0.0 1.6 11.1 15.7 8.31845-4 EuphMBOAT 1192-1-2 24.6 7.7 3.7 22.9 13.3 0.5 6.1 0.0 1.7 11.114.0 8.0 1845.9 EuphMBOAT 1192-1-2 23.9 8.3 3.9 22.0 14.2 0.5 5.3 0.01.5 12.0 14.7 8.4 1845-15 EuphMBOAT 1192-1-2 24.4 8.5 3.7 21.9 14.9 0.45.6 0.0 1.4 10.4 15.4 8.4 1845-5 EuphMBOAT 1192-1-2 25.6 8.7 3.6 19.015.8 0.3 6.6 0.0 1.6 10.3 15.7 8.2 1845-3 EuphMBOAT 1192-1-2 25.7 7.73.6 22.3 14.2 0.3 5.9 0.0 1.5 11.5 15.0 8.1 1845-14 EuphMBOAT 1192-1-228.5 8.0 3.7 20.6 15.6 0.0 7.2 0.0 1.7 11.5 13.8 7.6 1845-1 EuphMBOAT1192-1-2 27.1 8.4 3.4 21.0 15.1 0.3 7.8 0.0 1.4 10.7 13.7 7.5 1845-16EuphMBOAT 1192-1-2 28.2 8.2 3.3 18.8 16.7 0.5 8.4 0.0 1.6 13.3 12.1 6.6Top5 25.5 8.2 3.5 20.8 14.0 0.2 6.0 0.0 1.6 11.1 14.9 8.6 Avg. LA +EDA + DGLA + Event # MBOAT Bkgrnd ERA ETA ALA ERA ETA % D12Des % D9Elo %D8Des 1192-1-2 6.0 1.7 34.2 17.2 7.2 80% 42% 29% HD1-4 Vect Cont1192-1-2 5.6 3.7 17.8 15.0 13.7 65% 62% 48% HD1-7 Vect Cont 1192-1-2 5.94.1 27.9 13.4 13.0 73% 49% 49% HD1-13 Vect Cont 1192-1-2 7.4 4.0 27.817.2 12.6 77% 52% 42% HD1-9 Vect Cont 1192-1-2 7.4 3.8 25.9 18.0 11.873% 54% 40% HD1-6 Vect Cont 1192-1-2 6.5 3.4 25.1 17.1 11.7 74% 53% 41%HD1-10 Vect Cont 1192-1-2 6.9 3.4 28.6 17.1 11.6 76% 50% 40% HD1-5 VectCont 1192-1-2 6.6 3.1 29.1 17.3 11.4 78% 50% 40% HD1-11 Vect Cont1192-1-2 6.9 3.5 30.1 16.2 11.3 78% 48% 41% HD1-3 Vect Cont 1192-1-2 6.43.1 28.2 17.4 11.0 77% 50% 39% HD1-12 Vect Cont 1192-1-2 6.3 3.1 28.214.8 9.6 69% 46% 39% HD1-2 Vect Cont 1192-1-2 6.9 2.4 29.6 19.1 9.4 78%49% 33% HD1-8 Vect Cont 1192-1-2 6.5 2.3 29.6 18.9 9.2 77% 49% 33% HD1-1Vect Cont 1192-1-2 6.4 2.2 31.3 17.6 8.6 79% 45% 33% Top5 6.6 3.8 24.916.2 12.6 72% 54% 44% Avg. 1671-1 GmMBOAT1 1192-1-2 6.0 8.6 11.0 24.430.6 80% 83% 56% 1671-4 GmMBOAT1 1192-1-2 5.5 6.3 13.8 24.1 25.7 78% 78%52% 1671-11 GmMBOAT1 1192-1-2 6.6 6.9 13.7 25.3 25.0 79% 79% 50% 1671-9GmMBOAT1 1192-1-2 5.9 6.7 12.1 24.5 24.9 76% 80% 50% 1671-7 GmMBOAT11192-1-2 6.3 6.7 13.9 24.8 24.7 78% 78% 50% 1671-6 GmMBOAT1 1192-1-2 5.95.7 14.0 25.3 24.4 78% 78% 49% 1671-15 GmMBOAT1 1192-1-2 5.9 5.7 13.324.8 24.3 78% 79% 50% 1671-3 GmMBOAT1 1192-1-2 5.7 5.9 12.8 23.6 23.375% 79% 50% 1671-12 GmMBOAT1 1192-1-2 6.4 6.1 14.1 24.8 23.2 77% 77% 48%1671-2 GmMBOAT1 1192-1-2 6.6 5.8 15.8 24.8 21.3 77% 75% 46% 1671-8GmMBOAT1 1192-1-2 5.1 5.0 14.7 22.2 21.1 73% 75% 49% 1671-14 GmMBOAT11192-1-2 6.4 5.3 13.4 25.2 21.1 75% 78% 45% 1671-16 GmMBOAT1 1192-1-25.8 5.0 14.6 24.2 21.0 74% 76% 47% 1671-10 GmMBOAT1 1192-1-2 6.7 5.516.0 25.5 20.7 77% 74% 45% 1671-5 GmMBOAT1 1192-1-2 6.4 5.5 13.8 25.020.5 74% 77% 45% 1671-13 GmMBOAT1 1192-1-2 6.8 3.1 23.7 19.8 10.4 72%56% 34% Top5 6.1 7.0 12.9 24.6 26.2 78% 80% 51% Avg. 1672-3 GmMBOAT21192-1-2 6.2 5.3 13.6 27.3 22.6 78% 79% 45% 1672-4 GmMBOAT2 1192-1-2 6.46.0 12.6 26.0 22.2 74% 79% 46% 1672-9 GmMBOAT2 1192-1-2 6.4 6.2 13.523.9 21.9 74% 77% 48% 1672-7 GmMBOAT2 1192-1-2 6.1 5.8 11.5 25.1 21.773% 80% 46% 1672-8 GmMBOAT2 1192-1-2 5.6 4.4 14.1 25.3 20.0 74% 76% 44%1672-5 GmMBOAT2 1192-1-2 6.8 5.1 16.1 25.8 19.2 76% 74% 43% 1672-2GmMBOAT2 1192-1-2 6.2 4.7 15.1 24.4 18.6 73% 74% 43% 1672-1 GmMBOAT21192-1-2 6.2 5.1 13.3 23.1 18.0 69% 76% 44% 1672-6 GmMBOAT2 1192-1-2 7.04.6 15.0 25.2 17.4 73% 74% 41% Top5 6.1 5.5 13.1 25.5 21.7 75% 78% 46%Avg. 1673-5 CoMBOAT 1192-1-2 6.9 5.6 17.9 23.3 20.3 78% 71% 47% 1673-4CoMBOAT 1192-1-2 7.1 6.0 17.5 21.5 19.7 75% 70% 48% 1673-6 CoMBOAT1192-1-2 6.0 4.6 17.1 23.9 19.5 76% 72% 45% 1673-7 CoMBOAT 1192-1-2 6.45.7 19.8 18.3 19.0 75% 65% 51% 1673-11 CoMBOAT 1192-1-2 7.2 5.7 18.421.0 18.5 75% 68% 47% 1673-8 CoMBOAT 1192-1-2 6.5 4.8 15.7 24.0 18.4 75%73% 43% 1673-12 CoMBOAT 1192-1-2 7.3 5.5 21.6 20.9 17.9 77% 64% 46%1673-2 CoMBOAT 1192-1-2 8.2 5.8 19.5 22.8 17.7 77% 67% 44% 1673-10CoMBOAT 1192-1-2 6.9 5.0 22.2 19.6 16.7 76% 62% 46% 1673-1 CoMBOAT1192-1-2 6.4 4.0 21.8 23.1 16.5 79% 65% 42% 1673-3 CoMBOAT 1192-1-2 6.85.0 21.4 19.2 16.5 76% 62% 46% 1673-9 CoMBOAT 1192-1-2 7.3 4.6 20.9 21.415.7 77% 64% 42% Top5 6.7 5.5 18.1 21.6 19.4 76% 69% 47% Avg. 1674-1McMBOAT 1192-1-2 7.4 5.3 16.5 27.5 22.7 82% 75% 45% 1674-4 McMBOAT1192-1-2 7.1 6.1 13.5 25.9 22.6 77% 78% 47% 1674-2 McMBOAT 1192-1-2 7.66.2 17.4 22.4 21.5 77% 72% 49% 1674-3 McMBOAT 1192-1-2 7.2 5.7 17.4 23.221.0 77% 72% 47% 1674-5 McMBOAT 1192-1-2 7.6 5.8 17.1 23.9 20.6 77% 72%46% 1674-7 McMBOAT 1192-1-2 8.9 6.4 15.9 24.2 20.3 76% 74% 46% 1674-8McMBOAT 1192-1-2 7.0 5.2 17.1 22.1 19.5 75% 71% 47% 1674-6 McMBOAT1192-1-2 7.9 5.6 19.5 23.6 19.4 78% 69% 45% Top5 7.4 5.8 16.4 24.6 21.778% 74% 47% Avg. 1845-12 EuphMBOAT 1192-1-2 8.0 4.4 17.8 21.8 13.5 71%66% 38% 1845-6 EuphMBOAT 1192-1-2 7.6 3.5 21.2 22.4 11.9 73% 62% 35%1845-13 EuphMBOAT 1192-1-2 7.8 3.2 21.2 23.4 11.9 75% 62% 34% 1845-11EuphMBOAT 1192-1-2 7.5 3.1 20.2 22.9 11.6 73% 63% 34% 1845-8 EuphMBOAT1192-1-2 6.8 3.2 19.5 21.7 11.6 70% 63% 35% 1845-2 EuphMBOAT 1192-1-27.3 3.5 21.3 21.1 11.5 72% 60% 35% 1845-10 EuphMBOAT 1192-1-2 7.2 3.420.5 21.4 11.5 71% 62% 35% 1845-7 EuphMBOAT 1192-1-2 8.0 3.1 22.6 23.611.4 76% 61% 33% 1845-4 EuphMBOAT 1192-1-2 7.4 3.4 19.4 21.5 11.4 70%63% 35% 1845.9 EuphMBOAT 1192-1-2 6.4 2.9 19.4 21.1 11.3 70% 63% 35%1845-15 EuphMBOAT 1192-1-2 6.6 2.8 20.5 21.9 11.2 71% 62% 34% 1845-5EuphMBOAT 1192-1-2 7.4 3.0 22.3 23.0 11.2 75% 61% 33% 1845-3 EuphMBOAT1192-1-2 7.0 2.9 20.1 22.1 11.0 70% 62% 33% 1845-14 EuphMBOAT 1192-1-27.3 3.2 22.7 21.1 10.8 73% 58% 34% 1845-1 EuphMBOAT 1192-1-2 7.5 3.122.9 21.2 10.6 72% 58% 33% 1845-16 EuphMBOAT 1192-1-2 7.6 3.1 25.1 19.79.7 74% 54% 33% Top5 7.5 3.5 20.0 22.4 12.1 72% 63% 35% Avg.

TABLE 69 Fatty acid profile of T2 seed from events expressing MBOATs inDGLA/ETA-expressing transgenic event 1203-13-1-5 (EgD9Elo-EaD8Desfusion) T2 seed for 1203 (EgD9Elo-EaD8Des fusion) background eventtransformed with various MBOATs Event # MBOAT Bkgrnd % Oil 16:0 18:018:1 18:2 GLA 18:3 STA 20:0 20:1 EDA DGLA 1203-13-1-5 10.6 3.4 18.2 25.07.6 1.5 12.0 10.2 5.4 HD1- ALS 1203-13-1-5 22.6 9.0 3.8 24.0 20.1 0.05.4 0.0 2.1 11.5 11.1 6.0 10 HD1-4 ALS 1203-13-1-5 22.7 8.9 3.8 24.419.2 0.0 6.0 0.0 2.0 11.3 10.6 5.8 HD1-2 ALS 1203-13-1-5 25.1 9.4 3.622.3 21.9 0.0 5.9 0.0 2.1 11.6 10.7 5.7 HD1-6 ALS 1203-13-1-5 26.7 8.43.4 23.5 21.0 0.0 7.2 0.0 1.7 11.8 10.4 5.4 HD1-8 ALS 1203-13-1-5 25.28.5 3.7 24.9 20.3 0.0 6.7 0.0 2.0 12.1 9.7 5.2 HD1-1 ALS 1203-13-1-520.0 8.9 3.4 24.5 18.0 0.7 7.3 0.0 1.4 11.3 11.9 5.3 HD1-5 ALS1203-13-1-5 25.3 8.9 3.4 24.5 19.1 0.6 7.2 0.0 1.4 11.8 11.1 5.3 HD1-7ALS 1203-13-1-5 29.3 8.9 3.3 22.9 21.6 0.5 7.9 0.0 1.4 12.3 10.4 4.9HD1-3 ALS 1203-13-1-5 23.9 8.7 3.5 25.7 20.1 0.6 7.4 0.0 1.5 11.7 10.34.8 HD1-9 ALS 1203-13-1-5 22.7 8.0 3.4 26.3 19.8 0.6 7.0 0.0 1.5 12.210.7 4.7 Top5 24.5 8.8 3.7 23.8 20.5 0.0 6.2 0.0 2.0 11.7 10.5 5.7 Avg.1671-4 GmMBOAT1 1203-13-1-5 17.9 9.2 3.4 20.9 16.6 0.0 3.8 0.0 2.2 6.314.9 13.5 1671-3 GmMBOAT1 1203-13-1-5 18.7 8.9 3.2 22.8 15.3 0.6 4.5 0.01.5 5.4 16.1 14.1 1671-9 GmMBOAT1 1203-13-1-5 23.6 8.7 3.2 22.5 15.8 0.55.5 0.0 1.4 7.0 14.8 12.4 1671-2 GmMBOAT1 1203-13-1-5 20.8 8.3 3.3 24.717.0 0.0 4.1 0.0 1.9 6.7 13.9 12.0 1671-7 GmMBOAT1 1203-13-1-5 19.9 8.83.5 24.2 14.3 0.6 4.6 0.0 1.4 6.9 15.4 12.3 1671-6 GmMBOAT1 1203-13-1-522.4 8.1 3.4 22.3 16.6 0.0 3.9 0.0 2.0 6.9 16.0 11.4 1671- GmMBOAT11203-13-1-5 24.9 8.3 3.6 23.0 17.6 0.0 5.0 0.0 2.0 7.7 13.6 10.7 101671-5 GmMBOAT1 1203.13-1-5 16.0 8.4 3.3 25.0 16.6 0.6 5.1 0.0 1.5 7.714.7 10.3 1671-1 GmMBOAT1 1203-13-1-5 27.0 7.6 3.3 23.3 19.0 0.4 6.0 0.61.6 10.0 13.4 8.5 1671-8 GmMBOAT1 1203-13-1-5 24.9 9.8 3.4 23.3 21.4 0.05.9 0.0 1.8 11.0 10.9 5.7 Top5 20.2 8.8 3.3 23.0 15.8 0.3 4.5 0.0 1.76.4 15.0 12.9 Avg. 1672-6 GmMBOAT2 1203-13-1-5 22.4 7.8 3.5 21.6 15.00.0 3.7 1.6 3.1 7.4 13.2 9.5 1672-4 GmMBOAT2 1203-13-1-5 20.2 8.1 3.320.8 15.6 0.0 3.4 1.4 2.7 7.1 14.8 10.1 1672-8 GmMBOAT2 1203-13-1-5 23.28.2 3.4 23.5 15.3 0.0 4.0 0.7 2.2 8.3 14.1 8.8 1672- GmMBOAT21203-13-1-5 23.3 7.9 3.5 24.6 17.3 0.0 4.4 0.6 2.5 8.8 13.1 7.7 101672-7 GmMBOAT2 1203-13-1-5 19.8 8.1 3.4 21.5 17.6 0.8 6.5 0.8 1.2 8.214.3 9.8 1672-5 GmMBOAT2 1203-13-1-5 19.8 8.4 3.5 20.3 17.4 0.9 6.3 0.41.3 7.9 14.4 9.4 1672-3 GmMBOAT2 1203-13-1-5 20.0 8.3 3.3 20.0 19.3 0.77.0 0.4 1.2 9.0 14.1 8.9 1672-2 GmMBOAT2 1203-13-1-5 23.7 7.4 3.0 23.218.5 0.0 5.6 1.0 2.5 9.6 12.6 8.1 1672-1 GmMBOAT2 1203-13-1-5 22.1 8.83.5 22.9 19.4 0.8 8.1 0.5 1.1 11.7 10.9 5.6 1672-9 GmMBOAT2 1203-13-1-522.0 8.8 4.2 23.1 19.9 0.8 6.7 0.0 1.1 11.5 11.3 5.6 Top5 21.8 8.0 3.422.4 16.2 0.2 4.4 1.0 2.3 8.0 13.9 9.2 Avg. 1673- CoLPCAT 1203-13-1-519.6 9.5 3.6 22.7 17.0 1.1 3.8 0.0 2.0 8.8 14.4 9.1 10 1673-9 CoLPCAT1203-13-1-5 19.3 9.3 3.1 22.7 16.3 0.8 5.4 0.0 1.5 9.2 15.0 9.2 1673-5CoLPCAT 1203-13-1-5 21.9 9.3 3.3 22.3 17.2 0.6 5.4 0.0 1.5 8.7 15.0 9.11673-4 CoLPCAT 1203-13-1-5 19.8 8.6 3.7 25.2 16.5 0.8 4.3 0.0 2.1 8.613.4 8.2 1673-3 CoLPCAT 1203-13-1-5 23.1 8.6 3.6 24.1 17.6 0.5 5.7 0.61.5 9.9 13.2 7.4 1673-8 CoLPCAT 1203-13-1-5 22.7 8.6 3.5 25.2 18.9 0.05.5 0.0 1.9 9.9 12.1 7.0 1673-7 CoLPCAT 1203-13-1-5 22.3 8.4 3.6 25.117.1 0.6 6.1 0.0 1.5 10.2 13.5 7.0 1673-6 CoLPCAT 1203-13-1-5 26.5 7.93.5 24.6 19.9 0.0 6.3 0.0 1.9 11.3 11.3 6.0 1673-1 CoLPCAT 1203-13-1-522.7 8.2 3.6 27.1 17.8 0.5 6.7 0.0 1.5 10.4 11.9 5.9 1673- CoLPCAT1203-13-1-5 26.1 8.2 3.5 24.0 17.8 0.5 7.4 0.7 1.5 11.2 12.2 5.9 111673-2 CoLPCAT 1203-13-1-5 22.7 9.0 3.4 23.0 21.5 0.9 6.5 0.0 1.9 11.510.2 5.5 Top5 20.7 9.1 3.5 23.4 16.9 0.7 4.9 0.1 1.7 9.0 14.2 8.6 Avg.1674-2 McLPCAT 1203-13-1-5 19.9 9.5 3.1 19.4 13.5 0.6 4.4 0.0 1.6 4.717.8 14.9 1674-4 McLPCAT 1203-13-1-5 19.8 8.3 3.0 20.8 15.8 0.5 5.1 0.81.6 6.5 16.3 12.2 1674- McLPCAT 1203-13-1-5 21.3 8.1 3.3 23.1 16.7 0.04.4 0.0 2.0 6.4 15.0 11.3 13 1674-1 McLPCAT 1203-13-1-5 18.2 8.5 3.521.0 17.2 0.0 3.7 0.0 2.4 7.5 15.2 11.5 1674-7 McLPCAT 1203-13-1-5 23.39.1 3.4 22.6 16.8 0.0 4.5 0.0 2.0 7.9 14.4 10.5 1674- McLPCAT1203-13-1-5 20.9 8.8 3.6 18.9 16.2 0.7 5.2 0.7 1.6 8.3 16.7 10.7 101674-5 McLPCAT 1203-13-1-5 21.9 8.9 3.7 22.9 16.6 0.0 3.7 0.0 2.1 7.515.8 10.4 1674-3 McLPCAT 1203-13-1-5 22.3 8.4 3.9 24.4 15.8 0.0 3.5 0.02.2 8.1 14.9 9.6 1674- McLPCAT 1203-13-1-5 19.7 9.0 3.4 23.6 15.7 0.74.8 0.0 1.5 7.6 16.3 9.9 12 1674-6 McLPCAT 1203-13-1-5 26.7 8.0 3.3 21.716.7 0.5 5.9 0.7 1.4 9.2 15.4 8.9 1674-9 McLPCAT 1203-13-1-5 21.4 8.54.0 24.5 19.0 0.0 4.9 0.0 2.5 8.5 12.5 7.8 1674- McLPCAT 1203-13-1-519.2 10.3 4.1 26.1 16.5 0.0 4.3 0.0 2.6 8.7 11.6 7.9 11 1674- McLPCAT1203-13-1-5 21.7 9.4 3.5 27.1 19.6 0.6 6.8 0.0 1.4 10.0 10.7 5.3 141674-8 McLPCAT 1203-13-1-5 27.7 8.5 3.2 22.4 21.4 0.5 10.0 0.0 1.4 12.39.3 4.3 Top5 20.5 8.7 3.2 21.4 16.0 0.2 4.4 0.2 1.9 6.6 15.7 12.1 Avg.1845- EuphMBOAT 1203-13-1-5 22.8 10.1 3.0 20.2 15.2 0.5 7.6 0.4 1.2 8.112.9 9.9 11 1845- EuphMBOAT 1203-13-1-5 21.3 10.4 3.2 21.5 16.3 0.5 6.60.4 1.3 8.4 13.1 9.1 12 1845- EuphMBOAT 1203-13-1-5 23.3 10.3 3.0 19.818.9 0.5 7.5 0.9 1.3 9.0 11.9 8.3 10 1845-5 EuphMBOAT 1203-13-1-5 20.99.8 3.1 21.4 17.2 0.4 8.0 0.7 1.3 8.6 12.3 8.2 1845-6 EuphMBOAT1203-13-1-5 31.0 10.1 3.1 20.4 19.1 0.3 6.8 0.6 1.2 9.1 13.0 8.4 1845-4EuphMBOAT 1203-13-1-5 25.8 9.6 3.0 20.0 18.6 0.6 8.3 0.7 1.2 9.3 12.27.9 1845- EuphMBOAT 1203-13-1-5 26.9 10.2 3.1 21.0 19.1 0.6 7.1 0.3 1.29.1 12.1 7.8 14 1845-9 EuphMBOAT 1203-13-1-5 29.2 9.2 2.8 17.3 20.5 0.411.5 0.6 1.2 9.9 10.6 7.2 1845- EuphMBOAT 1203-13-1-5 21.4 9.8 3.3 21.117.7 0.4 7.8 0.8 1.4 9.4 12.3 7.3 16 1845-2 EuphMBOAT 1203-13-1-5 26.610.6 3.1 20.6 20.0 0.5 7.6 0.3 1.2 9.1 11.5 7.4 1845-7 EuphMBOAT1203-13-1-5 25.2 8.9 3.1 22.0 17.5 0.3 9.2 0.7 1.3 9.2 11.8 7.0 1845-EuphMBOAT 1203-13-1-5 28.2 9.7 2.9 19.5 20.1 0.5 8.8 0.7 1.2 9.9 11.37.1 15 1845-8 EuphMBOAT 1203-13-1-5 30.2 9.4 3.0 18.4 20.0 0.4 10.3 0.61.2 10.0 11.1 6.9 1845-3 EuphMBOAT 1203-13-1-5 25.1 9.1 3.0 20.7 19.30.3 10.2 0.2 1.3 9.3 11.3 6.6 1845-1 EuphMBOAT 1203-13-1-5 30.9 10.2 3.118.6 21.6 0.4 9.3 0.6 1.2 10.2 10.6 6.4 1845- EuphMBOAT 1203-13-1-5 27.39.3 3.0 22.5 20.5 0.4 8.4 0.8 1.2 9.7 10.9 6.3 13 Top5 23.8 10.2 3.120.7 17.3 0.4 7.3 0.6 1.2 8.7 12.6 8.8 Avg. LA + EDA + DGLA + Event #MBOAT Bkgrnd ERA ETA ALA ERA ETA % D12Des % D9Elo % D8Des 1203-13-1-54.4 1.4 32.6 14.6 6.9 75% 40% 32% HD1- ALS 1203-13-1-5 4.9 2.2 25.6 15.98.2 67% 49% 34% 10 HD1-4 ALS 1203-13-1-5 4.9 2.2 25.1 15.6 8.0 67% 48%34% HD1-2 ALS 1203-13-1-5 4.5 2.2 27.8 15.3 7.9 70% 45% 34% HD1-6 ALS1203-13-1-5 4.8 2.3 28.3 15.2 7.7 68% 45% 34% HD1-8 ALS 1203-13-1-5 4.62.3 27.0 14.3 7.5 66% 45% 35% HD1-1 ALS 1203-13-1-5 5.6 1.8 25.3 17.57.1 67% 49% 29% HD1-5 ALS 1203-13-1-5 5.1 1.6 26.3 16.2 6.9 67% 47% 30%HD1-7 ALS 1203-13-1-5 4.3 1.5 29.4 14.7 6.4 69% 42% 30% HD1-3 ALS1203-13-1-5 4.2 1.5 27.5 14.5 6.3 65% 43% 30% HD1-9 ALS 1203-13-1-5 4.21.5 26.8 14.9 6.2 65% 44% 29% Top5 4.7 2.2 26.8 15.2 7.9 68% 46% 34%Avg. 1671-4 GmMBOAT1 1203-13-1-5 4.7 4.5 20.5 19.5 18.1 74% 65% 48%1671-3 GmMBOAT1 1203-13-1-5 3.6 3.9 19.9 19.7 18.0 72% 65% 48% 1671-9GmMBOAT1 1203-13-1-5 4.6 3.8 21.3 19.3 16.2 72% 63% 46% 1671-2 GmMBOAT11203-13-1-5 4.0 4.2 21.1 17.9 16.2 69% 62% 48% 1671-7 GmMBOAT11203-13-1-5 4.5 3.6 18.9 19.8 15.9 69% 65% 44% 1671-6 GmMBOAT11203-13-1-5 4.7 3.6 20.5 20.7 15.0 72% 64% 42% 1671- GmMBOAT11203-13-1-5 4.6 3.8 22.7 18.2 14.5 71% 59% 44% 10 1671-5 GmMBOAT11203.13-1-5 4.2 2.5 21.7 18.9 12.8 68% 59% 40% 1671-1 GmMBOAT11203-13-1-5 4.0 2.3 25.0 17.4 10.7 70% 53% 38% 1671-8 GmMBOAT11203-13-1-5 4.7 2.1 27.3 15.5 7.8 68% 46% 33% Top5 4.3 4.0 20.3 19.316.9 71% 64% 47% Avg. 1672-6 GmMBOAT2 1203-13-1-5 4.4 9.1 18.7 17.6 18.672% 66% 51% 1672-4 GmMBOAT2 1203-13-1-5 4.5 8.4 18.9 19.3 18.5 73% 67%49% 1672-8 GmMBOAT2 1203-13-1-5 4.8 6.7 19.4 18.9 15.4 70% 64% 45% 1672-GmMBOAT2 1203-13-1-5 4.2 5.5 21.7 17.3 13.2 68% 59% 43% 10 1672-7GmMBOAT2 1203-13-1-5 4.5 3.3 24.1 18.7 13.1 72% 57% 41% 1672-5 GmMBOAT21203-13-1-5 4.9 3.1 23.7 19.2 12.5 73% 57% 39% 1672-3 GmMBOAT21203-13-1-5 4.9 3.1 26.3 18.9 12.0 74% 54% 39% 1672-2 GmMBOAT21203-13-1-5 4.7 3.9 24.1 17.2 12.0 70% 55% 41% 1672-1 GmMBOAT21203-13-1-5 4.7 2.2 27.5 15.6 7.7 69% 46% 33% 1672-9 GmMBOAT21203-13-1-5 4.8 2.1 26.6 16.1 7.7 69% 47% 32% Top5 4.5 6.6 20.5 18.415.8 71% 62% 46% Avg. 1673- CoLPCAT 1203-13-1-5 5.2 2.8 20.8 19.6 11.970% 60% 38% 10 1673-9 CoLPCAT 1203-13-1-5 4.8 2.8 21.7 19.8 11.9 70% 59%38% 1673-5 CoLPCAT 1203-13-1-5 4.8 2.7 22.7 19.8 11.8 71% 58% 37% 1673-4CoLPCAT 1203-13-1-5 4.8 2.9 20.8 18.3 11.1 67% 59% 38% 1673-3 CoLPCAT1203-13-1-5 4.5 2.2 23.3 17.7 9.6 68% 54% 35% 1673-8 CoLPCAT 1203-13-1-54.8 2.6 24.4 17.0 9.6 67% 52% 36% 1673-7 CoLPCAT 1203-13-1-5 4.9 2.123.1 18.4 9.1 67% 54% 33% 1673-6 CoLPCAT 1203-13-1-5 4.7 2.4 26.2 16.18.4 67% 48% 34% 1673-1 CoLPCAT 1203-13-1-5 4.5 1.9 24.5 16.4 7.8 64% 50%32% 1673- CoLPCAT 1203-13-1-5 5.3 1.9 25.2 17.5 7.8 68% 50% 31% 111673-2 CoLPCAT 1203-13-1-5 4.7 2.0 27.9 14.9 7.6 69% 45% 34% Top5 4.82.7 21.9 19.0 11.3 69% 58% 37% Avg. 1674-2 McLPCAT 1203-13-1-5 5.9 4.617.9 23.7 19.5 76% 71% 45% 1674-4 McLPCAT 1203-13-1-5 5.6 3.6 21.0 21.815.8 74% 64% 42% 1674- McLPCAT 1203-13-1-5 5.5 4.2 21.1 20.6 15.5 71%63% 43% 13 1674-1 McLPCAT 1203-13-1-5 5.1 3.5 20.9 20.2 15.0 73% 63% 43%1674-7 McLPCAT 1203-13-1-5 5.4 3.3 21.3 19.8 13.8 71% 61% 41% 1674-McLPCAT 1203-13-1-5 5.1 2.8 21.4 21.8 13.5 75% 62% 38% 10 1674-5 McLPCAT1203-13-1-5 5.3 3.1 20.3 21.1 13.5 71% 63% 39% 1674-3 McLPCAT1203-13-1-5 5.1 3.2 19.3 20.0 12.7 68% 63% 39% 1674- McLPCAT 1203-13-1-55.0 2.5 20.5 21.3 12.5 70% 62% 37% 12 1674-6 McLPCAT 1203-13-1-5 5.8 2.422.6 21.2 11.3 72% 59% 35% 1674-9 McLPCAT 1203-13-1-5 4.7 3.0 23.8 17.210.9 68% 54% 39% 1674- McLPCAT 1203-13-1-5 5.0 3.0 20.7 16.6 10.8 65%57% 40% 11 1674- McLPCAT 1203-13-1-5 4.1 1.6 26.4 14.8 6.9 64% 45% 32%14 1674-8 McLPCAT 1203-13-1-5 4.6 1.5 31.5 13.9 5.8 70% 39% 30% Top5 5.53.8 20.4 21.2 15.9 73% 64% 43% Avg. 1845- EuphMBOAT 1203-13-1-5 7.3 3.622.7 20.2 13.4 74% 60% 40% 11 1845- EuphMBOAT 1203-13-1-5 6.5 2.9 22.819.6 12.0 72% 58% 38% 12 1845- EuphMBOAT 1203-13-1-5 6.1 2.6 26.5 18.010.9 74% 52% 38% 10 1845-5 EuphMBOAT 1203-13-1-5 6.3 2.7 25.2 18.6 10.972% 54% 37% 1845-6 EuphMBOAT 1203-13-1-5 5.6 2.2 25.9 18.5 10.6 73% 53%36% 1845-4 EuphMBOAT 1203-13-1-5 6.2 2.5 26.9 18.4 10.3 74% 52% 36%1845- EuphMBOAT 1203-13-1-5 5.9 2.4 26.2 18.0 10.2 72% 52% 36% 14 1845-9EuphMBOAT 1203-13-1-5 6.3 2.6 31.9 16.9 9.8 77% 46% 37% 1845- EuphMBOAT1203-13-1-5 6.3 2.4 25.5 18.6 9.7 72% 53% 34% 16 1845-2 EuphMBOAT1203-13-1-5 5.8 2.2 27.6 17.3 9.6 73% 49% 36% 1845-7 EuphMBOAT1203-13-1-5 6.5 2.5 26.7 18.3 9.5 71% 51% 34% 1845- EuphMBOAT1203-13-1-5 5.9 2.3 28.9 17.3 9.5 74% 48% 35% 15 1845-8 EuphMBOAT1203-13-1-5 6.3 2.3 30.3 17.4 9.2 76% 47% 35% 1845-3 EuphMBOAT1203-13-1-5 6.2 2.5 29.5 17.4 9.1 73% 47% 34% 1845-1 EuphMBOAT1203-13-1-5 5.6 2.0 30.9 16.1 8.4 75% 44% 34% 1845- EuphMBOAT1203-13-1-5 5.1 1.9 29.0 16.0 8.2 70% 45% 34% 13 Top5 6.4 2.8 24.6 19.011.6 73% 55% 38% Avg.

TABLE 70 Fatty acid profile of T2 seed from events expressing MBOATs inARA/EPA-expressing event 1193-5-4-6 (EaD9Elo/EaD8Des/EaD5Des) T2 seedfor 1193 (EaD9Elo/EaD8Des/EaD5Des) background event transformed withvarious MBOATs 20:3 Event # MBOAT Bkgrnd % Oil 16:0 18:0 18:1 18:2 GLA18:3 STA 20:0 20:1 EDA (5, 11, 14) DGLA ARA 1193-5-4-6 8.3 3.2 16.4 20.50.0 7.6 0.0 1.5 13.0 14.6 0.5 6.7 HD1-1 ALS 1193-5-4-6 27.1 6.7 3.0 16.716.2 0.0 10.7 0.0 1.1 12.9 14.9 0.9 0.7 7.4 HD1-6 ALS 1193-5-4-6 21.07.9 3.5 18.1 16.0 0.0 5.8 2.0 3.1 11.1 16.4 0.0 0.0 7.0 HD1-9 ALS1193-5-4-6 22.8 6.8 3.3 18.6 15.1 0.6 9.9 0.0 1.1 12.0 15.4 0.8 0.7 7.1HD1-7 ALS 1193-5-4-6 26.6 6.7 3.3 16.8 16.5 0.5 8.3 0.3 1.5 13.0 15.60.9 0.5 6.9 HD1-5 ALS 1193-5-4-6 28.4 6.9 3.2 16.2 18.5 0.3 8.6 0.3 1.213.7 14.9 0.8 0.5 7.0 HD1-3 ALS 1193-5-4-6 27.6 6.9 3.4 17.4 17.1 0.59.1 0.0 1.3 13.7 14.6 0.9 0.6 6.5 HD1-10 ALS 1193-5-4-6 25.0 6.6 2.916.9 16.7 0.9 6.0 0.8 2.1 11.5 15.8 0.7 0.0 6.3 HD1-4 ALS 1193-5-4-624.3 6.6 3.0 18.4 16.0 0.8 6.8 0.6 1.8 12.9 15.0 0.6 0.0 5.9 HD1-8 ALS1193-5-4-6 27.5 7.1 3.5 19.0 16.8 0.0 6.4 1.2 2.5 12.5 16.1 0.7 0.0 5.9HD1-2 ALS 1193-5-4-6 31.4 6.5 3.3 19.0 16.8 0.4 7.4 1.1 2.4 12.9 13.60.1 0.0 4.4 25.2 7.0 3.3 17.3 16.5 0.3 8.7 0.5 1.6 12.6 15.4 0.7 0.5 7.11671-1 GmMBOAT1 1193-5-4-6 19.5 7.3 3.0 15.9 8.4 1.7 1.9 0.0 1.2 4.420.9 2.8 0.9 21.2 1671-18 GmMBOAT1 1193-5-4-6 25.1 8.7 2.9 18.1 8.1 0.03.3 0.0 1.1 5.7 20.2 0.9 0.6 19.1 1671-13 GmMBOAT1 1193-5-4-6 31.6 7.83.0 14.9 10.1 0.0 4.0 0.0 1.2 5.5 20.1 2.1 0.5 19.1 1671-15 GmMBOAT11193-5-4-6 31.6 7.6 3.0 14.3 10.2 0.0 4.2 0.0 1.3 5.4 21.3 2.6 0.4 17.51671-2 GmMBOAT1 1193-5-4-6 22.6 6.8 3.4 20.1 8.1 1.4 1.8 0.0 1.7 5.121.8 1.8 0.8 18.2 1671-7 GmMBOAT1 1193-5-4-6 26.2 6.8 3.1 20.2 7.3 1.12.1 0.0 1.3 5.0 22.4 2.3 0.6 17.7 1671-16 GmMBOAT1 1193-5-4-6 25.7 8.53.1 14.4 11.3 0.0 5.3 0.0 1.4 5.6 19.4 2.3 0.4 16.1 1671-17 GmMBOAT11193-5-4-6 22.0 8.7 3.2 17.7 11.2 0.0 4.1 0.0 1.3 5.2 20.0 1.8 0.6 16.01671-14 GmMBOAT1 1193-5-4-6 34.1 7.5 3.0 13.4 12.4 0.0 5.5 0.0 1.2 6.920.0 1.8 0.4 15.5 1671-12 GmMBOAT1 1193-5-4-6 19.7 8.9 3.1 16.1 12.4 0.45.3 0.0 1.3 6.8 18.2 1.2 0.8 14.9 1671-5 GmMBOAT1 1193-5-4-6 28.2 7.03.0 20.0 10.4 0.8 3.8 0.0 1.2 8.0 21.3 1.0 0.5 14.8 1671-10 GmMBOAT11193-5-4-6 26.7 6.6 3.3 20.4 10.6 1.1 3.2 0.0 1.5 7.1 20.3 1.5 0.8 14.81671-9 GmMBOAT1 1193-5-4-6 22.5 6.4 2.9 19.2 11.0 1.1 4.1 0.0 1.3 8.319.8 1.3 0.6 14.1 1671-11 GmMBOAT1 1193-5-4-6 30.8 6.4 3.1 19.7 9.9 0.83.2 0.0 1.4 7.3 22.1 1.6 0.5 14.3 1671-8 GmMBOAT1 1193-5-4-6 23.4 6.83.5 19.9 11.2 0.9 3.0 0.0 1.8 8.0 21.0 1.1 0.9 13.4 1671-6 GmMBOAT11193-5-4-6 26.3 6.5 3.4 20.5 11.1 0.9 3.2 0.0 1.7 7.1 21.5 2.0 0.8 12.01671-3 GmMBOAT1 1193-5-4-6 28.5 6.5 3.1 19.5 13.2 0.7 5.4 0.0 1.4 10.718.3 1.1 0.5 10.3 1671-4 GmMBOAT1 1193-5-4-6 33.7 6.4 3.1 16.8 19.4 0.38.9 0.0 1.6 14.0 14.2 1.0 0.5 5.2 26.1 7.6 3.1 16.6 9.0 0.6 3.1 0.0 1.35.2 20.8 2.1 0.6 19.0 1672-13 GmMBOAT2 1193-5-4-6 25.5 6.7 3.4 20.9 7.80.9 2.0 0.0 1.6 6.2 22.5 1.1 0.9 16.1 1672-2 GmMBOAT2 1193-5-4-6 30.07.4 3.0 22.4 9.2 0.8 2.8 0.0 1.0 5.7 21.9 0.7 0.7 15.1 1672-11 GmMBOAT21193-5-4-6 24.8 6.8 3.0 18.7 10.9 0.8 3.4 0.0 1.5 7.7 21.4 0.8 0.9 14.31672-5 GmMBOAT2 1193-5-4-6 23.2 6.8 3.2 18.4 11.1 0.8 3.3 0.0 1.6 7.121.8 1.0 1.0 14.3 1672-10 GmMBOAT2 1193-5-4-6 20.5 7.8 3.0 19.0 11.8 0.43.7 0.0 1.3 8.2 20.6 0.7 0.8 13.4 1672-9 GmMBOAT2 1193-5-4-6 26.0 6.33.5 20.9 9.9 0.6 2.9 0.0 1.7 7.3 21.2 1.2 0.9 13.3 1672-16 GmMBOAT21193-5-4-6 22.7 7.6 3.1 19.9 12.6 0.3 3.5 0.0 1.4 7.9 20.8 0.9 0.7 12.71672-7 GmMBOAT2 1193-5-4-6 25.9 6.8 3.2 19.7 11.8 0.8 3.7 0.0 1.5 8.120.5 0.7 0.9 12.3 1672-14 GmMBOAT2 1193-5-4-6 25.7 7.6 3.2 20.3 12.4 0.74.0 0.0 1.2 7.4 20.1 1.0 0.6 12.0 1672-8 GmMBOAT2 1193-5-4-6 28.2 7.13.2 19.8 12.4 0.7 4.4 0.0 1.3 8.0 19.8 1.3 0.6 11.8 1672-12 GmMBOAT21193-5-4-6 28.7 6.7 3.2 19.9 12.2 0.7 3.8 0.0 1.4 7.9 20.9 1.2 0.6 11.81672-4 GmMBOAT2 1193-5-4-6 27.8 7.2 3.1 19.5 13.2 0.7 4.5 0.0 1.3 8.419.8 1.0 0.6 11.3 1672-6 GmMBOAT2 1193-5-4-6 29.1 7.1 3.3 19.7 12.6 0.74.6 0.0 1.4 8.4 19.5 1.0 0.7 11.0 1672-1 GmMBOAT2 1193-5-4-6 30.1 6.83.5 20.0 12.1 0.6 4.2 0.0 1.7 8.1 19.3 1.3 0.9 11.1 1672-15 GmMBOAT21193-5-4-6 28.3 6.6 3.4 19.9 12.5 0.7 4.2 0.0 1.7 8.3 19.9 1.2 0.8 10.91672-3 GmMBOAT2 1193-5-4-6 27.9 6.6 3.5 22.0 11.1 0.9 3.7 0.0 1.7 8.319.5 1.3 0.8 10.6 24.8 7.1 3.1 19.9 10.2 0.7 3.0 0.0 1.4 7.0 21.6 0.90.8 14.7 1673-1 CoMBOAT 1193-5-4-6 31.4 6.8 3.2 18.6 11.0 0.6 3.3 0.01.5 6.8 22.1 1.1 0.8 13.8 1673-9 CoMBOAT 1193-5-4-6 28.9 6.8 3.3 20.712.3 0.7 4.5 0.0 1.6 8.8 19.3 0.7 0.8 10.4 1673-3 CoMBOAT 1193-5-4-628.8 7.3 3.4 17.2 14.5 0.6 5.1 0.0 1.7 9.3 19.0 0.8 0.7 10.2 1673-2CoMBOAT 1193-5-4-6 23.4 7.2 3.1 20.7 13.4 0.7 4.9 0.0 1.4 8.7 18.7 1.00.6 9.9 1673-12 CoMBOAT 1193-5-4-6 33.3 7.2 3.3 17.7 14.4 0.5 5.1 0.01.5 8.8 20.0 1.1 0.5 9.9 1673-4 CoMBOAT 1193-5-4-6 25.7 7.2 3.1 20.015.1 0.7 6.1 0.0 1.3 9.7 16.9 0.9 0.6 8.8 1673-7 CoMBOAT 1193-5-4-6 24.96.8 3.2 18.8 14.4 0.8 5.6 0.0 1.6 9.3 18.2 1.0 1.0 9.2 1673-11 CoMBOAT1193-5-4-6 28.2 6.6 3.4 20.2 13.2 0.7 4.9 0.0 1.7 9.0 19.1 1.1 0.8 9.11673-10 CoMBOAT 1193-5-4-6 25.5 6.8 3.0 18.8 14.5 0.3 6.1 0.0 1.5 11.117.7 0.6 0.7 8.5 1673-6 CoMBOAT 1193-5-4-6 28.6 6.6 3.1 18.3 15.3 0.26.4 0.0 1.6 11.1 17.9 1.1 0.5 8.0 1673-13 CoMBOAT 1193-5-4-6 27.9 6.93.3 18.4 16.7 0.6 6.3 0.0 1.7 10.5 17.3 1.1 0.7 7.5 1673-5 CoMBOAT1193-5-4-6 29.9 6.7 3.4 18.3 16.5 0.6 6.9 0.0 1.7 11.8 16.2 1.0 0.7 6.61673-8 CoMBOAT 1193-5-4-6 29.6 6.8 2.9 16.4 18.7 0.4 9.2 0.0 1.5 12.715.1 1.2 0.4 5.3 29.1 7.1 3.3 19.0 13.1 0.6 4.6 0.0 1.5 8.5 19.8 1.0 0.710.8 1674-6 McMBOAT 1193-5-4-6 32.0 6.8 3.4 20.1 9.4 0.6 2.5 0.0 1.6 5.823.3 1.3 0.9 14.4 1674-5 McMBOAT 1193-5-4-6 25.6 6.8 3.1 20.0 11.0 0.83.7 0.0 1.5 7.0 20.9 1.2 0.8 12.9 1674-7 McMBOAT 1193-5-4-6 22.1 7.1 3.321.2 11.2 0.9 4.0 0.0 1.4 8.1 19.2 0.8 1.0 11.7 1674-10 McMBOAT1193-5-4-6 23.8 6.4 3.2 18.9 12.0 0.8 3.8 0.0 1.6 8.0 20.1 1.1 1.0 11.81674-11 McMBOAT 1193-5-4-6 29.2 6.9 3.3 17.5 12.1 0.2 4.4 0.0 1.6 8.421.2 1.2 0.8 11.9 1674-8 McMBOAT 1193-5-4-6 29.3 6.7 3.3 19.0 11.9 0.74.1 0.0 1.7 8.0 20.3 1.3 1.0 11.5 1674-12 McMBOAT 1193-5-4-6 30.4 6.73.2 17.3 13.3 0.6 4.3 0.0 1.6 7.2 21.0 1.8 0.9 11.4 1674-3 McMBOAT1193-5-4-6 29.6 7.3 3.2 19.3 13.2 0.6 4.7 0.0 1.4 7.2 19.9 1.4 0.6 10.91674-1 McMBOAT 1193-5-4-6 31.8 7.0 3.1 19.1 13.3 0.6 4.8 0.0 1.4 7.219.9 1.7 0.6 10.5 1674-9 McMBOAT 1193-5-4-6 24.2 7.4 2.8 18.9 16.3 0.46.3 0.0 1.1 9.7 17.2 0.7 0.7 9.6 1674-2 McMBOAT 1193-5-4-6 29.5 6.4 3.520.7 17.6 0.6 6.5 0.0 1.8 12.9 15.3 0.7 0.7 5.7 1674-4 McMBOAT1193-5-4-6 33.5 7.0 3.4 16.5 20.4 0.4 9.6 0.0 1.7 14.1 12.7 0.8 0.5 4.526.5 6.8 3.2 19.5 11.1 0.7 3.7 0.0 1.5 7.5 20.9 1.1 0.9 12.5 1845-11EuphMBOAT 1193-5-4-6 30.2 7.3 3.1 18.9 14.7 0.5 5.7 0.0 1.4 10.1 18.70.8 0.6 9.1 1845-5 EuphMBOAT 1193-5-4-6 23.4 7.4 2.8 19.6 14.5 0.4 5.80.0 1.4 11.6 17.4 0.6 0.7 8.5 1845-13 EuphMBOAT 1193-5-4-6 24.3 6.8 2.918.9 16.2 0.3 5.7 0.0 1.5 12.3 17.5 0.8 0.6 7.7 1845-6 EuphMBOAT1193-5-4-6 26.3 7.1 3.4 21.0 14.7 0.7 5.6 0.0 1.8 10.7 17.3 1.0 0.8 7.11845-3 EuphMBOAT 1193-5-4-6 23.6 7.5 3.2 18.9 17.3 0.6 6.4 0.0 1.4 11.916.4 0.7 0.7 7.0 1845-12 EuphMBOAT 1193-5-4-6 28.7 6.3 3.2 18.6 16.5 0.66.7 0.0 1.7 11.9 16.6 0.9 0.7 6.9 1845-1 EuphMBOAT 1193-5-4-6 29.3 7.22.9 17.6 18.1 0.2 7.9 0.0 1.3 11.9 15.9 0.7 0.4 6.7 1845-10 EuphMBOAT1193-5-4-6 28.8 6.4 3.3 19.7 16.5 0.6 6.7 0.0 1.7 12.2 15.9 0.8 0.8 6.51845-2 EuphMBOAT 1193-5-4-6 28.0 6.6 3.3 19.2 16.7 0.6 7.0 0.0 1.7 11.816.1 1.0 0.6 6.4 1845-4 EuphMBOAT 1193-5-4-6 30.4 7.0 3.5 20.5 16.1 0.56.3 0.0 1.6 12.5 15.5 0.5 0.8 6.4 1845-7 EuphMBOAT 1193-5-4-6 27.0 7.32.9 18.0 19.8 0.3 7.7 0.0 1.3 12.4 15.0 0.6 0.5 6.1 1845-8 EuphMBOAT1193-5-4-6 31.7 6.7 3.3 18.2 18.0 0.5 7.6 0.0 1.6 12.4 15.3 0.9 0.6 6.01845-9 EuphMBOAT 1193-5-4-6 28.1 7.1 2.8 17.0 20.3 0.3 7.8 0.0 1.3 13.014.9 0.6 0.5 5.8 1845-14 EuphMBOAT 1193-5-4-6 29.1 6.8 3.5 18.2 19.6 0.57.9 0.0 1.9 13.3 14.9 0.9 0.0 5.1 25.6 7.2 3.1 19.5 15.5 0.5 5.8 0.0 1.511.3 17.5 0.8 0.7 7.9 20:4 (5, 11, 14, LA + EDA + DGLA + ARA + % % % %Event # MBOAT Bkgrnd ERA 17) ETA EPA ALA ERA ETA EPA D12Des D9Elo D8DesD5Des 1193-5-4-6 5.9 0.0 1.9 28.1 20.4 0.5 8.6 78% 51% 31% 95% HD1-1 ALS1193-5-4-6 6.4 0.0 0.0 2.3 26.9 21.4 0.7 9.7 78% 54% 33% 93% HD1-6 ALS1193-5-4-6 6.8 0.0 0.0 2.3 21.8 23.2 0.0 9.3 75% 60% 29% 100% HD1-9 ALS1193-5-4-6 6.5 0.0 0.0 2.1 25.0 21.9 0.7 9.2 75% 56% 31% 93% HD1-7 ALS1193-5-4-6 6.5 0.6 0.0 2.1 24.8 22.1 0.5 9.1 77% 56% 30% 95% HD1-5 ALS1193-5-4-6 5.9 0.0 0.0 2.0 27.1 20.7 0.5 8.9 78% 53% 31% 94% HD1-3 ALS1193-5-4-6 6.1 0.0 0.0 2.0 26.2 20.7 0.6 8.5 76% 53% 30% 93% HD1-10 ALS1193-5-4-6 6.1 4.6 0.0 2.1 22.7 21.9 0.0 8.4 76% 57% 28% 100% HD1-4 ALS1193-5-4-6 6.6 2.8 0.0 2.2 22.9 21.7 0.0 8.2 74% 57% 27% 100% HD1-8 ALS1193-5-4-6 6.3 0.0 0.0 2.0 23.2 22.4 0.0 7.9 74% 57% 26% 100% HD1-2 ALS1193-5-4-6 6.0 4.7 0.0 1.5 24.2 19.6 0.0 5.9 72% 51% 23% 100% 6.4 0.10.0 2.1 25.1 21.9 0.5 9.2 77% 56% 31% 95% 1671-1 GmMBOAT1 1193-5-4-6 3.81.6 0.0 5.0 10.3 24.7 0.9 26.2 80% 83% 52% 97% 1671-18 GmMBOAT11193-5-4-6 5.5 0.4 0.0 5.5 11.4 25.6 0.6 24.6 77% 82% 50% 98% 1671-13GmMBOAT1 1193-5-4-6 5.4 1.0 0.0 5.3 14.1 25.6 0.5 24.4 81% 78% 49% 98%1671-15 GmMBOAT1 1193-5-4-6 5.9 1.4 0.0 5.1 14.4 27.1 0.4 22.7 82% 78%46% 98% 1671-2 GmMBOAT1 1193-5-4-6 4.0 0.9 0.0 4.2 9.9 25.8 0.8 22.5 75%83% 47% 97% 1671-7 GmMBOAT1 1193-5-4-6 4.5 1.1 0.0 4.5 9.4 26.9 0.6 22.275% 84% 46% 98% 1671-16 GmMBOAT1 1193-5-4-6 5.9 1.3 0.0 5.0 16.7 25.30.4 21.2 82% 74% 46% 98% 1671-17 GmMBOAT1 1193-5-4-6 5.0 0.9 0.0 4.215.3 25.1 0.6 20.2 78% 75% 45% 97% 1671-14 GmMBOAT1 1193-5-4-6 6.9 0.90.0 4.5 18.0 26.9 0.4 20.0 83% 72% 43% 98% 1671-12 GmMBOAT1 1193-5-4-65.8 0.5 0.0 4.4 17.7 24.0 0.8 19.3 79% 71% 46% 96% 1671-5 GmMBOAT11193-5-4-6 4.8 0.0 0.0 3.4 14.2 26.0 0.5 18.2 75% 76% 42% 97% 1671-10GmMBOAT1 1193-5-4-6 4.8 0.8 0.0 3.4 13.8 25.1 0.8 18.1 74% 76% 43% 96%1671-9 GmMBOAT1 1193-5-4-6 5.2 0.7 0.0 3.9 15.1 25.0 0.6 17.9 75% 74%43% 97% 1671-11 GmMBOAT1 1193-5-4-6 5.3 0.9 0.0 3.6 13.2 27.4 0.5 17.975% 78% 40% 97% 1671-8 GmMBOAT1 1193-5-4-6 5.0 0.5 0.0 3.0 14.2 26.0 0.916.4 74% 75% 40% 95% 1671-6 GmMBOAT1 1193-5-4-6 5.3 1.2 0.0 2.8 14.326.8 0.8 14.8 73% 75% 37% 95% 1671-3 GmMBOAT1 1193-5-4-6 5.7 0.6 0.0 2.918.7 24.0 0.5 13.2 74% 67% 36% 96% 1671-4 GmMBOAT1 1193-5-4-6 6.5 0.50.0 1.6 28.3 20.7 0.5 6.8 77% 50% 26% 93% 4.9 1.1 0.0 5.0 12.0 25.7 0.624.0 79% 81% 49% 97% 1672-13 GmMBOAT2 1193-5-4-6 5.2 0.7 0.0 3.9 9.827.8 0.9 20.0 74% 83% 43% 96% 1672-2 GmMBOAT2 1193-5-4-6 5.0 0.6 0.0 3.612.0 26.9 0.7 18.7 72% 79% 42% 97% 1672-11 GmMBOAT2 1193-5-4-6 5.8 0.70.0 3.3 14.3 27.2 0.9 17.7 76% 76% 41% 95% 1672-5 GmMBOAT2 1193-5-4-65.9 0.5 0.0 3.2 14.4 27.7 1.0 17.5 77% 76% 40% 95% 1672-10 GmMBOAT21193-5-4-6 5.8 0.0 0.0 3.3 15.5 26.4 0.8 16.8 76% 74% 40% 95% 1672-9GmMBOAT2 1193-5-4-6 5.9 1.0 0.0 3.5 12.8 27.1 0.9 16.8 73% 78% 39% 95%1672-16 GmMBOAT2 1193-5-4-6 5.3 0.3 0.0 3.0 16.1 26.2 0.7 15.7 75% 73%39% 95% 1672-7 GmMBOAT2 1193-5-4-6 6.2 0.5 0.0 3.2 15.6 26.7 0.9 15.575% 73% 38% 95% 1672-14 GmMBOAT2 1193-5-4-6 5.8 0.6 0.0 3.2 16.4 25.90.6 15.2 74% 72% 38% 96% 1672-8 GmMBOAT2 1193-5-4-6 5.8 0.6 0.0 3.3 16.925.6 0.6 15.1 75% 71% 38% 96% 1672-12 GmMBOAT2 1193-5-4-6 6.0 0.5 0.03.1 16.0 26.9 0.6 14.9 75% 73% 37% 96% 1672-4 GmMBOAT2 1193-5-4-6 5.90.5 0.0 3.0 17.7 25.7 0.6 14.3 75% 70% 37% 96% 1672-6 GmMBOAT21193-5-4-6 6.2 0.5 0.0 3.1 17.3 25.8 0.7 14.2 75% 70% 37% 96% 1672-1GmMBOAT2 1193-5-4-6 6.7 0.8 0.0 3.0 16.3 26.0 0.9 14.1 74% 72% 37% 94%1672-15 GmMBOAT2 1193-5-4-6 6.4 0.7 0.0 2.9 16.7 26.3 0.8 13.7 74% 71%36% 94% 1672-3 GmMBOAT2 1193-5-4-6 5.8 1.1 0.0 3.0 14.8 25.4 0.8 13.571% 73% 36% 94% 5.6 0.5 0.0 3.5 13.2 27.2 0.8 18.1 75% 78% 41% 96%1673-1 CoMBOAT 1193-5-4-6 6.2 0.6 0.0 3.5 14.3 28.3 0.8 17.3 77% 76% 39%95% 1673-9 CoMBOAT 1193-5-4-6 6.3 0.7 0.0 3.0 16.9 25.6 0.8 13.4 73% 70%36% 94% 1673-3 CoMBOAT 1193-5-4-6 6.5 0.8 0.0 2.9 19.5 25.5 0.7 13.1 77%67% 35% 95% 1673-2 CoMBOAT 1193-5-4-6 6.0 0.6 0.0 2.9 18.3 24.6 0.6 12.873% 68% 35% 95% 1673-12 CoMBOAT 1193-5-4-6 6.5 0.7 0.0 2.8 19.5 26.5 0.512.7 77% 67% 33% 97% 1673-4 CoMBOAT 1193-5-4-6 5.8 0.5 0.0 3.1 21.3 22.80.6 11.9 74% 62% 35% 95% 1673-7 CoMBOAT 1193-5-4-6 6.8 0.6 0.0 2.7 20.025.0 1.0 11.9 75% 65% 34% 93% 1673-11 CoMBOAT 1193-5-4-6 6.6 0.9 0.0 2.718.1 25.6 0.8 11.8 74% 68% 33% 94% 1673-10 CoMBOAT 1193-5-4-6 6.8 0.60.0 2.9 20.6 24.5 0.7 11.4 75% 64% 33% 94% 1673-6 CoMBOAT 1193-5-4-6 6.80.5 0.0 2.6 21.6 24.7 0.5 10.6 76% 62% 31% 95% 1673-13 CoMBOAT1193-5-4-6 6.4 0.7 0.0 2.1 23.0 23.6 0.7 9.6 76% 60% 30% 94% 1673-5CoMBOAT 1193-5-4-6 6.8 0.6 0.0 2.1 23.5 23.0 0.7 8.6 75% 58% 29% 92%1673-8 CoMBOAT 1193-5-4-6 6.7 0.9 0.0 1.7 27.9 21.9 0.4 7.0 78% 51% 25%94% 6.3 0.7 0.0 3.0 17.7 26.1 0.7 13.9 75% 70% 36% 95% 1674-6 McMBOAT1193-5-4-6 6.3 0.6 0.0 3.0 11.8 29.6 0.9 17.4 75% 80% 38% 95% 1674-5McMBOAT 1193-5-4-6 6.1 0.6 0.0 3.7 14.7 27.0 0.8 16.6 75% 75% 39% 96%1674-7 McMBOAT 1193-5-4-6 6.1 0.5 0.0 3.4 15.2 25.3 1.0 15.1 73% 73% 39%94% 1674-10 McMBOAT 1193-5-4-6 6.8 0.7 0.5 3.2 15.9 26.9 1.5 15.1 76%73% 38% 91% 1674-11 McMBOAT 1193-5-4-6 6.8 0.6 0.0 3.2 16.5 28.1 0.815.1 78% 73% 36% 95% 1674-8 McMBOAT 1193-5-4-6 7.0 0.8 0.0 2.9 16.0 27.31.0 14.4 75% 73% 36% 94% 1674-12 McMBOAT 1193-5-4-6 7.1 1.0 0.0 2.8 17.628.1 0.9 14.2 78% 71% 35% 94% 1674-3 McMBOAT 1193-5-4-6 6.5 0.8 0.0 3.017.8 26.5 0.6 13.8 75% 70% 35% 96% 1674-1 McMBOAT 1193-5-4-6 6.8 0.9 0.03.1 18.1 26.8 0.6 13.6 76% 69% 35% 96% 1674-9 McMBOAT 1193-5-4-6 6.2 0.00.0 2.7 22.6 23.4 0.7 12.3 76% 62% 36% 95% 1674-2 McMBOAT 1193-5-4-6 5.60.5 0.0 1.5 24.0 20.9 0.7 7.2 72% 55% 27% 92% 1674-4 McMBOAT 1193-5-4-66.3 0.7 0.0 1.4 30.0 19.0 0.5 5.9 77% 46% 25% 92% 6.4 0.6 0.1 3.3 14.827.4 1.0 15.9 75% 75% 38% 94% 1845-11 EuphMBOAT 1193-5-4-6 6.7 0.0 0.02.4 20.4 25.4 0.6 11.5 75% 65% 32% 95% 1845-5 EuphMBOAT 1193-5-4-6 6.70.0 0.0 2.6 20.3 24.2 0.7 11.2 74% 64% 33% 94% 1845-13 EuphMBOAT1193-5-4-6 6.2 0.4 0.0 2.1 21.9 23.7 0.6 9.8 75% 61% 31% 94% 1845-6EuphMBOAT 1193-5-4-6 6.3 0.6 0.0 1.9 20.3 23.5 0.8 9.1 72% 62% 30% 92%1845-3 EuphMBOAT 1193-5-4-6 6.0 0.0 0.0 2.0 23.7 22.3 0.7 9.0 75% 57%30% 93% 1845-12 EuphMBOAT 1193-5-4-6 6.7 0.6 0.0 2.0 23.2 23.3 0.7 8.975% 59% 29% 93% 1845-1 EuphMBOAT 1193-5-4-6 6.6 0.5 0.0 2.1 26.0 22.50.4 8.8 77% 55% 29% 95% 1845-10 EuphMBOAT 1193-5-4-6 6.5 0.7 0.0 1.823.2 22.3 0.8 8.3 73% 57% 29% 92% 1845-2 EuphMBOAT 1193-5-4-6 6.6 0.70.0 1.9 23.6 22.6 0.6 8.2 74% 57% 28% 93% 1845-4 EuphMBOAT 1193-5-4-66.7 0.3 0.0 1.8 22.4 22.2 0.8 8.2 72% 58% 29% 91% 1845-7 EuphMBOAT1193-5-4-6 6.1 0.0 0.0 1.9 27.5 21.1 0.5 8.0 76% 52% 29% 94% 1845-8EuphMBOAT 1193-5-4-6 6.6 0.7 0.0 1.8 25.6 21.8 0.6 7.8 75% 54% 28% 93%1845-9 EuphMBOAT 1193-5-4-6 6.3 0.5 0.0 1.8 28.1 21.2 0.5 7.6 77% 51%28% 94% 1845-14 EuphMBOAT 1193-5-4-6 6.1 0.0 0.0 1.4 27.5 21.0 0.0 6.575% 50% 23% 100% 6.4 0.2 0.0 2.2 21.3 23.8 0.7 10.1 74% 62% 31% 94%

TABLE 71 Fatty acid profile of T3 homozygous seed from events expressingMBOATs in DGLA/ETA-expressing transgenic event 1022-4-9(EgD9Elo/TpomD8Des) T3seed for pKR1022 (EgD9Elo/TpomD8Des) backgroundevent transformed with various MBOATs Event # MBOAT Bkgrnd % Oil 16:018:0 18:1 18:2 GLA 18:3 STA 20:0 20:1 EDA DGLA ERA 1022-4-9 7.6 3.0 16.626.2 0.0 11.1 0.0 1.2 14.4 8.9 5.2 4.4 HD1-14-1 Vect Cont 1022-4-9 34.47.5 2.7 14.6 21.3 0.3 14.4 0.0 1.4 13.6 9.8 5.9 6.7 HD1-14-7 Vect Cont1022-4-9 34.5 7.4 2.6 14.1 20.5 0.1 14.5 0.0 1.5 14.6 10.1 5.9 7.0HD1-14-2 Vect Cont 1022-4-9 36.6 7.6 2.4 14.3 20.9 0.0 14.8 0.0 1.5 14.49.8 5.7 6.9 Avg. 35.2 7.5 2.6 14.4 20.9 0.1 14.6 0.0 1.5 14.2 9.9 5.86.8 StdDev 1.2 0.1 0.2 0.3 0.4 0.1 0.2 0.0 0.0 0.5 0.2 0.1 0.1 1671-9-7GmMBOAT1 1022-4-9 29.1 10.1 3.0 3.1 11.7 0.0 7.1 0.5 2.1 2.5 20.0 23.48.3 1671-9-5 GmMBOAT1 1022-4-9 31.2 7.8 2.4 13.6 10.2 0.0 4.9 0.2 1.44.5 19.3 20.3 8.1 1671-9-1 GmMBOAT1 1022-4-9 31.6 7.4 2.5 13.5 10.7 0.24.9 0.0 1.3 4.3 20.3 19.3 8.6 Avg. 30.6 8.4 2.6 10.1 10.9 0.1 5.7 0.21.6 3.7 19.9 21.0 8.3 StdDev 1.4 1.5 0.3 6.0 0.7 0.1 1.3 0.2 0.4 1.1 0.52.2 0.2 1672-15-4 GmMBOAT2 1022-4-9 29.5 7.2 2.5 12.4 12.2 0.4 6.3 0.01.6 4.5 18.8 19.4 7.9 1672-15-6 GmMBOAT2 1022-4-9 27 7.1 2.2 17.7 10.60.0 5.2 0.0 1.4 4.8 19.1 16.3 8.7 1672-15-1 GmMBOAT2 1022-4-9 32.3 6.62.4 16.8 11.4 0.4 4.8 0.0 1.5 4.9 20.5 16.1 8.4 Avg. 29.6 7.0 2.4 15.611.4 0.2 5.4 0.0 1.5 4.8 19.5 17.3 8.3 StdDev 2.6 0.3 0.1 2.8 0.8 0.20.8 0.0 0.1 0.2 0.9 1.8 0.5 1673-10-4 CoMBOAT 1022-4-9 26.3 6.8 2.3 14.613.7 0.4 8.1 0.0 1.4 9.2 16.5 13.2 8.6 1673-10-1 CoMBOAT 1022-4-9 30.96.5 2.3 13.7 14.9 0.1 9.0 0.2 1.7 8.4 17.4 13.0 8.4 1673-10-8 CoMBOAT1022-4-9 31.7 6.5 2.1 15.2 14.9 0.3 8.7 0.0 1.4 9.8 16.6 11.5 8.7 Avg.29.6 6.6 2.3 14.5 14.5 0.3 8.6 0.1 1.5 9.1 16.9 12.6 8.6 StdDev 2.9 0.20.1 0.8 0.7 0.2 0.5 0.1 0.2 0.7 0.5 0.9 0.2 1674-4-4 McMBOAT 1022-4-931.8 6.9 2.6 13.5 10.7 0.1 5.5 0.0 1.7 4.5 20.3 18.3 9.8 1674-4-3McMBOAT 1022-4-9 31.6 6.5 2.2 12.7 11.1 0.2 5.7 0.0 1.4 5.8 21.0 17.810.0 1674-4-6 McMBOAT 1022-4-9 32.1 7.8 2.6 13.6 13.8 0.0 7.6 0.3 1.95.8 17.9 15.5 8.6 Avg. 31.8 7.1 2.4 13.3 11.9 0.1 6.3 0.1 1.6 5.3 19.717.2 9.5 StdDev 0.3 0.7 0.2 0.5 1.7 0.1 1.1 0.2 0.2 0.8 1.6 1.5 0.7Event # MBOAT Bkgrnd ETA LA + ALA EDA + ERA DGLA + ETA % D12Des % D9Elo% D8Des 1022-4-9 1.2 37.3 13.3 6.3 77% 35% 32% HD1-14-1 Vect Cont1022-4-9 1.8 35.7 16.4 7.7 80% 40% 32% HD1-14-7 Vect Cont 1022-4-9 1.834.9 17.1 7.7 81% 41% 31% HD1-14-2 Vect Cont 1022-4-9 1.7 35.8 16.6 7.481% 40% 31% Avg. 1.8 35.5 16.7 7.6 81% 41% 31% StdDev 0.1 0.5 0.3 0.2 0%1% 1% 1671-9-7 GmMBOAT1 1022-4-9 8.3 18.8 28.3 31.7 96% 76% 53% 1671-9-5GmMBOAT1 1022-4-9 7.3 15.1 27.4 27.6 84% 78% 50% 1671-9-1 GmMBOAT11022-4-9 7.0 15.6 28.9 26.3 84% 78% 48% Avg. 7.5 16.5 28.2 28.5 88% 77%50% StdDev 0.6 2.0 0.8 2.8 7% 1% 3% 1672-15-4 GmMBOAT2 1022-4-9 7.0 18.526.6 26.4 85% 74% 50% 1672-15-6 GmMBOAT2 1022-4-9 6.9 15.8 27.9 23.2 79%76% 45% 1672-15-1 GmMBOAT2 1022-4-9 6.1 16.2 29.0 22.3 80% 76% 43% Avg.6.7 16.8 27.8 23.9 81% 76% 46% StdDev 0.5 1.5 1.2 2.1 3% 1% 3% 1673-10-4CoMBOAT 1022-4-9 5.1 21.8 25.1 18.3 82% 67% 42% 1673-10-1 CoMBOAT1022-4-9 4.4 23.9 25.8 17.4 83% 64% 40% 1673-10-8 CoMBOAT 1022-4-9 4.223.6 25.4 15.7 81% 63% 38% Avg. 4.6 23.1 25.4 17.1 82% 65% 40% StdDev0.5 1.1 0.4 1.3 1% 2% 2% 1674-4-4 McMBOAT 1022-4-9 6.0 16.2 30.1 24.484% 77% 45% 1674-4-3 McMBOAT 1022-4-9 5.7 16.8 31.0 23.5 85% 76% 43%1674-4-6 McMBOAT 1022-4-9 4.6 21.4 26.5 20.1 83% 69% 43% Avg. 5.5 18.129.2 22.7 84% 74% 44% StdDev 0.8 2.8 2.4 2.3 1% 5% 1%

A summary of the average fatty acid conversion efficiencies for the fiveevents having highest DGLA+ETA content in T2 seed from events expressingMBOATs in DGLA/ETA-expressing transgenic event1559-17-11(MaD6des/MaD6Elo) is shown in TABLE 72. Conversionefficiencies were calculated as described above. Also shown in TABLE 72is the relative % conversion for each step of the pathway where theAverage % Conversion for the Top5 events of each experiment is dividedby the Average % Conversion for the Top5 events of the control seedexpressing pHD1.

TABLE 72 Comparing average conversion efficiencies for each step of adelta-6 desaturase pathway from Arabidopsis T2 seed expressing MBOATs ina DGLA/ETA-expressing transgenic event 1559-17-11 Top5 Avg. for T2 seedof pKR1559 (MaD6Des, MaElo) background event transformed with variousMBOATs Top5 Top5 Top5 Avg. Avg. Avg. Rel. Rel. Rel. MBOAT Bkgrnd %D12Des % D6Des % D9Elo % D12Des % D6Des % D6Elo — 1559-17-11 76% 18% 31%1.00 1.00 1.00 GmMBOAT1 1559-17-11 80% 15% 77% 1.05 0.83 2.45 GmMBOAT21559-17-11 81% 21% 76% 1.06 1.13 2.42 CoMBOAT 1559-17-11 74% 15% 81%0.97 0.84 2.58 McMBOAT 1559-17-11 80% 22% 61% 1.06 1.20 1.93 EuphMBOAT1559-17-11-8 78% 26% 49% 1.03 1.45 1.57

A summary of the average fatty acid conversion efficiencies for the fiveevents having highest EDA/ERA content in T2 seed from events expressingMBOATs in EDA/ERA-expressing transgenic event 926-5-4-1 (EgD9Elo) isshown in TABLE 73. Conversion efficiencies were calculated as describedabove. Also shown in TABLE 73 is the relative % conversion for each stepof the pathway where the Average % Conversion for the Top5 events ofeach experiment is divided by the Average % Conversion for the Top5events of the control seed expressing pHD1.

TABLE 73 Comparing average conversion efficiencies for each step of adelta-9 elongase pathway from Arabidopsis T2 seed expressing MBOATs inEDA/ERA-expressing transgenic event 926-5-4-1 (EgD9Elo) Top5 Avg. forpKR926 (EgD9Elo) background event transformed with various MBOATs Top5Top5 Avg. Avg. Rel. Rel. MBOAT Bkgrnd % D12Des % D9Elo % D12Des % D9Elo— 80% 42% 1.00 1.00 GmMBOAT1 926-5-4-1 GmMBOAT2 926-5-4-1 83% 55% 1.031.34 CoMBOAT 926-5-4-1 84% 37% 1.05 0.90 McMBOAT 926-5-4-1 83% 55% 1.041.33 EuphMBOAT 926-5-4-1 82% 47% 1.02 1.12

A summary of the average fatty acid conversion efficiencies for the fiveevents having highest EDA/ERA content in T2 seed from events expressingMBOATs in EDA/ERA-expressing transgenic event 1191-4-11 (EaD9Elo) isshown in TABLE 74. Conversion efficiencies were calculated as describedabove. Also shown in TABLE 74 is the relative % conversion for each stepof the pathway where the Average % Conversion for the Top5 events ofeach experiment is divided by the Average % Conversion for the Top5events of the control seed expressing pHD1.

TABLE 74 Comparing average conversion efficiencies for each step of adelta-9 elongase pathway from Arabidopsis T2 seed expressing MBOATs inEDA/ERA-expressing transgenic event 1191-4-11 (EaD9Elo) Top5 Avg. forpKR1191(EaD9Elo) background event transformed with various MBOATs Top5Top5 Avg. Avg. Rel. Rel. MBOAT Bkgrnd % D12Des % D9Elo % D12Des % D9Elo— 86% 52% 1.00 1.00 GmMBOAT1 1191-4-11 GmMBOAT2 1191-4-11 CoMBOAT1191-4-11 87% 61% 1.01 1.18 McMBOAT 1191-4-11 88% 73% 1.03 1.40EuphMBOAT 1191-4-11

A summary of the average fatty acid conversion efficiencies for the fiveevents having highest DGLA/ETA content in T2 seed from events expressingMBOATs in DGLA/ETA-expressing transgenic event 1022-4-9(EgD9Elo/TpomD8Des) is shown in TABLE 75. Conversion efficiencies werecalculated as described above. Also shown in TABLE 75 is the relative %conversion for each step of the pathway where the Average % Conversionfor the Top5 events of each experiment is divided by the Average %Conversion for the Top5 events of the control seed expressing pHD1

TABLE 75 Comparing average conversion efficiencies for each step of adelta-9 elongase pathway from Arabidopsis T2 seed expressing MBOATs inDGLA/ETA-expressing transgenic event 1022-4-9 (EgD9Elo/TpomD8Des) Top5Avg. for T2 seed of pKR1022 (EgD9Elo/TpomD8Des) background eventtransformed with various MBOATs Top5 Top5 Top5 Avg. Avg. Avg. Rel. Rel.Rel. MBOAT Bkgrnd % D12Des % D9Elo % D8Des % D12Des % D9Elo % D8Des —1022-4-9 80% 45% 31% 1.00 1.00 1.00 GmMBOAT1 1022-4-9 82% 72% 49% 1.031.61 1.57 GmMBOAT2 1022-4-9 83% 73% 49% 1.04 1.64 1.58 CoMBOAT 1022-4-984% 64% 41% 1.05 1.42 1.31 McMBOAT 1022-4-9 85% 70% 41% 1.06 1.57 1.31EuphMBOAT 1022-4-9 78% 58% 38% 0.97 1.29 1.23

A summary of the average fatty acid conversion efficiencies for the fiveevents having highest DGLA/ETA content in T2 seed from events expressingMBOATs in DGLA/ETA-expressing transgenic event 1192-1-2(EaD9Elo/EaD8Des) is shown in TABLE 76. Conversion efficiencies werecalculated as described above. Also shown in TABLE 76 is the relative %conversion for each step of the pathway where the Average % Conversionfor the Top5 events of each experiment is divided by the Average %Conversion for the Top5 events of the control seed expressing pHD1.

TABLE 76 Comparing average conversion efficiencies for each step of adelta-9 elongase pathway from Arabidopsis T2 seed expressing MBOATs inDGLA/ETA-expressing transgenic event 1192-1-2 (EaD9Elo/EaD8Des) Top5Avg. for T2 seed of 1192 (EaD9Elo/EaD8Des) background event transformedwith various MBOATs Top5 Top5 Top5 Avg. Avg. Avg. Rel. Rel. Rel. MBOATBkgrnd % D12Des % D9Elo % D8Des % D12Des % D9Elo % D8Des — 1192-1-2 72%54% 44% 1.00 1.00 1.00 GmMBOAT1 1192-1-2 78% 80% 51% 1.08 1.48 1.17GmMBOAT2 1192-1-2 75% 78% 46% 1.03 1.45 1.05 CoMBOAT 1192-1-2 76% 69%47% 1.04 1.29 1.08 McMBOAT 1192-1-2 78% 74% 47% 1.08 1.37 1.07 EuphMBOAT1192-1-2 72% 63% 35% 1.00 1.18 0.80

A summary of the average fatty acid conversion efficiencies for the fiveevents having highest DGLA/ETA content in T2 seed from events expressingMBOATs in DGLA/ETA-expressing transgenic event 1203-13-1-5(EgD9Elo-EaD8Des fusion) is shown in TABLE 77. Conversion efficiencieswere calculated as described above. Also shown in TABLE 77 is therelative % conversion for each step of the pathway where the Average %Conversion for the Top5 events of each experiment is divided by theAverage % Conversion for the Top5 events of the control seed expressingpHD1.

TABLE 77 Comparing average conversion efficiencies for each step of adelta-9 elongase pathway from Arabidopsis T2 seed expressing MBOATs inDGLA/ETA-expressing transgenic event 1203-13-1-5 (EgD9Elo-EaD8Desfusion) Top5 Avg. for T2 seed of 1203 (EgD9Elo-EaD8Des fusion)background event transformed with various MBOATs Top5 Top5 Top5 Avg.Avg. Avg. Rel. Rel. Rel. MBOAT Bkgrnd % D12Des % D9Elo % D8Des % D12Des% D9Elo % D8Des — 1203-13-1-5 68% 46% 34% 1.00 1.00 1.00 GmMBOAT11203-13-1-5 71% 64% 47% 1.05 1.38 1.37 GmMBOAT2 1203-13-1-5 71% 62% 46%1.05 1.35 1.35 CoMBOAT 1203-13-1-5 69% 58% 37% 1.02 1.25 1.09 McMBOAT1203-13-1-5 73% 64% 43% 1.08 1.39 1.25 EuphMBOAT 1203-13-1-5 73% 55% 38%1.08 1.19 1.11

A summary of the average fatty acid conversion efficiencies for the fiveevents having highest ARA/EPA content in T2 seed from events expressingMBOATs in ARA/EPA-expressing event 1193-5-4-6 (EaD9Elo/EaD8Des/EaD5Des)is shown in TABLE 78. Conversion efficiencies were calculated asdescribed above. Also shown in TABLE 78 is the relative % conversion foreach step of the pathway where the Average % Conversion for the Top5events of each experiment is divided by the Average % Conversion for theTop5 events of the control seed expressing pHD1.

TABLE 78 Comparing average conversion efficiencies for each step of adelta-9 elongase pathway from Arabidopsis T2 seed expressing MBOATs inARA/EPA-expressing event 1193-5-4-6 (EaD9Elo/EaD8Des/EaD5Des) Top5 Avg.for T2 seed of 1193 (EaD9Elo/EaD8Des/EaD5Des) background eventtransformed with various MBOATs Top5 Top5 Top5 Top5 Avg. Avg. Avg. Avg.Rel. Rel. Rel. Rel. MBOAT Bkgrnd % D12Des % D9Elo % D8Des % D5Des %D12Des % D9Elo % D8Des % D5Des — 1193-5-4-6 77% 56% 31% 95% 1.00 1.001.00 1.00 GmMBOAT1 1193-5-4-6 79% 81% 49% 97% 1.03 1.45 1.59 1.02GmMBOAT2 1193-5-4-6 75% 78% 41% 96% 0.98 1.40 1.33 1.01 CoMBOAT1193-5-4-6 75% 70% 36% 95% 0.98 1.25 1.16 1.00 McMBOAT 1193-5-4-6 75%75% 38% 94% 0.98 1.34 1.24 0.99 EuphMBOAT 1193-5-4-6 74% 62% 31% 94%0.97 1.11 1.01 0.99

A summary of the average fatty acid conversion efficiencies for 3homozygous T3 seed pools from events expressing MBOATs inDGLA/ETA-expressing transgenic event 1022-4-9 (EgD9Elo/TpomD8Des) isshown in TABLE 79. Conversion efficiencies were calculated as describedabove. Also shown in TABLE 79 is the relative % conversion for each stepof the pathway where the Average % Conversion for the Top5 events ofeach experiment is divided by the Average % Conversion for the Top5events of the control seed expressing pHD1.

TABLE 79 Comparing average conversion efficiencies for each step of adelta-9 elongase pathway from Arabidopsis homozygous T3 seed expressingMBOATs in DGLA/ETA-expressing transgenic event 1022-4-9(EgD9Elo/TpomD8Des) Avg. for homozyous T3 seed of pKR1022(EgD9Elo/TpomD8Des) background event transformed with various MBOATsTop5 Top5 Top5 Top5 Avg. Avg. Avg. Avg. Rel. Rel. Rel. Rel. MBOAT Bkgrnd% D12Des % D9Elo % D8Des % D5Des % D12Des % D9Elo % D8Des % D5Des —1022-4-9 81% 41% 31% 95% 1.00 1.00 1.00 1.00 GmMBOAT1 1022-4-9 88% 77%50% 97% 1.09 1.91 1.61 1.02 GmMBOAT2 1022-4-9 81% 76% 46% 96% 1.01 1.861.48 1.01 CoMBOAT 1022-4-9 82% 65% 40% 95% 1.02 1.59 1.29 1.00 McMBOAT1022-4-9 84% 74% 44% 94% 1.04 1.82 1.40 0.99

The invention claimed is:
 1. An isolated polynucleotide comprising: (a)a nucleotide sequence encoding a polypeptide with membrane-boundO-acyltransferase (MBOAT) activity, wherein, based on the Clustal Vmethod of alignment with pairwise alignment default parameters ofKTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5, the polypeptidehas an amino acid sequence of at least 85% sequence identity whencompared to SEQ ID NO:12; or (b) the full complement of the nucleotidesequence of (a); and a heterologous promoter operably linked to either(a) or (b).
 2. The polynucleotide of claim 1, wherein the amino acidsequence of the polypeptide comprises SEQ ID NO:12.
 3. A host cellcomprising in its genome the polynucleotide of claims 1 or 2, whereinthe host cell is selected from the group consisting of a plant cell, amicrobial cell, and a yeast cell.
 4. A method for producing atransformed plant comprising (a) transforming a plant cell with thepolynucleotide of claim 1 or 2; and (b) regenerating a plant from thetransformed plant cell of step (a).
 5. The method of claim 4 wherein theplant is an oilseed plant selected from the group consisting of soybean,Brassica species, sunflower, maize, cotton, flax, and safflower.
 6. Themethod of claim 5 wherein the plant is a soybean plant.
 7. A transgenicseed comprising in its genome the polynucleotide of claims 1 or
 2. 8. Atransgenic seed obtained from the plant made by the method of claim 4;comprising said polynucleotide.
 9. A method for increasing the contentof at least one unusual fatty acid in an oilseed plant cell comprising:(a) transforming the oilseed plant cell with: (i) the polynucleotide ofclaims 1 or 2; and (ii) at least one additional recombinant constructcomprising an isolated polynucleotide, operably linked to at least oneregulatory sequence, encoding a polypeptide selected from the groupconsisting of a delta-4 desaturase, a delta-5 desaturase, a delta-6desaturase, a delta-8 desaturase, a delta-12 desaturase, a delta-15desaturase, a delta-17 desaturase, a delta-9 desaturase, a delta-9elongase, a C14/16 elongase, a C16/18 elongase, a C18/20 elongase, aC20/22 elongase, a DGAT, an MBOAT, a fatty acid conjugase, ahydroxylase, an acetylenase, an epoxidase, and a multizyme; (b)regenerating an oilseed plant from the transformed cell of step (a); and(c) selecting those seeds obtained from the plants of step (b) having anincreased level of at least one unusual fatty acid selected from thegroup consisting of GLA, STA, EDA, ERA, DGLA, ETA, ARA, and EPA; whencompared to—the level in seeds obtained from a transgenic plantcomprising at least one recombinant construct comprising an isolatedpolynucleotide, operably linked to at least one regulatory sequence,encoding the same polypeptide as encoded by the isolated polynucleotideof step (a)(ii), but not comprising the polynucleotide of claims 1 or 2.10. A method for increasing at least one conversion efficiency, whereinsaid conversion efficiency is at least one selected from the groupconsisting of: C₁₈ to C₂₀ elongation, delta-6 desaturation, delta-9elongation, delta-8 desaturation, conjugation to Eleostearic acid, andconjugation to Calendic acid, in an oilseed plant cell comprising: (a)transforming the oilseed plant cell with: (i) the polynucleotide ofclaims 1 or 2; and (ii) at least one additional recombinant constructcomprising an isolated polynucleotide, operably linked to at least oneregulatory sequence, encoding a polypeptide selected from the groupconsisting of a delta-4 desaturase, a delta-5 desaturase, a delta-6desaturase, a delta-8 desaturase, a delta-12 desaturase, a delta-15desaturase, a delta-17 desaturase, a delta-9 desaturase, a delta-9elongase, a C14/16 elongase, a C16/18 elongase, a C18/20 elongase, aC20/22 elongase, a DGAT, an MBOAT, a fatty acid conjugase, ahydroxylase, an acetylenase, an epoxidase, and a multizyme; (b)regenerating an oilseed plant from the transformed cell of step (a); and(c) selecting those seeds obtained from the plants of step (b) having anincreased C₁₈ to C₂₀ elongation conversion efficiency and an increaseddelta-6 desaturation conversion efficiency; when compared to the levelin seeds obtained from a transgenic plant comprising at least onerecombinant construct comprising an isolated polynucleotide, operablylinked to at least one regulatory sequence, encoding the samepolypeptide as encoded by the isolated polynucleotide of step (a)(ii),but not comprising the polynucleotide of claims 1 or
 2. 11. The methodof claim 10 wherein the increase of at least one of the conversionefficiencies is at least one selected from the group consisting of: theincrease of C₁₈ to C₂₀ elongation conversion efficiency by least1.1-fold, the delta-6 desaturation conversion efficiency by at least2-fold, the delta-9 elongation conversion efficiency by at least1.1-fold, the delta-8 desaturation conversion efficiency by at least1.2-fold, the conjugation conversion efficiency to Eleostearic acid byleast 1.2-fold, and the conjugation conversion efficiency to Calendicacid by at least 2.5-fold.
 12. An oil seed plant or oil seed comprising:(a the polynucleotide of claims 1 or 2; and (b) at least one additionalrecombinant construct comprising an isolated polynucleotide, operablylinked to at least one regulatory sequence, encoding a polypeptideselected from the group consisting of a delta-4 desaturase, a delta-5desaturase, a delta-6 desaturase, a delta-8 desaturase, a delta-12desaturase, a delta-15 desaturase, a delta-17 desaturase, a delta-9desaturase, a delta-9 elongase, a 014/16 elongase, a 016/18 elongase, a018/20 elongase, a C20/22 elongase, a DGAT, an MBOAT, a fatty acidconjugase, a hydroxylase, an acetylenase, an epoxidase, and a multizyme.13. The oilseed plant of claim 12, wherein the oilseed plant is selectedfrom the group consisting of soybean, Brassica species, sunflower,maize, cotton, flax, and safflower.
 14. A transgenic seed obtained fromthe oilseed plant of claim 13, wherein said seed comprises thepolynucleotide of (a) and the recombinant DNA construct of (b).
 15. Foodor feed comprising the seed of claim
 14. 16. Progeny plants obtainedfrom the oilseed plant of claim 12, wherein said progeny plants comprisethe polynucleotide of (a) and the recombinant DNA construct of (b).